FINLAY
EDICIONES

BOLETÍN VACCIENCIA

No. 6 (27 abril - 8 mayo/2020)

VaCyT

SiViFinlay

IFV INSTITUTO FINLAY DE VACUNAS

...vacunar es prevenir.

Análisis bibliométrico sobre rotavirus, vacunas

Fuente de información utilizada:

WEB OF SCIENCE™

Estrategia de búsqueda:
"(rotavirus)" AND (vaccine)"

Periodo de estudio 1999-2020

Las variables utilizadas en el análisis fueron:

⇒ Productividad científica por año.
⇒ Autores con mayor productividad científica.
⇒ Áreas de investigación estudiadas con mayor frecuencia.
⇒ Revistas con mayor número de publicaciones sobre el tema.
⇒ Instituciones que han trabajado el tema de estudio.
⇒ Países a la vanguardia sobre el tema.
⇒ Tipo de documento.

EN ESTE NÚMERO

Productividad científica por año



Autores con mayor productividad científica



Áreas de investigación estudiadas con mayor frecuencia



Revistas científicas que ha publicado sobre el tema en Web of Science (2019-2020)



Producción científica por países registrada en Web of Science (1999-2020)



Tipos de documentos



Instituciones que han trabajado el tema de estudio



La universidad de Oxford anunció que su vacuna contra el coronavirus funcionó exitosamente en monos

27 abr. Científicos del Instituto Jenner de la Universidad de Oxford, en el Reino Unido, anunciaron este lunes que su potencial vacuna contra el nuevo coronavirus pasó una nueva etapa con resultados positivos: funcionó exitosamente en monos macacos rhesus, quizás el animal más cercano a los humanos en términos biológicos.

El instituto lleva la delantera en este tipo de esfuerzos -ya ha comenzado sus pruebas en cientos de humanos, una etapa más avanzada que los que han comenzado a hacerlo en decenas- y adelantó que en el mejor de los escenarios y con aprobaciones de emergencia, podría tener los primeros millones de dosis en septiembre.

Con respecto a este último avance, los científicos explicaron que el mes pasado inocularon a seis monos de esta especie con la potencial vacuna. Luego los expusieron a altas dosis de Covid-19, las cuales habían enfermado a otros monos. No obstante, estos seis especímenes están en un buen estado de salud 28 días después de haber recibido la vacuna.

El doctor Vincent Muster, el científico que lideró el estudio, aclaró que todavía se encuentran analizando los resultados, pero adelantó que planea compartirlos la semana que viene y luego remitirlo a una publicación para que sean evaluados por otros colegas.

Lograr inmunidad en monos, no obstante, no significa que la vacuna vaya a funcionar en humanos. Pero el doctor Munster indicó que "el macaco rhesus es prácticamente lo más cercano a los humanos que tenemos".

El instituto Jenner no es el único grupo que ha probado su vacuna en monos. También es el caso de Sinovac Biotech, una compañía privada con sede en Beijing, que anunció resultados similares a finales de la semana pasada. Todos los monos inoculados en ese caso también resultaron inmunes a la enfermedad, mientras que cuatro del grupo de control desarrollaron altos niveles de ARN viral en varias partes del cuerpo y neumonía severa.

Otro dato alentador fue el hecho que la vacuna fuera efectiva contra distintas variantes de la enfermedad. El SARS-CoV-2 parece acumular mutaciones lentamente, lo que puede ser un desafío para los tratamientos. En experimentos con probetas, los investigadores de Sinovac mezclaron anticuerpos tomados de monos, ratas y ratones que recibieron su vacuna con cepas del virus aislado de pacientes con COVID-19 en China, Italia, Suiza, España y el Reino Unido. Los anticuerpos "neutralizaron" todas las cepas, que están "muy dispersas en el árbol filogénico", anotaron los investigadores.

No obstante, distintos profesionales han manifestado dudas acerca de cuán concluyentes son estos los estudios por dos motivos: que la cantidad de monos no es lo suficientemente grande para producir resultados estadísticamente significativos. Y que los monos no desarrollan los síntomas más graves que el SARS-CoV-2 causa en los humanos.

De hecho, los investigadores de Sinovac reconocen en el documento que "todavía es demasiado pronto para definir el mejor modelo animal para estudiar el SARS-CoV-2", pero señalaron que los macacos rhesus no vacunados que reciben el virus "imitan síntomas similares al Covid-19".

"Esto proporciona una fuerte evidencia de que el virus no está mutando de una manera que lo haría resistente a la vacuna #COVID19", tuiteó el inmunólogo Mark Slifka de la Oregon Health & Science University. "Bueno saber."

La diferencia entre las etapas en las que se encuentra la vacuna del Instituto Jenner y Sinovec tiene que ver con que el primero logró saltear una etapa inicial de prueba en humanos y pudo comenzar a administrar la vacuna a cientos de personas. Esto así debido a que ya había probado en ocasiones anteriores que vacunas similares no causaban daño a humanos, el objetivo de la primera etapa de vacunación.

En total, se espera que en el ensayo clínico liderado por Oxford haya 1.102 participantes en diferentes laboratorios de esta ciudad, Southampton, Londres y Bristol.

Fuente: Infobae. Disponible en https://bit.ly/3daZM2X

Comunidad científica pone sus ojos sobre prometedor fármaco que podría ayudar en casos graves de COVID-19

29 abr. Un estudio clínico preliminar efectuado por científicos en Francia, específicamente de la Asistencia Pública de Hospitales de París, logró constatar cómo el Tolicizumab disminuye los efectos nocivos de la avalancha de citoquinas que afecta a un porcentaje que oscila entre el 5% y el 10% de los pacientes afectados por coronavirus.

La artritis reumatoide es una enfermedad que implica la inflamación crónica de las articulaciones y cuya farmacología ha evolucionado de manera importante durante los últimos años, lo que ha redundado en el diseño de una serie de inmunoterapias que han resultado bastante exitosas en términos del impacto que tienen en los diferentes componentes que participan en el inicio y perpetuación de la respuesta inmune de los organismos afectados.

Una de las respuestas a la investigación farmacológica para este cuadro es el Tolicizumab (TCZ), el primer anticuerpo monoclonal inhibidor del receptor de la interleucina 6 (IL-6), citoquina con actividad proinflamatoria. Y al parecer, una esperanza para el tratamiento de los casos más graves de COVID-19.

Durante las últimas semanas, se ha hecho recurrente escuchar hablar de este remedio cuya molécula indicada en el tratamiento de la artritis reumatoide evidencia resultados positivos contra el coronavirus, lo que podría consolidarla como una solución para el tratamiento de pacientes críticos que se hayan contagiado con el virus, lo que incluso podría evitar someterlos al temido uso de respiradores e incluso ahorrarles una prolongada estadía en las unidades de cuidados intensivos (UCI).

Publicaciones europeas alusivas a sus auspiciosos resultados así lo certifican. Es el caso de un estudio clínico preliminar efectuado por científicos en Francia, específicamente de la Asistencia Pública de Hospitales de París, quienes lograron constatar cómo el fármaco disminuye los efectos nocivos de la avalancha de citoquinas que afecta a un porcentaje que oscila entre el 5% y el 10% de los pacientes afectados por coronavirus.

Los pacientes con los que se experimentó fueron seleccionados de entre los hospitalizados por neumonía moderada o grave como respuesta al COVID-19 que no requirieron reanimación al ser ingresados a estas unidades críticas. El objetivo primario, cita La Tercera, fue la combinación de la necesidad de ventilación mecánica o no invasiva o el riesgo de muerte en 14 días de internación.

La muestra aleatoria alcanzó a un total de 129 pacientes: 65 para el tratamiento habitual más una intervención con Tocilizumab y 64 para el grupo control. Sorpresivamente, aquellos afectados por una neumonía grave que recibieron el antirreumático presentaron una menos necesidad de apelar a la respiración artificial y una menor tasa de mortalidad, un resultado ciertamente auspicioso aunque no del todo concluyente. No al menos en esta etapa.

El prometedor estudio fue coordinado por los profesores Olivier Hermine, hematólogo del Hospital Pediátrico Necker, del Instituto de enfermedades genéticas Imagine, Xavier Mariette, reumatólogo del Hospital Bicêtre, quienes trabajaron bajo la dirección científica de Pierre-Louis Tharaux, especialista cardiovascular del Hospital Europeo Georges Pompidou, entre otros profesionales del grupo Corimuno-Toci.

En relación al mecanismo de acción del anticuerpo, Hermine, coordinador del estudio explicó a Qué Pasa que este opera bloqueando el receptor de IL-6, específicamente "previniendo las interacciones de IL -6 que se expresa en muchas células", con lo que "previene la hiperactivación del sistema inmune después de la infección por el virus".

Si el Tocilizumab arroja buenos resultados en todos los casos graves de Covid-19, el investigador aclara que de momento, "los datos son demasiado prematuros para responder a esa pregunta".

Como sea, los resultados del experimento que se inició el 27 de marzo que continúa en curso en varios hospitales de París, no se han oficializado en detalle porque sus responsable se encuentran a la espera de la evaluación de una comisión científica para su publicación en una revista médica.

Fuente: elDESCONCIERTO.cl. Disponible en https://bit.ly/2LmcK2h

Dos antiguas alumnas de la Universidad de Navarra investigan en California un tratamiento para la Covid-19

29 abr. Han elaborado un modelo para optimizar la dosis de hidroxicloroquina que se aplica a pacientes con coronavirus.

La pamplonesa Belén Pérez Solans y la alicantina María García-Cremades Mira, antiguas alumnas de la Universidad de Navarra, han elaborado en California un modelo para optimizar la dosis de hidroxicloroquina que se aplica a los pacientes con Covid-19, y que ha dado buen resultado en algunos enfermos.

El estudio ha sido publicado recientemente en la revista 'Clinical Pharmacology & Therapeutics' de la Sociedad Americana de Farmacología Clínica y Terapéutica, ha explicado la Universidad de Navarra en un comunicado.

Las dos investigadoras, antiguas alumnas del programa de doctorado de la Facultad de Farmacia y Nutrición, se encuentran actualmente en la Universidad de California, San Francisco (UCSF), en una estancia postdoctoral que pretende implementar tratamientos innovadores y más efectivos, y establecer un buen marco de prevención de enfermedades infecciosas como el VIH, la tuberculosis o la malaria.

Precisamente es esa investigación la que les ha llevado a estudiar la hidroxicloroquina como un posible tratamiento para los pacientes contagiados por coronavirus.

Las científicas han relacionado las características farmacocinéticas de la hidroxicloroquina con niveles de carga viral en pacientes con un síndrome respiratorio agudo severo (SARS-CoV-2), "integrando así datos disponibles en el ámbito clínico con datos de replicación viral in vitro, y con información sobre reacciones adversas a nivel cardiovascular", ha detallado la navarra Belén Pérez.

La investigación farmacéutica frente al coronavirus "se centra actualmente en diseñar estrategias para analizar e integrar toda la información disponible de los fármacos que han mostrado cierta eficacia en los pacientes", según ha explicado María García-Cremades Mira.

"De ahí que, en estos momentos, cuestiones como decidir la dosis efectiva para tratar pacientes infectados con Covid-19 representa un gran desafío ante la escasez de resultados de ensayos clínicos", ha remarcado.

De esta manera, han explorado diferentes regímenes de dosificación que maximizan la eficacia y minimizan la toxicidad del fármaco con el objetivo de poder informar los ensayos clínicos de hidroxicloroquina en pacientes contagiados.

Las investigadoras coinciden en que este trabajo resalta la importancia de la investigación encaminada al desarrollo de modelos de enfermedad / farmacocinética/farmacodinámica que permiten generar escenarios "in silico", con el fin de individualizar tratamientos de una manera más eficiente.

Este modo de trabajar es similar al que emplea el grupo de Farmacometría y Farmacología de Sistemas de la Facultad de Farmacia y Nutrición, y que constituyó el marco de sus doctorados. Ambos se desarrollaron en el ámbito de la Oncología y estuvieron supervisados por Iñaki Fernández de Trocóniz. Se realizaron en colaboración con la empresa farmacéutica Eli&Lilly en el primer caso, y con el departamento de Oncología Médica de la Clínica Universidad de Navarra, junto con la doctora Marta Santisteban, en el segundo.

Fuente: Cope. Disponible en https://bit.ly/3dq5ez5

La vacuna que utiliza al mensajero del virus ya inició pruebas en humanos

30 abr. Como un engaño. Así trabaja una de las vacunas que busca proteger a las personas del contagio del nuevo coronavirus SarsCoV2 y que esta semana logró el permiso para iniciar pruebas en humano, ensayo clínico que se realizará en Alemania en los próximos días.

La farmacéutica Pfizer y BioNTech (empresa biotecnológica alemana) desde el 2018 venían trabajando en un vacuna contra el virus de la influenza y es esta misma base la que utilizarán ahora para el desarrollo de una vacuna contra el virus causante de Covid-19: el mensaje.

Cuando los virus ingresan al organismo, buscan una especie de llave para entrar a las células y una vez dentro, replicarse así mismos para seguir contagiando.

El trabajo que vienen desarrollando ambas compañías utiliza el ARN mensajero del virus, es decir, la señal que usa el nuevo coronavirus para producir la proteína y la infección, pero que ahora producirá una proteína que en lugar de contagiar, estimulará al sistema inmune para producir anticuerpos contra el SARS-CoV-2.

"Lo que se hace es usar la información genética del virus, buscar una molécula de su ARN mensajero para producir una proteína y a partir de esa información, un anticuerpo que proteja del virus", explica Alejandro Cané, especialista en pediatría y enfermedades infecciosas pediátricas y jefe de asuntos científicos y médicos para América del Norte de la división de vacunas de Pfizer.

El ARN mensajero que se utiliza en esta vacuna, no trabaja con el virus completo, sino solo con una parte de la información genética de él, por lo que tampoco puede causar la enfermedad, ni siquiera en forma atenuada.

"Cuando se piensa en el desarrollo de una vacuna, desde que se piensa la vacuna hasta que llega al mercado, pasan entre cinco y siete años, desde el origen a la publicación", explica Cané, encargado de supervisar todas las actividades médicas y científicas relacionadas con la vacunas en la región.

Actualmente se encuentran trabajando con cuatro candidatos de ARN mensajero, es decir cuatro variantes de un prototipo de vacuna que ya comenzarán a probar luego que Alemania autorizará el ensayo clínico en humanos. Este es el cuarto ensayo que se aprueba en el mundo para una vacuna que prevenga el contagio con el virus.

La vacuna, fue bautizada con el nombre de BNT162 y será probada en 200 adultos sanos para evaluar su seguridad y la respuesta del sistema inmune. Antes, ya se había probado en modelo animal (ratones) con éxito.

Una de sus ventajas es precisamente que con el modelo de ARN mensajero, se puede producir una vacuna rápidamente a gran escala y en grandes volúmenes.

"Es difícil predecir cuándo estará lista la vacuna. Si todo sale bien, y la agencia europea, la FDA y la OMS, es probable que pueda estar lista a fin de año y a escala en el primer cuarto del próximo año", dice Cané.

A mediados de mayo, el ensayo se realizará en Estados Unidos. En China, la vacuna también se esta testeando, ya que la BioNTech tenía un acuerdo previo con ellos. Son los mismos componentes de la vacuna que se está probando en personas de distintos lugares y con distinta información genética, agrega el jefe de asuntos científicos y médicos para América del Norte de la división de vacunas de Pfizer.

La farmacéutica norteamericana dice estar comprometida con la accesibilidad de la vacuna, algo que según Cané, también es extensible a otros laboratorios, situación de unidad y preocupación mundial que se ha logrado en esta pandemia.

"En situación de pandemia, hay muchas vacunas que están hoy en investigación, diferentes

Uy

Conozca las seis vacunas que se están probando contra el coronavirus

30 abr. Frente a la pandemia por coronavirus decenas de científicos alrededor del mundo llevan a cabo investigaciones para desarrollar una vacuna que sea efectiva para el virus.

Las pruebas de laboratorio para la vacuna de COVID-19 se dividen en tres fases, primero con un número pequeño de participantes sanos y después con números más grandes de personas y grupos de control para medir qué tan segura es y cuáles son las dosis más efectivas, revela la BBC.

No obstante, en los últimos tres meses más de 90 profesionales han trabajado en una vacuna que pueda frenar la pandemia de las cuales ya seis están siendo ensayados en humanos.

La primera: Vacuna mRNA-1273, probada en Estados Unidos por Moderna Therapeutics, una empresa de biotecnología que busca demostrar que con la vacuna el sistema inmune de una persona para generar una respuesta para combatir al virus y evitar la enfermedad, indica la BBC.

Sin embargo, la mRNA-1273 no está producida con el virus que causa el coronavirus, sino en un ARN mensajero o ácido ribonucleico mensajero.

La segunda: Vacuna INO-4800 de Inovio, una empresa de biotecnología en Pensilvania, también se basa en una nueva estrategia de investigación. Está centrada en la inyección directa de ADN a través de un plásmido para que las células del paciente produzcan los anticuerpos para combatir la infección.

A pesar de esto, ninguna de estas tecnologías han producido hasta ahora un fármaco apto para el uso humano, según explicó el doctor Felipe Tapia, del Grupo de Ingeniería de Bioprocesos del Instituto Max Planck de Magdeburgo, Alemania.

Tapia dijo que "Podría decirse que hay una expectativa muy grande en el desarrollo de estas vacunas, pero hay que ser un poco cuidadosos porque son vacunas que no tienen el historial de otros tipos de vacunas, como las inactivadas".

Asimismo, en China se están probando tres vacunas en humanos, la primera es Vacuna AD5-nCoV, de CanSino Biologics, esta utiliza como vector una versión no replicante de un adenovirus, el virus que causa el resfriado común, con este el gen de la proteína S busca provocar una respuesta inmune para combatir la infección.

La segunda vacuna LV-SMENP-DC del Instituto Médico Genoinmune de Shenzhen, es un medicamento centrado en células dendríticas modificadas con vectores lentivirales. Además, la tercera y mejor candidata entre las vacunas chinas en una es una vacuna de virus inactivado del Instituto de Productos Biológicos de Wuhan, subordinado al Grupo Farmacéutico Nacional de China, Sinopharm, relata la BBC.

Esta busca producir partículas de virus en reactores y después purificar esos virus para que pierdan su capacidad de enfermar.

"Esta es la tecnología más común y la plataforma de producción más experimentada en producción de vacunas", expuso Felipe Tapia del Instituto Max Planck.

Y por último está la vacuna ChAdOx1 del Instituto Jenner de la Universidad de Oxford, Reino Unido, es una vacuna recombinante similar a la de la empresa china CanSino, esta usa como vector una versión atenuada de un adenovirus del chimpancé que ha sido modificado para que no se reproduzca en humanos.

"Lo que están haciendo ellos es producir en un reactor un virus que no es dañino pero en su superficie expresa la proteína del coronavirus y así genera una respuesta inmune", explica el experto del Instituto Max Planck.

Fuente: Diario Libre. Disponible en https://bit.ly/2WD39u3

Unas seis vacunas contra el coronavirus ya se encuentran avanzadas y en estadio clínico

1 may. El Consejo Superior de Investigaciones Científicas (CSIC) ya tiene un candidato a vacuna contra el coronavirus SARS-CoV-2 y comenzará los ensayos preclínicos con animals próximamente, según ha anunciado el Ministerio de Ciencia e Innovación de España.

El logro corresponde a los investigadores del Centro Nacional de Biotecnología (CNB), liderados por Mariano Esteban junto a Juan García Arriaza, y se basa en una modificación de la vacuna que se utilizó para erradicar la viruela en los años 70 del siglo XX.

En concreto, para el desarrollo de la vacuna están utilizando una cepa muy atenuada del virus Vaccinia (llamado MVA), de la familia del virus de la viruela, como vector viral para insertarle genes del nuevo coronavirus que puedan inducir una buena respuesta inmune frente al SARS-CoV-2.

Según ha indicado el Ministerio en una nota de prensa, existe la posibilidad de que una sola dosis de la vacuna induzca protección, algo que este mismo equipo de laboratorio ya ha conseguido en la generación de vacunas anteriores contra el ébola, zika y chikungunya.

De esta manera, la investigación arranca una nueva fase en el desarrollo de su proyecto de vacuna, que se prolongará durante varios meses también.

A mediados de abril, el ministro Duque ya anunció que los investigadores españoles estaban cerca de un "candidato a vacuna" que, según explicó, es "un producto que empezamos a probar" y que comportaría todavía mucho tiempo. "Una vez se genera la inmunidad, podemos empezar a hacer pruebas muy cautelosas con humanos", señaló.

Por todo ello, para una vacuna probada y segura la espera podría llegar a ser de más un año. "Normalmente se tarda hasta 5 años en hacerla, antes del año que viene no creemos que sea posible", aseveró en la rueda de prensa del pasado 17 de abril.

Fuente: rtve. Disponible en https://bit.ly/3cLzBjS

Coronavirus: apuntan a una inmunidad persistente de 12 años a la Covid-19

3 may. La actual pandemia del coronavirus Covid-19 ya ha dejado en todo el mundo más de **tres millones de contagios y más de 200.000 muertes.** Un virus sobre el que giran numerosas incógnitas, pero la principal sin duda es la que se hacen en estos momentos todos los investigadores: **¿Genera inmunidad?**

Según un estudio publicado en MedRxiv (un repositorio de estudios en pre-publicación, que todavía no han sido revisados) señala que el coronavirus Covid -19 podría presentar una inmunidad en aquellos pacientes que ya han superado el virus **de 12 años**. Para aventurar esta afirmación, los investigadores se

basan en el brote del SARS Co-V de 2002, similar al actual **coronavirus de Wuhan**.

El estudio señala que durante **el brote de SARS de 2002**, los profesionales sanitarios estuvieron altamente expuestos al virus, lo que provocó un alto número de contagios entre este colectivo, al igual que está sucediendo ahora.

Los anticuerpos contra el virus alcanzaron su punto máximo en 2004, disminuyendo rápidamente a partir de ese año y hasta 2006. Posteriormente, los anticuerpos contra el virus que es similar al coronavirus Covid-19 comenzaron a desaparecer de forma más lenta, desapareciendo del todo en 2015.

"Los anticuerpos contra el SARS-CoV pueden persistir durante al menos 12 años.

La presencia de anticuerpos del SARS-CoV podría proporcionar protección contra este virus y otros betacoronavirus, como el actual Covid-19", concluye el

Fuente: redacción médica. Disponible en https://bit.ly/2WCv1i1

CORONAVIRUS | Investigadores españoles evalúan la acción preventiva de esta hormona frente al contagio del Covid-19

4 may. El Hospital Universitario La Paz (Madrid) ha puesto en marcha un ensayo clínico, junto a otros siete hospitales españoles, para evaluar la eficacia y seguridad del medicamento melatonina 2mg de liberación prolongada en la profilaxis de la infección por SARS-CoV-2 en personal sanitario en riesgo.

El estudio, que ha contando con la colaboración de la compañía farmacéutica española Exeltis, es multicéntrico, aleatorizado y controlado con placebo, que contará con la participación de un total de 450 profesionales sanitarios, y cuyo objetivo será comprobar si el uso preventivo de este medicamento podría evitar el contagio entre el personal con alto riesgo de infección.

"Melatonina tiene la ventaja de ser un fármaco ya comercializado, con un buen perfil de seguridad y un precio asequible, y por tanto un buen candidato a estudiar para prevenir la infección por SARS-CoV-2", señala el doctor Alberto M. Borobia, coordinador del estudio, del Servicio de Farmacología Clínica y de la Unidad Central de Investigación Clínica y Ensayos Clínicos del Hospital Universitario La Paz, quien ve necesaria la búsqueda de estrategias de prevención de infección por SARS-CoV-2 que permitan reducir su transmisión, "especialmente en personal sanitario y asistencial, que presentan un alto riesgo de contagio.

La melatonina es una hormona natural producida por la glándula pineal. Desde el punto de vista fisiológico, la secreción de melatonina aumenta poco después del anochecer, alcanza su pico máximo entre las dos y las cuatro de la madrugada y disminuye durante la segunda mitad de la noche. La melatonina se asocia al con-

trol de los ritmos circadianos y a la adaptación al ciclo de luz-oscuridad. También se asocia a un efecto hipnótico y a una mayor propensión al sueño. Por ello, el medicamento conteniendo melatonina 2mg de liberación prolongada está indicado para el tratamiento del insomnio primario.

Pero además de las anteriores, esta hormona también posee propiedades como potente antioxidante con actividad antiinflamatoria, y ha mostrado tanto efectos protectores frente a infecciones virales en animales, como efectos positivos en condiciones clínicas con fisiopatología similar como al SARS27. Esto, unido a su bajo precio y buen perfil de seguridad, hace de la melatonina un buen candidato para probar su uso en Covid-19.

El diseño y desarrollo del estudio está liderado por la Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC) y



Servicio de Farmacología Clínica del Hospital Universitario La Paz, junto con el Servicio de Cuidados Intensivos Pediátricos y Sección de Enfermedades Infecciosas del Servicio de Medicina Interna del mismo hospital. También han colaborado en este proyecto María Teresa García, del Instituto de Investigación 12 de Octubre, encargada del desarrollo del CRD y el sistema de randomización, y Fernando Torcelly, que ha elaborado el diario electrónico usado por los sujetos.

La Unidad Central de Investigación Clínica y Ensayos Clínicos del Hospital La Paz es una de las plataformas de apoyo a la investigación del Instituto de Investigación de La Paz (IdiPAZ). La UCICEC se creó con la ayuda obtenida de la iniciativa de los Ministerios de Sanidad y Consumo y de Ciencia e Innovación para constituir estructuras de apoyo a la investigación, y actualmente está integrada en la Red de Investigación Clínica Española (SCReN).

Fuente: .El Digital de Albacete. Disponible en https://bit.ly/3cLLHct

Covid-19: Avances en la investigación de la Ivermectina como posible cura

4 may. Desde la Universidad Nacional del Centro de la Provincia de Buenos Aires se informa de avances muy importantes en la concreción de un proyecto para evaluar el efecto antiviral del fármaco ivermectina frente a la COVID-19.

Según informó el Dr. Carlos Lanusse al Rector de la UNICEN, Cr. Roberto Tassara, las acciones y estado de avance incluyen la conformación de un Consorcio Científico Multicéntrico, el diseño de un proyecto de colaboración científica muy avanzado, como así también de la aprobación de un protocolo clínico por parte del Comité de Bioética y el ANMAT, entre otras cuestiones significativas.

En relación a ello, se ha conformado un Consorcio Científico Multicéntrico para realizar la investigación correspondiente (ensayo clínico en pacientes infectados), donde participan reconocidas instituciones/centros: Instituto de Investigaciones de Enfermedades Tropicales, de la Universidad Nacional de Salta, el Laboratorio de Farmacología,

CIVETAN, Facultad de Ciencias Veterinarias de la UNICEN, la Universidad Nacional de Quilmes, el Hospital Juan P. Garrahan, el Laboratorio ELEA-Phoenix S.A., la Fundación Mundo Sano y el Centro de Educación Médica e Investigaciones Clínicas (CEMIC).

Por otra parte, se ha diseñado en forma conjunta un proyecto de colaboración científica titulado "Evaluación del efecto antiviral del fármaco ivermectina contra el SARS-CoV-2", que incluye, entre otras cuestiones, el enorme desafío de evaluar la potencial acción de este fármaco en pacientes infectados y bajo estrictas condiciones controladas.

Esta Idea Proyecto ha sido una de las 50 seleccionadas -sobre más de 900 postulaciones- por parte de la Agencia Nacional de Promoción Científica y Tecnológica para ser financiada (tras la presentación de un proyecto completo y la documentación pertinente).

Asimismo, se ha avanzado en la aprobación del Protocolo Clínico para estos ensayos por parte del Comité de Bioética correspondiente y por parte del ANMAT (certificación pendiente pero con trámite muy avanzado). Esto es un paso crítico en el planteo experimental que se definió considerando que se utilizará un fármaco a niveles de dosificación diferentes a los usuales.

Aclara el Dr. Lanusse, que la situación amerita mucha cautela evitando generar expectativas desmesuradas, ya que deben ser científicamente corroboradas, si bien se ha generado un profundo interés a nivel mundial en relación a este tema, observado en la notable y creciente demanda internacional sobre información de aspectos farmacológicos de esta droga, ante la necesidad mundial de buscar alternativas para el tratamiento de la COVID-19.

Fuente: LA VOZ DE TANDIL. Disponible en https://bit.ly/36cUK3G

Investigador afirma que el SARS-CoV-2 daña la hemoglobina y que la hidroxicloroquina promete inmunidad contra el coronavirus

6 may. Una investigadora italiana de farmacología afirma que la COVID-19 daña la hemoglobina, afectando por ello la capacidad de los glóbulos rojos para transportar oxígeno por todo el cuerpo, afectando los pulmones y conduce al síndrome de dificultad respiratoria aguda (SDRA).



En una explicación de su tesis al periódico, The Jerusalem Post, Annalisa Chiusolo dijo que su teoría proporciona las respuestas a varias preguntas sobre el nuevo coronavirus, incluida la mayor vulnerabilidad demostrada por los hombres, particularmente los diabéticos, de enfermarse gravemente por el virus, así como la menor tasa de infección por el SARS-CoV-2 entre mujeres embarazadas y niños. Chiusolo cree que comprender este mecanismo puede allanar el camino para un descubrimiento más rápido de medicamentos altamente efectivos para tratar el virus.

Chiusolo, graduada de la Facultad de Farmacia de la Universidad de Perugia, Italia, y quien trabaja como farmacéutica en el país, ha publicado su teoría en algunos de los principales periódicos italianos. Según Chiusolo, el SARS-CoV-2 depende de las porfirinas para sobrevivir y posiblemente para replicarse, lo que hace que ataque la hemoglobina, la proteína que transporta oxígeno en la sangre, con el resultado de menos oxígeno disponible para el cuerpo. Como resultado de menos oxígeno, el dióxido de carbono se acumula. Chiusolo también evaluó el uso de la hidroxicloroquina para tratar el SARS-CoV-2 y descubrió que, además de tener un efecto antiviral e inmunomodulador, el fármaco se une a la ferriprotoporfirina del éster metílico de ecgonina (EME), bloqueando así la enzima clave de la malaria. La ferriprotoporfirina es el grupo responsable de la unión de la hemoglobina al oxígeno. Chiusolo cree que se puede utilizar un mecanismo similar contra el SARS-CoV-2. Su teoría es respaldada por un estudio realizado por una universidad china que demuestra que el SARS-CoV-2 se une a la cadena beta de la hemoglobina, inhibiendo así el metabolismo de la EME.

Según Chiusolo, la hidroxicloroquina podría actuar como profiláctico, evitando o limitando los síntomas de la COVID-19, mientras se formula una vacuna que estimula específicamente la respuesta de anticuerpos del cuerpo. Chiusolo cree que la hidroxicloroquina podría hacer que el paciente sea inmune al COVID-19 y/o limitar sus efectos secundarios, pero admitió que el medicamento tiene algunos efectos secundarios graves, especialmente entre los pacientes con enfermedades cardíacas.

Fuente: LabMedica. Disponible en https://bit.ly/2WOBNl6

EEUU aprobó que la vacuna de la compañía Moderna contra el coronavirus pase a la segunda fase de prueba

7 may. La Administración de Drogas y Alimentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó que la vacuna de la compañía Moderna para el coronavirus proceda a la fase dos de su estudio.

La información la dio a conocer la propia compañía este jueves en un comunicado de prensa, en el que indicó que se estima que la nueva fase comience en breve.

"La Administración de Drogas y Alimentos de los EEUU (FDA) completó su revisión de la solicitud de Investigación de Nuevos Medicamentos (IND) de la compañía para su nuevo candidato a la vacuna contra el coronavirus (SARS-CoV-2 o COVID-19) (ARNm-1273), que le permite pasar a la Fase 2 de estudio. Se espera que comience en breve. El protocolo de finalización para el estudio de Fase 3 del ARNm-1273, se espera que comience a principios del verano de 2020", indica el comunicado de Moderna.

La vacuna mRNA-1273 fue la primera norteamericana en comenzar las pruebas clínicas en Estados Unidos. El ensayo ayudará a los investigadores a evaluar si la vacuna es segura, quién produce la respuesta inmune más fuerte que podría defenderse de la cepa letal y cuál debería ser la dosis eficiente para tratar el mal.

Esta vacuna -como todas las que están en proceso- utiliza una tecnología basada en genes conocida como ARN mensajero. El ARN mensajero, o ARNm, lleva instrucciones del ADN a las células del cuerpo para producir ciertas proteínas. Una vacuna de ARNm nunca ha sido aprobada para prevenir enfermedades infecciosas.

La de Moderna no es la única que está en proceso

Pfizer anunció que aceleró los tiempos de su investigación para desarrollar una vacuna contra el nuevo coronavirus y, de ser las próximas etapas exitosas, podría tenerla lista para ser usada en casos de emergencia a partir del otoño boreal (finales de septiembre). La empresa, que está trabajando con BioNTech SE en el proyecto, ya había comenzado sus

pruebas en Alemania. E indicó que, de obtener aprobación oficial del Gobierno de los Estados Unidos, podría continuar con los testeos en su territorio a partir de la semana que viene.

"Esta es una crisis y todos necesitamos una solución de manera desesperada", indicó el CEO de la compañía, Albert Bourla.

Todas las líneas de tiempo consideradas normales en los procesos para desarrollar y aprobar vacunas han sido aceleradas significativamente como consecuencia del impacto de la pandemia. Un sinnúmero de autoridades sanitarias han advertido que el período mínimo para desarrollar una vacuna oscila entre los 12 y los 18 meses en el mejor de los casos. Y que el tiempo promedio entre la primera fase de testeo y su llegada al mercado es de casi 11 años, con una tasa de éxito del 6 por ciento.

Otro de los actores que ha anunciado progresos en su búsqueda de la vacuna es el Instituto Jenner de la Universidad de Oxford. En su caso, los científicos aseguraron que, en el escenario más optimista y con aprobaciones de emergencia, podrían tener las primeras millones de dosis en septiembre. "Esa es nuestra línea de tiempo. Será difícil de hacer, pero no imposible", dijo el director del instituto, Adrian Hill.

Fuente: infobae. Disponible en https://bit.ly/3e6xCXg

VaCyT SiViFinlay IFV INSTITUTO FINLAY DE VACUNAS

...vacunar es prevenir.

FINLAY EDICIONES

VACCI MONITOR

VacciMonitor es una revista con más de 25 años de difundir los resultados científicos sobre vacunas de instituciones nacionales e internacionales y así coadyuvar a la visibilidad de este sector de la ciencia en Cuba y otros países, principalmente de Hispanoamérica. **http://vaccimonitor.finlay.edu.cu**

Está dedicada a la Vacunología y se incluyen temáticas de Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Programas de Vacunaciones, Estudios Preclínicos y Clínicos, Biología molecular, Bioinformática, Biomodelos Experimentales, Inmunodiagnosticadores, Tecnologías de Producción, Validación, Aseguramiento de la Calidad y Aspectos regulatorios.

Arbitrada, de acceso abierto y bajo la Licencia Creative Commons está indexada en:

EBSCO Information Services

Scopus

DOAJ DIRECTORY OF OPEN ACCESS JOURNALS

SciELO

redalyc.org

WEB OF SCIENCE™

HINARI Research in Health

latindex Sistema Regional de Información en Línea para Revistas Científicas de América Latina, el Caribe, España y Portugal

SeCiMed

Artículos científicos publicados en Medline

Filters activated: Publication date from 2020/04/27 to 2020/05/08. "Vaccine" (Mesh)

1. The search for an HIV **vaccine**, the journey continues.

Dieffenbach CW, Fauci AS.

J Int AIDS Soc. 2020 May;23(5):e25506. doi: 10.1002/jia2.25506. No abstract available.

PMID: 32418357

2. Efficacy and safety of native and recombinant zona pellucida immunocontraceptive **vaccines** in donkeys.

French H, Peterson E, Schulman M, Roth R, Crampton M, Conan A, Marchi S, Knobel D, Bertschinger H.

Theriogenology. 2020 May 6;153:27-33. doi: 10.1016/j.theriogenology.2020.04.041. [Epub ahead of print]

PMID: 32417608

3. Efficient mucosal vaccination of a novel classical swine fever virus E2-Fc fusion protein mediated by neonatal Fc receptor.

Li J, Li X, Ma H, Ren X, Hao G, Zhang H, Zhao Z, Fang K, Li X, Rong Z, Sun S, Chen H, Qian P.

Vaccine. 2020 May 7. pii: S0264-410X(20)30631-9. doi: 10.1016/j.**vaccine**.2020.05.013. [Epub ahead of print]

PMID: 32417139

4. Mathematics for medical practitioners and patients: Understanding how **vaccines** work for the community.

Ramsay N, Sidhu H, Waters EK.

Aust J Gen Pract. 2020 May;49(5):293-294. No abstract available.

PMID: 32416656

5. Are we getting close to development of a universal influenza **vaccine**?

[No authors listed]

J Paediatr Child Health. 2020 May;56(5):824. doi: 10.1111/jpc.14815. No abstract available.

PMID: 32416044

6. What influenza vaccination programmes are preferred by healthcare personnel? A discrete choice experiment.

Liao Q, Ng TWY, Cowling BJ.

Vaccine. 2020 May 7. pii: S0264-410X(20)30630-7. doi: 10.1016/j.**vaccine**.2020.05.012. [Epub ahead of print]

PMID: 32414654

7. Comparison of Sheep, Goats, and Calves as Infection Models for Mycobacterium avium subsp. paratuberculosis.

Stabel JR, Bannantine JP, Hostetter JM.

Vet Immunol Immunopathol. 2020 May 5;225:110060. doi: 10.1016/j.vetimm.2020.110060. [Epub ahead of print]

PMID: 32413513

8. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.

Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Gou M, Li X, Sun L, Cao T, Wang P, Zhou C, Zhang R, Liang P, Guo H, Wang X, Qin CF, Chen F, Dong C.

Immunity. 2020 May 3. pii: S1074-7613(20)30181-3. doi: 10.1016/j.immuni.2020.04.023. [Epub ahead of print]

PMID: 32413330

9. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.

Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell

CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J; HCA Lung Biological Network. Electronic address: lung-network@humancellatlas.org; HCA Lung Biological Network.

Cell. 2020 Apr 27. pii: S0092-8674(20)30500-6. doi: 10.1016/j.cell.2020.04.035. [Epub ahead of print]

PMID: 32413319

10. SnapShot: COVID-19.

Oberfeld B, Achanta A, Carpenter K, Chen P, Gilette NM, Langat P, Said JT, Schiff AE, Zhou AS, Barczak AK, Pillai S.

Cell. 2020 May 14;181(4):954-954.e1. doi: 10.1016/j.cell.2020.04.013. Epub 2020 Apr 30.

PMID: 32413300

11. Immune Therapy Opportunities in Ovarian Cancer.

Kandalaft LE, Odunsi K, Coukos G.

Am Soc Clin Oncol Educ Book. 2020 May;40:1-13. doi: 10.1200/EDBK_280539.

PMID: 32412818

12. Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer **Vaccines**.

Solomon BJ, Beavis PA, Darcy PK.

Am Soc Clin Oncol Educ Book. 2020 May;40:1-6. doi: 10.1200/EDBK_281101.

PMID: 32412805

13. Increased Susceptibility of Cattle to Intranasal RVFV Infection.

Kroeker AL, Smid V, Embury-Hyatt C, Collignon B, Pinette M, Babiuk S, Pickering B.

Front Vet Sci. 2020 Apr 29;7:137. doi: 10.3389/fvets.2020.00137. eCollection 2020.

PMID: 32411730

14. Conjugation of Synthetic Trisaccharide of *Staphylococcus aureus* Type 8 Capsular Polysaccharide Elicits Antibodies Recognizing Intact Bacterium.

Zhao M, Qin C, Li L, Xie H, Ma B, Zhou Z, Yin J, Hu J.

Front Chem. 2020 Apr 28;8:258. doi: 10.3389/fchem.2020.00258. eCollection 2020.

PMID: 32411658

15. An Erythrocyte Membrane-Associated Antigen, PvTRAg-26 of *Plasmodium vivax*: A Study of Its Antigenicity and Immunogenicity.

Fan L, Xia J, Shen J, Fang Q, Xia H, Zheng M, Han JH, Han ET, Wang B, Xu Y.

Front Public Health. 2020 Apr 28;8:148. doi: 10.3389/fpubh.2020.00148. eCollection 2020.

PMID: 32411650

16. Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections.

Aid M, Ram DR, Bosinger SE, Barouch DH, Reeves RK.

Front Cell Infect Microbiol. 2020 Apr 29;10:194. doi: 10.3389/fcimb.2020.00194. eCollection 2020.

PMID: 32411625

17. A T3SS Regulator Mutant of *Vibrio alginolyticus* Affects Antibiotic Susceptibilities and Provides Significant Protection to *Danio rerio* as a Live Attenuated **Vaccine**.

Zhou S, Tu X, Pang H, Hoare R, Monaghan SJ, Luo J, Jian J.

Front Cell Infect Microbiol. 2020 Apr 28;10:183. doi: 10.3389/fcimb.2020.00183. eCollection 2020.

PMID: 32411620

18. Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.

Nelson PP, Rath BA, Fragkou PC, Antalis E, Tsiodras S, Skevaki C.

Front Cell Infect Microbiol. 2020 Apr 29;10:181. doi: 10.3389/fcimb.2020.00181. eCollection 2020. Review.

PMID: 32411619

19. Protection against a chlamydial respiratory challenge by a chimeric **vaccine** formulated with the *Chlamydia muridarum* major outer membrane protein variable domains using the *Neisseria lactamica* porin B as a scaffold.

Tifrea DF, Pal S, Fairman J, Massari P, de la Maza LM.

NPJ **Vaccines**. 2020 May 8;5:37. doi: 10.1038/s41541-020-0182-9. eCollection 2020.

PMID: 32411400

20. Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques.

Blasi M, Wescott EC, Baker EJ, Mildenberg B, LaBranche C, Rountree W, Haynes BF, Saunders KO, Moody MA, Negri D, Santra S, Cara A, Klotman ME.

NPJ **Vaccines**. 2020 May 8;5:36. doi: 10.1038/s41541-020-0186-5. eCollection 2020.

PMID: 32411399

21. Model of **vaccine** efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity.

Burn Aschner C, Knipe DM, Herold BC.

NPJ **Vaccines**. 2020 May 7;5:35. doi: 10.1038/s41541-020-0184-7. eCollection 2020.

PMID: 32411398

22. Recent advances in the epidemiology and prevention of *Streptococcus pneumoniae* infections.

Feldman C, Anderson R.

F1000Res. 2020 May 7;9. pii: F1000 Faculty Rev-338. doi: 10.12688/f1000research.22341.1. eCollection 2020. Review.

PMID: 32411353

23. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.

Joachim A, Ahmed MIM, Pollakis G, Rogers L, Hoffmann VS, Munseri P, Aboud S, Lyamuya EF, Bakari M, Robb ML, Wahren B, Sandstrom E, Nilsson C, Biberfeld G, Geldmacher C, Held K.

Front Immunol. 2020 Apr 28;11:719. doi: 10.3389/fimmu.2020.00719. eCollection 2020.

PMID: 32411138

24. Tracking of an Oral *Salmonella*-Based **Vaccine** for Type 1 Diabetes in Non-obese Diabetic Mice.

Mbongue JC, Alhoshani A, Rawson J, Garcia PA, Gonzalez N, Ferreri K, Kandeel F, Husseiny MI.

Front Immunol. 2020 Apr 28;11:712. doi: 10.3389/fimmu.2020.00712. eCollection 2020.

PMID: 32411136

25. [1]IFN-α Modulates Memory Tfh Cells and Memory B Cells in Mice, Following Recombinant FMDV Adenoviral Challenge.

Duan X, Sun P, Lan Y, Shen C, Zhang X, Hou S, Chen J, Ma B, Xia Y, Su C.

Front Immunol. 2020 Apr 29;11:701. doi: 10.3389/fimmu.2020.00701. eCollection 2020.

PMID: 32411135

26. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.

Shi T, Song X, Wang Y, Liu F, Wei J.

Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020. Review.

PMID: 32411132

27. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.

Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, Hung CF, Karakousis PC.

Front Immunol. 2020 Apr 28;11:680. doi: 10.3389/fimmu.2020.00680. eCollection 2020.

PMID: 32411131

28. The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection.

Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, van den Berg RA, Jongert E, Dover D, Sadoff J, Hendriks J, Gardner MJ, Ballou WR, Regules JA, van der Most R, Aderem A, Ockenhouse CF, Hill AV, Wille-Reece U, Zak DE.

Front Immunol. 2020 Apr 28;11:669. doi: 10.3389/fimmu.2020.00669. eCollection 2020.

PMID: 32411130

29. Expression of Two Foreign Genes by a Newcastle Disease Virus Vector From the Optimal Insertion Sites through a Combination of the ITU and IRES-Dependent Expression Approaches.

He L, Zhang Z, Yu Q.

Front Microbiol. 2020 Apr 28;11:769. doi: 10.3389/fmicb.2020.00769. eCollection 2020.

PMID: 32411112

30. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.

Dariya B, Nagaraju GP.

Cytokine Growth Factor Rev. 2020 May 6. pii: S1359-6101(20)30078-2. doi: 10.1016/j.cytogfr.2020.05.001. [Epub ahead of print] Review.

PMID: 32409230

31. A Review of Current Interventions for COVID-19 Prevention.

Pradhan D, Biswasroy P, Kumar Naik P, Ghosh G, Rath G.

Arch Med Res. 2020 Apr 30. pii: S0188-4409(20)30615-9. doi: 10.1016/j.arcmed.2020.04.020. [Epub ahead of print] Review.

PMID: 32409144

32. In vitro characterization and immunogenicity of chitosan nanoparticles loaded with native and inactivated extracellular proteins from a field strain of Clostridium perfringens associated with necrotic enteritis.

Akerele G, Ramadan N, Renu S, Renukaradhya GJ, Shanmugasundaram R, Selvaraj RK.

Vet Immunol Immunopathol. 2020 Jun;224:110059. doi: 10.1016/j.vetimm.2020.110059. Epub 2020 Apr 30.

PMID: 32408182

33. **Vaccine** hesitancy is strongly associated with distrust of conventional medicine, and only weakly associated with trust in alternative medicine.

Hornsey MJ, Lobera J, Díaz-Catalán C.

Soc Sci Med. 2020 May 5;255:113019. doi: 10.1016/j.socscimed.2020.113019. [Epub ahead of print]

PMID: 32408085

34. Development and validation of serological markers for detecting recent Plasmodium vivax infection.

Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, Obadia T, Robinson LJ, Matsuura F, Liu ZSJ, Li-Wai-Suen CSN, Tham WH, Healer J, Huon C, Chitnis CE, Nguitragool W, Monteiro W, Proietti C, Doolan DL, Siqueira AM, Ding XC, Gonzalez IJ, Kazura J, Lacerda M, Sattabongkot J, Tsuboi T, Mueller I.

Nat Med. 2020 May;26(5):741-749. doi: 10.1038/s41591-020-0841-4. Epub 2020 May 11.

PMID: 32405064

35. Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunity.

Moyer TJ, Kato Y, Abraham W, Chang JYH, Kulp DW, Watson N, Turner HL, Menis S, Abbott RK, Bhiman JN, Melo MB, Simon HA, Herrera-De la Mata S, Liang S, Seumois G, Agarwal Y, Li N, Burton DR, Ward AB, Schief WR, Crotty S, Irvine DJ.

Nat Med. 2020 May;26(5):804. doi: 10.1038/s41591-020-0861-0.

PMID: 32405059

36. Coronavirus drugs trials must get bigger and more collaborative.

[No authors listed]

Nature. 2020 May;581(7807):120. doi: 10.1038/d41586-020-01391-9. No abstract available.

PMID: 32405023

37. Biomolecular uptake effects on chitosan/tripolyphosphate micro- and nanoparticle stability.

Cai Y, Lapitsky Y.

Colloids Surf B Biointerfaces. 2020 Apr 28;193:111081. doi: 10.1016/j.colsurfb.2020.111081. [Epub ahead of print]

PMID: 32403037

38. Therapeutic potential of Nitazoxanide against Newcastle disease virus: A possible modulation of host cytokines.

Antony F, Vashi Y, Morla S, Vandna, Mohan H, Kumar S.

Cytokine. 2020 May 3;131:155115. doi: 10.1016/j.cyto.2020.155115. [Epub ahead of print]

PMID: 32403005

39. Large-scale seroprevalence and risk factors associated with Bluetongue virus in Iran.

Bakhshesh M, Otarod V, Fallah Mehrabadi MH.

Prev Vet Med. 2020 Apr 30;179:104994. doi: 10.1016/j.prevetmed.2020.104994. [Epub ahead of print]

PMID: 32402914

40. Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?

Grimm C, Tang R.

Cell Calcium. 2020 May 6;88:102212. doi: 10.1016/j.ceca.2020.102212. [Epub ahead of print]

PMID: 32402856

41. Preface.

Koff WC.

Vaccine. 2020 May 8. pii: S0264-410X(20)30562-4. doi: 10.1016/j.**vaccine**.2020.04.058. [Epub ahead of print] No abstract available.

PMID: 32402757

42. Parents' receptiveness to oral health clinic-based vaccination.

Dean TC, Gilliland AE, Cameron JE.

Vaccine. 2020 May 8. pii: S0264-410X(20)30535-1. doi: 10.1016/j.**vaccine**.2020.03.062. [Epub ahead of print]

PMID: 32402756

43. Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein.

Atcheson E, Reyes-Sandoval A.

Vaccine. 2020 May 8. pii: S0264-410X(20)30559-4. doi: 10.1016/j.**vaccine**.2020.03.063. [Epub ahead of print]

PMID: 32402755

44. Routine immunization coverage in Pakistan: a survey of children under 1 year of age in community-based vaccination areas.

Sreevatsava M, Burman AL, Wahdan A, Safdar RM, O'Leary A, Amjad R, Salam A, Quershi M, Ishaq R, Khan J, Khan J, Parker EPK, Sheikh Mahamud A, Ahmed J.

Vaccine. 2020 May 8. pii: S0264-410X(20)30585-5. doi: 10.1016/j.**vaccine**.2020.04.068. [Epub ahead of print]

PMID: 32402754

45. A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies **vaccines**.

Morgenroth A, Jakel V, Hanke-Robinson H, Müller T, Freuling C, Cussler K, Duchow K, Krämer B, Bastian M.

Vaccine. 2020 May 8. pii: S0264-410X(20)30561-2. doi: 10.1016/j.**vaccine**.2020.04.057. [Epub ahead of print]

PMID: 32402753

46. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate **vaccine**.

Kaur R, Pichichero M.

Vaccine. 2020 May 8. pii: S0264-410X(20)30580-6. doi: 10.1016/j.**vaccine**.2020.04.063. [Epub ahead of print]

PMID: 32402752

47. Effectiveness of quadrivalent influenza **vaccine** in pregnant women and infants, 2018-2019.

Maltezou HC, Asimakopoulos G, Stavrou S, Daskalakis G, Koutroumanis P, Sindos M, Theodora M, Katerelos P, Kostis E, Gavrili S, Kossyvakis A, Theodoridou M, Mentis A, Drakakis P, Loutradis D, Rodolakis A.

Vaccine. 2020 May 8. pii: S0264-410X(20)30564-8. doi: 10.1016/j.**vaccine**.2020.04.060. [Epub ahead of print]

PMID: 32402751

48. Salmonella Enteritidis ghost **vaccine** carrying the hemagglutinin globular head (HA1) domain from H1N1 virus protects against salmonellosis and influenza in chickens.

Won G, Senevirathne A, Lee JH.

Vaccine. 2020 May 8. pii: S0264-410X(20)30594-6. doi: 10.1016/j.**vaccine**.2020.04.077. [Epub ahead of print]

PMID: 32402750

49. Atopic dermatitis incidence and risk factors in young adults in Castellon (Spain): A prospective cohort study.

Arnedo-Pena A, Puig-Barberà J, Artero-Civera A, Romeu-Garcia MA, Meseguer-Ferrer N, Fenollosa-Amposta C, Vizcaino-Batllés A, Silvestre-Silvester E, Pac-Sa MR, Segura-Navas L, Dubón MA, Fabregat-Puerto J, Bellido-Blasco JB.

Allergol Immunopathol (Madr). 2020 May 8. pii: S0301-0546(20)30062-8. doi: 10.1016/j.aller.2020.01.004. [Epub ahead of print]

PMID: 32402624

50. Functional characterization of a glutathione S-transferase in Trichinella spiralis invasion, development and reproduction.

Yang DQ, Liu F, Bai Y, Zeng J, Hao HN, Yue X, Hu CX, Long SR, Liu RD, Wang ZQ, Cui J.

Vet Parasitol. 2020 May 5:109128. doi: 10.1016/j.vetpar.2020.109128. [Epub ahead of print]

PMID: 32402492

51. Detection of a gE-deleted Pseudorabies virus strain in an Italian red fox.

Moreno A, Chiapponi C, Sozzi E, Morelli A, Silenzi V, Gobbi M, Lavazza A, Paniccià M.

Vet Microbiol. 2020 May;244:108666. doi: 10.1016/j.vetmic.2020.108666. Epub 2020 Apr 11.

PMID: 32402347

52. Characterization of ten paramyxovirus type 1 viruses isolated from pigeons in China during 1996-2019.

Tian Y, Xue R, Yang W, Li Y, Xue J, Zhang G.

Vet Microbiol. 2020 May;244:108661. doi: 10.1016/j.vetmic.2020.108661. Epub 2020 Mar 27.

PMID: 32402346

53. Inducing cellular immune responses with a marked Mycobacterium avium subsp. paratuberculosis strain in dairy calves.

Luo L, De Buck J.

Vet Microbiol. 2020 May;244:108665. doi: 10.1016/j.vetmic.2020.108665. Epub 2020 Apr 11.

PMID: 32402345

54. PCV2 co-infection does not impact PRRSV MLV1 safety but enhances virulence of a PRRSV MLV1-like strain in infected SPF pigs.

Eclercy J, Larcher T, Andraud M, Renson P, Bernard C, Bigault L, Ledevin M, Paboeuf F, Grasland B, Rose N, Bourry O.

Vet Microbiol. 2020 May;244:108656. doi: 10.1016/j.vetmic.2020.108656. Epub 2020 Mar 24.

PMID: 32402344

55. Characterization of Pasteurella multocida isolates from rabbits in China.

Zhu W, Fan Z, Qiu R, Chen L, Wei H, Hu B, Chen M, Wang F.

Vet Microbiol. 2020 May;244:108649. doi: 10.1016/j.vetmic.2020.108649. Epub 2020 Mar 19.

PMID: 32402342

56. Challenge studies for registration of canine core **vaccines**: is it time to update the European Pharmacopeia?

Decaro N, Elia G, Buonavoglia C.

Vet Microbiol. 2020 May;244:108659. doi: 10.1016/j.vetmic.2020.108659. Epub 2020 Apr 13. No abstract available.

PMID: 32402341

57. Vertical transmission of ALV from ALV-J positive parents caused severe immunosuppression and significantly reduced marek's disease **vaccine** efficacy in three-yellow chickens.

Wang P, Lin L, Shi M, Li H, Gu Z, Li M, Gao Y, Teng H, Mo M, Wei T, Wei P.

Vet Microbiol. 2020 May;244:108683. doi: 10.1016/j.vetmic.2020.108683. Epub 2020 Apr 17.

PMID: 32402336

58. Immune response and protective efficacy of intramuscular and intradermal vaccination with porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) modified live **vaccine** against highly pathogenic PRRSV-2 (HP-PRRSV-2) challenge, either alone or in combination with of PRRSV-1.

Madapong A, Saeng-Chuto K, Chaikhumwang P, Tantituvanont A, Saardrak K, Pedrazuela Sanz R, Miranda Alvarez J, Nilubol D.

Vet Microbiol. 2020 May;244:108655. doi: 10.1016/j.vetmic.2020.108655. Epub 2020 Mar 27.

PMID: 32402335

59. The first complete genome sequence and pathogenicity characterization of fowl adenovirus 11 from chickens with inclusion body hepatitis in Pakistan.

Wang J, Zaheer I, Saleemi MK, Qi X, Gao Y, Cui H, Li K, Gao L, Fayyaz A, Hussain A, Liu C, Zhang Y, Wang X, Pan Q.

Vet Microbiol. 2020 May;244:108670. doi: 10.1016/j.vetmic.2020.108670. Epub 2020 Apr 14.

PMID: 32402334

60. Mycoplasma gallisepticum strain ts-304 is a safe and effective live attenuated **vaccine** for use in chickens.

Kanci Condello A, Underwood GJ, Shil PK, Noormohammadi AH, Markham PF, Wawegama NK, Browning GF.

Vet Microbiol. 2020 May;244:108654. doi: 10.1016/j.vetmic.2020.108654. Epub 2020 Mar 23.

PMID: 32402331

61. Physical wastage of immunobiological products in the state of Ceará, Brazil, 2014-2016.

Seabra Filho FT, Moura ADA, Braga AVL, Jereissati NCC, Câncio KS, Silva MGCD.

Epidemiol Serv Saude. 2020;29(2):e2019004. doi: 10.5123/51679-49742020000200003. Epub 2020 May 8. English, Portuguese.

PMID: 32401882

62. Human **Vaccines** & Immunotherapeutics: news.

[No authors listed]

Hum Vaccin Immunother. 2020 May 3;16(5):1003. doi: 10.1080/21645515.2020.1754079. No abstract available.

PMID: 32401682

63. Building **vaccine** acceptance through communication and advocacy.

Feemster KA.

Hum Vaccin Immunother. 2020 May 3;16(5):1004-1006. doi: 10.1080/21645515.2020.1746603. No abstract available.

PMID: 32401681

64. Coronavirus disease (COVID-19) - impact on **vaccine** preventable diseases.

Hungerford D, Cunliffe NA.

Euro Surveill. 2020 May;25(18). doi: 10.2807/1560-7917.ES.2020.25.18.2000756. No abstract available.

PMID: 32400359

65. Recent advances in influenza **vaccines**.

Pawelec G, McElhaney J.

F1000Res. 2020 Apr 28;9. pii: F1000 Faculty Rev-305. doi: 10.12688/f1000research.22611.1. eCollection 2020. Review.

PMID: 32399192

66. Malaria **vaccines**: facing unknowns.

Palacpac NMQ, Horii T.

F1000Res. 2020 Apr 27;9. pii: F1000 Faculty Rev-296. doi: 10.12688/f1000research.22143.1. eCollection 2020. Review.

PMID: 32399189

67. The immune response to influenza in older humans: beyond immune senescence.

McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G.

Immun Ageing. 2020 May 7;17:10. doi: 10.1186/s12979-020-00181-1. eCollection 2020. Review.

PMID: 32399058

68. Aboard the LetB express.

Powers MJ, Trent MS.

Nat Struct Mol Biol. 2020 May;27(5):403-405. doi: 10.1038/s41594-020-0431-7. No abstract available.

PMID: 32398824

69. Diminished Co-inhibitory Molecule 2B4 expression is Associated with Preserved iNKT cell Phenotype in HIV Long-term Non-progressors.

Ansari AW, Ahmad F, Shankar EM, Kong YY, Tan HY, Jacobs R, Larsson M, Velu V, Kamarulzaman A, Schmidt RE.

J Acquir Immune Defic Syndr. 2020 May 7. doi: 10.1097/QAI.0000000000002399. [Epub ahead of print]

PMID: 32398557

70. Seasonal drivers of tuberculosis: evidence from over 100 years of notifications in Cape Town.

Andrews JR, Cobelens F, Horsburgh CR, Hatherill M, Basu S, Hermans S, Wood R.

Int J Tuberc Lung Dis. 2020 May 1;24(5):477-484. doi: 10.5588/ijtld.19.0274.

PMID: 32398196

71. Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA **Vaccines**.

Anderluzzi G, Lou G, Gallorini S, Brazzoli M, Johnson R, O'Hagan DT, Baudner BC, Perrie Y.

Vaccines (Basel). 2020 May 8;8(2). pii: E212. doi: 10.3390/vaccines8020212.

PMID: 32397231

72. The Effects of Pre-Existing Antibodies on Live-Attenuated Viral **Vaccines**.

Mok DZL, Chan KR.

Viruses. 2020 May 8;12(5). pii: E520. doi: 10.3390/v12050520. Review.

PMID: 32397218

73. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 **Vaccine** Development.

Pushko P, Tretyakova I.

Viruses. 2020 May 8;12(5). pii: E518. doi: 10.3390/v12050518. Review.

PMID: 32397182

74. TRiC/CCT Complex, a Binding Partner of NS1 Protein, Supports the Replication of Zika Virus in Both Mammalians and Mosquitoes.

Wang Y, Uraki R, Hwang J, Fikrig E.

Viruses. 2020 May 8;12(5). pii: E519. doi: 10.3390/v12050519.

PMID: 32397176

75. Where do we Stand after Decades of Studying Human Cytomegalovirus?

Gugliesi F, Coscia A, Griffante G, Galitska G, Pasquero S, Albano C, Biolatti M.

Microorganisms. 2020 May 8;8(5). pii: E685. doi: 10.3390/microorganisms8050685. Review.

PMID: 32397070

76. Salmonella Typhoid Toxin PltB Subunit and Its Non-typhoidal Salmonella Ortholog Confer Differential Host Adaptation and Virulence.

Lee S, Yang YA, Milano SK, Nguyen T, Ahn C, Sim JH, Thompson AJ, Hillpot EC, Yoo G, Paulson JC, Song J.

Cell Host Microbe. 2020 May 5. pii: S1931-3128(20)30232-8. doi: 10.1016/j.chom.2020.04.005. [Epub ahead of print]

PMID: 32396840

77. A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver T_{RM} Cell-Mediated Immunity against Malaria in Mice.

Valencia-Hernandez AM, Ng WY, Ghazanfari N, Ghilas S, de Menezes MN, Holz LE, Huang C, English K, Naung M, Tan PS, Tullett KM, Steiner TM, Enders MH, Beattie L, Chua YC, Jones CM, Cozijnsen A, Mollard V, Cai Y, Bowen DG, Purcell AW, La Gruta NL, Villadangos JA, de Koning-Ward T, Barry AE,

Barchet W, Cockburn IA, McFadden GI, Gras S, Lahoud MH, Bertolino P, Schittenhelm RB, Caminschi I, Heath WR, Fernandez-Ruiz D.

Cell Host Microbe. 2020 May 6. pii: S1931-3128(20)30237-7. doi: 10.1016/j.chom.2020.04.010. [Epub ahead of print]

PMID: 32396839

78. [Measles vaccination: why and how?]

Rümke HC, Ruitenberg EJ.

Ned Tijdschr Geneeskd. 2020 May 7;164. pii: D4773. Dutch.

PMID: 32395946

79. Successful intervention for overwhelming postsplenectomy infection caused by non-**vaccine** pneumococcal serotype 23A.

Kojima Y, Ikeda K, Matsumura A, Shimohama S, Chang B, Yoshida T, Hamada K, Ito A, Ito T.

Oxf Med Case Reports. 2020 May 6;2020(3):omaa018. doi: 10.1093/omcr/omaa018. eCollection 2020 Mar.

PMID: 32395252

80. Free and perfectly safe but only partially effective **vaccines** can harm everyone.

Talamàs E, Vohra R.

Games Econ Behav. 2020 May 8. doi: 10.1016/j.geb.2020.05.001. [Epub ahead of print]

PMID: 32395013

81. Pandemic Influenza **Vaccines**: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?

Rockman S, Laurie K, Barr I.

Vaccines (Basel). 2020 May 7;8(2). pii: E211. doi: 10.3390/vaccines8020211.

PMID: 32392812

82. Opsonic Activity of Conservative Versus Variable Regions of the Group A *Streptococcus* M Protein.

Dai C, Khalil ZG, Hussein WM, Yang J, Wang X, Zhao L, Capon RJ, Toth I, Stephenson RJ.

Vaccines (Basel). 2020 May 7;8(2). pii: E210. doi: 10.3390/vaccines8020210.

PMID: 32392777

83. The Bioinformatic and In Vitro Studies of Clostridioides Difficile Aminopeptidase M24 Revealed the Immunoreactive KKGIK Peptide.

Pacyga K, Razim A, Martirosian G, Aptekorz M, Szuba A, Gamian A, Myc A, Górska S.

Cells. 2020 May 7;9(5). pii: E1146. doi: 10.3390/cells9051146.

PMID: 32392707

84. A critical review speculating on the protective efficacies of autogenous *Streptococcus suis* bacterins as used in Europe.

Rieckmann K, Pendzialek SM, Vahlenkamp T, Baums CG.

Porcine Health Manag. 2020 May 6;6:12. doi: 10.1186/s40813-020-00150-6. eCollection 2020. Review.

PMID: 32391166

85. Comparison of *Mycoplasma hyopneumoniae* and porcine circovirus 2 commercial **vaccines** efficacy when applied separate or combined under experimental conditions.

Sibila M, Guevara G, Cuadrado R, Pleguezuelos P, Pérez D, Pérez de Rozas A, Huerta E, Llorens A, Valero O, Pérez M, López C, Krejci R, Segalés J.

Porcine Health Manag. 2020 May 4;6:11. doi: 10.1186/s40813-020-00148-0. eCollection 2020.

PMID: 32391165

86. Characterization of Chlamydia trachomatis ompA Genotypes Among Sexually Transmitted Disease Patients in Korea.

Chung Y, Han M, Park JY, Kim I, Kim JS.

Clin Lab. 2020 May 1;66(5). doi: 10.7754/Clin.Lab.2019.191018.

PMID: 32390381

87. Antiviral activity of furanocoumarins isolated from Angelica dahurica against influenza a viruses H1N1 and H9N2.

Lee BW, Ha TK, Cho HM, An JP, Kim SK, Kim CS, Kim E, Oh WK.

J Ethnopharmacol. 2020 May 7:112945. doi: 10.1016/j.jep.2020.112945. [Epub ahead of print]

PMID: 32389854

88. Strengthening screening for infectious diseases and vaccination among migrants in Europe: What is needed to close the implementation gaps?

Noori T, Hargreaves S, Greenaway C, van der Werf M, Driedger M, Morton RL, Hui C, Requena-Mendez A, Agbata E, Myran DT, Pareek M, Campos-Matos I, Nielsen RT, Semenza J, Nellums LB, Pottie K; ECDC ad hoc scientific panel.

Travel Med Infect Dis. 2020 May 7:101715. doi: 10.1016/j.tmaid.2020.101715. [Epub ahead of print]

PMID: 32389827

89. The interaction between pubertal timing and childhood maltreatment on the risk of human papillomavirus infection among adolescent girls and young women.

Niu L, Hoyt LT, Salandy A, Nucci-Sack A, Shankar V, Strickler H, Burk RD, Schlecht NF, Diaz A.

Prev Med. 2020 May 7:106126. doi: 10.1016/j.ypmed.2020.106126. [Epub ahead of print]

PMID: 32389680

90. Impact of a **vaccine** intervention on county-level rates of acute hepatitis B in West Virginia, 2011-2018.

Tressler SR, Smith GS, Hendricks B.

Prev Med. 2020 May 7:106121. doi: 10.1016/j.ypmed.2020.106121. [Epub ahead of print]

PMID: 32389678

91. Exploring the early phase of implementation of a **vaccine**-based clinical decision support system in the community pharmacy.

Frederick KD, Gatwood JD, Atchley DR, Rein LJ, Ali SG, Brookhart AL, Crain J, Hagemann TM, Ramachandran S, Chiu CY, Hohmeier KC.

J Am Pharm Assoc (2003). 2020 May 7. pii: S1544-3191(20)30154-0. doi: 10.1016/j.japh.2020.03.024. [Epub ahead of print]

PMID: 32389555

92. Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster **Vaccine**.

Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL.

Am J Prev Med. 2020 Apr 30. pii: S0749-3797(20)30081-7. doi: 10.1016/j.amepre.2020.01.017. [Epub ahead of print]

PMID: 32389533

93. Human challenge trial workshop: Focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019.

Bekeredjian-Ding I, Van Molle W, Baay M, Neels P; PEI speakers and session chairs, Conrad C, van Diepen A, Fortune S, Goetz K, Gorringe A, Hoft D, Johnson RA, Kremsner P, Krut O, Levy Y, Metzger W, Oeppling V, Stibitz S, Talaat KR, Thomas S, Wildfire A, Yakubu BN.

Biologicals. 2020 May 4. pii: S1045-1056(20)30045-2. doi: 10.1016/j.biologicals.2020.04.005. [Epub ahead of print]

PMID: 32389512

94. Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies.

Webber C, Peyrani P, Balmer P, Serra L.

Vaccine. 2020 May 7. pii: S0264-410X(20)30260-7. doi: 10.1016/j.**vaccine**.2020.02.048. [Epub ahead of print] Review.

PMID: 32389497

95. Dissociation of TRIF bias and adjuvanticity.

Richard K, Perkins DJ, Harberts EM, Song Y, Gopalakrishnan A, Shirey KA, Lai W, Vlk A, Mahurkar A, Nallar S, Hawkins LD, Ernst RK, Vogel SN.

Vaccine. 2020 May 7. pii: S0264-410X(20)30536-3. doi: 10.1016/j.**vaccine**.2020.04.042. [Epub ahead of print]

PMID: 32389496

96. Antibody responses to influenza A(H1N1)pdm infection.

Wraith S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Rajabhathor A, Lopez R, Guglia AF, Sanchez N, Amanat F, Gresh L, Kuan G, Krammer F, Gordon A.

Vaccine. 2020 May 7. pii: S0264-410X(20)30586-7. doi: 10.1016/j.**vaccine**.2020.04.069. [Epub ahead of print]

PMID: 32389495

97. Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.

Tempia S, Walaza S, Moyes J, McMorrow ML, Cohen AL, Edoka I, Fraser H, Treurnicht FK, Hellferscee O, Wolter N, von Gottberg A, McAnerney JM, Dawood H, Variava E, Cohen C.

Vaccine. 2020 May 7. pii: S0264-410X(20)30539-9. doi: 10.1016/j.**vaccine**.2020.04.045. [Epub ahead of print]

PMID: 32389494

98. DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment.

Kumar A, Pandey SC, Samant M.

Acta Trop. 2020 May 7:105512. doi: 10.1016/j.actatropica.2020.105512. [Epub ahead of print] Review.

PMID: 32389452

99. [Cellular immunity evaluation of five mycobacterium tuberculosis recombinant proteins and their compositions].

Yan YH, Li MC, Liu HC, Xiao TY, Li N, Lou YL, Wan KL.

Zhonghua Yu Fang Yi Xue Za Zhi. 2020 May 6;54(5):539-545. doi: 10.3760/cma.j.cn112150-20191119-00872. Chinese.

PMID: 32388956

100. Is copper beneficial for COVID-19 patients?

Raha S, Mallick R, Basak S, Duttaroy AK.

Med Hypotheses. 2020 May 5;142:109814. doi: 10.1016/j.mehy.2020.109814. [Epub ahead of print]

PMID: 32388476

101. Intracellular delivery of drugs by chitosan-based multi-liposomal complexes.

Grozdova I, Melik-Nubarov N, Efimova A, Ezhov A, Krivtsov G, Litmanovich E, Yaroslavov A.

Colloids Surf B Biointerfaces. 2020 May 5;193:111062. doi: 10.1016/j.colsurfb.2020.111062. [Epub ahead of print]

PMID: 32388392

102. Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.

Tamminen K, Heinimäki S, Gröhn S, Blazevic V.

Mol Immunol. 2020 May 7;123:26-31. doi: 10.1016/j.molimm.2020.04.001. [Epub ahead of print]

PMID: 32388275

103. Dynamic proteomic analysis of Phanerochaete chrysosporium under copper stress.

Okay S, Yildirim V, Büttner K, Becher D, Özcengiz G.

Ecotoxicol Environ Saf. 2020 Jul 15;198:110694. doi: 10.1016/j.ecoenv.2020.110694. Epub 2020 May 7.

PMID: 32388186

104. Methylprednisolone pulse therapy in 31 patients with refractory epilepsy: A single-center retrospective analysis.

Kimizu T, Takahashi Y, Oboshi T, Horino A, Omatsu H, Koike T, Yoshitomi S, Yamaguchi T, Otani H, Ikeda H, Imai K, Shigematsu H.

Epilepsy Behav. 2020 May 6;109:107116. doi: 10.1016/j.yebeh.2020.107116. [Epub ahead of print]

PMID: 32388139

105. Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context.

Paital B.

Sci Total Environ. 2020 Apr 29;729:139088. doi: 10.1016/j.scitotenv.2020.139088. [Epub ahead of print] Review.

PMID: 32388136

106. Distinctive cellular response to aluminum based adjuvants.

Nies I, Hidalgo K, Bondy SC, Campbell A.

Environ Toxicol Pharmacol. 2020 Apr 29;78:103404. doi: 10.1016/j.etap.2020.103404. [Epub ahead of print]

PMID: 32388105

107. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.

Pandey K, Mifsud NA, Lim Kam Sian TCC, Ayala R, Ternette N, Ramarathinam SH, Purcell AW.

Mol Immunol. 2020 May 5;123:7-17. doi: 10.1016/j.molimm.2020.04.008. [Epub ahead of print]

PMID: 32387766

108. Designing a **vaccine** for fascioliasis using immunogenic 24 kDa mu-class glutathione s-transferase.

Kalita J, Padhi AK, Tripathi T.

Infect Genet Evol. 2020 May 7;83:104352. doi: 10.1016/j.meegid.2020.104352. [Epub ahead of print]

PMID: 32387753

109. Rational application of nanoadjuvant for mucosal **vaccine** delivery system.

Dewangan HK.

J Immunol Methods. 2020 May 6:112791. doi: 10.1016/j.jim.2020.112791. [Epub ahead of print] Review.

PMID: 32387695

110. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, Memish ZA.

Travel Med Infect Dis. 2020 May 6:101735. doi: 10.1016/j.tmaid.2020.101735. [Epub ahead of print] Review.

PMID: 32387694

111. Human Papilloma Virus (HPV) and Vaccination.

Erden F, Karagoz H.

J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30823-9. doi: 10.1016/j.jaad.2020.04.167. [Epub ahead of print] No abstract available.

PMID: 32387667

112. Manganese complex $[Mn(CO)_3(tpa-\kappa^3N)]Br$ increases antibiotic sensitivity in multidrug resistant Streptococcus pneumoniae.

Liakopoulos A, La Ragione RM, Nagel C, Schatzschneider U, Rozen DE, Betts JW.

J Glob Antimicrob Resist. 2020 May 6. pii: S2213-7165(20)30124-7. doi: 10.1016/j.jgar.2020.04.031. [Epub ahead of print]

PMID: 32387640

113. COVID-19: the First Documented Coronavirus Pandemic in History.

Liu YC, Kuo RL, Shih SR.

Biomed J. 2020 May 5. pii: S2319-4170(20)30044-5. doi: 10.1016/j.bj.2020.04.007. [Epub ahead of print]

PMID: 32387617

114. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2.

van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, Owen CJ, Pang J, Tan CCS, Boshier FAT, Ortiz AT, Balloux F.

Infect Genet Evol. 2020 May 5:104351. doi: 10.1016/j.meegid.2020.104351. [Epub ahead of print]

PMID: 32387564

115. Characterization of the Japanese flounder NLRP3 inflammasome in restricting Edwardsiella piscicida colonization in vivo.

Chen H, Ding S, Tan J, Yang D, Zhang Y, Liu Q.

Fish Shellfish Immunol. 2020 May 6. pii: S1050-4648(20)30309-0. doi: 10.1016/j.fsi.2020.04.063. [Epub ahead of print]

PMID: 32387560

116. Urban-rural differences in immune responses to mycobacterial and tetanus **vaccine** antigens in a tropical setting: A role for helminths?

Kabagenyi J, Natukunda A, Nassuuna J, Sanya RE, Nampijja M, Webb EL, Elliott AM, Nkurunungi G.

Parasitol Int. 2020 May 5:102132. doi: 10.1016/j.parint.2020.102132. [Epub ahead of print]

PMID: 32387542

117. Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.

Salinas FM, Nebreda AD, Vázquez L, Gentilini MV, Marini V, Benedetti M, Nabaes Jodar MS, Viegas M, Shayo C, Bueno CA.

Antiviral Res. 2020 May 6;179:104817. doi: 10.1016/j.antiviral.2020.104817. [Epub ahead of print]

PMID: 32387475

118. Inducible expression of antigens in plants: a study focused on peptides related to multiple sclerosis immunotherapy.

Arevalo-Villalobos JI, Govea-Alonso DO, Bañuelos-Hernández B, González-Ortega O, Zarazúa S, Rosales-Mendoza S.

J Biotechnol. 2020 May 5. pii: S0168-1656(20)30076-6. doi: 10.1016/j.jbiotec.2020.03.013. [Epub ahead of print]

PMID: 32387449

119. Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.

Hanvatananukul P, Prasarakee C, Sarachai S, Aurpibul L, Sintupat K, Khampan R, Saheng J, Sudjaritruk T.

Int J Infect Dis. 2020 May 6. pii: S1201-9712(20)30304-0. doi: 10.1016/j.ijid.2020.04.088. [Epub ahead of print]

PMID: 32387447

120. Genetic variation in IL-10 influences the progression of hepatitis B infection.

Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP.

Int J Infect Dis. 2020 May 6. pii: S1201-9712(20)30297-6. doi: 10.1016/j.ijid.2020.04.079. [Epub ahead of print]

PMID: 32387446

121. Varicella seroepidemiology and immunization in a cohort of future healthcare workers in the pre-vaccination era.

Trevisan A, Nicolli A, De Nuzzo D, Lago L, Artuso E, Maso S.

Int J Infect Dis. 2020 May 5. pii: S1201-9712(20)30298-8. doi: 10.1016/j.ijid.2020.04.082. [Epub ahead of print]

PMID: 32387376

122. Current development of COVID-19 diagnostics, **vaccines** and therapeutics.

Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S.

Microbes Infect. 2020 May 6. pii: S1286-4579(20)30079-4. doi: 10.1016/j.micinf.2020.05.001. [Epub ahead of print]

PMID: 32387332

123. A plant-derived cocaine hydrolase prevents cocaine overdose lethality and attenuates cocaine-induced drug seeking behavior.

Larrimore KE, Kannan L, Kendle RP, Jamal T, Barcus M, Stefanko K, Kilbourne J, Brimijoin S, Zhan CG, Neisewander J, Mor TS.

Prog Neuropsychopharmacol Biol Psychiatry. 2020 May 6:109961. doi: 10.1016/j.pnpbp.2020.109961. [Epub ahead of print]

PMID: 32387315

124. A Machine Learning Approach to Management of Heart Failure Populations.

Jing L, Ulloa Cerna AE, Good CW, Sauers NM, Schneider G, Hartzel DN, Leader JB, Kirchner HL, Hu Y, Riviello DM, Stough JV, Gazes S, Haggerty A, Raghunath S, Carry BJ, Haggerty CM, Fornwalt BK.

JACC Heart Fail. 2020 Apr 29. pii: S2213-1779(20)30138-4. doi: 10.1016/j.jchf.2020.01.012. [Epub ahead of print]

PMID: 32387064

125. COVID-19 and Moral Imperialism in Multinational Clinical Research.

Hellmann F, Williams-Jones B, Garrafa V.

Arch Med Res. 2020 Apr 29. pii: S0188-4409(20)30571-3. doi: 10.1016/j.arcmed.2020.04.017. [Epub ahead of print]

PMID: 32387041

126. Intent to obtain pediatric influenza **vaccine** among mothers in four middle income countries.

Wagner AL, Gordon A, Tallo VL, Simaku A, Porter RM, Edwards LJ, Duka E, Abu-Khader I, Gresh L, Sciuto C, Azziz-Baumgartner E, Bino S, Sanchez F, Kuan G, de Jesus JN, Simões EAF, Hunt DR, Arbaji AK, Thompson MG.

Vaccine. 2020 May 6. pii: S0264-410X(20)30508-9. doi: 10.1016/j.**vaccine**.2020.04.028. [Epub ahead of print]

PMID: 32387013

127. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate **vaccine** (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.

Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M.

Vaccine. 2020 May 6. pii: S0264-410X(20)30584-3. doi: 10.1016/j.**vaccine**.2020.04.067. [Epub ahead of print]

PMID: 32387012

128. Tortoises, hares, and **vaccines**: A cautionary note for SARS-CoV-2 **vaccine** development.

Poland GA.

Vaccine. 2020 May 1. pii: S0264-410X(20)30590-9. doi: 10.1016/j.**vaccine**.2020.04.073. [Epub ahead of print] No abstract available.

PMID: 32387011

129. A therapeutic HIV-1 **vaccine** reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy.

Pallikkuth S, Bolivar H, Fletcher MA, Babic DZ, De Armas LR, Gupta S, Termini JM, Arheart KL, Stevenson M, Tung FY, Fischl MA, Pahwa S, Stone GW.

Vaccine. 2020 May 6. pii: S0264-410X(20)30485-0. doi: 10.1016/j.**vaccine**.2020.04.015. [Epub ahead of print]

PMID: 32387010

130. A single dose of quadrivalent human papillomavirus (HPV) **vaccine** is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.

Batmunkh T, Dalmau MT, Munkhsaikhan ME, Khorolsuren T, Namjil N, Surenjav U, Toh ZQ, Licciardi PV, Russell FM, Garland SM, Mulholland K, von Mollendorf C.

Vaccine. 2020 May 6. pii: S0264-410X(20)30534-X. doi: 10.1016/j.**vaccine**.2020.04.041. [Epub ahead of print]

PMID: 32387009

131. Effect of immune regulatory pathways after immunization with GMZ2 malaria **vaccine** candidate in healthy lifelong malaria-exposed adults.

Nouatin O, Ateba Ngoa U, Ibáñez J, Dejon-Agobe JC, Mordmüller B, Edoa JR, Mougeni F, Brückner S, Bouyoukou Hounkpatin A, Esen M, Theisen M, Moutairou K, Hoffman SL, Issifou S, Luty AJF, Loembe MM, Agnandji ST, Lell B, Kremsner PG, Adegnika AA.

Vaccine. 2020 May 5. pii: S0264-410X(20)30540-5. doi: 10.1016/j.**vaccine**.2020.04.046. [Epub ahead of print]

PMID: 32386747

132. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Tifrea DF, Pal S, le Bon C, Cocco MJ, Zoonens M, de la Maza LM.

Vaccine. 2020 Apr 30. pii: S0264-410X(20)30582-X. doi: 10.1016/j.**vaccine**.2020.04.065. [Epub ahead of print]

PMID: 32386746

133. Why do parents not re-vaccinate their child for influenza? A prospective cohort study.

Smith LE, Amlôt R, Weinman J, Yiend J, Rubin GJ.

Vaccine. 2020 May 5. pii: S0264-410X(20)30509-0. doi: 10.1016/j.**vaccine**.2020.04.029. [Epub ahead of print]

PMID: 32386745

134. The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.

Palma P, McManus M, Cotugno N, Rocca S, Rossi P, Luzuriaga K.

Lancet HIV. 2020 May;7(5):e359-e365. doi: 10.1016/S2352-3018(20)30100-4. Review.

PMID: 32386722

135. A protracted iGAS outbreak in a long-term care facility 2014-2015: control measures and the use of whole-genome sequencing.

Degala S, Puleston R, Bates R, Borges-Stewart R, Coelho J, Kapatai G, Chalker V, Mair-Jenkins J.

J Hosp Infect. 2020 May;105(1):70-77. doi: 10.1016/j.jhin.2019.12.004.

PMID: 32386676

136. Can blocking inflammation enhance immunity during aging?

Chambers ES, Akbar AN.

J Allergy Clin Immunol. 2020 May;145(5):1323-1331. doi: 10.1016/j.jaci.2020.03.016. Review.

PMID: 32386656

137. Influence of immune aging on **vaccine** responses.

Gustafson CE, Kim C, Weyand CM, Goronzy JJ.

J Allergy Clin Immunol. 2020 May;145(5):1309-1321. doi: 10.1016/j.jaci.2020.03.017. Review.

PMID: 32386655

138. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.

Hu Z, Rolt A, Hu X, Ma CD, Le DJ, Park SB, Houghton M, Southall N, Anderson DE, Talley DC, Lloyd JR, Marugan JC, Liang TJ.

Cell Chem Biol. 2020 Apr 30. pii: S2451-9456(20)30143-4. doi: 10.1016/j.chembiol.2020.04.006. [Epub ahead of print]

PMID: 32386595

139. Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.

Fauver JR, Petrone ME, Hodcroft EB, Shioda K, Ehrlich HY, Watts AG, Vogels CBF, Brito AF, Alpert T, Muyombwe A, Razeq J, Downing R, Cheemarla NR, Wyllie AL, Kalinich CC, Ott IM, Quick J, Loman NJ, Neugebauer KM, Greninger AL, Jerome KR, Roychoudhury P, Xie H, Shrestha L, Huang ML, Pitzer VE, Iwasaki A, Omer SB, Khan K, Bogoch II, Martinello RA, Foxman EF, Landry ML, Neher RA, Ko AI, Grubaugh ND.

Cell. 2020 May 4. pii: S0092-8674(20)30484-0. doi: 10.1016/j.cell.2020.04.021. [Epub ahead of print]

PMID: 32386545

140. A Call for **Vaccine** Against COVID-19: Implications for Cardiovascular Morbidity and Healthcare Utilization.

Ho JSY, Tambyah PA, Sia CH.

Cardiovasc Drugs Ther. 2020 May 8. doi: 10.1007/s10557-020-06985-z. [Epub ahead of print] No abstract available.

PMID: 32385785

141. Effects of gE/gI deletions on the miRNA expression of PRV-infected PK-15 cells.

Liu X, Zhou Y, Luo Y, Chen Y.

Virus Genes. 2020 May 8. doi: 10.1007/s11262-020-01760-6. [Epub ahead of print]

PMID: 32385550

142. Rapid colorimetric loop-mediated isothermal amplification for hypersensitive point-of-care Staphylococcus aureus enterotoxin A gene detection in milk and pork products.

Srimongkol G, Ditmangklo B, Choopara I, Thaniyavarn J, Dean D, Kokpol S, Vilaivan T, Somboonna N.

Sci Rep. 2020 May 8;10(1):7768. doi: 10.1038/s41598-020-64710-0.

PMID: 32385390

143. Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein.

Piai A, Fu Q, Cai Y, Ghantous F, Xiao T, Shaik MM, Peng H, Rits-Volloch S, Chen W, Seaman MS, Chen B, Chou JJ.

Nat Commun. 2020 May 8;11(1):2317. doi: 10.1038/s41467-020-16165-0.

PMID: 32385256

144. Tcf1^{+} cells are required to maintain the inflationary T cell pool upon MCMV infection.

Welten SPM, Yermanos A, Baumann NS, Wagen F, Oetiker N, Sandu I, Pedrioli A, Oduro JD, Reddy ST, Cicin-Sain L, Held W, Oxenius A.

Nat Commun. 2020 May 8;11(1):2295. doi: 10.1038/s41467-020-16219-3.

PMID: 32385253

145. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.

Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, Haden K, Cobbold M, Hunt DF, Weiss G, Gaughan E, Slingluff CL Jr.

J Immunother Cancer. 2020 May;8(1). pii: e000262. doi: 10.1136/jitc-2019-000262.

PMID: 32385144

146. Innate Molecular and Cellular Signature in the Skin Preceding Long-Lasting T Cell Responses after Electroporated DNA Vaccination.

Adam L, Tchitchek N, Todorova B, Rosenbaum P, Joly C, Poux C, Chapon C, Spetz AL, Ustav M, Le Grand R, Martinon F.

J Immunol. 2020 May 8. pii: ji1900517. doi: 10.4049/jimmunol.1900517. [Epub ahead of print]

PMID: 32385135

147. Rapid COVID-19 **vaccine** development.

Graham BS.

Science. 2020 May 8. pii: eabb8923. doi: 10.1126/science.abb8923. [Epub ahead of print]

PMID: 32385100

148. Chest radiograph findings in children aged 2-59 months hospitalised with community-acquired pneumonia, prior to the introduction of pneumococcal conjugate **vaccine** in India: a prospective multisite observational study.

Awasthi S, Rastogi T, Mishra N, Chauhan A, Mohindra N, Shukla RC, Agarwal M, Pandey CM, Kohli N, Study Group C.

BMJ Open. 2020 May 7;10(5):e034066. doi: 10.1136/bmjopen-2019-034066.

PMID: 32385059

149. Transcutaneous Administration of Dengue **Vaccines**.

Andreata-Santos R, Alves RPDS, Pereira SA, Pereira LR, Freitas CL, Pereira SS, Venceslau-Carvalho AA, Castro-Amarante MF, Favaro MTP, Mathias-Santos C, Amorim JH, Ferreira LCS.

Viruses. 2020 May 6;12(5). pii: E514. doi: 10.3390/v12050514.

PMID: 32384822

150. MGMS2: Membrane Glycolipid Mass Spectrum Simulator for polymicrobial samples.

Ryu SY, Wendt GA, Ernst RK, Goodlett DR.

Rapid Commun Mass Spectrom. 2020 May 8:e8824. doi: 10.1002/rcm.8824. [Epub ahead of print]

PMID: 32384576

151. Novel coronavirus 2019 (COVID-19): A case report and review of treatments.

Douedi S, Miskoff J.

Medicine (Baltimore). 2020 May;99(19):e20207. doi: 10.1097/MD.0000000000020207.

PMID: 32384516

152. First isolation and characterization of Brucella suis from yak.

Yang X, Wang N, Cao X, Bie P, Xing Z, Yin S, Jiang H, Wu Q.

Genome. 2020 May 8. doi: 10.1139/gen-2019-0101. [Epub ahead of print]

PMID: 32384250

153. Receptive anal sex contributes substantially to heterosexually-acquired HIV infections among at-risk women in Twenty US Cities: results from a modelling analysis.

Elmes J, Silhol R, Hess KL, Gedge LM, Nordsletten A, Staunton R, Anton P, Shacklett B, McGowan I, Dang Q, Adimora AA, Dimitrov DT, Aral S, Handanagic S, Paz-Bailey G, Boily MC; NHBS Study Group.

Am J Reprod Immunol. 2020 May 8:e13263. doi: 10.1111/aji.13263. [Epub ahead of print]

PMID: 32384198

154. A call for caution in use of pertussis **vaccine** effectiveness studies to estimate waning immunity: A Canadian Immunization Research Network Study.

Crowcroft NS, Schwartz KL, Savage RD, Chen C, Johnson C, Li Y, Marchand-Austin A, Bolotin S, Deeks SL, Jamieson FB, Drews SJ, Russell ML, Svenson LW, Simmonds K, Righolt CH, Bell C, Mahmud SM, Kwong JC.

Clin Infect Dis. 2020 May 8. pii: ciaa518. doi: 10.1093/cid/ciaa518. [Epub ahead of print]

PMID: 32384142

155. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.

Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, Yang JS, Kim JA, Yun MR, Kim DW, Kim SS, Zhang Y, Shi W, Wang L, Graham BS, Mascola JR, Wang N, McLellan JS, Lee JY, Lee H.

PLoS One. 2020 May 8;15(5):e0232757. doi: 10.1371/journal.pone.0232757. eCollection 2020.

PMID: 32384116

156. First outbreak of bovine haemorrhagic septicaemia caused by Pasteurella multocida type B in Spain - Short communication.

Cuevas I, Carbonero A, Cano D, Pacheco IL, Marín JC, Borge C.

Acta Vet Hung. 2020 May 4. doi: 10.1556/004.2020.00014. [Epub ahead of print]

PMID: 32384069

157. Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020.

Randhawa AK, Fisher LH, Greninger AL, Li SS, Andriesen J, Corey L, Jerome KR.

JAMA. 2020 May 8. doi: 10.1001/jama.2020.8097. [Epub ahead of print] No abstract available.

PMID: 32383728

158. Credibility of polymeric and ceramic membrane filtration in the removal of bacteria and virus from water: A review.

Goswami KP, Pugazhenthi G.

J Environ Manage. 2020 May 8;268:110583. doi: 10.1016/j.jenvman.2020.110583. [Epub ahead of print] Review.

PMID: 32383664

159. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.

Choudhury A, Mukherjee S.

J Med Virol. 2020 May 8. doi: 10.1002/jmv.25987. [Epub ahead of print]

PMID: 32383269

160. Evaluation of SARS-CoV-2 neutralizing antibodies using of a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples.

Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, Marchi S, Montomoli E.

J Med Virol. 2020 May 8. doi: 10.1002/jmv.25986. [Epub ahead of print]

PMID: 32383254

161. Covid-19 and drug therapy, what we learned.

Provenzani A, Polidori P.

Int J Clin Pharm. 2020 May 7. doi: 10.1007/s11096-020-01049-6. [Epub ahead of print]

PMID: 32382873

162. Lessons from COVID-19 in children: Key hypotheses to guide preventative and therapeutic strategies.

Singh T, Heston SM, Langel SN, Blasi M, Hurst JH, Fouda GG, Kelly MS, Permar SR.

Clin Infect Dis. 2020 May 8. pii: ciaa547. doi: 10.1093/cid/ciaa547. [Epub ahead of print]

PMID: 32382748

163. Zebrafish as an alternative animal model in human and animal vaccination research.

Bailone RL, Fukushima HCS, Ventura Fernandes BH, De Aguiar LK, Corrêa T, Janke H, Grejo Setti P, Roça RO, Borra RC.

Lab Anim Res. 2020 May 7;36:13. doi: 10.1186/s42826-020-00042-4. eCollection 2020. Review.

PMID: 32382525

164. The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review.

Haghani M, Bliemer MCJ, Goerlandt F, Li J.

Saf Sci. 2020 May 7:104806. doi: 10.1016/j.ssci.2020.104806. [Epub ahead of print]

PMID: 32382213

165. Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.

Chuang YM, He L, Pinn ML, Tsai YC, Cheng MA, Farmer E, Karakousis PC, Hung CF.

Cell Mol Immunol. 2020 May 7. doi: 10.1038/s41423-020-0439-2. [Epub ahead of print]

PMID: 32382128

166. SwiftReg cluster registration automatically reduces flow cytometry data variability including batch effects.

Rebhahn JA, Quataert SA, Sharma G, Mosmann TR.

Commun Biol. 2020 May 7;3(1):218. doi: 10.1038/s42003-020-0938-9.

PMID: 32382076

167. Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable.

Mavian C, Pond SK, Marini S, Magalis BR, Vandamme AM, Dellicour S, Scarpino SV, Houldcroft C, Villabona-Arenas J, Paisie TK, Trovão NS, Boucher C, Zhang Y, Scheuermann RH, Gascuel O, Lam TT, Suchard MA, Abecasis A, Wilkinson E, de Oliveira T, Bento AI, Schmidt HA, Martin D, Hadfield J, Faria N, Grubaugh ND, Neher RA, Baele G, Lemey P, Stadler T, Albert J, Crandall KA, Leitner T, Stamatakis A, Prosperi M, Salemi M.

Proc Natl Acad Sci U S A. 2020 May 7. pii: 202007295. doi: 10.1073/pnas.2007295117. [Epub ahead of print] No abstract available.

PMID: 32381734

168. Vaccination strategies to enhance immunity in neonates.

Kollmann TR, Marchant A, Way SS.

Science. 2020 May 8;368(6491):612-615. doi: 10.1126/science.aaz9447. Review.

PMID: 32381718

169. Combination prevention for COVID-19.

Cohen MS, Corey L.

Science. 2020 May 8;368(6491):551. doi: 10.1126/science.abc5798. No abstract available.

PMID: 32381692

170. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.

Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL.

J Clin Microbiol. 2020 May 7. pii: JCM.00941-20. doi: 10.1128/JCM.00941-20. [Epub ahead of print]

PMID: 32381641

171. The global **vaccine** action plan monitoring and evaluation/accountability framework: Perspective.

Cherian T, Arora N, MacDonald NE.

Vaccine. 2020 May 4. pii: S0264-410X(20)30529-6. doi: 10.1016/j.**vaccine**.2020.04.036. [Epub ahead of print] No abstract available.

PMID: 32381481

172. Is flu vaccination opt-out feasible? Evidence from vaccination programme implementers and managers in the English National Health Service.

Bell S, Chantler T, Paterson P, Mounier-Jack S.

Vaccine. 2020 May 4. pii: S0264-410X(20)30506-5. doi: 10.1016/j.**vaccine**.2020.04.026. [Epub ahead of print]

PMID: 32381480

173. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.

Nogareda F, Gunregjav N, Sarankhuu A, Munkhbat E, Ichinnorov E, Nymadawa P, Wannemuehler K, Mulders MN, Hagan J, Patel MK.

Vaccine. 2020 May 4. pii: S0264-410X(20)30504-1. doi: 10.1016/j.**vaccine**.2020.04.024. [Epub ahead of print]

PMID: 32381479

174. Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI?

Wenzel HHB, Van Kol KGG, Nijman HW, Lemmens VEPP, Van der Aa MA, Ebisch RMF, Bekkers RLM.

Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31015-5. doi: 10.1016/j.ygyno.2020.04.705. [Epub ahead of print]

PMID: 32381363

175. Comparative genomics of whole-cell pertussis **vaccine** strains from India.

Alai S, Ghattargi VC, Gautam M, Patel K, Pawar SP, Dhotre DP, Shaligram U, Gairola S.

BMC Genomics. 2020 May 7;21(1):345. doi: 10.1186/s12864-020-6724-8.

PMID: 32381023

176. Live-attenuated Salmonella enterica serotype Choleraesuis **vaccine** with regulated delayed fur mutation confer protection against Streptococcus suis in mice.

Li YA, Chen Y, Du YZ, Guo W, Chu D, Fan J, Wang X, Bellefleur M, Wang S, Shi H.

BMC Vet Res. 2020 May 7;16(1):129. doi: 10.1186/s12917-020-02340-4.

PMID: 32381017

177. Response to a DNA **vaccine** against the H5N1 virus depending on the chicken line and number of doses.

Kalenik BM, Góra-Sochacka A, Stachyra A, Olszewska-Tomczyk M, Fogtman A, Sawicka R, Śmietanka K, Sirko A.

Virol J. 2020 May 7;17(1):66. doi: 10.1186/s12985-020-01335-9.

PMID: 32381003

178. Malaria in Venezuela: changes in the complexity of infection reflects the increment in transmission intensity.

Pacheco MA, Forero-Peña DA, Schneider KA, Chavero M, Gamardo A, Figuera L, Kadakia ER, Grillet ME, Oliveira-Ferreira J, Escalante AA.

Malar J. 2020 May 7;19(1):176. doi: 10.1186/s12936-020-03247-z.

PMID: 32380999

179. Development of SARS-CoV-2 **vaccines**: should we focus on mucosal immunity?

Moreno-Fierros L, García-Silva I, Rosales-Mendoza S.

Expert Opin Biol Ther. 2020 May 7. doi: 10.1080/14712598.2020.1767062. [Epub ahead of print] No abstract available.

PMID: 32380868

180. Arthritogenic Alphavirus **Vaccines**: Serogrouping Versus Cross-Protection in Mouse Models.

Nguyen W, Nakayama E, Yan K, Tang B, Le TT, Liu L, Cooper TH, Hayball JD, Faddy HM, Warrilow D, Allcock RJN, Hobson-Peters J, Hall RA, Rawle DJ, Lutzky VP, Young P, Oliveira NM, Hartel G, Howley PM, Prow NA, Suhrbier A.

Vaccines (Basel). 2020 May 5;8(2). pii: E209. doi: 10.3390/vaccines8020209.

PMID: 32380760

181. The Role of Bacterial Membrane Vesicles in the Dissemination of Antibiotic Resistance and as Promising Carriers for Therapeutic Agent Delivery.

Uddin MJ, Dawan J, Jeon G, Yu T, He X, Ahn J.

Microorganisms. 2020 May 5;8(5). pii: E670. doi: 10.3390/microorganisms8050670. Review.

PMID: 32380740

182. Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women.

Valasoulis G, Pouliakis A, Michail G, Kottaridi C, Spathis A, Kyrgiou M, Paraskevaidis E, Daponte A.

Cancers (Basel). 2020 May 5;12(5). pii: E1164. doi: 10.3390/cancers12051164.

PMID: 32380733

183. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.

Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y, Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L, Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C.

Nature. 2020 May 7. doi: 10.1038/s41586-020-2312-y. [Epub ahead of print]

PMID: 32380511

184. Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions.

Schuemann J, Bagley A, Berbeco R, Bromma K, Butterworth KT, Byrne H, Chithrani DB, Cho SH, Cook JR, Favaudon V, Gholami YH, Gargioni E, Hainfeld JF, Hespeels F, Heuskin AC, Ibeh UM, Kuncic Z, Kunjachan S, Lacombe S, Lucas S, Lux F, McMahon SJ, Nevozhay D, Ngwa W, Payne JD, Penninckx S, Porcel E, Prise KM, Rabus H, Ridwan SM, Rudek B, Sanche L, Singh B, Smilowitz HM, Sokolov KV, Sridhar S, Stanishevskiy Y, Sung W, Tillement O, Virani NA, Yantasee W, Krishnan S.

Phys Med Biol. 2020 May 7. doi: 10.1088/1361-6560/ab9159. [Epub ahead of print]

PMID: 32380492

185. What dentists need to know about COVID-19.

Baghizadeh Fini M.

Oral Oncol. 2020 Jun;105:104741. doi: 10.1016/j.oraloncology.2020.104741. Epub 2020 Apr 28. Review.

PMID: 32380453

186. Convalescent plasma in Covid-19: Possible mechanisms of action.

Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R, Mantilla RD, Shoenfeld Y, Anaya JM.

Autoimmun Rev. 2020 May 5:102554. doi: 10.1016/j.autrev.2020.102554. [Epub ahead of print] Review.

PMID: 32380316

187. Methylation in Mycobacterium-host interaction and implications for novel control measures.

Asaad M, Abo-Kadoum MA, Nzungize L, Uae M, Nzaou SAE, Xie J.

Infect Genet Evol. 2020 May 4;83:104350. doi: 10.1016/j.meegid.2020.104350. [Epub ahead of print] Review.

PMID: 32380312

188. PREVALENCE AND OUTCOME OF LASSA FEVER AMONG HOSPITALIZED PATIENTS IN EBONYI STATE, NIGERIA, 2018 - 2019.

Nwafor Ifeanyi E, Emeka OO, Ojide Chiedozie K, Odeh Elizabeth C, Abu Augustine M, Chika-Igwenyi Nneka M, Nwidi Demian U, Unigwe Uche S, Ajayi Nnenna A, Eke Matthew AS, Mary O, Azuka A, Venatius O, Rosemary D, Igboke Nancy C, Josephine O, Ogbonnaya O.

Virus Res. 2020 May 4:198000. doi: 10.1016/j.virusres.2020.198000. [Epub ahead of print]

PMID: 32380207

189. Lipid-encapsulated oral therapeutic peptide **vaccines** reduce tumour growth in an orthotopic mouse model of colorectal cancer.

Naciute M, Niemi V, Kemp RA, Hook S.

Eur J Pharm Biopharm. 2020 May 4. pii: S0939-6411(20)30117-X. doi: 10.1016/j.ejpb.2020.04.020. [Epub ahead of print]

PMID: 32380167

190. Structural features of $HtpG_{Mtb}$ and HtpG-$ESAT6_{Mtb}$ **vaccine** antigens against tuberculosis: Molecular determinants of antigenic synergy and cytotoxicity modulation.

Moreira M, Ruggiero A, Esposito L, Choi HG, Kim HJ, Berisio R.

Int J Biol Macromol. 2020 May 4;158:305-317. doi: 10.1016/j.ijbiomac.2020.04.252. [Epub ahead of print]

PMID: 32380102

191. Adaption of a conventional ELISA to a 96-well ELISA-Array for measuring the antibody responses to influenza virus proteins and **vaccines**.

Waltari E, Carabajal E, Sanyal M, Friedland N, McCutcheon KM.

J Immunol Methods. 2020 May 4:112789. doi: 10.1016/j.jim.2020.112789. [Epub ahead of print]

PMID: 32380014

192. Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.

Medeiros CMP, Moreira EUM, Pires CV, Torres LM, Guimarães LFF, Alves JRS, Lima BAS, Fontes CJF, Costa HL, Brito CFA, Sousa TN, Ntumngia FB, Adams JH, Kano FS, Carvalho LH.

PLoS One. 2020 May 7;15(5):e0232786. doi: 10.1371/journal.pone.0232786. eCollection 2020.

PMID: 32379804

193. emm Types and clusters and macrolide resistance of pediatric group A streptococcal isolates in Central Greece during 2011-2017.

Grivea IN, Syrogiannopoulos GA, Michoula AN, Gazeti G, Malli E, Tsilipounidaki K, Fouzas S, Anthracopoulos MB, Petinaki E.

PLoS One. 2020 May 7;15(5):e0232777. doi: 10.1371/journal.pone.0232777. eCollection 2020.

PMID: 32379802

194. The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study.

Wu Q, Jia M, Chen H, Zhang S, Liu Y, Prem K, Qian M, Yu H.

PLoS One. 2020 May 7;15(5):e0232129. doi: 10.1371/journal.pone.0232129. eCollection 2020.

PMID: 32379783

195. A genetically hmgb2 attenuated blood stage P. berghei induces crossed-long live protection.

Briquet S, Lawson-Hogban N, Peronet R, Mécheri S, Vaquero C.

PLoS One. 2020 May 7;15(5):e0232183. doi: 10.1371/journal.pone.0232183. eCollection 2020.

PMID: 32379764

196. Eliminating yellow fever epidemics in Africa: **Vaccine** demand forecast and impact modelling.

Jean K, Hamlet A, Benzler J, Cibrelus L, Gaythorpe KAM, Sall A, Ferguson NM, Garske T.

PLoS Negl Trop Dis. 2020 May 7;14(5):e0008304. doi: 10.1371/journal.pntd.0008304. [Epub ahead of print]

PMID: 32379756

197. 3CL Hydrolase Based Multi Epitope Peptide **Vaccine** Against Sars-CoV-2 Using Immunoinformatics.

Jakhar R, Kaushik S, Gakhar SK.

J Med Virol. 2020 May 7. doi: 10.1002/jmv.25993. [Epub ahead of print]

PMID: 32379348

198. The Equitable Distribution of COVID-19 Therapeutics and **Vaccines**.

Bollyky TJ, Gostin LO, Hamburg MA.

JAMA. 2020 May 7. doi: 10.1001/jama.2020.6641. [Epub ahead of print] No abstract available.

PMID: 32379268

199. Influenza or Meningococcal Immunization During Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials.

Clark DR, Omer SB, Tapia MD, Nunes MC, Cutland CL, Tielsch JM, Wairagkar N, Madhi SA; for BMGF Supported Maternal Influenza Immunization Trials Investigators Group.

Pediatr Infect Dis J. 2020 May 1. doi: 10.1097/INF.0000000000002629. [Epub ahead of print]

PMID: 32379201

200. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate **Vaccine** (MenACWY-CRM) in Children 2-10 Years of Age: ERRATUM.

[No authors listed]

Pediatr Infect Dis J. 2020 May 5. doi: 10.1097/INF.0000000000002753. [Epub ahead of print] No abstract available.

PMID: 32379196

201. Demand for BCG **Vaccine** Due to Unproven Claims of its Role in Preventing COVID-19 Is Causing Shortages of **Vaccines** for Infants in Japan.

Kuroda N.

Pediatr Infect Dis J. 2020 May 5. doi: 10.1097/INF.0000000000002724. [Epub ahead of print] No abstract available.

PMID: 32379194

202. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of HCV With a Novel Mechanism of Action.

Jiang X, Tan J, Wang Y, Chen J, Li J, Jiang Z, Quan Y, Jin J, Li YH, Cen S, Li Y, Peng ZG, Li ZR.

J Med Chem. 2020 May 7. doi: 10.1021/acs.jmedchem.0c00232. [Epub ahead of print]

PMID: 32378892

203. COVID-19 and toxicity from potential treatments: Panacea or poison.

Wong A.

Emerg Med Australas. 2020 May 7. doi: 10.1111/1742-6723.13537. [Epub ahead of print]

PMID: 32378805

204. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses.

Nikaeen G, Abbaszadeh S, Yousefinejad S.

Nanomedicine (Lond). 2020 May 7. doi: 10.2217/nnm-2020-0117. [Epub ahead of print]

PMID: 32378459

205. A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis.

Kumar A, Pandey SC, Samant M.

Parasite Immunol. 2020 May 7:e12727. doi: 10.1111/pim.12727. [Epub ahead of print] Review.

PMID: 32378226

206. A novel cancer immunotherapy utilizing autologous tumour tissue.

Park H, Gladstone M, Shanley C, Goodrich R, Guth A.

Vox Sang. 2020 May 6. doi: 10.1111/vox.12935. [Epub ahead of print]

PMID: 32378223

207. Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity.

Anamika J, Nikhar V, Laxmikant G, Priya S, Sonal V, Vyas SP.

Drug Deliv Transl Res. 2020 May 7. doi: 10.1007/s13346-020-00770-z. [Epub ahead of print]

PMID: 32378173

208. BCG-Related Inflammatory Syndromes in Severe Combined Immunodeficiency After TCRαβ+/CD19+ Depleted HSCT.

Laberko A, Yukhacheva D, Rodina Y, Abramov D, Konovalov D, Radygina S, Shelikhova L, Pershin D, Kadnikova O, Maschan M, Maschan A, Balashov D, Shcherbina A.

J Clin Immunol. 2020 May 6. doi: 10.1007/s10875-020-00774-x. [Epub ahead of print]

PMID: 32377975

209. Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.

Lee YH, Pang SW, Revai Lechtich E, Shah K, Simon SE, Ponnusamy S, Narayanan R, Poh CL, Tan KO.

J Cancer Res Clin Oncol. 2020 May 6. doi: 10.1007/s00432-020-03231-9. [Epub ahead of print]

PMID: 32377840

210. Towards effective COVID-19 **vaccines**: Updates, perspectives and challenges (Review).

Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, Spandidos DA, Tsatsakis A.

Int J Mol Med. 2020 May 6. doi: 10.3892/ijmm.2020.4596. [Epub ahead of print]

PMID: 32377694

211. COVID-19 **vaccines**: breaking record times to first-in-human trials.

Kim YC, Dema B, Reyes-Sandoval A.

NPJ **Vaccines**. 2020 Apr 30;5:34. doi: 10.1038/s41541-020-0188-3. eCollection 2020.

PMID: 32377399

212. Design of a broadly reactive Lyme disease **vaccine**.

Kamp HD, Swanson KA, Wei RR, Dhal PK, Dharanipragada R, Kern A, Sharma B, Sima R, Hajdusek O, Hu LT, Wei CJ, Nabel GJ.

NPJ **Vaccines**. 2020 May 1;5:33. doi: 10.1038/s41541-020-0183-8. eCollection 2020.

PMID: 32377398

213. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.

Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, Dong L, Cui X, Miao Y, Wang D, Dong J, Xiao C, Chen W, Wang H.

Cell Discov. 2020 May 4;6:31. doi: 10.1038/s41421-020-0168-9. eCollection 2020.

PMID: 32377375

214. Reverse Genetics Assembly of Newcastle Disease Virus Genome Template Using Asis-Sal-Pac BioBrick Strategy.

Tavassoli A, Soleymani S, Haghparast A, Hashemi Tabar G, Bassami MR, Dehghani H.

Biol Proced Online. 2020 May 1;22:9. doi: 10.1186/s12575-020-00119-3. eCollection 2020.

PMID: 32377174

215. A novel **vaccine** target for malaria.

Wrighton KH.

Nat Rev Microbiol. 2020 May 6. doi: 10.1038/s41579-020-0380-5. [Epub ahead of print] No abstract available.

PMID: 32377016

216. In-silico identification of the **vaccine** candidate epitopes against the Lassa virus hemorrhagic fever.

Baral P, Pavadai E, Gerstman BS, Chapagain PP.

Sci Rep. 2020 May 6;10(1):7667. doi: 10.1038/s41598-020-63640-1.

PMID: 32376973

217. Childhood **vaccines** and antibiotic use in low- and middle-income countries.

Lewnard JA, Lo NC, Arinaminpathy N, Frost I, Laxminarayan R.

Nature. 2020 May;581(7806):94-99. doi: 10.1038/s41586-020-2238-4. Epub 2020 Apr 29.

PMID: 32376956

218. Spatial early warning signals of social and epidemiological tipping points in a coupled behaviour-disease network.

Phillips B, Anand M, Bauch CT.

Sci Rep. 2020 May 6;10(1):7611. doi: 10.1038/s41598-020-63849-0.

PMID: 32376908

219. High residual carriage of **vaccine**-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate **vaccine** in Malawi.

Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, Everett D, Kamng'ona AW, Mwalukomo TS, Mataya AA, Mwansambo C, Banda M, Gupta S, Diggle P, French N, Heyderman RS.

Nat Commun. 2020 May 6;11(1):2222. doi: 10.1038/s41467-020-15786-9.

PMID: 32376860

220. Neoantigen-based EpiGVAX **vaccine** initiates antitumor immunity in colorectal cancer.

Kim VM, Pan X, Soares KC, Azad NS, Ahuja N, Gamper CJ, Blair AB, Muth S, Ding D, Ladle BH, Zheng L.

JCI Insight. 2020 May 7;5(9). pii: 136368. doi: 10.1172/jci.insight.136368.

PMID: 32376802

221. Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy.

Sebastian M, Hsiao CJ, Futch HS, Eisinger RS, Dumeny L, Patel S, Gobena M, Katikaneni DS, Cohen J, Carpenter AM, Spiryda L, Heldermon CD, Jin L, Brantly ML.

JCI Insight. 2020 May 7;5(9). pii: 136141. doi: 10.1172/jci.insight.136141.

PMID: 32376795

222. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis.

Brook B, Harbeson DJ, Shannon CP, Cai B, He D, Ben-Othman R, Francis F, Huang J, Varankovich N, Liu A, Bao W, Bjerregaard-Andersen M, Schaltz-Buchholzer F, Sanca L, Golding CN, Larsen KL, Levy O, Kampmann B; EPIC Consortium, Tan R, Charles A, Wynn JL, Shann F, Aaby P, Benn CS, Tebbutt SJ, Kollmann TR, Amenyogbe N.

Sci Transl Med. 2020 May 6;12(542). pii: eaax4517. doi: 10.1126/scitranslmed.aax4517.

PMID: 32376769

223. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein.

Pillay TS.

J Clin Pathol. 2020 May 6. pii: jclinpath-2020-206658. doi: 10.1136/jclinpath-2020-206658. [Epub ahead of print]

PMID: 32376714

224. Detecting and Monitoring Porcine Hemagglutinating Encephalomyelitis Virus, an Underresearched Betacoronavirus.

Mora-Díaz JC, Magtoto R, Houston E, Baum D, Carrillo-Ávila JA, Temeeyasen G, Zimmerman J, Piñeyro P, Giménez-Lirola L.

mSphere. 2020 May 6;5(3). pii: e00199-20. doi: 10.1128/mSphere.00199-20.

PMID: 32376700

225. Systematic Profiling of Full-Length Ig and TCR Repertoire Diversity in Rhesus Macaque through Long Read Transcriptome Sequencing.

Brochu HN, Tseng E, Smith E, Thomas MJ, Jones AM, Diveley KR, Law L, Hansen SG, Picker LJ, Gale M Jr, Peng X.

J Immunol. 2020 May 6. pii: ji1901256. doi: 10.4049/jimmunol.1901256. [Epub ahead of print]

PMID: 32376650

226. Differential Vpu-mediated CD4 and tetherin downregulation function among major HIV-1 group M subtypes.

Umviligihozo G, Cobarrubias KD, Chandrarathna S, Jin SW, Reddy N, Byakwaga H, Muzoora C, Bwana MB, Lee GQ, Hunt PW, Martin JN, Brumme CJ, Bangsberg DR, Karita E, Allen S, Hunter E, Ndung'u T, Brumme ZL, Brockman MA.

J Virol. 2020 May 6. pii: JVI.00293-20. doi: 10.1128/JVI.00293-20. [Epub ahead of print]

PMID: 32376625

227. Absence of long-term protection in domestic pigs immunized with attenuated African swine fever virus isolate OURT88/3 or BeninΔMFG correlates with increased levels of regulatory T cells and IL-10.

Sánchez-Cordón PJ, Jabbar T, Chapman D, Dixon LK, Montoya M.

J Virol. 2020 May 6. pii: JVI.00350-20. doi: 10.1128/JVI.00350-20. [Epub ahead of print]

PMID: 32376618

228. Rapid development of an inactivated **vaccine** candidate for SARS-CoV-2.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C.

Science. 2020 May 6. pii: eabc1932. doi: 10.1126/science.abc1932. [Epub ahead of print]

PMID: 32376603

229. Design of a peptide-based subunit **vaccine** against novel coronavirus SARS-CoV-2.

Kalita P, Padhi AK, Zhang KYJ, Tripathi T.

Microb Pathog. 2020 May 4;145:104236. doi: 10.1016/j.micpath.2020.104236. [Epub ahead of print]

PMID: 32376359

230. Replication of live attenuated influenza **vaccine** viruses in human nasal epithelial cells is associated with H1N1 **vaccine** effectiveness.

Hawksworth A, Lockhart R, Crowe J, Maeso R, Ritter L, Dibben O, Bright H.

Vaccine. 2020 May 3. pii: S0264-410X(20)30462-X. doi: 10.1016/j.**vaccine**.2020.04.004. [Epub ahead of print]

PMID: 32376111

231. Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A **vaccine** in patients with hemophilia and other bleeding disorders: A randomized study.

Nakasone M, Lopes MH, Sartori AMC, Sandoval EPN, Villaça PR, D'Amico EA, Carneiro JDA.

Vaccine. 2020 May 3. pii: S0264-410X(20)30533-8. doi: 10.1016/j.**vaccine**.2020.04.040. [Epub ahead of print]

PMID: 32376110

232. Differentially regulated promoters for antigen expression in Salmonella **vaccine** strains.

Stojanov M, Besançon H, Snäkä T, Nardelli-Haefliger D, Curtiss R 3rd, Baud D.

Vaccine. 2020 May 3. pii: S0264-410X(20)30541-7. doi: 10.1016/j.**vaccine**.2020.04.047. [Epub ahead of print]

PMID: 32376109

233. **Vaccine** indicator and reminder band to improve demand for vaccination in Northern Nigeria: A qualitative evaluation of implementation outcomes.

Obi-Jeff C, Rakhshani NS, Bello-Malabu JI, Nwangwu C, Nwaononiwu E, Eboreime E, Wonodi C.

Vaccine. 2020 May 3. pii: S0264-410X(20)30505-3. doi: 10.1016/j.**vaccine**.2020.04.025. [Epub ahead of print]

PMID: 32376107

234. Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates.

Gladstone RA, Lo SW, Goater R, Yeats C, Taylor B, Hadfield J, Lees JA, Croucher NJ, van Tonder AJ, Bentley LJ, Quah FX, Blaschke AJ, Pershing NL, Byington CL, Balaji V, Hryniewicz W, Sigauque B, Ravikumar KL, Almeida SCG, Ochoa TJ, Ho PL, du Plessis M, Ndlangisa KM, Cornick JE, Kwambana-Adams B, Benisty R, Nzenze SA, Madhi SA, Hawkins PA, Pollard AJ, Everett DB, Antonio M, Dagan R, Klugman KP, von Gottberg A, Metcalf BJ, Li Y, Beall BW, McGee L, Breiman RF, Aanensen DM, Bentley SD, The Global Pneumococcal Sequencing Consortium.

Microb Genom. 2020 Apr 30. doi: 10.1099/mgen.0.000357. [Epub ahead of print]

PMID: 32375991

235. Meningococcal core and accessory phasomes vary by clonal complex.

Wanford JJ, Holmes JC, Bayliss CD, Green LR.

Microb Genom. 2020 Apr 29. doi: 10.1099/mgen.0.000367. [Epub ahead of print]

PMID: 32375989

236. Serum immunoglobulin E reactivity to cross-reacting panallergen components in north-eastern Poland patients pollen sensitized.

Kowal K, Pampuch A, Sacharzewska E, Swiebocka E, Siergiejko Z, Siergiejko G, Chruszcz M, DuBuske L.

Allergy Asthma Proc. 2020 May 1;41(3):183-191. doi: 10.2500/aap.2020.41.200002.

PMID: 32375962

237. Recent advances on innate immune pathways related to host-parasite cross-talk in cystic and alveolar echinococcosis.

Bakhtiar NM, Spotin A, Mahami-Oskouei M, Ahmadpour E, Rostami A.

Parasit Vectors. 2020 May 6;13(1):232. doi: 10.1186/s13071-020-04103-4. Review.

PMID: 32375891

238. Antiviral Activities of Compounds Isolated from *Pinus densiflora* (Pine Tree) against the Influenza A Virus.

Ha TKQ, Lee BW, Nguyen NH, Cho HM, Venkatesan T, Doan TP, Kim E, Oh WK.

Biomolecules. 2020 May 4;10(5). pii: E711. doi: 10.3390/biom10050711.

PMID: 32375402

239. MHC Class I Regulation: The Origin Perspective.

Sznarkowska A, Mikac S, Pilch M.

Cancers (Basel). 2020 May 4;12(5). pii: E1155. doi: 10.3390/cancers12051155.

PMID: 32375397

240. Virome of a Feline Outbreak of Diarrhea and Vomiting Includes Bocaviruses and a Novel Chapparvovirus.

Li Y, Gordon E, Idle A, Altan E, Seguin MA, Estrada M, Deng X, Delwart E.

Viruses. 2020 May 4;12(5). pii: E506. doi: 10.3390/v12050506.

PMID: 32375386

241. Tracking Australian Hajj Pilgrims' Health Behavior before, during and after Hajj, and the Effective Use of Preventive Measures in Reducing Hajj-Related Illness: A Cohort Study.

Alqahtani AS, Tashani M, Heywood AE, Almohammed ABS, Booy R, Wiley KE, Rashid H.

Pharmacy (Basel). 2020 May 4;8(2). pii: E78. doi: 10.3390/pharmacy8020078.

PMID: 32375320

242. Host Protective Immune Responses against Influenza A Virus Infection.

Jung HE, Lee HK.

Viruses. 2020 May 3;12(5). pii: E504. doi: 10.3390/v12050504. Review.

PMID: 32375274

243. Coronavirus Pandemic-Therapy and **Vaccines**.

Lundstrom K.

Biomedicines. 2020 May 3;8(5). pii: E109. doi: 10.3390/biomedicines8050109. Review.

PMID: 32375268

244. Flu Vaccination Attitudes, Behaviours, and Knowledge among Health Workers.

Arghittu A, Dettori M, Azara A, Gentili D, Serra A, Contu B, Castiglia P.

Int J Environ Res Public Health. 2020 May 3;17(9). pii: E3185. doi: 10.3390/ijerph17093185.

PMID: 32375260

245. HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells.

Marone G, Rossi FW, Pecoraro A, Pucino V, Criscuolo G, Paulis A, Spadaro G, Marone G, Varricchi G.

Vaccines (Basel). 2020 May 3;8(2). pii: E208. doi: 10.3390/vaccines8020208.

PMID: 32375243

246. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.

Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team, Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS.

Cell. 2020 Apr 29. pii: S0092-8674(20)30494-3. doi: 10.1016/j.cell.2020.04.031. [Epub ahead of print]

PMID: 32375025

247. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate.

Becerra-Flores M, Cardozo T.

Int J Clin Pract. 2020 May 6. doi: 10.1111/ijcp.13525. [Epub ahead of print]

PMID: 32374903

248. Incidence of pharyngitis, sinusitis, acute otitis media, and outpatient antibiotic prescribing preventable by vaccination against group A Streptococcus in the United States.

Lewnard JA, King LM, Fleming-Dutra KE, Link-Gelles R, Van Beneden CA.

Clin Infect Dis. 2020 May 6. pii: ciaa529. doi: 10.1093/cid/ciaa529. [Epub ahead of print]

PMID: 32374829

249. Antimicrobial Stewardship: A Potentially Important Benefit of a Group A Streptococcus **Vaccine** in Areas with Low Rates of Acute Rheumatic Fever.

Tanz RR, Shulman ST.

Clin Infect Dis. 2020 May 6. pii: ciaa533. doi: 10.1093/cid/ciaa533. [Epub ahead of print] No abstract available.

PMID: 32374821

250. A typology of beliefs and misperceptions about the influenza disease and **vaccine** among older adults in Singapore.

Cummings CL, Kong WY, Orminski J.

PLoS One. 2020 May 6;15(5):e0232472. doi: 10.1371/journal.pone.0232472. eCollection 2020.

PMID: 32374754

251. C57BL/6 α1,3-galactosyltransferase Knockout Mouse (α-GalT-KO) as an Animal Model for Experimental Chagas Disease.

Ayala EV, Rodrigues da Cunha GM, Azevedo MA, Calderon M, Jimenez J, Venuto AP, Gazzinelli RT, Lavalle R, Riva A, Hincapie R, Finn MG, Marques AF.

ACS Infect Dis. 2020 May 6. doi: 10.1021/acsinfecdis.0c00061. [Epub ahead of print]

PMID: 32374586

252. *Yamadazyma cocois* f.a., sp. nov., an ascomycetous yeast isolated from coconuts.

Maksimova IA, Glushakova AM, Thanh VN, Kachalkin AV.

Int J Syst Evol Microbiol. 2020 May 6. doi: 10.1099/ijsem.0.004203. [Epub ahead of print]

PMID: 32374249

253. Immunogenicity and Protective Efficacy of an EB66® Cell Culture-Derived Duck Tembusu Virus **Vaccine**.

Yang Z, Wang J, Wang X, Duan H, He P, Yang G, Liu L, Cheng H, Wang X, Pan J, Zhao J, Yu H, Yang B, Liu Y, Lin J.

Avian Pathol. 2020 May 6:1-37. doi: 10.1080/03079457.2020.1763914. [Epub ahead of print]

PMID: 32374185

254. Meta-analysis of immunogenicity and safety of human rabies vaccination under Zagreb and Essen regimens.

Li T, Wang X, Cheng H.

J Comp Eff Res. 2020 May 6. doi: 10.2217/cer-2019-0202. [Epub ahead of print]

PMID: 32374178

255. Sensitive Top-Down Proteomics Analysis of a Low Number of Mammalian Cells Using a Nanodroplet Sample Processing Platform.

Zhou M, Uwugiaren N, Williams SM, Moore RJ, Zhao R, Goodlett D, Dapic I, Paša-Tolić L, Zhu Y.

Anal Chem. 2020 May 6. doi: 10.1021/acs.analchem.0c00467. [Epub ahead of print]

PMID: 32374172

256. An Environmental and Health Perspective for COVID-19 Outbreak: Meteorology and Air Quality Influence, Sewage Epidemiology Indicator, Hospitals Disinfection, Drug Therapies and Recommendations.

Barcelo D.

J Environ Chem Eng. 2020 May 5:104006. doi: 10.1016/j.jece.2020.104006. [Epub ahead of print]

PMID: 32373461

257. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both *in vitro* and *in vivo*.

Xia L, Zheng ZZ, Liu JY, Chen YJ, Ding JC, Xia NS, Luo WX, Liu W.

Clin Transl Immunology. 2020 May 3;9(5):e01135. doi: 10.1002/cti2.1135. eCollection 2020 May.

PMID: 32373345

258. Trials of BCG **vaccine** will test for covid-19 protection.

Lawton G.

New Sci. 2020 May 2;246(3280):9. doi: 10.1016/S0262-4079(20)30836-8. Epub 2020 May 1. No abstract available.

PMID: 32372835

259. A **vaccine** is still a long way off.

Arnold C.

New Sci. 2020 May 2;246(3280):6. doi: 10.1016/S0262-4079(20)30831-9. Epub 2020 May 1.

PMID: 32372831

260. Estimands and inference in cluster-randomized **vaccine** trials.

Kilpatrick KW, Hudgens MG, Halloran ME.

Pharm Stat. 2020 May 5. doi: 10.1002/pst.2026. [Epub ahead of print]

PMID: 32372535

261. The Australian burden of invasive group A streptococcal disease - a narrative review.

Wright CM, Langworthy K, Manning L.

Intern Med J. 2020 May 5. doi: 10.1111/imj.14885. [Epub ahead of print]

PMID: 32372512

262. The inverse autotransporters of Yersinia ruckeri YrInv and YrIlm contribute to biofilm formation and virulence.

Wrobel A, Saragliadis A, Pérez-Ortega J, Sittman C, Göttig S, Liskewicz K, Spence MH, Schneider K, Leo JC, Arenas J, Linke D.

Environ Microbiol. 2020 May 5. doi: 10.1111/1462-2920.15051. [Epub ahead of print]

PMID: 32372498

263. HPV genotype contribution to cervical cancer and precancer: implication for screening and vaccination in Japan.

Onuki M, Matsumoto K, Iwata T, Yamamoto K, Aoki Y, Maenohara S, Tsuda N, Kamiura S, Takehara K, Horie K, Tasaka N, Yahata H, Takei Y, Aoki Y, Kato H, Motohara T, Nakamura K, Ishikawa M, Kato T, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yaegashi N, Yoshikawa H, Mint Study Group F.

Cancer Sci. 2020 May 6. doi: 10.1111/cas.14445. [Epub ahead of print]

PMID: 32372453

264. Barriers to Effective Tick Management and Tick-Bite Prevention in the United States (Acari: Ixodidae).

Eisen L, Stafford KC.

J Med Entomol. 2020 May 6. pii: tjaa079. doi: 10.1093/jme/tjaa079. [Epub ahead of print]

PMID: 32372075

265. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.

Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y.

J Hum Genet. 2020 May 6. doi: 10.1038/s10038-020-0771-5. [Epub ahead of print]

PMID: 32372051

266. Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies.

Bruxelle JF, Kirilenko T, Qureshi Q, Lu N, Trattnig N, Kosma P, Pantophlet R.

Sci Rep. 2020 May 5;10(1):7582. doi: 10.1038/s41598-020-64500-8.

PMID: 32371950

267. Association between media attention and presentation of vaccination information on Canadian chiropractors' websites: a prospective mixed-methods cohort study.

Kim Y, Akhtar AM, Natalwalla S, Goshua A, Wilson K, Busse JW.

CMAJ Open. 2020 May 5;8(2):E338-E345. doi: 10.9778/cmajo.20190204. Print 2020 Apr-Jun.

PMID: 32371527

268. Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy.

Amundson B, Lai L, Mulligan MJ, Xu Y, Zheng Z, Kundu S, Lennox JL, Waldrop-Valverde D, Franklin D, Swaims-Kohlmeier A, Letendre SL, Anderson AM.

J Neuroimmunol. 2020 Apr 27;344:577246. doi: 10.1016/j.jneuroim.2020.577246. [Epub ahead of print]

PMID: 32371201

269. Stemming cholera tides in Zimbabwe through mass vaccination.

Mukandavire Z, Manangazira P, Nyabadza F, Cuadros DF, Musuka G, Morris JG Jr.

Int J Infect Dis. 2020 May 1. pii: S1201-9712(20)30210-1. doi: 10.1016/j.ijid.2020.03.077. [Epub ahead of print]

PMID: 32371191

270. [Clarification on thiomersal in **vaccines**].

Aguilar Anyaypoma YM.

Aten Primaria. 2020 May 1. pii: S0212-6567(19)30368-3. doi: 10.1016/j.aprim.2019.07.012. [Epub ahead of print] Spanish. No abstract available.

PMID: 32371017

271. Comparison of personal and shared frameshift neoantigen **vaccines** in a mouse mammary cancer model.

Peterson M, Murphy SN, Lainson J, Zhang J, Shen L, Diehnelt CW, Johnston SA.

BMC Immunol. 2020 May 5;21(1):25. doi: 10.1186/s12865-020-00350-3.

PMID: 32370785

272. SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and **Vaccine** Developments.

Cao Z, Wu Y, Faucon E, Sabatier JM.

Infect Disord Drug Targets. 2020 May 5. doi: 10.2174/1871526520999200505174704. [Epub ahead of print] No abstract available.

PMID: 32370727

273. Identification of Novel Cytotoxic T Lymphocyte Epitopes of Drug-Resistance Related Protein InhA from Mycobacterium tuberculosis.

Li D, Dou Z, Wu Y, Qi Y, Chen J, Gao Y.

Protein Pept Lett. 2020 May 5. doi: 10.2174/0929866527666200505215346. [Epub ahead of print]

PMID: 32370703

274. Epistemic Egocentrism and Processing of **Vaccine** Misinformation (Vis-à-vis Scientific Evidence): The Case of **Vaccine**-Autism Link.

Shen L, Zhou Y.

Health Commun. 2020 May 5:1-12. doi: 10.1080/10410236.2020.1761074. [Epub ahead of print]

PMID: 32370560

275. Nanoparticles to Improve the Efficacy of **Vaccines**.

Yun CH, Cho CS.

Pharmaceutics. 2020 May 2;12(5). pii: E418. doi: 10.3390/pharmaceutics12050418.

PMID: 32370192

276. Molecular Evolution and Structural Mapping of N-Terminal Domain in Spike Gene of Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Naeem A, Hamed ME, Alghoribi MF, Aljabr W, Alsaran H, Enani MA, Alosaimi B.

Viruses. 2020 May 2;12(5). pii: E502. doi: 10.3390/v12050502.

PMID: 32370153

277. A Replication-Defective Influenza Virus **Vaccine** Confers Complete Protection against H7N9 Viral Infection in Mice.

Landreth S, Lu Y, Pandey K, Zhou Y.

Vaccines (Basel). 2020 May 2;8(2). pii: E207. doi: 10.3390/vaccines8020207.

PMID: 32370136

278. Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy.

Gao J, Zhang W, Ehrhardt A.

Cancers (Basel). 2020 May 2;12(5). pii: E1139. doi: 10.3390/cancers12051139. Review.

PMID: 32370135

279. Innovative Alternatives for Continuous *In Vitro* Culture of *Babesia bigemina* in Medium Free of Components of Animal Origin.

Álvarez Martínez JA, Figueroa Millán JV, Ueti MW, Rojas-Martínez C.

Pathogens. 2020 May 1;9(5). pii: E343. doi: 10.3390/pathogens9050343.

PMID: 32370024

280. Autologous Splenocyte Reinfusion Improves Antibody-Mediated Immune Response to the 23-Valent Pneumococcal Polysaccharide-Based **Vaccine** in Splenectomized Mice.

Li SC, Kabeer MH.

Biomolecules. 2020 May 1;10(5). pii: E704. doi: 10.3390/biom10050704.

PMID: 32369978

281. At the heart of COVID-19.

Khan IH, Zahra SA, Zaim S, Harky A.

J Card Surg. 2020 May 5. doi: 10.1111/jocs.14596. [Epub ahead of print] Review.

PMID: 32369872

282. The role of viral particle integrity in the serological assessment of foot-and-mouth disease virus **vaccine**-induced immunity in swine.

Mansilla FC, Turco CS, Miraglia MC, Bessone FA, Franco R, Pérez-Filgueira M, Sala JM, Capozzo AV.

PLoS One. 2020 May 5;15(5):e0232782. doi: 10.1371/journal.pone.0232782. eCollection 2020.

PMID: 32369529

283. Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages.

Alaluf E, Vokaer B, Detavernier A, Azouz A, Splittgerber M, Carrette A, Boon L, Libert F, Soares MP, Le Moine A, Goriely S.

JCI Insight. 2020 May 5. pii: 133929. doi: 10.1172/jci.insight.133929. [Epub ahead of print]

PMID: 32369450

284. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

Percival MM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, Shustov A, Tseng YD, Liu C, Pergam S, Libby EN, Scott BL, Smith SD, Green DJ, Gopal AK, Cowan AJ.

JCO Oncol Pract. 2020 May 5:OP2000241. doi: 10.1200/OP.20.00241. [Epub ahead of print]

PMID: 32369409

285. Pooling of Nasopharyngeal Swab Specimens for SARS-CoV-2 detection by RT-PCR.

Torres I, Albert E, Navarro D.

J Med Virol. 2020 May 5. doi: 10.1002/jmv.25971. [Epub ahead of print]

PMID: 32369202

286. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza **Vaccines** in Individuals 65 Years or Older.

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney KK.

JAMA Netw Open. 2020 May 1;3(5):e204079. doi: 10.1001/jamanetworkopen.2020.4079.

PMID: 32369177

287. Physician-to-Physician Electronic Consultation: A Tool for the Pediatric Infectious Diseases Specialist to Document Encounters and Quantify Effort.

Gonzalez BE, Sabella C, Esper FP, Daniels HL, Saracusa C, Boutros J, Foster CB.

J Pediatric Infect Dis Soc. 2020 May 5. pii: piaa041. doi: 10.1093/jpids/piaa041. [Epub ahead of print]

PMID: 32369170

288. The roles of dietary, nutritional, and lifestyle interventions in adipose tissue adaptation and obesity.

Bjørklund G, Tippairote T, Dadar M, Lizcano F, Aaseth J, Borisova O.

Curr Med Chem. 2020 May 4. doi: 10.2174/0929867327666200505090449. [Epub ahead of print]

PMID: 32368968

289. Severe acute respiratory syndrome-coronavirus 2 and novel coronavirus disease 2019: An extraordinary pandemic.

Singh S, Sharma BB.

Lung India. 2020 May-Jun;37(3):268-271. doi: 10.4103/lungindia.lungindia_170_20.

PMID: 32367852

290. SARS-CoV-2 variants: relevance for symptom granularity, epidemiology, immunity (herd, **vaccines**), virus origin and containment?

Danchin A, Timmis K.

Environ Microbiol. 2020 May 4. doi: 10.1111/1462-2920.15053. [Epub ahead of print]

PMID: 32367648

291. A Liquid chromatography coupled to quadrupole/time-of-flight mass spectrometer (LC-QTOF-MS) method for identification analysis of saponins from Quillaja saponaria bark extracts in foot-and-mouth disease **vaccines**: development, validation and applicability.

de Andrade DF, Jank L, Rego VB, Minozzo R, Sfoggia MVB, Bavaresco Á, Barreto F.

Biomed Chromatogr. 2020 May 5:e4873. doi: 10.1002/bmc.4873. [Epub ahead of print]

PMID: 32367529

292. A novel variant in C5ORF42 gene is associated with Joubert syndrome.

Mardani R, Taghizadeh E, Taheri F, Raeisi M, Karimzadeh MR, Rostami D, Ferns GA, Ghayour-Mobarhan M.

Mol Biol Rep. 2020 May 4. doi: 10.1007/s11033-020-05465-9. [Epub ahead of print]

PMID: 32367316

293. Detection of Group A Beta Hemolytic Streptococci Species, emm, and Exotoxin Genes Isolated from Patients with Tonsillopharyngitis.

Altun M, Mericli Yapıcı B.

Curr Microbiol. 2020 May 4. doi: 10.1007/s00284-020-01994-5. [Epub ahead of print]

PMID: 32367278

294. Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.

Moyad MA.

Curr Urol Rep. 2020 May 4;21(5):22. doi: 10.1007/s11934-020-00972-5. Review.

PMID: 32367257

295. Vaccination against the Epstein-Barr virus.

Rühl J, Leung CS, Münz C.

Cell Mol Life Sci. 2020 May 4. doi: 10.1007/s00018-020-03538-3. [Epub ahead of print] Review.

PMID: 32367191

296. Identification and Prediction of Tuberculosis in Eastern China: Analyses from 10-year Population-based Notification Data in Zhejiang Province, China.

Liu K, Li T, Vongpradith A, Wang F, Peng Y, Wang W, Chai C, Chen S, Zhang Y, Zhou L, Chen X, Bian Q, Chen B, Wang X, Jiang J.

Sci Rep. 2020 May 4;10(1):7425. doi: 10.1038/s41598-020-64387-5.

PMID: 32367050

297. Ex vivo pulsed dendritic cell vaccination against cancer.

Gu YZ, Zhao X, Song XR.

Acta Pharmacol Sin. 2020 May 4. doi: 10.1038/s41401-020-0415-5. [Epub ahead of print]

PMID: 32366940

298. Non-vector-borne transmission of lumpy skin disease virus.

Aleksandr K, Olga B, David WB, Pavel P, Yana P, Svetlana K, Alexander N, Vladimir R, Dmitriy L, Alexander S.

Sci Rep. 2020 May 4;10(1):7436. doi: 10.1038/s41598-020-64029-w.

PMID: 32366872

299. A human monoclonal antibody blocking SARS-CoV-2 infection.

Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ.

Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y. Erratum in: Nat Commun. 2020 May 14;11(1):2511.

PMID: 32366817

300. An Evidence Based Perspective on mRNA-SARS-CoV-2 **Vaccine** Development.

Wang F, Kream RM, Stefano GB.

Med Sci Monit. 2020 May 5;26:e924700. doi: 10.12659/MSM.924700. Review.

PMID: 32366816

301. Case for persuasion in parental informed consent to promote rational **vaccine** choices.

O'Neill J.

J Med Ethics. 2020 May 4. pii: medethics-2020-106068. doi: 10.1136/medethics-2020-106068. [Epub ahead of print]

PMID: 32366701

302. Site-specific glycan analysis of the SARS-CoV-2 spike.

Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M.

Science. 2020 May 4. pii: eabb9983. doi: 10.1126/science.abb9983. [Epub ahead of print]

PMID: 32366695

303. OpiA, a type six secretion system substrate, localizes to the cell pole and plays a role in bacterial growth and viability in *Francisella tularensis* LVS.

Cantlay S, Haggerty K, Horzempa J.

J Bacteriol. 2020 May 4. pii: JB.00048-20. doi: 10.1128/JB.00048-20. [Epub ahead of print]

PMID: 32366588

304. Developing a **vaccine** for covid-19.

Caddy S.

BMJ. 2020 May 4;369:m1790. doi: 10.1136/bmj.m1790. No abstract available.

PMID: 32366511

305. IL-26, a non-canonical mediator of DNA inflammatory stimulation, promotes TNBC engraftment and progression in association with neutrophils.

Trotter TN, Shuptrine CW, Tsao LC, Marek RD, Acharya C, Wei JP, Yang XY, Lei G, Wang T, Lyerly HK, Hartman ZC.

Cancer Res. 2020 May 4. pii: canres.3825.2018. doi: 10.1158/0008-5472.CAN-18-3825. [Epub ahead of print]

PMID: 32366475

306. The impact of sex and gender on immunotherapy outcomes.

Klein SL, Morgan R.

Biol Sex Differ. 2020 May 4;11(1):24. doi: 10.1186/s13293-020-00301-y. Review.

PMID: 32366281

307. **Vaccine** Design Informed by Virus-Induced Immunity.

Penkert RR, Hankins JS, Young NS, Hurwitz JL.

Viral Immunol. 2020 May;33(4):342-350. doi: 10.1089/vim.2019.0138. Epub 2020 May 5.

PMID: 32366204

308. Defining Essential Services for Deaf and Hard of Hearing Children during the COVID-19 Pandemic.

Pattisapu P, Evans SS, Noble AR, Norton SJ, Ou HC, Sie KCY, Horn DL.

Otolaryngol Head Neck Surg. 2020 May 5:194599820925058. doi: 10.1177/0194599820925058. [Epub ahead of print]

PMID: 32366178

309. Codon Usage and Phenotypic Divergences of SARS-CoV-2 Genes.

Dilucca M, Forcelloni S, Georgakilas AG, Giansanti A, Pavlopoulou A.

Viruses. 2020 Apr 30;12(5). pii: E498. doi: 10.3390/v12050498.

PMID: 32366025

310. Intention to Pay for HPV Vaccination among Women of Childbearing Age in Vietnam.

Le XTT, Nguyen PTN, Do TTT, Nguyen TH, Le HT, Nguyen CT, Ha GH, Hoang CL, Tran BX, Latkin CA, Ho RCM, Ho CSH.

Int J Environ Res Public Health. 2020 Apr 30;17(9). pii: E3144. doi: 10.3390/ijerph17093144.

PMID: 32365964

311. **Vaccine**-Mediated Mechanisms Controlling *Francisella tularensis* SCHU S4 Growth in a Rat Co-Culture System.

Lindgren H, Eneslätt K, Golovliov I, Gelhaus C, Rydén P, Wu T, Sjöstedt A.

Pathogens. 2020 Apr 30;9(5). pii: E338. doi: 10.3390/pathogens9050338.

PMID: 32365846

312. Opportunities for Conventional and in Situ Cancer **Vaccine** Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review.

Bouzid R, Peppelenbosch M, Buschow SI.

Cancers (Basel). 2020 Apr 30;12(5). pii: E1121. doi: 10.3390/cancers12051121. Review.

PMID: 32365838

313. Emerging Role of Exosomes in Diagnosis and Treatment of Infectious and Inflammatory Bowel Diseases.

Larabi A, Barnich N, Nguyen HTT.

Cells. 2020 Apr 30;9(5). pii: E1111. doi: 10.3390/cells9051111. Review.

PMID: 32365813

314. Genetic Diversity and Sequence Polymorphism of Two Genes Encoding Theileria parva Antigens Recognized by $CD8^+$ T Cells among Vaccinated and Unvaccinated Cattle in Malawi.

Chatanga E, Hayashida K, Muleya W, Kusakisako K, Moustafa MAM, Salim B, Katakura K, Sugimoto C, Nonaka N, Nakao R.

Pathogens. 2020 Apr 30;9(5). pii: E334. doi: 10.3390/pathogens9050334.

PMID: 32365795

315. Current State of Anthrax **Vaccines** and Key R&D Gaps Moving Forward.

Clark A, Wolfe DN.

Microorganisms. 2020 Apr 29;8(5). pii: E651. doi: 10.3390/microorganisms8050651. Review.

PMID: 32365729

316. Recombinant Filamentous Bacteriophages Encapsulated in Biodegradable Polymeric Microparticles for Stimulation of Innate and Adaptive Immune Responses.

Jamaledin R, Sartorius R, Di Natale C, Vecchione R, De Berardinis P, Netti PA.

Microorganisms. 2020 Apr 29;8(5). pii: E650. doi: 10.3390/microorganisms8050650.

PMID: 32365728

317. Sendai Virus, a Strong Inducer of Anti-Lentiviral State in Ovine Cells.

Pablo-Maiso L, Echeverría I, Rius-Rocabert S, Luján L, Garcin D, Andrés D, Nistal-Villán E, Reina R.

Vaccines (Basel). 2020 Apr 29;8(2). pii: E206. doi: 10.3390/vaccines8020206.

PMID: 32365702

318. Lipocalin2 Induced by Bacterial Flagellin Protects Mice against Cyclophosphamide Mediated Neutropenic Sepsis.

Lim D, Kim HK, Jeong JH, Jung YS, Lee SE, Jang HC, Jung SI, Choi HS, Rhee JH, Lee SG, Park C, Song M, Choy HE.

Microorganisms. 2020 Apr 29;8(5). pii: E646. doi: 10.3390/microorganisms8050646.

PMID: 32365611

319. Laser Scanning Confocal Microscopy Was Used to Validate the Presence of *Burkholderia Pseudomallei* or *B. Mallei* in Formalin-Fixed Paraffin Embedded Tissues.

Amemiya K, Zeng X, Bearss JJ, Cote CK, Soffler C, Bernhards RC, Dankmeyer JL, Ribot WJ, Trevino SR, Welkos SL, Worsham PL, Waag DM.

Trop Med Infect Dis. 2020 Apr 29;5(2). pii: E65. doi: 10.3390/tropicalmed5020065.

PMID: 32365605

320. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms.

Alanagreh L, Alzoughool F, Atoum M.

Pathogens. 2020 Apr 29;9(5). pii: E331. doi: 10.3390/pathogens9050331. Review.

PMID: 32365466

321. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform.

Thao TTN, Labroussaa F, Ebert N, V'kovski P, Stalder H, Portmann J, Kelly J, Steiner S, Holwerda M, Kratzel A, Gultom M, Schmied K, Laloli L, Hüsser L, Wider M, Pfaender S, Hirt D, Cippà V, Crespo-Pomar S, Schröder S, Muth D, Niemeyer D, Corman V, Müller MA, Drosten C, Dijkman R, Jores J, Thiel V.

Nature. 2020 May 4. doi: 10.1038/s41586-020-2294-9. [Epub ahead of print]

PMID: 32365353

322. [Bats and humans].

Sönnerborg A.

Lakartidningen. 2020 Apr 29;117. pii: F3UA. Swedish.

PMID: 32365214

323. Balancing Expediency and Scientific Rigor in SARS-CoV-2 **Vaccine** Development.

Graepel KW, Kochhar S, Clayton EW, Edwards KE.

J Infect Dis. 2020 May 4. pii: jiaa234. doi: 10.1093/infdis/jiaa234. [Epub ahead of print] No abstract available.

PMID: 32365191

324. Immunogenicity and safety of porcine circovirus-free human rotavirus **vaccine** in healthy infants: a phase III, randomized trial.

Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group.

J Infect Dis. 2020 May 4. pii: jiaa210. doi: 10.1093/infdis/jiaa210. [Epub ahead of print]

PMID: 32365189

325. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease.

Powell LA, Fox JM, Kose N, Kim AS, Majedi M, Bombardi R, Carnahan RH, Slaughter JC, Morrison TE, Diamond MS, Crowe JE Jr.

PLoS Pathog. 2020 May 4;16(5):e1008517. doi: 10.1371/journal.ppat.1008517. [Epub ahead of print]

PMID: 32365139

326. Better together: Elements of successful scientific software development in a distributed collaborative community.

Koehler Leman J, Weitzner BD, Renfrew PD, Lewis SM, Moretti R, Watkins AM, Mulligan VK, Lyskov S, Adolf-Bryfogle J, Labonte JW, Krys J; RosettaCommons Consortium, Bystroff C, Schief W, Gront D, Schueler-Furman O, Baker D, Bradley P, Dunbrack R, Kortemme T, Leaver-Fay A, Strauss CEM, Meiler J, Kuhlman B, Gray JJ, Bonneau R.

PLoS Comput Biol. 2020 May 4;16(5):e1007507. doi: 10.1371/journal.pcbi.1007507. eCollection 2020 May. Review.

PMID: 32365137

327. Structure and functional analysis of the Legionella pneumophila chitinase ChiA reveals a novel mechanism of metal-dependent mucin degradation.

Rehman S, Grigoryeva LS, Richardson KH, Corsini P, White RC, Shaw R, Portlock TJ, Dorgan B, Zanjani ZS, Fornili A, Cianciotto NP, Garnett JA.

PLoS Pathog. 2020 May 4;16(5):e1008342. doi: 10.1371/journal.ppat.1008342. eCollection 2020 May.

PMID: 32365117

328. Cytokine signatures of Plasmodium vivax infection during pregnancy and delivery outcomes.

Dobaño C, Bardají A, Arévalo-Herrera M, Martínez-Espinosa FE, Bôtto-Menezes C, Padilla N, Menegon M, Kochar S, Kochar SK, Unger H, Ome-Kaius M, Rosanas-Urgell A, Malheiros A, Castellanos ME, Hans D, Desai M, Casellas A, Chitnis CE, Severini C, Mueller I, Rogerson S, Menéndez C, Requena P.

PLoS Negl Trop Dis. 2020 May 4;14(5):e0008155. doi: 10.1371/journal.pntd.0008155. eCollection 2020 May.

PMID: 32365058

329. Administration with Vaccinia Virus Encoding Canine Parvovirus 2 *vp2* Elicits Systemic Immune Responses in Mice and Dogs.

Zhao W, Wang X, Li Y, Li Y.

Viral Immunol. 2020 May 4. doi: 10.1089/vim.2019.0164. [Epub ahead of print]

PMID: 32364832

330. Patterns of Influenza Vaccination and **Vaccine** Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness.

Chung JR, Flannery B, Gaglani M, Smith ME, Reis EC, Hickey RW, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Segaloff HE, Kim SS, Patel MM.

JAMA Pediatr. 2020 May 4. doi: 10.1001/jamapediatrics.2020.0372. [Epub ahead of print]

PMID: 32364599

331. Simplifying Glycan Profiling through a High-Throughput Micropermethylation Strategy.

Shajahan A, Supekar NT, Chapla D, Heiss C, Moremen KW, Azadi P.

SLAS Technol. 2020 May 4:2472630320912929. doi: 10.1177/2472630320912929. [Epub ahead of print]

PMID: 32364434

332. Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: A systematic review.

Verwey C, Nunes MC, Dangor Z, Madhi SA.

Pediatr Pulmonol. 2020 May 4. doi: 10.1002/ppul.24804. [Epub ahead of print] Review.

PMID: 32364320

333. COVID-19 and paediatric health services: A survey of paediatric physicians in Australia and New Zealand.

Foley DA, Kirk M, Jepp C, Brophy-Williams S, Tong SYC, Davis JS, Blyth CC, O'Brien MP, Bowen AC, Yeoh DK; Study endorsed by ASID CRN and ANZPID Group.

J Paediatr Child Health. 2020 May 4. doi: 10.1111/jpc.14903. [Epub ahead of print]

PMID: 32364301

334. Optimizing the case-crossover design for use in shared exposure settings.

Braeye T, Hens N.

Epidemiol Infect. 2020 May 4:1-29. doi: 10.1017/S0950268820000916. [Epub ahead of print] No abstract available.

PMID: 32364110

335. Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.

Wang W, Bai L, Xu D, Li W, Cui J.

Curr Cancer Drug Targets. 2020 May 4. doi: 10.2174/1568009620666200504111914. [Epub ahead of print]

PMID: 32364076

336. Effective Delivery of Nef-MPER-V3 Fusion Protein Using LDP12 Cell Penetrating Peptide for Development of Preventive/Therapeutic HIV-1 **Vaccine**.

Sabaghzadeh S, Sadat SM, Rohollah F, Bolhassani A.

Protein Pept Lett. 2020 May 4. doi: 10.2174/0929866527666200504121400. [Epub ahead of print]

PMID: 32364062

337. Experimental Analysis of T-Cell Epitopes for Designing Liver Cancer **Vaccine** Predicted by System Level Immunoinformatics Approach.

Muhammad SA, Zafar S, Rizvi SZ, Imran I, Munir F, Jamshed MB, Ali A, Wu X, Shahid N, Zaeem M, Zhang Q.

Am J Physiol Gastrointest Liver Physiol. 2020 May 4. doi: 10.1152/ajpgi.00068.2020. [Epub ahead of print]

PMID: 32363891

338. Chemical Synthesis and Immunological Evaluation of Helicobacter pylori Serotype O6 Tridecasaccharide O-Antigen Containing a Unique DD-Heptoglycan.

Yin J, Tian G, Hu J, Qin C, Li L, Zou X, Cai J, Seeberger PH.

Angew Chem Int Ed Engl. 2020 May 3. doi: 10.1002/anie.202004267. [Epub ahead of print]

PMID: 32363752

339. Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.

Pinheiro M, Gage JC, Clifford GM, Demarco M, Cheung LC, Chen Z, Yeager M, Cullen M, Boland JF, Chen X, Raine-Bennett T, Steinberg M, Bass S, Befano B, Xiao Y, Tenet V, Walker J, Zuna R, Poitras NE, Gold MA, Dunn T, Yu K, Zhu B, Burdett L, Turan S, Lorey T, Castle PE, Wentzensen N, Burk RD, Schiffman M, Mirabello L.

Int J Cancer. 2020 May 4. doi: 10.1002/ijc.33033. [Epub ahead of print]

PMID: 32363580

340. A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.

Cunnama L, Gomez GB, Siapka M, Herzel B, Hill J, Kairu A, Levin C, Okello D, DeCormier Plosky W, Garcia Baena I, Sweeney S, Vassall A, Sinanovic E.

Pharmacoeconomics. 2020 May 4. doi: 10.1007/s40273-020-00910-w. [Epub ahead of print] Review.

PMID: 32363543

341. Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.

Shajahan A, Supekar NT, Gleinich AS, Azadi P.

Glycobiology. 2020 May 4. pii: cwaa042. doi: 10.1093/glycob/cwaa042. [Epub ahead of print]

PMID: 32363391

342. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.

Lei J, Ploner A, Lehtinen M, Sparén P, Dillner J, Elfström KM.

Br J Cancer. 2020 May 4. doi: 10.1038/s41416-020-0850-6. [Epub ahead of print]

PMID: 32362659

343. Using Facebook to increase coverage of HPV vaccination among Danish girls: An assessment of a Danish social media campaign.

Loft LH, Pedersen EA, Jacobsen SU, Søborg B, Bigaard J.

Vaccine. 2020 Apr 30. pii: S0264-410X(20)30512-0. doi: 10.1016/j.**vaccine**.2020.04.032. [Epub ahead of print]

PMID: 32362529

344. Immunization with PhtD truncated fragments reduces nasopharyngeal colonization by Streptococcus pneumoniae.

André GO, Assoni L, Rodriguez D, Leite LCC, Dos Santos TEP, Ferraz LFC, Converso TR, Darrieux M.

Vaccine. 2020 Apr 30. pii: S0264-410X(20)30544-2. doi: 10.1016/j.**vaccine**.2020.04.050. [Epub ahead of print]

PMID: 32362528

345. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria **vaccine** alongside bed nets in Lilongwe, Malawi.

Bell GJ, Loop M, Topazian HM, Hudgens M, Mvalo T, Juliano JJ, Kamthunzi P, Tegha G, Mofolo I, Hoffman I, Bailey JA, Emch M.

Vaccine. 2020 May 22;38(25):4079-4087. doi: 10.1016/j.**vaccine**.2020.04.031. Epub 2020 Apr 30.

PMID: 32362527

346. Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas.

Bzhalava Z, Arroyo Mühr LS, Dillner J.

Vaccine. 2020 May 22;38(25):4066-4070. doi: 10.1016/j.**vaccine**.2020.04.049. Epub 2020 Apr 30.

PMID: 32362526

347. **Vaccine** stock management in primary health care facilities in OR Tambo District, Eastern Cape, South Africa.

Iwu CJ, Ngcobo N, McCaul M, Mangqalaza H, Magwaca A, Chikte U, Wiysonge CS.

Vaccine. 2020 May 22;38(25):4111-4118. doi: 10.1016/j.**vaccine**.2020.04.019. Epub 2020 Apr 30.

PMID: 32362525

348. Socioeconomic inequality trends in childhood vaccination coverage in India: Findings from multiple rounds of National Family Health Survey.

Khan N, Saggurti N.

Vaccine. 2020 May 22;38(25):4088-4103. doi: 10.1016/j.**vaccine**.2020.04.023. Epub 2020 Apr 30.

PMID: 32362524

349. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control.

Liu S, Bi Y, Liu Y.

Theor Biol Med Model. 2020 May 4;17(1):6. doi: 10.1186/s12976-020-00124-9.

PMID: 32362279

350. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.

Umesh, Kundu D, Selvaraj C, Singh SK, Dubey VK.

J Biomol Struct Dyn. 2020 May 2:1-9. doi: 10.1080/07391102.2020.1763202. [Epub ahead of print]

PMID: 32362243

351. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.

Kumar D, Kumari K, Jayaraj A, Kumar V, Kumar RV, Dass SK, Chandra R, Singh P.

J Biomol Struct Dyn. 2020 May 4:1-14. doi: 10.1080/07391102.2020.1752310. [Epub ahead of print]

PMID: 32362235

352. Integrative analysis of microRNA and mRNA expression profiles of monocyte-derived dendritic cells differentiation during experimental cerebral malaria.

Assis PA, Fernandes Durso D, Chacon Cavalcante F, Zaniratto R, Carvalho-Silva AC, Cunha-Neto E, Golenbock DT, Rodrigues Pinto Ferreira L, Tostes Gazzinelli R.

J Leukoc Biol. 2020 May 3. doi: 10.1002/JLB.1MA0320-731R. [Epub ahead of print]

PMID: 32362022

353. Factors associated with the uptake of the UK routine childhood immunization schedule in a bi-ethnic population.

Santorelli G, Mason D, Cartwright C, Inamdar L, Tomes C, Wright J.

Eur J Public Health. 2020 May 3. pii: ckaa069. doi: 10.1093/eurpub/ckaa069. [Epub ahead of print]

PMID: 32361768

354. Improving efficacy of glycoconjugate **vaccines**: from chemical conjugates to next generation constructs.

Berti F, Micoli F.

Curr Opin Immunol. 2020 Apr 30;65:42-49. doi: 10.1016/j.coi.2020.03.015. [Epub ahead of print] Review.

PMID: 32361591

355. Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?

Melgaço JG, Azamor T, Ano Bom APD.

Cell Immunol. 2020 Apr 28;353:104114. doi: 10.1016/j.cellimm.2020.104114. [Epub ahead of print]

PMID: 32361409

356. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.

Fleming AB, Raabe V.

J Clin Virol. 2020 Apr 28;127:104388. doi: 10.1016/j.jcv.2020.104388. [Epub ahead of print] No abstract available.

PMID: 32361326

357. Live attenuated TB **vaccines** representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro-American genetic background confers optimal **vaccine** potential.

Pérez I, Uranga S, Sayes F, Frigui W, Samper S, Arbués A, Aguiló N, Brosch R, Martín C, Gonzalo-Asensio J.

EBioMedicine. 2020 Apr 28;55:102761. doi: 10.1016/j.ebiom.2020.102761. [Epub ahead of print]

PMID: 32361249

358. Revisiting Aminocoumarins for the Treatment of Melioidosis.

Willcocks SJ, Cia F, Francisco AF, Wren BW.

Int J Antimicrob Agents. 2020 Apr 30:106002. doi: 10.1016/j.ijantimicag.2020.106002. [Epub ahead of print]

PMID: 32361027

359. Follow-up studies in COVID-19 recovered patients - is it mandatory?

Balachandar V, Mahalaxmi I, Subramaniam M, Kaavya J, Senthil Kumar N, Laldinmawii G, Narayanasamy A, Janardhana Kumar Reddy P, Sivaprakash P, Kanchana S, Vivekanandhan G, Cho SG.

Sci Total Environ. 2020 Apr 27;729:139021. doi: 10.1016/j.scitotenv.2020.139021. [Epub ahead of print] Review.

PMID: 32360909

360. Rotavirus and autoimmunity.

Gómez-Rial J, Rivero-Calle I, Salas A, Martinón-Torres F.

J Infect. 2020 Apr 30. pii: S0163-4453(20)30267-X. doi: 10.1016/j.jinf.2020.04.041. [Epub ahead of print] Review.

PMID: 32360880

361. Decreased prevalence of Moraxella catarrhalis in addition to Streptococcus pneumoniae in children with upper respiratory tract infection after introduction of conjugated pneumococcal **vaccine** - A retrospective cohort study.

Littorin N, Rünow E, Ahl J, Resman F, Riesbeck K.

Clin Microbiol Infect. 2020 Apr 30. pii: S1198-743X(20)30259-7. doi: 10.1016/j.cmi.2020.04.033. [Epub ahead of print]

PMID: 32360778

362. Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus.

Ngonghala CN, Iboi E, Eikenberry S, Scotch M, MacIntyre CR, Bonds MH, Gumel AB.

Math Biosci. 2020 May 1;325:108364. doi: 10.1016/j.mbs.2020.108364. [Epub ahead of print]

PMID: 32360770

363. Hepatitis B virus **vaccine**: A potential therapeutic alternative for the treatment of warts.

Nofal A, Elsayed E, Abdelshafy AS.

J Am Acad Dermatol. 2020 Apr 29. pii: S0190-9622(20)30749-0. doi: 10.1016/j.jaad.2020.04.128. [Epub ahead of print] No abstract available.

PMID: 32360758

364. Forecasting the timeframe of 2019-nCoV and human cells interaction with reverse engineering.

Sohail A, Nutini A.

Prog Biophys Mol Biol. 2020 Apr 29. pii: S0079-6107(20)30026-2. doi: 10.1016/j.pbiomolbio.2020.04.002. [Epub ahead of print]

PMID: 32360608

365. Fermentation, purification and immunogenicity of a recombinant tumor multi-epitope **vaccine**, VBP3.

Zhang L, Chen X, Deng Y, Jiang C, Deng N.

Protein Expr Purif. 2020 Apr 28;174:105658. doi: 10.1016/j.pep.2020.105658. [Epub ahead of print]

PMID: 32360598

366. Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer.

Li T, Zhou X, Wang J, Liu Z, Han S, Wan L, Sun X, Chen H.

Pharmacol Res. 2020 Apr 30;157:104843. doi: 10.1016/j.phrs.2020.104843. [Epub ahead of print]

PMID: 32360582

367. A family of serine protease inhibitors (serpins) and its expression profiles in the ovaries of Rhipicephalus haemaphysaloides.

Xu Z, Yan Y, Cao J, Zhou Y, Zhang H, Xu Q, Zhou J.

Infect Genet Evol. 2020 Apr 29:104346. doi: 10.1016/j.meegid.2020.104346. [Epub ahead of print]

PMID: 32360539

368. Candidate drugs against SARS-CoV-2 and COVID-19.

McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C.

Pharmacol Res. 2020 Apr 29;157:104859. doi: 10.1016/j.phrs.2020.104859. [Epub ahead of print] Review.

PMID: 32360480

369. A cutting-edge immunoinformatics approach for design of multi-epitope oral **vaccine** against dreadful human malaria.

Pritam M, Singh G, Swaroop S, Singh AK, Pandey B, Singh SP.

Int J Biol Macromol. 2020 Apr 29;158:159-179. doi: 10.1016/j.ijbiomac.2020.04.191. [Epub ahead of print]

PMID: 32360460

370. Kinetics of transcriptional response against poly (I:C) and infectious salmon anemia virus (ISAV) in Atlantic salmon kidney (ASK) cell line.

Andresen AMS, Boudinot P, Gjøen T.

Dev Comp Immunol. 2020 Apr 29;110:103716. doi: 10.1016/j.dci.2020.103716. [Epub ahead of print]

PMID: 32360383

371. Commonly Used Adjuvant Human **Vaccines**: Advantages and Side Effects.

Villarreal R, Casale TB.

J Allergy Clin Immunol Pract. 2020 Apr 28. pii: S2213-2198(20)30402-5. doi: 10.1016/j.jaip.2020.04.045. [Epub ahead of print]

PMID: 32360184

372. Evaluation of seven commercial African swine fever virus detection kits and three Taq polymerases on 300 well-characterized field samples.

Schoder ME, Tignon M, Linden A, Vervaeke M, Cay AB.

J Virol Methods. 2020 Apr 29;280:113874. doi: 10.1016/j.jviromet.2020.113874. [Epub ahead of print]

PMID: 32360149

373. A three-dimensional A549 cell culture model to study respiratory syncytial virus infections.

Saleh F, Harb A, Soudani N, Zaraket H.

J Infect Public Health. 2020 Apr 29. pii: S1876-0341(20)30412-3. doi: 10.1016/j.jiph.2020.03.011. [Epub ahead of print]

PMID: 32360024

374. Hospital-based surveillance of severe rotavirus gastroenteritis and rotavirus strains in young Taiwanese children.

Kung YH, Chi H, Liu CC, Huang YC, Huang YC, Wu FT, Huang LM; Taiwan Pediatric Infectious Disease Alliance.

J Formos Med Assoc. 2020 Apr 28. pii: S0929-6646(20)30111-X. doi: 10.1016/j.jfma.2020.03.019. [Epub ahead of print]

PMID: 32359880

375. Gonococcal **vaccines**: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.

Gottlieb SL, Ndowa F, Hook EW 3rd, Deal C, Bachmann L, Abu-Raddad L, Chen XS, Jerse A, Low N, MacLennan CA, Petousis-Harris H, Seib KL, Unemo M, Vincent L, Giersing BK; Gonococcal **Vaccine** PPC Expert Advisory Group.

Vaccine. 2020 Apr 28. pii: S0264-410X(20)30317-0. doi: 10.1016/j.**vaccine**.2020.02.073. [Epub ahead of print]

PMID: 32359875

376. Validation of the new Swedish vaccination register - Accuracy and completeness of register data.

Chrapkowska C, Galanis I, Kark M, Lepp T, Lindstrand A, Roth A, Nilsson A.

Vaccine. 2020 May 22;38(25):4104-4110. doi: 10.1016/j.**vaccine**.2020.04.020. Epub 2020 Apr 28.

PMID: 32359874

377. The RH5-CyRPA-Ripr Complex as a Malaria **Vaccine** Target.

Ragotte RJ, Higgins MK, Draper SJ.

Trends Parasitol. 2020 Jun;36(6):545-559. doi: 10.1016/j.pt.2020.04.003. Epub 2020 Apr 28. Review.

PMID: 32359873

378. Pharmacist and pharmacy intern perceptions of adolescent vaccination administration.

McCauley LM, Lake LM, Madison NR, Huntsman RE, Baker CM.

J Am Pharm Assoc (2003). 2020 Apr 29. pii: S1544-3191(20)30115-1. doi: 10.1016/j.japh.2020.03.002. [Epub ahead of print]

PMID: 32359813

379. Trends in school-level vaccination coverage from 2015 to 2018: Increases in exemption rates and declines in herd immunity in Arizona.

Sangha P, McCullough JM.

Vaccine. 2020 May 22;38(25):4071-4078. doi: 10.1016/j.**vaccine**.2020.04.030. Epub 2020 Apr 30.

PMID: 32359798

380. Distribution of HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles and haplotypes in Jingpo minority in Yunnan province of China.

Tao Y, Shi L, Liu S, Yao Y, Shi L.

Hum Immunol. 2020 Apr 29. pii: S0198-8859(20)30159-2. doi: 10.1016/j.humimm.2020.04.008. [Epub ahead of print]

PMID: 32359785

381. In-ovo Newcastle disease virus **vaccine** strain TS09-C protects commercial chickens against Newcastle disease in the presence of maternally derived antibodies.

Fan S, Wu Y, Wang H, Shang Y, Luo Q, Zhang T, Zhang R, Zhang W, Luo L, Shao H, Wen G.

Poult Sci. 2020 May;99(5):2438-2443. doi: 10.1016/j.psj.2020.01.006. Epub 2020 Mar 20.

PMID: 32359578

382. Sequencing and phylogenetic analysis of partial S1 genes of avian orthoreovirus isolates in Shandong province during 2015-2017.

Chen H, Yan M, Tang Y, Diao Y.

Poult Sci. 2020 May;99(5):2416-2423. doi: 10.1016/j.psj.2019.11.067. Epub 2020 Feb 28.

PMID: 32359576

383. COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives.

Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J, Veit M, Su S.

Trends Mol Med. 2020 May;26(5):483-495. doi: 10.1016/j.molmed.2020.02.008. Epub 2020 Mar 21. Review.

PMID: 32359479

384. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29.

Alexander SPH, Armstrong J, Davenport AP, Davies J, Faccenda E, Harding SD, Levi-Schaffer F, Maguire JJ, Pawson AJ, Southan C, Spedding MJ.

Br J Pharmacol. 2020 May 1. doi: 10.1111/bph.15094. [Epub ahead of print] Review.

PMID: 32358833

385. Significance of norovirus in occupational health: a review of published norovirus outbreaks in Central and Northern Europe.

Hofmann FM, Olawumi E, Michaelis M, Stößel U, Hofmann F.

Int Arch Occup Environ Health. 2020 May 1. doi: 10.1007/s00420-020-01543-4. [Epub ahead of print] Review.

PMID: 32358716

386. The American College of Nuclear Medicine Guidance on Operating Procedures for a Nuclear Medicine Facility During COVID-19 Pandemic.

Tulchinsky M, Osmany S.

Clin Nucl Med. 2020 May 1. doi: 10.1097/RLU.0000000000003146. [Epub ahead of print]

PMID: 32358234

387. Demystifying BCG **Vaccine** and COVID-19 Relationship.

Kumar J, Meena J.

Indian Pediatr. 2020 Apr 30. pii: S097475591600168. [Epub ahead of print] No abstract available.

PMID: 32358227

388. Risk of MS relapse after yellow fever vaccination: A self-controlled case series.

Huttner A, Eperon G, Lascano AM, Roth S, Schwob JM, Siegrist CA, Lalive PH.

Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4). pii: e726. doi: 10.1212/NXI.0000000000000726. Print 2020 Jul.

PMID: 32358223

389. The structural basis of African swine fever virus pA104R binding to DNA and its inhibition by stilbene derivatives.

Liu R, Sun Y, Chai Y, Li S, Li S, Wang L, Su J, Yu S, Yan J, Gao F, Zhang G, Qiu HJ, Gao GF, Qi J, Wang H.

Proc Natl Acad Sci U S A. 2020 May 1. pii: 201922523. doi: 10.1073/pnas.1922523117. [Epub ahead of print]

PMID: 32358196

390. A respiratory syncytial virus (RSV) F protein nanoparticle **vaccine** focuses antibody responses to a conserved neutralization domain.

Swanson KA, Rainho-Tomko JN, Williams ZP, Lanza L, Peredelchuk M, Kishko M, Pavot V, Alamares-Sapuay J, Adhikarla H, Gupta S, Chivukula S, Gallichan S, Zhang L, Jackson N, Yoon H, Edwards D, Wei CJ, Nabel GJ.

Sci Immunol. 2020 May 1;5(47). pii: eaba6466. doi: 10.1126/sciimmunol.aba6466.

PMID: 32358170

391. CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent **Vaccine** against *Coccidioides posadasii* Infection.

Campuzano A, Zhang H, Ostroff GR, Dos Santos Dias L, Wüthrich M, Klein BS, Yu JJ, Lara HH, Lopez-Ribot JL, Hung CY.

J Immunol. 2020 May 1. pii: ji1900793. doi: 10.4049/jimmunol.1900793. [Epub ahead of print]

PMID: 32358020

392. The role of antigen-spreading in the efficacy of immunotherapies.

Brossart P.

Clin Cancer Res. 2020 May 1. pii: clincanres.0305.2020. doi: 10.1158/1078-0432.CCR-20-0305. [Epub ahead of print]

PMID: 32357962

393. An 81 nucleotide deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (Jan-Mar 2020).

Holland LA, Kaelin EA, Maqsood R, Estifanos B, Wu LI, Varsani A, Halden RU, Hogue BG, Scotch M, Lim ES.

J Virol. 2020 May 1. pii: JVI.00711-20. doi: 10.1128/JVI.00711-20. [Epub ahead of print]

PMID: 32357959

394. Genomic heterogeneity of Dichelobacter nodosus within and between UK sheep flocks and between age groups within a flock.

Davies PL, Blanchard AM, Staley CE, Bollard NJ, Coffey TJ, Tötemeyer S.

BMC Microbiol. 2020 May 1;20(1):107. doi: 10.1186/s12866-020-01769-9.

PMID: 32357840

395. **Vaccine** and Cell Based Therapeutic Approaches in Acute Myeloid Leukemia.

Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H.

Curr Cancer Drug Targets. 2020 May 1. doi: 10.2174/1568009620666200502011059. [Epub ahead of print]

PMID: 32357813

396. Escherichia coli ST131 clones harbouring AggR and AAF/V fimbriae causing bacteremia in Mozambican children: Emergence of new variant of fimH27 subclone.

Mandomando I, Vubil D, Boisen N, Quintó L, Ruiz J, Sigaúque B, Nhampossa T, Garrine M, Massora S, Aide P, Nhacolo A, Pons MJ, Bassat Q, Vila J, Macete E, Scheutz F, Levine MM, Ruiz-Perez F, Nataro JP, Alonso PL.

PLoS Negl Trop Dis. 2020 May 1;14(5):e0008274. doi: 10.1371/journal.pntd.0008274. eCollection 2020 May.

PMID: 32357189

397. A systematic comparison of triterpenoid biosynthetic enzymes for the production of oleanolic acid in Saccharomyces cerevisiae.

Dale MP, Moses T, Johnston EJ, Rosser SJ.

PLoS One. 2020 May 1;15(5):e0231980. doi: 10.1371/journal.pone.0231980. eCollection 2020.

PMID: 32357188

398. Pneumococcal (Pneumonia) **Vaccines**.

Shah P, Woytanowski JR, Hadeh A, Sockrider M.

Am J Respir Crit Care Med. 2020 May 1;201(9):P17-P18. doi: 10.1164/rccm.2019P17. No abstract available.

PMID: 32356685

399. Averting transmission: A pivotal target to manage amoebiasis.

Rawat A, Singh P, Jyoti A, Kaushik S, Srivastava VK.

Chem Biol Drug Des. 2020 Apr 30. doi: 10.1111/cbdd.13699. [Epub ahead of print] Review.

PMID: 32356312

400. [Pandemic Disaster from a Legal and Medical Point of View].

Walus A, Holbe F.

Gesundheitswesen. 2020 Apr 30. doi: 10.1055/a-1152-4836. [Epub ahead of print] German.

PMID: 32356300

401. COVID-19: Therapeutics and Their Toxicities.

Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM.

J Med Toxicol. 2020 Apr 30. doi: 10.1007/s13181-020-00777-5. [Epub ahead of print] Review.

PMID: 32356252

402. Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Berendam SJ, Nelson AN, Goswami R, Persaud D, Haigwood NL, Chahroudi A, Fouda GG, Permar SR.

Curr HIV/AIDS Rep. 2020 May 1. doi: 10.1007/s11904-020-00495-1. [Epub ahead of print] Review.

PMID: 32356090

403. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and **vaccine** route.

Edelman R, Deming ME, Toapanta FR, Heuser MD, Chrisley L, Barnes RS, Wasserman SS, Blackwelder WC, Handwerger BS, Pasetti M, Siddiqui KM, Sztein MB.

Immun Ageing. 2020 Apr 28;17:9. doi: 10.1186/s12979-020-00179-9. eCollection 2020.

PMID: 32355503

404. Geospatial clustering, seasonal trend and forecasting of Kyasanur Forest Disease in the state of Goa, India, 2015-2018.

Oliveira A, Selvaraj K, Tripathy JP, Betodkar U, Cacodcar J, Quadros N, Wadkar A.

Trop Med Health. 2020 Apr 28;48:27. doi: 10.1186/s41182-020-00213-y. eCollection 2020.

PMID: 32355449

405. A field comparison of heterologous and homologous routes of administration of modified live **vaccines** for the control of bovine respiratory disease in recently weaned beef calves.

Erickson N, Ellis J, Waldner C, Lardner H, Gow S, Campbell J, Berenik A.

Can Vet J. 2020 May;61(5):530-533.

PMID: 32355354

406. Prevention of respiratory infections with alpha- and gamma-herpesviruses in weanling foals by using a modified live intra-nasal equine influenza **vaccine**.

Salco R, Bowers J, Hernandez V, Barnum S, Pusterla N.

Can Vet J. 2020 May;61(5):517-520.

PMID: 32355351

407. Inactivated **vaccine** for SARS-CoV-2.

Risson E.

Nat Rev Immunol. 2020 Apr 30. doi: 10.1038/s41577-020-0334-1. [Epub ahead of print] No abstract available.

PMID: 32355330

408. A novel **vaccine** target for malaria.

Wrighton KH.

Nat Rev Drug Discov. 2020 Apr 30. doi: 10.1038/d41573-020-00082-4. [Epub ahead of print] No abstract available.

PMID: 32355320

409. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy.

Zhong XF, Sun X.

Acta Pharmacol Sin. 2020 Apr 30. doi: 10.1038/s41401-020-0414-6. [Epub ahead of print]

PMID: 32355277

410. Scores of coronavirus **vaccines** are in competition - how will scientists choose the best?

Callaway E.

Nature. 2020 Apr 30. doi: 10.1038/d41586-020-01247-2. [Epub ahead of print] No abstract available.

PMID: 32355243

411. Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.

Zebertavage LK, Alice A, Crittenden MR, Gough MJ.

Sci Rep. 2020 Apr 30;10(1):7376. doi: 10.1038/s41598-020-64408-3.

PMID: 32355214

412. Intranasal immunization with outer membrane vesicle pertussis **vaccine** confers broad protection through mucosal IgA and Th17 responses.

Raeven RHM, Rockx-Brouwer D, Kanojia G, van der Maas L, Bindels THE, Ten Have R, van Riet E, Metz B, Kersten GFA.

Sci Rep. 2020 Apr 30;10(1):7396. doi: 10.1038/s41598-020-63998-2.

PMID: 32355188

413. Structure of P46, an immunodominant surface protein from Mycoplasma hyopneumoniae: interaction with a monoclonal antibody.

Guasch A, Montané J, Moros A, Piñol J, Sitjà M, González-González L, Fita I.

Acta Crystallogr D Struct Biol. 2020 May 1;76(Pt 5):418-427. doi: 10.1107/S2059798320003903. Epub 2020 Apr 15.

PMID: 32355038

414. COVID-19 shot protects monkeys.

Cohen J.

Science. 2020 May 1;368(6490):456-457. doi: 10.1126/science.368.6490.456. No abstract available.

PMID: 32355008

415. Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study.

Paraskevaidis E, Athanasiou A, Paraskevaidi M, Bilirakis E, Galazios G, Kontomanolis E, Dinas K, Loufopoulos A, Nasioutziki M, Kalogiannidis I, Athanasiadis A, Papanikolaou A, Vatopoulou A, Grimbizis G, Tsolakidis D, Daponte A, Valasoulis G, Gritzeli S, Michail G, Adonakis G, Paschopoulos M, Tsonis O, Anaforidou ME, Batistatou A, Kyrgiou M; HeCPA (Hellenic Cervical Pathology Academic) Group.

In Vivo. 2020 May-Jun;34(3):1445-1449. doi: 10.21873/invivo.11927.

PMID: 32354944

416. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis.

Lau TS, Chan LK, Man GC, Wong CH, Lee JH, Yim SF, Cheung TH, McNeish IA, Kwong J.

Cancer Immunol Res. 2020 Apr 30. pii: canimm.0616.2019. doi: 10.1158/2326-6066.CIR-19-0616. [Epub ahead of print]

PMID: 32354736

417. HPV **vaccine** uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention.

Scarinci IC, Hansen B, Kim YI.

Vaccine. 2020 May 22;38(25):4125-4134. doi: 10.1016/j.**vaccine**.2020.03.052. Epub 2020 Apr 27.

PMID: 32354671

418. Influenza **vaccine** in patients on biological therapy; also with belimumab.

Callejas Rubio JL, Valero Ubierna C, Ortego Centeno N.

Med Clin (Barc). 2020 Apr 27. pii: S0025-7753(20)30161-5. doi: 10.1016/j.medcli.2019.12.026. [Epub ahead of print] English, Spanish. No abstract available.

PMID: 32354554

419. Parents' perspectives about **vaccine** hesitancies and **vaccine** rejection, in the west of Turkey.

Akbas Gunes N.

J Pediatr Nurs. 2020 Apr 27. pii: S0882-5963(20)30079-8. doi: 10.1016/j.pedn.2020.04.001. [Epub ahead of print]

PMID: 32354456

420. Infection with the sheep gastrointestinal nematode Teladorsagia circumcincta increases luminal pathobionts.

Cortés A, Wills J, Su X, Hewitt RE, Robertson J, Scotti R, Price DRG, Bartley Y, McNeilly TN, Krause L, Powell JJ, Nisbet AJ, Cantacessi C.

Microbiome. 2020 Apr 30;8(1):60. doi: 10.1186/s40168-020-00818-9.

PMID: 32354347

421. A Novel Recombinant Newcastle Disease Virus Vectored DIVA **Vaccine** against Peste des Petits Ruminants in Goats.

Murr M, Hoffmann B, Grund C, Römer-Oberdörfer A, Mettenleiter TC.

Vaccines (Basel). 2020 Apr 28;8(2). pii: E205. doi: 10.3390/vaccines8020205.

PMID: 32354145

422. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges.

Sivasankarapillai VS, Pillai AM, Rahdar A, Sobha AP, Das SS, Mitropoulos AC, Mokarrar MH, Kyzas GZ.

Nanomaterials (Basel). 2020 Apr 28;10(5). pii: E852. doi: 10.3390/nano10050852. Review.

PMID: 32354113

423. Systemic Sclerosis and Vaccinations: A Register-Based Cohort Study about Seasonal Influenza and Streptococcus pneumoniae Vaccination Rate and Uptake from Liguria Regional Center, Northwest Italy.

Murdaca G, Noberasco G, Battaglini A, Vassallo C, Giusti F, Greco M, Schiavi C, Sticchi L, Icardi G, Orsi A.

Vaccines (Basel). 2020 Apr 28;8(2). pii: E204. doi: 10.3390/vaccines8020204.

PMID: 32354027

424. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design.

Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A.

Int J Mol Sci. 2020 Apr 28;21(9). pii: E3099. doi: 10.3390/ijms21093099.

PMID: 32353978

425. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.

Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P.

Vaccines (Basel). 2020 Apr 28;8(2). pii: E203. doi: 10.3390/vaccines8020203.

PMID: 32353934

426. $CD8^+$ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma.

García-Marín R, Reda S, Riobello C, Cabal VN, Suárez-Fernández L, Vivanco B, López F, Llorente JL, Hermsen MA.

Vaccines (Basel). 2020 Apr 28;8(2). pii: E202. doi: 10.3390/vaccines8020202.

PMID: 32353928

427. The Antifungal pipeline: the need is established, are there new compounds?

Li D, She X, Calderone R.

FEMS Yeast Res. 2020 Apr 30. pii: foaa023. doi: 10.1093/femsyr/foaa023. [Epub ahead of print]

PMID: 32353872

428. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ.

Nature. 2020 Apr 30. doi: 10.1038/s41586-020-2286-9. [Epub ahead of print]

PMID: 32353859

429. Xanthenedione (and intermediates involved in their synthesis) inhibit Zika virus migration to the central nervous system in murine neonatal models.

Poly da Silva ÍE, Lopes da Silva M, Dias RS, Santos EG, Brangioni de Paula MC, Silva de Oliveira A, Costa da Silveira Oliveira AF, Marques de Oliveira F, Canedo da Silva C, Teixeira RR, Oliveira de Paula S.

Microbes Infect. 2020 Apr 27. pii: S1286-4579(20)30074-5. doi: 10.1016/j.micinf.2020.04.007. [Epub ahead of print]

PMID: 32353601

430. Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection.

Zhong Y, Chen J, Liu Y, Zhang Y, Tang C, Wang X, Wang P, Chen W, Wei B, Liu M.

Microb Pathog. 2020 Apr 27;145:104229. doi: 10.1016/j.micpath.2020.104229. [Epub ahead of print]

PMID: 32353579

431. Genotyping coronavirus SARS-CoV-2: methods and implications.

Yin C.

Genomics. 2020 Apr 27. pii: S0888-7543(20)30318-9. doi: 10.1016/j.ygeno.2020.04.016. [Epub ahead of print]

PMID: 32353474

432. Towards an understanding of the adsorption of vaporized hydrogen peroxide (VHP) residues on glass vials after a VHP decontamination process using a miniaturized tool.

Kushwah V, Poms J, Vuylsteke B, Peter A, Paudel A.

J Pharm Sci. 2020 Apr 27. pii: S0022-3549(20)30205-7. doi: 10.1016/j.xphs.2020.04.012. [Epub ahead of print]

PMID: 32353452

433. What policy makers need to know about COVID-19 protective immunity.

Altmann DM, Douek DC, Boyton RJ.

Lancet. 2020 May 16;395(10236):1527-1529. doi: 10.1016/S0140-6736(20)30985-5. Epub 2020 Apr 27. No abstract available.

PMID: 32353328

434. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.

Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS.

Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29.

PMID: 32353252

435. Quantitative proteomic analysis to determine differentially expressed proteins in axenic amastigotes of Leishmania tropica and Leishmania major.

Ashrafmansouri M, Amiri-Dashatan N, Ahmadi N, Rezaei-Tavirani M, SeyyedTabaei S, Haghighi A.

IUBMB Life. 2020 Apr 30. doi: 10.1002/iub.2300. [Epub ahead of print]

PMID: 32353219

436. Do plasma cells contribute to the determination of their lifespan?

Tarlinton D.

Immunol Cell Biol. 2020 Apr 30. doi: 10.1111/imcb.12346. [Epub ahead of print] Review.

PMID: 32353190

437. Willingness to pay for oral cholera **vaccines** in urban Bangladesh.

Sarker AR, Islam Z, Sultana M, Sheikh N, Mahumud RA, Islam MT, Meer RV, Morton A, Khan AI, Clemens JD, Qadri F, Khan JAM.

PLoS One. 2020 Apr 30;15(4):e0232600. doi: 10.1371/journal.pone.0232600. eCollection 2020.

PMID: 32353086

438. Murine gammaherpesvirus infection is skewed toward Igλ+ B cells expressing a specific heavy chain V-segment.

Collins CM, Scharer CD, Murphy TJ, Boss JM, Speck SH.

PLoS Pathog. 2020 Apr 30;16(4):e1008438. doi: 10.1371/journal.ppat.1008438. eCollection 2020 Apr.

PMID: 32353066

439. Ehrlichia chaffeensis TRP120-mediated ubiquitination and proteasomal degradation of tumor suppressor FBW7 increases oncoprotein stability and promotes infection.

Wang JY, Zhu B, Patterson LL, Rogan MR, Kibler CE, McBride JW.

PLoS Pathog. 2020 Apr 30;16(4):e1008541. doi: 10.1371/journal.ppat.1008541. eCollection 2020 Apr.

PMID: 32353058

440. A qPCR assay for Bordetella pertussis cells that enumerates both live and dead bacteria.

Ramkissoon S, MacArthur I, Ibrahim M, de Graaf H, Read RC, Preston A.

PLoS One. 2020 Apr 30;15(4):e0232334. doi: 10.1371/journal.pone.0232334. eCollection 2020.

PMID: 32353041

441. Determining hematological, biochemical and immunological reference values in healthy adults with high-risk for HIV acquisition in Mozambique.

Cumbane V, Imbach M, Chissumba RM, Macicame I, Eller LA, Lawlor J, Milazzo M, Li Q, Crowell T, Mutombene M, Guiliche O, Viegas E, Nwoga C, Yates A, Michael N, Robb M, Polyak CS, Jani IV, Bhatt N.

PLoS One. 2020 Apr 30;15(4):e0232018. doi: 10.1371/journal.pone.0232018. eCollection 2020.

PMID: 32352972

442. Progress Toward Maternal and Neonatal Tetanus Elimination - Worldwide, 2000-2018.

Njuguna HN, Yusuf N, Raza AA, Ahmed B, Tohme RA.

MMWR Morb Mortal Wkly Rep. 2020 May 1;69(17):515-520. doi: 10.15585/mmwr.mm6917a2.

PMID: 32352953

443. The Role of Psychiatric-Mental Health Nurses and Nurse Practitioners in HPV **Vaccine** Uptake: Offering Unified Messaging.

Townsend H, Bartlett R.

J Psychosoc Nurs Ment Health Serv. 2020 May 1;58(5):2-4. doi: 10.3928/02793695-20200417-02. No abstract available.

PMID: 32352552

444. Prototype pathogen approach for pandemic preparedness: world on fire.

Graham BS, Corbett KS.

J Clin Invest. 2020 Apr 30. pii: 139601. doi: 10.1172/JCI139601. [Epub ahead of print]

PMID: 32352406

445. Inadequate awareness of cervical cancer and its prevention among young women of Delhi, India: public health policy implications.

Sharma P, Bhilwar M, Tiwari P, Parija PP, Saha SK, Mehra K.

Int J Adolesc Med Health. 2020 May 1. pii: /j/ijamh.ahead-of-print/ijamh-2019-0108/ijamh-2019-0108.xml. doi: 10.1515/ijamh-2019-0108. [Epub ahead of print]

PMID: 32352403

446. The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions.

Hens N, Vranck P, Molenberghs G.

Eur Heart J Acute Cardiovasc Care. 2020 Apr 30:2048872620924922. doi: 10.1177/2048872620924922. [Epub ahead of print]

PMID: 32352314

447. Latency characteristics in specific pathogen free chickens 21 and 35 days after intratracheal inoculation with **vaccine** or field strains of infectious laryngotracheitis virus.

Thilakarathne DS, Hartley CA, Diaz-Méndez A, Quinteros JA, Fakhri O, Coppo MJ, Devlin JM.

Avian Pathol. 2020 Apr 30:1-35. doi: 10.1080/03079457.2020.1754331. [Epub ahead of print]

PMID: 32352307

448. Epitope based **vaccine** prediction for SARS-COV-2 by deploying immuno-informatics approach.

Joshi A, Joshi BC, Mannan MA, Kaushik V.

Inform Med Unlocked. 2020 Apr 29:100338. doi: 10.1016/j.imu.2020.100338. [Epub ahead of print]

PMID: 32352026

449. Pilchard orthomyxovirus (POMV). II. Causative agent of salmon orthomyxoviral necrosis, a new disease of farmed Atlantic salmon Salmo salar.

Godwin SE, Morrison RN, Knowles G, Cornish MC, Hayes D, Carson J.

Dis Aquat Organ. 2020 Apr 30;139:51-68. doi: 10.3354/dao03469.

PMID: 32351236

450. Infectious hematopoietic necrosis virus truncated G protein effect on survival, immune response, and disease resistance in rainbow trout.

Hua X, Feng Y, Guan X, Wang Y, Zhou Y, Ren X, Li D, Gao S, Huang J, Guan X, Shi W, Liu M.

Dis Aquat Organ. 2020 Apr 30;139:25-33. doi: 10.3354/dao03463.

PMID: 32351234

451. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC.

FASEB J. 2020 May;34(5):6027-6037. doi: 10.1096/fj.202000919. Epub 2020 Apr 29. Review.

PMID: 32350928

452. Glycomics and glycoproteomics of viruses: Mass spectrometry applications and insights toward structure-function relationships.

Cipollo JF, Parsons LM.

Mass Spectrom Rev. 2020 Apr 29. doi: 10.1002/mas.21629. [Epub ahead of print] Review.

PMID: 32350911

453. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.

Khan Z, Karataş Y, Rahman H.

Adv Ther. 2020 Apr 29. doi: 10.1007/s12325-020-01351-9. [Epub ahead of print]

PMID: 32350686

454. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship.

Oberemok VV, Laikova KV, Yurchenko KA, Fomochkina II, Kubyshkin AV.

Inflamm Res. 2020 Apr 30. doi: 10.1007/s00011-020-01352-y. [Epub ahead of print]

PMID: 32350571

455. Rewiring of glucose metabolism defines trained immunity induced by oxidized low-density lipoprotein.

Keating ST, Groh L, Thiem K, Bekkering S, Li Y, Matzaraki V, van der Heijden CDCC, van Puffelen JH, Lachmandas E, Jansen T, Oosting M, de Bree LCJ, Koeken VACM, Moorlag SJCFM, Mourits VP, van Diepen J, Strienstra R, Novakovic B, Stunnenberg HG, van Crevel R, Joosten LAB, Netea MG, Riksen NP.

J Mol Med (Berl). 2020 Apr 30. doi: 10.1007/s00109-020-01915-w. [Epub ahead of print]

PMID: 32350546

456. Performance of metabonomic serum analysis for diagnostics in paediatric tuberculosis.

Andreas NJ, Basu Roy R, Gomez-Romero M, Horneffer-van der Sluis V, Lewis MR, Camuzeaux SSM, Jiménez B, Posma JM, Tientcheu L, Egere U, Sillah A, Togun T, Holmes E, Kampmann B.

Sci Rep. 2020 Apr 29;10(1):7302. doi: 10.1038/s41598-020-64413-6.

PMID: 32350385

457. Phylodynamic analysis and evaluation of the balance between anthropic and environmental factors affecting IBV spreading among Italian poultry farms.

Franzo G, Tucciarone CM, Moreno A, Legnardi M, Massi P, Tosi G, Trogu T, Ceruti R, Pesente P, Ortali G, Gavazzi L, Cecchinato M.

Sci Rep. 2020 Apr 29;10(1):7289. doi: 10.1038/s41598-020-64477-4.

PMID: 32350378

458. Selection of viral variants during persistent infection of insectivorous bat cells with Middle East respiratory syndrome coronavirus.

Banerjee A, Subudhi S, Rapin N, Lew J, Jain R, Falzarano D, Misra V.

Sci Rep. 2020 Apr 29;10(1):7257. doi: 10.1038/s41598-020-64264-1.

PMID: 32350357

459. Delayed expression of PD1 and TIGIT on HIV-specific CD8 T-cells in untreated HLA-B*57:01 individuals followed from early infection.

Scharf L, Tauriainen J, Buggert M, Hartogensis W, Nolan DJ, Deeks SG, Salemi M, Hecht FM, Karlsson AC.

J Virol. 2020 Apr 29. pii: JVI.02128-19. doi: 10.1128/JVI.02128-19. [Epub ahead of print]

PMID: 32350076

460. Comparison of Commercially Available and Laboratory Developed Assays for *in vitro* Detection of SARS-CoV-2 in Clinical Laboratories.

Lieberman JA, Pepper G, Naccache SN, Huang ML, Jerome KR, Greninger AL.

J Clin Microbiol. 2020 Apr 29. pii: JCM.00821-20. doi: 10.1128/JCM.00821-20. [Epub ahead of print]

PMID: 32350048

461. Use of Standing Orders for Vaccination Among Pediatricians.

Cataldi J, O'Leary ST, Lindley MC, Allison MA, Hurley LP, Crane LA, Brtnikova M, Beaty B, McBurney E, Kempe A.

Pediatrics. 2020 May;145(5). pii: e20191855. doi: 10.1542/peds.2019-1855.

PMID: 32350023

462. Regional variation in human papillomavirus vaccination uptake and completion among adolescents 13-17 in the state of Texas.

Conrey R, Valencia V, Cioletti A, Williams-Brown MY.

Vaccine. 2020 May 22;38(25):4119-4124. doi: 10.1016/j.**vaccine**.2020.03.059. Epub 2020 Apr 27.

PMID: 32349907

463. Mapping Immunodominant Antibody Epitopes of Abrin.

Alcalay R, Falach R, Gal Y, Sapoznikov A, Sabo T, Kronman C, Mazor O.

Antibodies (Basel). 2020 Apr 27;9(2). pii: E11. doi: 10.3390/antib9020011.

PMID: 32349421

464. Distribution and Genetic Variability of Sapoviruses in Africa.

Makhaola K, Moyo S, Kebaabetswe LP.

Viruses. 2020 Apr 27;12(5). pii: E490. doi: 10.3390/v12050490. Review.

PMID: 32349380

465. Virus-Like Particles as an Immunogenic Platform for Cancer **Vaccines**.

Caldeira JC, Perrine M, Pericle F, Cavallo F.

Viruses. 2020 Apr 27;12(5). pii: E488. doi: 10.3390/v12050488. Review.

PMID: 32349216

466. HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies.

Rantalainen K, Berndsen ZT, Antanasijevic A, Schiffner T, Zhang X, Lee WH, Torres JL, Zhang L, Irimia A, Copps J, Zhou KH, Kwon YD, Law WH, Schramm CA, Verardi R, Krebs SJ, Kwong PD, Doria-Rose NA, Wilson IA, Zwick MB, Yates JR 3rd, Schief WR, Ward AB.

Cell Rep. 2020 Apr 28;31(4):107583. doi: 10.1016/j.celrep.2020.107583.

PMID: 32348769

467. $CD4^+$ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection.

Wen J, Wang YT, Valentine KM, Dos Santos Alves RP, Xu Z, Regla-Nava JA, Ngono AE, Young MP, Ferreira LCS, Shresta S.

Cell Rep. 2020 Apr 28;31(4):107566. doi: 10.1016/j.celrep.2020.107566.

PMID: 32348763

468. Antiviral Effects of Bovine Lactoferrin on Human Norovirus.

Oda H, Kolawole AO, Mirabelli C, Wakabayashi H, Tanaka M, Yamauchi K, Abe F, Wobus CE.

Biochem Cell Biol. 2020 Apr 29. doi: 10.1139/bcb-2020-0035. [Epub ahead of print]

PMID: 32348689

469. Tetravalent Dengue **Vaccine** in Healthy Children. Reply.

Biswal S, Tricou V, Dean H.

N Engl J Med. 2020 Apr 30;382(18):1770-1771. doi: 10.1056/NEJMc2000987. No abstract available.

PMID: 32348660

470. Tetravalent Dengue **Vaccine** in Healthy Children.

Swaminathan S, Khanna N.

N Engl J Med. 2020 Apr 30;382(18):1769-1770. doi: 10.1056/NEJMc2000987. No abstract available.

PMID: 32348659

471. Tetravalent Dengue **Vaccine** in Healthy Children.

Salvana EM.

N Engl J Med. 2020 Apr 30;382(18):1769. doi: 10.1056/NEJMc2000987. No abstract available.

PMID: 32348658

472. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria.

Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM.

Risk Anal. 2020 Apr 29. doi: 10.1111/risa.13485. [Epub ahead of print]

PMID: 32348621

473. Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.

Al-Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae F, Ng SC, Rubin DT, Christensen B.

Aliment Pharmacol Ther. 2020 Apr 29. doi: 10.1111/apt.15779. [Epub ahead of print] Review.

PMID: 32348598

474. COVID-19: Is Everything Appropriate to Create an Effective **Vaccine**?

Cioffi A.

J Infect Dis. 2020 Apr 29. pii: jiaa216. doi: 10.1093/infdis/jiaa216. [Epub ahead of print] No abstract available.

PMID: 32348489

475. Maintaining immunogenicity of blood stage and sexual stage subunit malaria **vaccines** when formulated in combination.

Parzych EM, Miura K, Long CA, Burns JM Jr.

PLoS One. 2020 Apr 29;15(4):e0232355. doi: 10.1371/journal.pone.0232355. eCollection 2020.

PMID: 32348377

476. Measuring universal health coverage in reproductive, maternal, newborn and child health: An update of the composite coverage index.

Wehrmeister FC, Barros AJD, Hosseinpoor AR, Boerma T, Victora CG.

PLoS One. 2020 Apr 29;15(4):e0232350. doi: 10.1371/journal.pone.0232350. eCollection 2020.

PMID: 32348356

477. Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controls.

Piralam B, Prosperi C, Thamthitiwat S, Bunthi C, Sawatwong P, Sangwichian O, Higdon MM, Watson NL, Deloria Knoll M, Paveenkittiporn W, Chara C, Hurst CP, Akarasewi P, Rhodes J, Maloney SA, O'Brien KL, Baggett HC.

PLoS One. 2020 Apr 29;15(4):e0232151. doi: 10.1371/journal.pone.0232151. eCollection 2020.

PMID: 32348330

478. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States.

Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, Rankin D, Halasa N, Talbot HK, Reed C.

Emerg Infect Dis. 2020 Apr 29;26(8). doi: 10.3201/eid2608.191493. [Epub ahead of print]

PMID: 32348234

479. Early drop of circulating T cells negatively correlates with the protective immune response to Yellow Fever vaccination.

Bovay A, Speiser DE, Fuertes Marraco SA.

Hum Vaccin Immunother. 2020 Apr 29:1-8. doi: 10.1080/21645515.2020.1750249. [Epub ahead of print]

PMID: 32348192

480. Developing **Vaccines** for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Billington J, Deschamps I, Erck SC, Gerberding JL, Hanon E, Ivol S, Shiver JW, Spencer JA, Van Hoof J.

Health Secur. 2020 Apr 29. doi: 10.1089/hs.2020.0043. [Epub ahead of print]

PMID: 32348165

481. One Peptide for Them All: Gold Nanoparticles of Different Sizes Are Stabilized by a Common Peptide Amphiphile.

Egorova EA, van Rijt MMJ, Sommerdijk N, Gooris GS, Bouwstra JA, Boyle AL, Kros A.

ACS Nano. 2020 May 4. doi: 10.1021/acsnano.0c01021. [Epub ahead of print]

PMID: 32348119

482. Glycine significantly enhances bacterial membrane vesicle production: a powerful approach for isolation of LPS-reduced membrane vesicles of probiotic Escherichia coli.

Hirayama S, Nakao R.

Microb Biotechnol. 2020 Apr 29. doi: 10.1111/1751-7915.13572. [Epub ahead of print]

PMID: 32348028

483. Impaired mucociliary motility enhances antigen-specific nasal IgA immune responses to a cholera toxin-based nasal **vaccine**.

Lan H, Suzuki H, Nagatake T, Hosomi K, Ikegami K, Setou M, Kunisawa J.

Int Immunol. 2020 Apr 29. pii: dxaa029. doi: 10.1093/intimm/dxaa029. [Epub ahead of print]

PMID: 32347929

484. Immunogenicity of influenza **vaccine** in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness.

Meng Z, Zhang J, Shi J, Zhao W, Huang X, Cheng L, Yang X.

Hum Vaccin Immunother. 2020 Apr 29:1-10. doi: 10.1080/21645515.2020.1747375. [Epub ahead of print]

PMID: 32347787

485. Immunogenicity and safety of an inactivated quadrivalent influenza **vaccine**: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.

Hu Y, Shao M, Hu Y, Liang Q, Jia N, Chu K, Xu L, Li J, Li C, Zhu F.

Hum Vaccin Immunother. 2020 Apr 29:1-8. doi: 10.1080/21645515.2020.1721994. [Epub ahead of print]

PMID: 32347785

486. A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio **vaccine**.

Tang R, Li G, Zhang C, Zhi H, Zhu J, Wang J, Liang Q, Hu Y, Li C.

Hum Vaccin Immunother. 2020 Apr 29:1-8. doi: 10.1080/21645515.2020.1745593. [Epub ahead of print]

PMID: 32347778

487. Lower influenza-specific cell-mediated immune responses in individuals with atopic dermatitis compared with healthy controls.

Jalbert E, Lussier S, Johnson MJ, Jepson B, Calatroni A, David G, Leung D, Weinberg A.

Hum Vaccin Immunother. 2020 Apr 29:1-9. doi: 10.1080/21645515.2020.1747374. [Epub ahead of print]

PMID: 32347777

488. Herpes simplex virus type 2 trivalent protein **vaccine** containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.

Egan K, Hook LM, Naughton A, Friedman HM, Awasthi S.

Hum Vaccin Immunother. 2020 Apr 29:1-5. doi: 10.1080/21645515.2020.1749509. [Epub ahead of print]

PMID: 32347775

489. Meningococcal infections among refugees and immigrants: silent threats of past, present and future.

Dinleyici EC, Borrow R.

Hum Vaccin Immunother. 2020 Apr 29:1-6. doi: 10.1080/21645515.2020.1744979. [Epub ahead of print]

PMID: 32347773

490. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster **vaccine** in two parallel randomized trials.

Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL.

Hum Vaccin Immunother. 2020 Apr 29:1-6. doi: 10.1080/21645515.2020.1741312. [Epub ahead of print]

PMID: 32347767

491. Identification and Design of a Next-Generation Multi Epitopes Bases Peptide **Vaccine** Candidate Against Prostate Cancer: An In Silico Approach.

Patra P, Bhattacharya M, Sharma AR, Ghosh P, Sharma G, Patra BC, Mallick B, Lee SS, Chakraborty C.

Cell Biochem Biophys. 2020 Apr 28. doi: 10.1007/s12013-020-00912-7. [Epub ahead of print]

PMID: 32347457

492. Macrophage targeted nanocarrier delivery systems in HIV therapeutics.

Khan T, Mayuresh Patkar M, Momin M, Omri A.

Expert Opin Drug Deliv. 2020 Apr 29. doi: 10.1080/17425247.2020.1762565. [Epub ahead of print]

PMID: 32347124

493. Efficacy of recombinant N- and C-terminal derivative of EmIMP1 against *E. maxima* infection in chickens.

Chen H, Huang C, Chen Y, Mohsin M, Li L, Lin X, Huang Z, Yin G.

Br Poult Sci. 2020 Apr 29. doi: 10.1080/00071668.2020.1759787. [Epub ahead of print]

PMID: 32347110

494. The ethical challenges of the SARS-CoV-2 pandemic in the global south and the global north - same and different.

Schuklenk U.

Dev World Bioeth. 2020 Apr 28. doi: 10.1111/dewb.12263. [Epub ahead of print]

PMID: 32346958

495. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase.

Mirza MU, Froeyen M.

J Pharm Anal. 2020 Apr 28. doi: 10.1016/j.jpha.2020.04.008. [Epub ahead of print]

PMID: 32346490

496. COVID-19 **vaccine** design: the Janus face of immune enhancement.

Hotez PJ, Corry DB, Bottazzi ME.

Nat Rev Immunol. 2020 Apr 28. doi: 10.1038/s41577-020-0323-4. [Epub ahead of print] No abstract available.

PMID: 32346094

497. Cancer therapy tool informs COVID-19 **vaccines**.

Saffern M.

Nat Rev Immunol. 2020 Apr 28. doi: 10.1038/s41577-020-0326-1. [Epub ahead of print] No abstract available.

PMID: 32346092

498. Guiding patients to appropriate vaccination during pregnancy.

Heavey E.

Nurse Pract. 2020 Apr 27. doi: 10.1097/01.NPR.0000666180.07149.f6. [Epub ahead of print]

PMID: 32345831

499. Patterns and Disparities in Human Papillomavirus (HPV) **Vaccine** Uptake for Young Female Adolescents among US States: NIS-Teen (2008-2016).

Yoo W, Koskan A, Scotch M, Pottinger H, Huh WK, Helitzer D.

Cancer Epidemiol Biomarkers Prev. 2020 Apr 28. pii: cebp.1103.2019. doi: 10.1158/1055-9965.EPI-19-1103. [Epub ahead of print]

PMID: 32345710

500. Optimization of an Experimental **Vaccine** To Prevent Escherichia coli Urinary Tract Infection.

Forsyth VS, Himpsl SD, Smith SN, Sarkissian CA, Mike LA, Stocki JA, Sintsova A, Alteri CJ, Mobley HLT.

mBio. 2020 Apr 28;11(2). pii: e00555-20. doi: 10.1128/mBio.00555-20.

PMID: 32345645

501. Short-term associations between legionnaires' disease incidence and meteorological variables in Belgium, 2011-2019.

Braeye T, Echahidi F, Meghraoui A, Laisnez V, Hens N.

Epidemiol Infect. 2020 Apr 29:1-21. doi: 10.1017/S0950268820000886. [Epub ahead of print] No abstract available.

PMID: 32345387

502. DIC in COVID-19: Implications for Prognosis and Treatment?

Seitz R, Schramm W.

J Thromb Haemost. 2020 Apr 28. doi: 10.1111/jth.14878. [Epub ahead of print]

PMID: 32344469

503. Correction: ALVAC-HIV B/C candidate HIV **vaccine** efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

Schifanella L, Barnett SW, Bissa M, Galli V, Doster MN, Vaccari M, Tomaras GD, Shen X, Phogat S, Pal R, Montefiori DC, LaBranche CC, Rao M, Trinh HV, Washington-Parks R, Liyanage NPM, Gorini G, Brown DR, Liang F, Loré K, Venzon DJ, Magnanelli W, Metrinko M, Kramer J, Breed M, Alter G, Ruprecht RM, Franchini G.

PLoS Pathog. 2020 Apr 28;16(4):e1008531. doi: 10.1371/journal.ppat.1008531. eCollection 2020 Apr.

PMID: 32343743

504. Group 1 CD1-restricted T cells contribute to control of systemic Staphylococcus aureus infection.

Visvabharathy L, Genardi S, Cao L, He Y, Alonzo F 3rd, Berdyshev E, Wang CR.

PLoS Pathog. 2020 Apr 28;16(4):e1008443. doi: 10.1371/journal.ppat.1008443. eCollection 2020 Apr.

PMID: 32343740

505. Inpatient morbidity and mortality of measles in the United States.

Chovatiya R, Silverberg JI.

PLoS One. 2020 Apr 28;15(4):e0231329. doi: 10.1371/journal.pone.0231329. eCollection 2020.

PMID: 32343688

506. Mortality burden from seasonal influenza in Chongqing, China, 2012-2018.

Qi L, Li Q, Ding XB, Gao Y, Ling H, Liu T, Xiong Y, Su K, Tang WG, Feng LZ, Liu QY.

Hum Vaccin Immunother. 2020 Apr 28:1-7. doi: 10.1080/21645515.2019.1693721. [Epub ahead of print]

PMID: 32343618

507. Full-length genomic sequencing and characterization of Borna disease virus 1 isolates: Lessons in epidemiology.

Guo Y, He P, Sun L, Zhang X, Xu X, Tang T, Zhou W, Li Q, Zou D, Bode L, Xie P.

J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25951. [Epub ahead of print]

PMID: 32343416

508. Nanoparticle-based immunotherapy: state of the art and future perspectives.

Di Gioacchino M, Petrarca C, Gatta A, Scarano G, Farinelli A, Della Valle L, Lumaca A, Del Biondo P, Paganelli R, Di Giampaolo L.

Expert Rev Clin Immunol. 2020 Apr 28. doi: 10.1080/1744666X.2020.1762572. [Epub ahead of print]

PMID: 32343153

509. A delayed fractionated dose RTS,S AS01 **vaccine** regimen mediates protection via improved T follicular helper and B cell responses.

Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, Pahwa S.

Elife. 2020 Apr 29;9. pii: e51889. doi: 10.7554/eLife.51889.

PMID: 32342859

510. Safety and Immunogenicity of an AS03$_B$-Adjuvanted Inactivated Tetravalent Dengue Virus **Vaccine** Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.

Lin L, Lyke KE, Koren M, Jarman RG, Eckels KH, Lepine E, McArthur MA, Currier JR, Friberg H, Moris P, Keiser PB, De La Barrera R, Vaughn DW, Paris RM, Thomas SJ, Schmidt AC.

Am J Trop Med Hyg. 2020 Apr 27. doi: 10.4269/ajtmh.19-0738. [Epub ahead of print]

PMID: 32342848

511. The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19.

Armengaud J, Delaunay-Moisan A, Thuret JY, van Anken E, Acosta-Alvear D, Aragón T, Arias C, Blondel M, Braakman I, Collet JF, Courcol R, Danchin A, Deleuze JF, Lavigne JP, Lucas S, Michiels T, Moore ERB, Nixon-Abell J, Rossello-Mora R, Shi Z, Siccardi AG, Sitia R, Tillett D, Timmis KN, Toledano MB, van der Sluijs P, Vicenzi E.

Environ Microbiol. 2020 Apr 28. doi: 10.1111/1462-2920.15039. [Epub ahead of print]

PMID: 32342578

512. Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination.

McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N, Loutfy M, Trottier S, Smaill F, Klein MB, Harris M, Cohen J, Yudin MH, Wobeser W, Money D; CTN 236 HPV in HIV Study Team.

Int J Gynaecol Obstet. 2020 Apr 27. doi: 10.1002/ijgo.13185. [Epub ahead of print]

PMID: 32342504

513. Human Papillomavirus Vaccination and Physical and Mental Health Complaints Among Female Students in Secondary Education Institutions in Denmark.

Gazibara T, Thygesen LC, Algren MH, Tolstrup JS.

J Gen Intern Med. 2020 Apr 27. doi: 10.1007/s11606-020-05845-8. [Epub ahead of print]

PMID: 32342482

514. Obtaining and Characteristic of Antibodies to Vibrio cholerae Protective Antigens Conjugated with Gold Nanoparticles.

Dykman LA, Volokh OA, Gromova OV, Durakova OS, Vorobeva SA, Kireev MN, Livanova LF, Nikiforov AK, Shchyogolev SY, Kutyrev VV.

Dokl Biochem Biophys. 2020 Jan;490(1):19-21. doi: 10.1134/S1607672920010068. Epub 2020 Apr 27.

PMID: 32342306

515. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening.

Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM.

Nat Biotechnol. 2020 Apr 27. doi: 10.1038/s41587-020-0505-4. [Epub ahead of print]

PMID: 32341563

516. Viral contamination in biologic manufacture and implications for emerging therapies.

Barone PW, Wiebe ME, Leung JC, Hussein ITM, Keumurian FJ, Bouressa J, Brussel A, Chen D, Chong M, Dehghani H, Gerentes L, Gilbert J, Gold D, Kiss R, Kreil TR, Labatut R, Li Y, Müllberg J, Mallet L, Menzel C, Moody M, Monpoeho S, Murphy M, Plavsic M, Roth NJ, Roush D, Ruffing M, Schicho R, Snyder R, Stark D, Zhang C, Wolfrum J, Sinskey AJ, Springs SL.

Nat Biotechnol. 2020 May;38(5):563-572. doi: 10.1038/s41587-020-0507-2. Epub 2020 Apr 27. Review.

PMID: 32341561

517. SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA.

Wang Y, Fan X, Song Y, Liu Y, Liu R, Wu J, Li X, Yuan Q, Fu G, Xia N, Han J.

Cell Mol Immunol. 2020 Apr 27. doi: 10.1038/s41423-020-0431-x. [Epub ahead of print]

PMID: 32341522

518. A competing-risks model explains hierarchical spatial coupling of measles epidemics en route to national elimination.

Lau MSY, Becker AD, Korevaar HM, Caudron Q, Shaw DJ, Metcalf CJE, Bjørnstad ON, Grenfell BT.

Nat Ecol Evol. 2020 Apr 27. doi: 10.1038/s41559-020-1186-6. [Epub ahead of print]

PMID: 32341514

519. Closer and closer? Maternal immunization: current promise, future horizons.

Engmann C, Fleming JA, Khan S, Innis BL, Smith JM, Hombach J, Sobanjo-Ter Meulen A.

J Perinatol. 2020 Apr 27. doi: 10.1038/s41372-020-0668-3. [Epub ahead of print] Review.

PMID: 32341454

520. Antibody Responses in Hepatitis C Infection.

Law M.

Cold Spring Harb Perspect Med. 2020 Apr 27. pii: a036962. doi: 10.1101/cshperspect.a036962. [Epub ahead of print]

PMID: 32341067

521. Improving Birth Dose Hepatitis B Vaccination Rates: A Quality Improvement Intervention.

Bradshaw C, DiFrisco E, Schweizer W, Pavsic J, Demarco K, Weckesser J, Gold-VonSimson G, Rosenberg RE.

Hosp Pediatr. 2020 May;10(5):430-437. doi: 10.1542/hpeds.2019-0294.

PMID: 32341000

522. Covid-19: What do we know so far about a **vaccine**?

Mahase E.

BMJ. 2020 Apr 27;369:m1679. doi: 10.1136/bmj.m1679. No abstract available.

PMID: 32340998

523. Global regulatory agility during covid-19 and other health emergencies.

Mak TK, Lim JC, Thanaphollert P, Mahlangu GN, Cooke E, Lumpkin MM.

BMJ. 2020 Apr 27;369:m1575. doi: 10.1136/bmj.m1575. No abstract available.

PMID: 32340997

524. A novel class of chikungunya virus small molecule inhibitors that targets the viral capping machinery.

Abdelnabi R, Kovacikova K, Moesslacher J, Donckers K, Battisti V, Leyssen P, Langer T, Puerstinger G, Quérat G, Li C, Decroly E, Tas A, Marchand A, Chaltin P, Coutard B, van Hemert M, Neyts J, Delang L.

Antimicrob Agents Chemother. 2020 Apr 27. pii: AAC.00649-20. doi: 10.1128/AAC.00649-20. [Epub ahead of print]

PMID: 32340991

525. Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of **Vaccine**-Strain Measles Viruses for Cancer Therapy?

Peikert T.

J Thorac Oncol. 2020 May;15(5):689-691. doi: 10.1016/j.jtho.2020.02.018. No abstract available.

PMID: 32340675

526. Caring for Africa's sickle cell children: will we rise to the challenge?

Oron AP, Chao DL, Ezeanolue EE, Ezenwa LN, Piel FB, Ojogun OT, Uyoga S, Williams TN, Nnodu OE.

BMC Med. 2020 Apr 28;18(1):92. doi: 10.1186/s12916-020-01557-2.

PMID: 32340612

527. Targeting the N332-supersite of the HIV-1 envelope for **vaccine** design.

Moyo T, Kitchin D, Moore PL.

Expert Opin Ther Targets. 2020 Apr 27:1-11. doi: 10.1080/14728222.2020.1752183. [Epub ahead of print]

PMID: 32340497

528. Pneumococcal conjugate **vaccines**; choice of schedule and product development.

Lee J.

Clin Exp Pediatr. 2020 Apr 27. doi: 10.3345/cep.2019.01739. [Epub ahead of print] No abstract available.

PMID: 32340086

529. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Thompson KM, Kalkowska DA.

Risk Anal. 2020 Apr 27. doi: 10.1111/risa.13484. [Epub ahead of print]

PMID: 32339327

530. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019.

Zhou H, Liu LP, Fang M, Li YM, Zheng YW.

Histol Histopathol. 2020 Apr 27:18223. doi: 10.14670/HH-18-223. [Epub ahead of print] Review.

PMID: 32339250

531. Does apolipoprotein E genotype predict COVID-19 severity?

Goldstein MR, Poland GA, Graeber CW.

QJM. 2020 Apr 27. pii: hcaa142. doi: 10.1093/qjmed/hcaa142. [Epub ahead of print] No abstract available.

PMID: 32339247

532. Evolutionary Selection against Short Nucleotide Sequences in Viruses and their Related Hosts.

Zarai Y, Zafrir Z, Siridechadilok B, Suphatrakul A, Ruppin M, Julander J, Tuller T.

DNA Res. 2020 Apr 27. pii: dsaa008. doi: 10.1093/dnares/dsaa008. [Epub ahead of print]

PMID: 32339222

533. Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis.

Potluri R, Kumar A, Maheshwari V, Smith C, Oriol Mathieu V, Luhn K, Callendret B, Bhandari H.

PLoS One. 2020 Apr 27;15(4):e0230406. doi: 10.1371/journal.pone.0230406. eCollection 2020.

PMID: 32339195

534. Evidence of rotavirus **vaccine** impact in sub-Saharan Africa: Systematic review and meta-analysis.

Godfrey O, Zhang W, Amponsem-Boateng C, Bonney Oppong T, Zhao Q, Li D.

PLoS One. 2020 Apr 27;15(4):e0232113. doi: 10.1371/journal.pone.0232113. eCollection 2020.

PMID: 32339187

535. Detection of virus-neutralising antibodies and associated factors against rabies in the vaccinated household dogs of Kathmandu Valley, Nepal.

Rimal S, Ojha KC, Chaisowwong W, Shah Y, Pant DK, Sirimalaisuwan A.

PLoS One. 2020 Apr 27;15(4):e0231967. doi: 10.1371/journal.pone.0231967. eCollection 2020.

PMID: 32339182

536. Comparison of immunity against canine distemper, adenovirus and parvovirus after vaccination with two multivalent canine **vaccines**.

Cunha RDS, da Silva Junior CL, Costa CA, de Aguiar HM, Junqueira Júnior DG.

Vet Med Sci. 2020 Apr 27. doi: 10.1002/vms3.274. [Epub ahead of print]

PMID: 32338828

537. COVID-19-Related Web Search Behaviors and Infodemic Attitudes in Italy: Infodemiological Study.

Rovetta A, Bhagavathula AS.

JMIR Public Health Surveill. 2020 May 5;6(2):e19374. doi: 10.2196/19374.

PMID: 32338613

538. COVID-19 in Children: Clinical Approach and Management.

Sankar J, Dhochak N, Kabra SK, Lodha R.

Indian J Pediatr. 2020 Jun;87(6):433-442. doi: 10.1007/s12098-020-03292-1. Epub 2020 Apr 27. Review.

PMID: 32338347

539. **Vaccine** Plasmid Topology Monitoring by Capillary Gel Electrophoresis.

Cook KS, Luo J, Guttman A, Thompson L.

Curr Mol Med. 2020 Apr 27. doi: 10.2174/1566524020666200427110452. [Epub ahead of print]

PMID: 32338220

540. T-cell Epitope-based **Vaccine** design for Nipah Virus by Reverse Vaccinology approach.

Krishnamoorthy PKP, Subasree S, Arthi U, Imam M, Gowda C, Prasanna Dr.

Comb Chem High Throughput Screen. 2020 Apr 27. doi: 10.2174/1386207323666200427114343. [Epub ahead of print]

PMID: 32338213

541. Integrating Bioinformatics Strategies In Cancer Immunotherapy: Current And Future Perspectives.

Washah HN, Salifu EY, Soremekun O, Elrashedy AA, Munsamy G, Olotu FA, Soliman MES.

Comb Chem High Throughput Screen. 2020 Apr 27. doi: 10.2174/1386207323666200427113734. [Epub ahead of print]

PMID: 32338212

542. The Messenger Apps of the cell: Extracellular Vesicles as Regulatory Messengers of Microglial Function in the CNS.

Olanrewaju AA, Hakami RM.

J Neuroimmune Pharmacol. 2020 Apr 27. doi: 10.1007/s11481-020-09916-9. [Epub ahead of print] Review.

PMID: 32337651

543. Dynamics of conflict during the Ebola outbreak in the Democratic Republic of the Congo 2018-2019.

Kraemer MUG, Pigott DM, Hill SC, Vanderslott S, Reiner RC Jr, Stasse S, Brownstein JS, Gutierrez B, Dennig F, Hay SI, Wint GRW, Pybus OG, Castro MC, Vinck P, Pham PN, Nilles EJ, Cauchemez S.

BMC Med. 2020 Apr 27;18(1):113. doi: 10.1186/s12916-020-01574-1.

PMID: 32336281

544. Comment on "Will HPV vaccination prevent cervical cancer".

Zhang S, Zhao F.

BMC Med. 2020 Apr 27;18(1):115. doi: 10.1186/s12916-020-01589-8. No abstract available.

PMID: 32336280

545. Anesthesia and COVID-19: What We Should Know and What We Should Do.

Tang LY, Wang J.

Semin Cardiothorac Vasc Anesth. 2020 Jun;24(2):127-137. doi: 10.1177/1089253220921590. Epub 2020 Apr 27. Review.

PMID: 32336243

546. Development of a β-HPV **vaccine**: Updates on an emerging frontier of skin cancer prevention.

Gupta R, Rady PL, Doan HQ, Tyring SK.

J Clin Virol. 2020 May;126:104348. doi: 10.1016/j.jcv.2020.104348. Epub 2020 Apr 4. Review.

PMID: 32334327

547. Any Number of HPV **Vaccine** Doses Reduces Risk of Cervical Cancer.

Rosenberg K.

Am J Nurs. 2020 May;120(5):71. doi: 10.1097/01.NAJ.0000662844.04174.df. No abstract available.

PMID: 32332373

548. Development of a Specific and Sensitive HPAEC-PAD Method for Quantification of Vi Polysaccharide Applicable to other Polysaccharides Containing Amino Uronic Acids.

Giannelli C, Raso MM, Palmieri E, De Felice A, Pippi F, Micoli F.

Anal Chem. 2020 May 5;92(9):6304-6311. doi: 10.1021/acs.analchem.9b05107. Epub 2020 Apr 24.

PMID: 32330386

549. Against pandemic research exceptionalism.

London AJ, Kimmelman J.

Science. 2020 May 1;368(6490):476-477. doi: 10.1126/science.abc1731. Epub 2020 Apr 23. No abstract available.

PMID: 32327600

550. Adjuvant Chemotherapy.

Hellyer JA, Wakelee HA.

Thorac Surg Clin. 2020 May;30(2):179-185. doi: 10.1016/j.thorsurg.2020.01.003. Epub 2020 Mar 2. Review.

PMID: 32327176

551. ptsI gene in the phosphotransfer system is a potential target for developing a live attenuated Salmonella **vaccine**.

Zhi Y, Lin SM, Ahn KB, Ji HJ, Guo HC, Ryu S, Seo HS, Lim S.

Int J Mol Med. 2020 May;45(5):1327-1340. doi: 10.3892/ijmm.2020.4505. Epub 2020 Feb 18.

PMID: 32323733

552. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19.

Saqrane S, El Mhammedi MA.

New Microbes New Infect. 2020 Apr 14;35:100680. doi: 10.1016/j.nmni.2020.100680. eCollection 2020 May. Review.

PMID: 32322402

553. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics).

Hamid S, Mir MY, Rohela GK.

New Microbes New Infect. 2020 Apr 14;35:100679. doi: 10.1016/j.nmni.2020.100679. eCollection 2020 May. Review.

PMID: 32322401

554. Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Esswein SR, Gristick HB, Jurado A, Peace A, Keeffe JR, Lee YE, Voll AV, Saeed M, Nussenzweig MC, Rice CM, Robbiani DF, MacDonald MR, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2020 May 5;117(18):9865-9875. doi: 10.1073/pnas.1919269117. Epub 2020 Apr 22.

PMID: 32321830

555. Serogroup a meningococcal conjugate **vaccines**: building sustainable and equitable **vaccine** strategies.

Sherman AC, Stephens DS.

Expert Rev **Vaccines**. 2020 Apr 29:1-9. doi: 10.1080/14760584.2020.1760097. [Epub ahead of print]

PMID: 32321332

556. Neurological Insights of COVID-19 Pandemic.

Das G, Mukherjee N, Ghosh S.

ACS Chem Neurosci. 2020 May 6;11(9):1206-1209. doi: 10.1021/acschemneuro.0c00201. Epub 2020 Apr 22.

PMID: 32320211

557. Viruses to fight other viruses: the influenza **vaccine** case.

Bengoechea JA.

EMBO Mol Med. 2020 May 8;12(5):e12059. doi: 10.15252/emmm.202012059. Epub 2020 Apr 22.

PMID: 32320128

558. COVID-19: How has the scientific community risen to the challenge?

Straiton J.

Biotechniques. 2020 May;68(5):232-234. doi: 10.2144/btn-2020-0041. Epub 2020 Apr 22.

PMID: 32319301

559. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.

Shetty R, Ghosh A, Honavar SG, Khamar P, Sethu S.

Indian J Ophthalmol. 2020 May;68(5):693-702. doi: 10.4103/ijo.IJO_639_20. Review.

PMID: 32317431

560. The CpG molecular structure controls the mineralization of calcium phosphate nanoparticles and their immunostimulation efficacy as **vaccine** adjuvants.

Khalifehzadeh R, Arami H.

Nanoscale. 2020 May 7;12(17):9603-9615. doi: 10.1039/c9nr09782a. Epub 2020 Apr 21.

PMID: 32314980

561. The p53 Saga: Early Steps in the Development of Tumor Immunotherapy.

DeLeo AB, Appella E.

J Immunol. 2020 May 1;204(9):2321-2328. doi: 10.4049/jimmunol.1901343. Review.

PMID: 32312843

562. COVID-19 disrupts **vaccine** delivery.

Nelson R.

Lancet Infect Dis. 2020 May;20(5):546. doi: 10.1016/S1473-3099(20)30304-2. Epub 2020 Apr 17. No abstract available.

PMID: 32311326

563. COVID-19: endgames.

The Lancet Infectious Diseases.

Lancet Infect Dis. 2020 May;20(5):511. doi: 10.1016/S1473-3099(20)30298-X. Epub 2020 Apr 17. No abstract available.

PMID: 32311325

564. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.

Zimmermann P, Curtis N.

Pediatr Infect Dis J. 2020 May;39(5):355-368. doi: 10.1097/INF.0000000000002660. Review.

PMID: 32310621

565. Hepatitis A Hospitalization Costs, United States, 2017.

Hofmeister MG, Yin S, Aslam MV, Teshale EH, Spradling PR.

Emerg Infect Dis. 2020 May;26(5):1040-1041. doi: 10.3201/eid2605.191224.

PMID: 32310068

566. Maternal supplementation of energy and protein, but not methionine hydroxy analog, enhanced postnatal growth and response to vaccination in Bos indicus-influenced beef offspring.

Moriel P, Vedovatto M, Palmer EA, Oliveira RA, Silva HM, Ranches J, Vendramini JMB.

J Anim Sci. 2020 May 1;98(5). pii: skaa123. doi: 10.1093/jas/skaa123.

PMID: 32309862

567. Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data.

Reynisson B, Barra C, Kaabinejadian S, Hildebrand WH, Peters B, Nielsen M.

J Proteome Res. 2020 Apr 30. doi: 10.1021/acs.jproteome.9b00874. [Epub ahead of print]

PMID: 32308001

568. Short-term immunogenicity and safety of hepatitis-A and varicella **vaccines** in HIV-exposed uninfected and HIV-unexposed South African children.

Mutsaerts EAML, Nunes MC, Bhikha S, Ikulinda BT, Jose L, Koen A, Moultrie A, Grobbee DE, Klipstein-Grobusch K, Weinberg A, Madhi SA.

Vaccine. 2020 May 8;38(22):3862-3868. doi: 10.1016/j.**vaccine**.2020.03.045. Epub 2020 Apr 16.

PMID: 32307279

569. Immunostimulation by starch hydrogel-based oral **vaccine** using formalin-killed cells against edwardsiellosis in Japanese eel, Anguilla japonica.

Jun JW, Kang JW, Giri SS, Yun S, Kim HJ, Guen Kim S, Kim SW, Han SJ, Kwon J, Oh WT, Park SC.

Vaccine. 2020 May 8;38(22):3847-3853. doi: 10.1016/j.**vaccine**.2020.03.046. Epub 2020 Apr 16.

PMID: 32307278

570. Evaluation of a competitive inhibition ELISA based on the recombinant protein tSAG1 to detect anti-*Neospora caninum* antibodies in cattle.

Novoa MB, Valentini BS, Sarli M, Torioni-de-Echaide SM, Primo ME, Echaide IE.

J Vet Diagn Invest. 2020 May;32(3):401-408. doi: 10.1177/1040638720916711. Epub 2020 Apr 20.

PMID: 32306865

571. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment.

Boopathi S, Poma AB, Kolandaivel P.

J Biomol Struct Dyn. 2020 Apr 30:1-10. doi: 10.1080/07391102.2020.1758788. [Epub ahead of print]

PMID: 32306836

572. Gold nanoparticles for preparation of antibodies and **vaccines** against infectious diseases.

Dykman LA.

Expert Rev **Vaccines**. 2020 Apr 28:1-13. doi: 10.1080/14760584.2020.1758070. [Epub ahead of print]

PMID: 32306785

573. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.

Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, Baeza J.

Rev Esp Anestesiol Reanim. 2020 May;67(5):245-252. doi: 10.1016/j.redar.2020.03.004. Epub 2020 Apr 14. English, Spanish.

PMID: 32303365

574. African Horse Sickness Fever in Vaccinated Horses: Short Communication.

Wernery U, Joseph S, Raghavan R, Dyer B, Spendrup S.

J Equine Vet Sci. 2020 May;88:102967. doi: 10.1016/j.jevs.2020.102967. Epub 2020 Mar 5.

PMID: 32303305

575. Adverse Events Following Immunization Among Children With Epilepsy: A Self-Controlled Case Series.

Top KA, Righolt CH, Hawken S, Donelle J, Pabla G, Brna P, Deeks SL, Smith B, Wilson K, Mahmud SM.

Pediatr Infect Dis J. 2020 May;39(5):454-459. doi: 10.1097/INF.0000000000002553.

PMID: 32301921

576. A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio **Vaccines** in Two South Indian Districts.

Arora NK, Das MK, Poluru R, Kashyap NK, Mathew T, Mathai J, Aggarwal MK, Haldar P, Verstraeten T, Zuber PLF; INCLEN **Vaccine** Safety Study Group.

Pediatr Infect Dis J. 2020 May;39(5):389-396. doi: 10.1097/INF.0000000000002594.

PMID: 32301918

577. Evolutionary Views of Tuberculosis: Indoleamine 2,3-Dioxygenase Catalyzed Nicotinamide Synthesis Reflects Shifts in Macrophage Metabolism: Indoleamine 2,3-Dioxygenase Reflects Altered Macrophage Metabolism During Tuberculosis Pathogenesis.

Suchard MS, Adu-Gyamfi CG, Cumming BM, Savulescu DM.

Bioessays. 2020 May;42(5):e1900220. doi: 10.1002/bies.201900220.

PMID: 32301149

578. Human papilloma virus-associated metachronous squamous cell carcinoma of the larynx and uterine cervix: Case report and review of the literature.

Carbajal-Mamani S, Chheda N, Esnakula A, Cardenas-Goicoechea J.

Gynecol Oncol Rep. 2020 Apr 7;32:100568. doi: 10.1016/j.gore.2020.100568. eCollection 2020 May.

PMID: 32300633

579. Adverse events of interest vary by influenza **vaccine** type and brand: Sentinel network study of eight seasons (2010-2018).

Cross JW, Joy M, McGee C, Akinyemi O, Gatenby P, de Lusignan S.

Vaccine. 2020 May 8;38(22):3869-3880. doi: 10.1016/j.**vaccine**.2020.03.034. Epub 2020 Apr 13.

PMID: 32299719

580. **Vaccine** confidence: the keys to restoring trust.

Badur S, Ota M, Öztürk S, Adegbola R, Dutta A.

Hum Vaccin Immunother. 2020 May 3;16(5):1007-1017. doi: 10.1080/21645515.2020.1740559. Epub 2020 Apr 16.

PMID: 32298198

581. Postherpetic Neuralgia: Current Evidence on the Topical Film-Forming Spray with Bupivacaine Hydrochloride and a Review of Available Treatment Strategies.

Ngo AL, Urits I, Yilmaz M, Fortier L, Anya A, Oh JH, Berger AA, Kassem H, Sanchez MG, Kaye AD, Urman RD, Herron EW, Cornett EM, Viswanath O.

Adv Ther. 2020 May;37(5):2003-2016. doi: 10.1007/s12325-020-01335-9. Epub 2020 Apr 15. Review.

PMID: 32297285

582. Cluster Analysis: Vaccination Attitudes and Beliefs of Healthcare Personnel.

Bardenheier BH, Lindley MC, Ball SW, de Perio MA, Laney S, Gravenstein S.

Am J Health Behav. 2020 May 1;44(3):302-312. doi: 10.5993/AJHB.44.3.3.

PMID: 32295678

583. Reverse vaccinology approach to design a novel multi-epitope **vaccine** candidate against COVID-19: an *in silico* study.

Enayatkhani M, Hasaniazad M, Faezi S, Guklani H, Davoodian P, Ahmadi N, Einakian MA, Karmostaji A, Ahmadi K.

J Biomol Struct Dyn. 2020 May 2:1-16. doi: 10.1080/07391102.2020.1756411. [Epub ahead of print]

PMID: 32295479

584. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.

Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, Lee CS, Jun S, Park D, Kim HG, Kim SJ, Lee JO, Kim BT, Park EC, Kim SI.

ACS Nano. 2020 Apr 28;14(4):5135-5142. doi: 10.1021/acsnano.0c02823. Epub 2020 Apr 20.

PMID: 32293168

585. Ebola **vaccine**? Family first! Evidence from using a brief measure on Ebola **vaccine** demand in a national household survey during the outbreak in Sierra Leone.

Jalloh MF, Wallace AS, Bunnell RE, Carter RJ, Redd JT, Nur SA, Zeebari Z, Ekström AM, Nordenstedt H.

Vaccine. 2020 May 8;38(22):3854-3861. doi: 10.1016/j.**vaccine**.2020.03.044. Epub 2020 Apr 11.

PMID: 32291102

586. [Letters to the article "Aluminium adjuvant exposure through **vaccines** in France in 2018"].

Académie nationale de pharmacie. Electronic address: info@acadpharm.org.

Ann Pharm Fr. 2020 May;78(3):273-275. doi: 10.1016/j.pharma.2020.03.001. Epub 2020 Mar 30. French. No abstract available.

PMID: 32291071

587. Evidence based management guideline for the COVID-19 pandemic - Review article.

Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R.

Int J Surg. 2020 May;77:206-216. doi: 10.1016/j.ijsu.2020.04.001. Epub 2020 Apr 11. Review.

PMID: 32289472

588. Construction expression and immunogenicity of a novel trivalent outer membrane protein (OmpU-A-II) from three bacterial pathogens in Japanese eels (Anguilla japonica).

Zhao J, Wu L, Zhai S, Lin P, Guo S.

J Fish Dis. 2020 May;43(5):519-529. doi: 10.1111/jfd.13132. Epub 2020 Apr 13.

PMID: 32285473

589. HPV vaccination and cancer prevention.

Athanasiou A, Bowden S, Paraskevaidi M, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Kyrgiou M.

Best Pract Res Clin Obstet Gynaecol. 2020 May;65:109-124. doi: 10.1016/j.bpobgyn.2020.02.009. Epub 2020 Mar 5. Review.

PMID: 32284298

590. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate **vaccine** in healthy 5-year-old children.

Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C.

Vaccine. 2020 May 8;38(22):3902-3908. doi: 10.1016/j.**vaccine**.2020.02.030. Epub 2020 Apr 11.

PMID: 32284274

591. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.

Joe CCD, Chatterjee S, Lovrecz G, Adams TE, Thaysen-Andersen M, Walsh R, Locarnini SA, Smooker P, Netter HJ.

Vaccine. 2020 May 8;38(22):3892-3901. doi: 10.1016/j.**vaccine**.2020.03.007. Epub 2020 Apr 10.

PMID: 32284273

592. Immunogenicity and safety of a quadrivalent inactivated influenza **vaccine** in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.

Chang CY, Cho CY, Lai CC, Lu CY, Chang LY, Hung MC, Huang LM, Wu KG.

Vaccine. 2020 May 8;38(22):3839-3846. doi: 10.1016/j.**vaccine**.2020.03.048. Epub 2020 Apr 10.

PMID: 32284272

593. Adjuvant Human Papillomavirus **Vaccine** to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.

Lichter K, Krause D, Xu J, Tsai SHL, Hage C, Weston E, Eke A, Levinson K.

Obstet Gynecol. 2020 May;135(5):1070-1083. doi: 10.1097/AOG.0000000000003833.

PMID: 32282601

594. Whole leukemia cell **vaccines**: Past progress and future directions.

Ji YS, Park SK, Ryu S.

Vaccine. 2020 May 8;38(22):3811-3820. doi: 10.1016/j.**vaccine**.2020.03.042. Epub 2020 Apr 9. Review.

PMID: 32280046

595. Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein **vaccines**.

Gary E, O'Connor M, Chakhtoura M, Tardif V, Kumova OK, Malherbe DC, Sutton WF, Haigwood NL, Kutzler MA, Haddad EK.

Vaccine. 2020 May 8;38(22):3821-3831. doi: 10.1016/j.**vaccine**.2020.03.047. Epub 2020 Apr 10.

PMID: 32280045

596. Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination.

Maurelli M, Bellinato F, Gisondi P, Girolomoni G.

Vaccine. 2020 May 6;38(21):3808-3809. doi: 10.1016/j.**vaccine**.2020.03.051. Epub 2020 Apr 9. No abstract available.

PMID: 32280044

597. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.

Quiambao BP, Ambas C, Diego S, Bosch Castells V, Korejwo J, Petit C, Rasuli A, Houillon G.

Vaccine. 2020 May 6;38(21):3740-3746. doi: 10.1016/j.**vaccine**.2020.03.043. Epub 2020 Apr 9.

PMID: 32280042

598. Success ofrotavirus vaccination in Finland, a register based study measuring impact beyond overall effectiveness.

Solastie A, Leino T, Ollgren J.

Vaccine. 2020 May 6;38(21):3766-3772. doi: 10.1016/j.**vaccine**.2020.03.022. Epub 2020 Apr 9.

PMID: 32280041

599. Classification of measles cases from 2014 to 2018: Implications for progress towards measles elimination in China.

Cui A, Zhang Y, Zhu Z, Wang H, Mao N, Song J, Xu W.

Vaccine. 2020 May 8;38(22):3832-3838. doi: 10.1016/j.**vaccine**.2020.03.049. Epub 2020 Apr 10.

PMID: 32280040

600. Recombinant E^{rns}-E2 protein **vaccine** formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection.

Wang S, Yang G, Nie J, Yang R, Du M, Su J, Wang J, Wang J, Zhu Y.

Vaccine. 2020 May 8;38(22):3881-3891. doi: 10.1016/j.**vaccine**.2020.03.020. Epub 2020 Apr 10.

PMID:
32280039

601. T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 **vaccine** has greater T cell epitope overlap with field strains than monovalent PCV2 **vaccines**.

Bandrick M, Gutiérrez AH, Desai P, Rincon G, Martin WD, Terry FE, De Groot AS, Foss DL.

Vet Immunol Immunopathol. 2020 May;223:110034. doi: 10.1016/j.vetimm.2020.110034. Epub 2020 Mar 6.

PMID: 32278900

602. A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector $CD8^+$ T-cell responses by DNA vaccination.

Stifter K, Dekhtiarenko I, Krieger J, Tissot AC, Seufferlein T, Wagner M, Schirmbeck R.

Vaccine. 2020 May 6;38(21):3711-3719. doi: 10.1016/j.**vaccine**.2020.04.003. Epub 2020 Apr 9.

PMID: 32278524

603. Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection.

Singh AK, Wang X, Sun W.

Vaccine. 2020 May 6;38(21):3720-3728. doi: 10.1016/j.**vaccine**.2020.03.055. Epub 2020 Apr 8.

PMID: 32278523

604. A single lentivector DNA based immunization contains a late heterologous SIVmac251 mucosal challenge infection.

Chebloune Y, Moussa M, Arrode-Brusés G, Ronfort C, Bose D, Gagnon J, Gumber S, Villinger T, Byrareddy SN, Kozlowski PA, Gosse L, Dereuddre-Bosquet N, Le Grand R, Villinger F.

Vaccine. 2020 May 6;38(21):3729-3739. doi: 10.1016/j.**vaccine**.2020.03.053. Epub 2020 Apr 9.

PMID: 32278522

605. Bacillus Calmette-Guérin (BCG) **vaccine** safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms.

Kim JH, Lee H, Shin JY.

Vaccine. 2020 May 6;38(21):3702-3710. doi: 10.1016/j.**vaccine**.2020.04.007. Epub 2020 Apr 9.

PMID: 32278521

606. The state of **vaccine** safety science: systematic reviews of the evidence.

Dudley MZ, Halsey NA, Omer SB, Orenstein WA, O'Leary ST, Limaye RJ, Salmon DA.

Lancet Infect Dis. 2020 May;20(5):e80-e89. doi: 10.1016/S1473-3099(20)30130-4. Epub 2020 Apr 9. Review.

PMID: 32278359

607. Strengthening vaccination programmes and health systems in the European Union: A framework for action.

Siciliani L, Wild C, McKee M, Kringos D, Barry MM, Barros PP, De Maeseneer J, Murauskiene L, Ricciardi W; members of the Expert Panel on Effective Ways of Investing in Health.

Health Policy. 2020 May;124(5):511-518. doi: 10.1016/j.healthpol.2020.02.015. Epub 2020 Mar 6. Review.

PMID: 32276852

608. Primary care physician support for harmonizing HPV vaccination recommendations across genders - United States, 2018.

Meites E, Markowitz LE, Kempe A, O'Leary ST, Crane LA, Hurley LP, Brtnikova M, Beaty BL, Stokley S, Lindley MC.

Vaccine. 2020 May 6;38(21):3699-3701. doi: 10.1016/j.**vaccine**.2020.03.038. Epub 2020 Apr 8.

PMID: 32276802

609. Negative effect on immune response of repeated influenza vaccination and waning effectiveness in interseason for elderly people.

Sugishita Y, Nakayama T, Sugawara T, Ohkusa Y.

Vaccine. 2020 May 6;38(21):3759-3765. doi: 10.1016/j.**vaccine**.2020.03.025. Epub 2020 Apr 8.

PMID: 32276801

610. Why does Japan have so few cases of COVID-19?

Iwasaki A, Grubaugh ND.

EMBO Mol Med. 2020 May 8;12(5):e12481. doi: 10.15252/emmm.202012481. Epub 2020 Apr 28.

PMID: 32275804

611. RNA Origami Nanostructures for Potent and Safe Anticancer Immunotherapy.

Qi X, Liu X, Matiski L, Rodriguez Del Villar R, Yip T, Zhang F, Sokalingam S, Jiang S, Liu L, Yan H, Chang Y.

ACS Nano. 2020 Apr 28;14(4):4727-4740. doi: 10.1021/acsnano.0c00602. Epub 2020 Apr 15.

PMID: 32275389

612. Yeast Mycocins: a great potential for application in health.

Nascimento BL, Delabeneta MF, Rosseto LRB, Junges DSB, Paris AP, Persel C, Gandra RF.

FEMS Yeast Res. 2020 May 1;20(3). pii: foaa016. doi: 10.1093/femsyr/foaa016.

PMID: 32275311

613. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.

Jafari A, Rezaei-Tavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H.

Cancer Invest. 2020 Apr 27:1-19. doi: 10.1080/07357907.2020.1752227. [Epub ahead of print]

PMID: 32274949

614. A Map of Racial and Ethnic Disparities in Influenza **Vaccine** Uptake in the Medicare Fee-for-Service Program.

Hall LL, Xu L, Mahmud SM, Puckrein GA, Thommes EW, Chit A.

Adv Ther. 2020 May;37(5):2224-2235. doi: 10.1007/s12325-020-01324-y. Epub 2020 Apr 9.

PMID: 32274750

615. The COVID-19 **vaccine** development landscape.

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S.

Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5. No abstract available.

PMID: 32273591

616. Age inappropriate influenza vaccination in infants less than 6 months old, 2010-2018.

Suragh TA, Hibbs B, Marquez P, McNeil MM.

Vaccine. 2020 May 6;38(21):3747-3751. doi: 10.1016/j.**vaccine**.2020.03.039. Epub 2020 Apr 6.

PMID: 32273185

617. Immunogenicity and safety of an adjuvanted inactivated polio **vaccine**, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.

Sáez-Llorens X, Thierry-Carstensen B, Stoey LS, Sørensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV.

Vaccine. 2020 May 6;38(21):3780-3789. doi: 10.1016/j.**vaccine**.2020.02.066. Epub 2020 Apr 6.

PMID: 32273184

618. Evaluation of a Dual Fentanyl/Heroin **Vaccine** on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats.

Townsend EA, Bremer PT, Faunce KE, Negus SS, Jaster AM, Robinson HL, Janda KD, Banks ML.

ACS Chem Neurosci. 2020 May 6;11(9):1300-1310. doi: 10.1021/acschemneuro.0c00064. Epub 2020 Apr 22.

PMID: 32271538

619. Advancements in prophylactic and therapeutic nanovaccines.

Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R.

Acta Biomater. 2020 May;108:1-21. doi: 10.1016/j.actbio.2020.03.020. Epub 2020 Apr 5. Review.

PMID: 32268235

620. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.

Rokni M, Ghasemi V, Tavakoli Z.

Rev Med Virol. 2020 May;30(3):e2107. doi: 10.1002/rmv.2107. Epub 2020 Apr 8. Review.

PMID: 32267987

621. **Vaccine** Communication as Weaponized Identity Politics.

Broniatowski DA, Quinn SC, Dredze M, Jamison AM.

Am J Public Health. 2020 May;110(5):617-618. doi: 10.2105/AJPH.2020.305616. No abstract available.

PMID: 32267750

622. Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope.

Bajic G, Maron MJ, Caradonna TM, Tian M, Mermelstein A, Fera D, Kelsoe G, Kuraoka M, Schmidt AG.

ACS Infect Dis. 2020 May 8;6(5):1182-1191. doi: 10.1021/acsinfecdis.0c00008. Epub 2020 Apr 20.

PMID: 32267676

623. Exploring Evolutionary Constraints in the Proteomes of Zika, Dengue, and Other Flaviviruses to Find Fitness-Critical Sites.

Nunez-Castilla J, Rahaman J, Ahrens JB, Balbin CA, Siltberg-Liberles J.

J Mol Evol. 2020 May;88(4):399-414. doi: 10.1007/s00239-020-09941-5. Epub 2020 Apr 7.

PMID: 32266427

624. Pertussis in adults: which **vaccine**?

Palù G.

Ann Ig. 2020 May-Jun;32(3):319-322. doi: 10.7416/ai.2020.2354. No abstract available.

PMID: 32266369

625. "Vaccinate your child for best protection": attitude towards vaccination in a group of pregnant women.

Squeri R, Trimarchi G, Alessi V, Squeri A, Ceccio C, Costa GB, Genovese C.

Ann Ig. 2020 May-Jun;32(3):245-253. doi: 10.7416/ai.2020.2347.

PMID: 32266362

626. Is there an association between self-reported vaccination knowledge and the immunization behaviour of Health Sciences students.

Provenzano S, Gentile L, Cuda A, Santangelo OE, Dallagiacoma G, Gianfredi V.

Ann Ig. 2020 May-Jun;32(3):223-233. doi: 10.7416/ai.2020.2345.

PMID: 32266360

627. Validation of an Italian tool to assess **vaccine** literacy in adulthood vaccination: a pilot study.

Biasio LR, Giambi C, Fadda G, Lorini C, Bonaccorsi G, D'Ancona F.

Ann Ig. 2020 May-Jun;32(3):205-222. doi: 10.7416/ai.2020.2344.

PMID: 32266359

628. Breadth of Antibody Responses during Influenza Virus Infection and Vaccination.

Kubo M, Miyauchi K.

Trends Immunol. 2020 May;41(5):394-405. doi: 10.1016/j.it.2020.03.005. Epub 2020 Apr 4. Review.

PMID: 32265127

629. The low carriage prevalence of pneumococcus among community-dwelling older people: A cross-sectional study in Japan.

Yasuda I, Suzuki M, Dhoubhadel BG, Terada M, Satoh A, Sando E, Hiraoka T, Kurihara M, Matsusaka N, Kawahara F, Ariyoshi K, Morimoto K.

Vaccine. 2020 May 6;38(21):3752-3758. doi: 10.1016/j.**vaccine**.2020.03.033. Epub 2020 Apr 4.

PMID: 32265047

630. Congenital Cytomegalovirus and Hearing Loss.

Andronaco DW.

J Obstet Gynecol Neonatal Nurs. 2020 May;49(3):293-304. doi: 10.1016/j.jogn.2020.02.005. Epub 2020 Apr 4.

PMID: 32259513

631. Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer **vaccine** immunotherapy.

Hayashi S, Imanishi R, Adachi M, Ikejima S, Nakata J, Morimoto S, Fujiki F, Nishida S, Tsuboi A, Hosen N, Nakajima H, Hasegawa K, Oka Y, Sugiyama H, Oji Y.

Biomed Rep. 2020 May;12(5):244-250. doi: 10.3892/br.2020.1289. Epub 2020 Mar 5.

PMID: 32257187

632. Selective and ATP-competitive kinesin KIF18A inhibitor suppresses the replication of influenza A virus.

Cho YB, Hong S, Kang KW, Kang JH, Lee SM, Seo YJ.

J Cell Mol Med. 2020 May;24(10):5463-5475. doi: 10.1111/jcmm.15200. Epub 2020 Apr 6.

PMID: 32253833

633. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X.

Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.

PMID: 32253318

634. Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates.

Szilagyi P, Albertin C, Gurfinkel D, Beaty B, Zhou X, Vangala S, Rice J, Campbell JD, Whittington MD, Valderrama R, Breck A, Roth H, Meldrum M, Tseng CH, Rand C, Humiston SG, Schaffer S, Kempe A.

Pediatrics. 2020 May;145(5). pii: e20192689. doi: 10.1542/peds.2019-2689. Epub 2020 Apr 6.

PMID: 32253263

635. Childhood vaccination coverage and equity impact in Ethiopia by socioeconomic, geographic, maternal, and child characteristics.

Geweniger A, Abbas KM.

Vaccine. 2020 Apr 29;38(20):3627-3638. doi: 10.1016/j.**vaccine**.2020.03.040. Epub 2020 Apr 3.

PMID: 32253099

636. A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC **vaccine**.

Gutiérrez RL, Porter CK, Jarell A, Alcala A, Riddle MS, Turiansky GW.

Vaccine. 2020 May 6;38(21):3773-3779. doi: 10.1016/j.**vaccine**.2020.02.079. Epub 2020 Apr 3.

PMID: 32253098

637. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.

Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, Selmi C.

J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2. Review.

PMID: 32253068

638. Varicella under vedolizumab: Should we wait for the disease or propose the **vaccine**?

Abreu C, Filipe R, Lopes S, Sarmento A.

J Clin Virol. 2020 May;126:104333. doi: 10.1016/j.jcv.2020.104333. Epub 2020 Mar 19. No abstract available.

PMID: 32252006

639. Modified bacterial outer membrane vesicles induce autoantibodies for tumor therapy.

Huang W, Shu C, Hua L, Zhao Y, Xie H, Qi J, Gao F, Gao R, Chen Y, Zhang Q, Li W, Yuan M, Ye C, Ma Y.

Acta Biomater. 2020 May;108:300-312. doi: 10.1016/j.actbio.2020.03.030. Epub 2020 Apr 3.

PMID: 32251780

640. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza **vaccine** for older adults in Argentina.

Nguyen VH, Vizzotti C, Uruena A, Giglio N, Magneres C, Richmond H.

Vaccine. 2020 Apr 29;38(20):3682-3689. doi: 10.1016/j.**vaccine**.2020.02.081. Epub 2020 Apr 2.

PMID: 32249017

641. Preclinical Evaluation of **Vaccines** to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

Townsend EA, Banks ML.

CNS Drugs. 2020 May;34(5):449-461. doi: 10.1007/s40263-020-00722-8.

PMID: 32248427

642. The Leptospira interrogans LIC10774 is a multifunctional surface protein that binds calcium and interacts with host components.

Passalia FJ, Carvalho E, Heinemann MB, Vieira ML, Nascimento ALTO.

Microbiol Res. 2020 May;235:126470. doi: 10.1016/j.micres.2020.126470. Epub 2020 Mar 19.

PMID: 32247916

643. Blue Light-Directed Cell Migration, Aggregation, and Patterning.

Zhang J, Luo Y, Poh CL.

J Mol Biol. 2020 May 1;432(10):3137-3148. doi: 10.1016/j.jmb.2020.03.029. Epub 2020 Apr 2.

PMID: 32247761

644. Development of a high-yield live-virus **vaccine** production platform using a novel fixed-bed bioreactor.

Berrie DM, Waters RC, Montoya C, Chatel A, Vela EM.

Vaccine. 2020 Apr 29;38(20):3639-3645. doi: 10.1016/j.**vaccine**.2020.03.041. Epub 2020 Apr 1.

PMID: 32247568

645. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses.

Amaral MP, Apostolico JS, Tomita N, Coirada FC, Lunardelli VAS, Fernandes ER, Souza HFS, Astray RM, Boscardin SB, Rosa DS.

Vaccine. 2020 Apr 29;38(20):3653-3664. doi: 10.1016/j.**vaccine**.2020.03.037. Epub 2020 Apr 2.

PMID: 32247567

646. Development of a multivalent enterovirus subunit **vaccine** based on immunoinformatic design principles for the prevention of HFMD.

Deng H, Yu S, Guo Y, Gu L, Wang G, Ren Z, Li Y, Li K, Li R.

Vaccine. 2020 Apr 29;38(20):3671-3681. doi: 10.1016/j.**vaccine**.2020.03.023. Epub 2020 Apr 2.

PMID: 32247566

647. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV.

Xie M, Chen Q.

Int J Infect Dis. 2020 May;94:119-124. doi: 10.1016/j.ijid.2020.03.071. Epub 2020 Apr 1. Review.

PMID: 32247050

648. Use of real-world data for HPV **vaccine** trial follow-up in the Nordic region.

Enerly E, Berger S, Kjær SK, Sundström K, Campbell S, Tryggvadóttir L, Munk C, Hortlund M; Thomas Group. Electronic address: thomas_group@merck.com, Joshi A, Saah AJ, Nygård M.

Contemp Clin Trials. 2020 May;92:105996. doi: 10.1016/j.cct.2020.105996. Epub 2020 Apr 1.

PMID: 32247041

649. Effect of a school-based educational intervention on HPV and HPV **vaccine** knowledge and willingness to be vaccinated among Chinese adolescents : a multi-center intervention follow-up study.

Zhang X, Liu CR, Wang ZZ, Ren ZF, Feng XX, Ma W, Gao XH, Zhang R, Brown MD, Qiao YL, Geng Q, Li J.

Vaccine. 2020 Apr 29;38(20):3665-3670. doi: 10.1016/j.**vaccine**.2020.03.032. Epub 2020 Mar 31.

PMID: 32245644

650. Herpes zoster **vaccine** coverage in Australia before and after introduction of a national vaccination program.

Lin J, Wood JG, Bernardo C, Stocks NP, Liu B.

Vaccine. 2020 Apr 29;38(20):3646-3652. doi: 10.1016/j.**vaccine**.2020.03.036. Epub 2020 Mar 31.

PMID: 32245643

651. Investigational non-JAK inhibitors for chronic phase myelofibrosis.

Bankar A, Gupta V.

Expert Opin Investig Drugs. 2020 Apr 29:1-14. doi: 10.1080/13543784.2020.1751121. [Epub ahead of print]

PMID: 32245330

652. SARS-CoV-2: a time for clear and immediate action.

Poland GA.

Lancet Infect Dis. 2020 May;20(5):531-532. doi: 10.1016/S1473-3099(20)30250-4. Epub 2020 Mar 31. No abstract available.

PMID: 32243818

653. Ensuring global access to COVID-19 **vaccines**.

Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK.

Lancet. 2020 May 2;395(10234):1405-1406. doi: 10.1016/S0140-6736(20)30763-7. Epub 2020 Mar 31. No abstract available.

PMID: 32243778

654. Protection following simultaneous vaccination with three or four different attenuated live **vaccine** types against infectious bronchitis virus.

Jackwood MW, Clark R, Cheng S, Jordan BJ.

Avian Pathol. 2020 Apr 30:1-7. doi: 10.1080/03079457.2020.1748173. [Epub ahead of print]

PMID: 32242456

655. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.

Andrews K, Hamers AAJ, Sun X, Neale G, Verbist K, Tedrick P, Nichols KE, Pereira S, Geraghty DE, Pillai AB.

Cytotherapy. 2020 May;22(5):276-290. doi: 10.1016/j.jcyt.2020.01.011. Epub 2020 Mar 29.

PMID: 32238299

656. Immune interference (blunting) in the context of maternal immunization with Tdap-containing **vaccines**: is it a class effect?

Kandeil W, Savic M, Ceregido MA, Guignard A, Kuznetsova A, Mukherjee P.

Expert Rev **Vaccines**. 2020 May 7:1-12. doi: 10.1080/14760584.2020.1749597. [Epub ahead of print]

PMID: 32237928

657. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management.

Rebhan K, Laukhtina E, Shariat SF, Gust KM.

Curr Opin Urol. 2020 May;30(3):457-466. doi: 10.1097/MOU.0000000000000765.

PMID: 32235284

658. A DNA **Vaccine** Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus.

Gonzalez-Valdivieso J, Borrego B, Girotti A, Moreno S, Brun A, Bermejo-Martin JF, Arias FJ.

Mol Pharm. 2020 May 4;17(5):1608-1620. doi: 10.1021/acs.molpharmaceut.0c00054. Epub 2020 Apr 10.

PMID: 32233501

659. Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.

Rathore AS, Sarker A, Gupta RD.

Appl Microbiol Biotechnol. 2020 May;104(10):4333-4344. doi: 10.1007/s00253-020-10541-y. Epub 2020 Mar 30.

PMID: 32232529

660. Evaluation of Human Papillomavirus Vaccination After Pharmacist-Led Intervention: A Pilot Project in an Ambulatory Clinic at a Large Academic Urban Medical Center.

Cebollero J, Walton SM, Cavendish L, Quairoli K, Cwiak C, Kottke MJ.

Public Health Rep. 2020 May/Jun;135(3):313-321. doi: 10.1177/0033354920914340. Epub 2020 Mar 30.

PMID: 32228133

661. Quantification of residual hydrophobic fusion peptide with monomer and dimer forms using reversed-phase liquid chromatography.

Cai CX, Schneck NA, Ivleva VB, Gulla K, Zhang Y, Gowetski D, Paula Lei Q.

J Chromatogr B Analyt Technol Biomed Life Sci. 2020 May 1;1144:122073. doi: 10.1016/j.jchromb.2020.122073. Epub 2020 Mar 19.

PMID: 32224438

662. Free convective PCR: From principle study to commercial applications-A critical review.

Miao G, Zhang L, Zhang J, Ge S, Xia N, Qian S, Yu D, Qiu X.

Anal Chim Acta. 2020 Apr 29;1108:177-197. doi: 10.1016/j.aca.2020.01.069. Epub 2020 Jan 31. Review.

PMID: 32222239

663. Strong HPV **Vaccine** Response Predicts Better Survival with Chemotherapy.

[No authors listed]

Cancer Discov. 2020 May;10(5):637. doi: 10.1158/2159-8290.CD-RW2020-046. Epub 2020 Mar 27.

PMID: 32220926

664. Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors.

Kaid C, Madi RADS, Astray R, Goulart E, Caires-Junior LC, Mitsugi TG, Moreno ACR, Castro-Amarante MF, Pereira LR, Porchia BFMM, de Andrade TO, Landini V, Sanches DS, Pires CG, Tanioka RKO, Pereira MCL, Barbosa IN, Massoco CO, Ferreira LCS, Okamoto OK, Zatz M.

Mol Ther. 2020 May 6;28(5):1276-1286. doi: 10.1016/j.ymthe.2020.03.004. Epub 2020 Mar 10.

PMID: 32220305

665. Epidemiology of Covid-19. Reply.

Swerdlow DL, Finelli L, Lipsitch M.

N Engl J Med. 2020 May 7;382(19):1869-1870. doi: 10.1056/NEJMc2005157. Epub 2020 Mar 27. No abstract available.

PMID: 32220201

666. SARS-CoV-2: a storm is raging.

Pedersen SF, Ho YC.

J Clin Invest. 2020 May 1;130(5):2202-2205. doi: 10.1172/JCI137647.

PMID: 32217834

667. Use of plasmids for expression of proteins from the genus Leishmania in Escherichia coli: current state and perspectives.

Ribeiro VT, de Sá Leitão ALO, de Paiva Vasconcelos LTC, Filho MAO, Martins DRA, de Sousa Júnior FC, Dos Santos ES.

Appl Microbiol Biotechnol. 2020 May;104(10):4273-4280. doi: 10.1007/s00253-020-10548-5. Epub 2020 Mar 25. Review.

PMID: 32215706

668. Biomimic strategies for modulating the interaction between particle adjuvants and antigen-presenting cells.

Wu J, Ma G.

Biomater Sci. 2020 May 7;8(9):2366-2375. doi: 10.1039/c9bm02098e. Epub 2020 Mar 26.

PMID: 32215399

669. Clinical activity of a htert (vx-001) cancer **vaccine** as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.

Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de Las Penas R, Majem M, Chella A, Griesinger F, Bournakis E, Sadjadian P, Kotsakis A, Chinet T, Syrigos KN, Correale P, Gallou C, Jamet JM, Vetsika EK, Kosmatopoulos K, Georgoulias V; Vx-001-201 trial team.

Br J Cancer. 2020 May;122(10):1461-1466. doi: 10.1038/s41416-020-0785-y. Epub 2020 Mar 25.

PMID: 32210365

670. Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding.

Orlandi C, Deredge D, Ray K, Gohain N, Tolbert W, DeVico AL, Wintrode P, Pazgier M, Lewis GK.

Structure. 2020 May 5;28(5):516-527.e5. doi: 10.1016/j.str.2020.03.001. Epub 2020 Mar 24.

PMID: 32209433

671. Virus isolation and full-length genome sequencing of a representative canine distemper virus wild type strain of the South America 2 clade.

Romanutti C, Keller L, La Torre J, Panzera Y, Fuques E, Pérez R, Gallo Calderon M.

J Virol Methods. 2020 May;279:113857. doi: 10.1016/j.jviromet.2020.113857. Epub 2020 Mar 20.

PMID: 32205180

672. Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, 2011-2017.

Suo L, Lu L, Zhao D, Pang X.

Vaccine. 2020 Apr 29;38(20):3690-3696. doi: 10.1016/j.**vaccine**.2020.01.087. Epub 2020 Mar 20.

PMID: 32204940

673. Rational use of face masks in the COVID-19 pandemic.

Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ.

Lancet Respir Med. 2020 May;8(5):434-436. doi: 10.1016/S2213-2600(20)30134-X. Epub 2020 Mar 20. No abstract available.

PMID: 32203710

674. An imperfect **vaccine** reduces pathogen virulence.

York A.

Nat Rev Microbiol. 2020 May;18(5):265. doi: 10.1038/s41579-020-0358-3. No abstract available.

PMID: 32203298

675. Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.

Bonate PL, Van Sant C, Cho K, Zook EC, Smith LR, Boutsaboualoy S, Ye M, Wang X, Wu R, Koester A, Rammelsberg D, Goldwater R, Marbury TC.

Clin Pharmacol Drug Dev. 2020 May;9(4):444-455. doi: 10.1002/cpdd.792. Epub 2020 Mar 23.

PMID: 32202705

676. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

Einsele H, Ljungman P, Boeckh M.

Blood. 2020 May 7;135(19):1619-1629. doi: 10.1182/blood.2019000956.

PMID: 32202631

677. Superior adjuvanticity of the genetically fused D1 domain of Neisseria meningitides Ag473 lipoprotein among three Toll-like receptor ligands.

Lu H, Zhang X, Wang Y, Zong Y, Wang Y, Zhang X, Xia X, Sun H.

Biosci Rep. 2020 Apr 30;40(4). pii: BSR20193675. doi: 10.1042/BSR20193675.

PMID: 32202301

678. Evaluation of the immune response of a H7N9 candidate **vaccine** virus derived from the fifth wave A/Guangdong/17SF003/2016.

Dong J, Chen P, Wang Y, Lv Y, Xiao J, Li Q, Li Z, Zhang B, Niu X, Li C, Pan W, Chen L.

Antiviral Res. 2020 May;177:104776. doi: 10.1016/j.antiviral.2020.104776. Epub 2020 Mar 19.

PMID: 32201204

679. Tetanus, diphtheria and acellular pertussis (Tdap) **vaccine** for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.

Cho BH, Acosta AM, Leidner AJ, Faulkner AE, Zhou F.

Prev Med. 2020 May;134:106066. doi: 10.1016/j.ypmed.2020.106066. Epub 2020 Mar 19.

PMID: 32199910

680. Enhanced efficacy of a multi-epitope **vaccine** for type A and O foot-and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist.

Lei Y, Shao J, Ma F, Lei C, Chang H, Zhang Y.

Mol Immunol. 2020 May;121:118-126. doi: 10.1016/j.molimm.2020.02.018. Epub 2020 Mar 18.

PMID: 32199211

681. Characterization of the inflammasome component SmASC in turbot (Scophthalmus maximus).

Wang W, Tan J, Wang Z, Zhang Y, Liu Q, Yang D.

Fish Shellfish Immunol. 2020 May;100:324-333. doi: 10.1016/j.fsi.2020.03.032. Epub 2020 Mar 18.

PMID: 32198069

682. Higher education associated with better national tetanus vaccination coverage: A population-based assessment.

Rencken CA, Dunsiger S, Gjelsvik A, Amanullah S.

Prev Med. 2020 May;134:106063. doi: 10.1016/j.ypmed.2020.106063. Epub 2020 Mar 18.

PMID: 32197975

683. Safety and immunogenicity of a tetravalent dengue **vaccine** in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.

Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Saldaña de Suman O, Montenegro N, DeAntonio R, Mazara S, Vargas M, Mendoza D, Rauscher M, Brose M, Lefevre I, Tuboi S, Borkowski A, Wallace D.

Lancet. 2020 May 2;395(10234):1434-1443. doi: 10.1016/S0140-6736(20)30556-0. Epub 2020 Mar 17.

PMID: 32197107

684. Evaluation of a tetravalent dengue **vaccine** by serostatus and serotype.

Wilder-Smith A.

Lancet. 2020 May 2;395(10234):1402-1404. doi: 10.1016/S0140-6736(20)30603-6. Epub 2020 Mar 17. No abstract available.

PMID: 32197106

685. Efficacy of a tetravalent dengue **vaccine** in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.

Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, López-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D; TIDES study group.

Lancet. 2020 May 2;395(10234):1423-1433. doi: 10.1016/S0140-6736(20)30414-1. Epub 2020 Mar 17. Erratum in: Lancet. 2020 Apr 4;395(10230):1114.

PMID: 32197105

686. Disease X: accelerating the development of medical countermeasures for the next pandemic.

Simpson S, Kaufmann MC, Glozman V, Chakrabarti A.

Lancet Infect Dis. 2020 May;20(5):e108-e115. doi: 10.1016/S1473-3099(20)30123-7. Epub 2020 Mar 17. Review.

PMID: 32197097

687. Characterization of Aeromonas salmonicida and A. sobria isolated from cultured salmonid fish in Korea and development of a **vaccine** against furunculosis.

Lim J, Hong S.

J Fish Dis. 2020 May;43(5):609-620. doi: 10.1111/jfd.13158. Epub 2020 Mar 20.

PMID: 32196710

688. PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.

Wippold JA, Wang H, Tingling J, Leibowitz JL, de Figueiredo P, Han A.

Lab Chip. 2020 May 7;20(9):1628-1638. doi: 10.1039/c9lc01165j. Epub 2020 Mar 20.

PMID: 32196032

689. Teres minor injury related to **vaccine** administration.

Natanzi N, Hebroni F, Bodor M.

Radiol Case Rep. 2020 Mar 14;15(5):552-555. doi: 10.1016/j.radcr.2020.02.009. eCollection 2020 May.

PMID: 32194884

690. Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China.

Li W, Wang Y, Yu B, Tan Q, Zhou J, Hu J, Wu Y, Wang B, Li H.

Virus Res. 2020 May;281:197937. doi: 10.1016/j.virusres.2020.197937. Epub 2020 Mar 16.

PMID: 32194139

691. Genetic characterization of mumps viruses associated with the resurgence of mumps in the United States: 2015-2017.

McNall RJ, Wharton AK, Anderson R, Clemmons N, Lopareva EN, Gonzalez C, Espinosa A, Probert WS, Hacker JK, Liu G, Garfin J, Strain AK, Boxrud D, Bryant PW, George KS, Davis T, Griesser RH, Shult P, Bankamp B, Hickman CJ, Wroblewski K, Rota PA.

Virus Res. 2020 May;281:197935. doi: 10.1016/j.virusres.2020.197935. Epub 2020 Mar 16.

PMID: 32194138

692. Russian Twitter Accounts and the Partisan Polarization of **Vaccine** Discourse, 2015-2017.

Walter D, Ophir Y, Jamieson KH.

Am J Public Health. 2020 May;110(5):718-724. doi: 10.2105/AJPH.2019.305564. Epub 2020 Mar 19.

PMID: 32191516

693. Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.

Odedra A, McCarthy JS.

Am J Trop Med Hyg. 2020 May;102(5):934-939. doi: 10.4269/ajtmh.19-0351.

PMID: 32189610

694. Study on the Changes of Chemical Constituents in Different Compatibilities of Ginseng-Prepared Rehmannia Root and Their Effects on Bone Marrow Inhibition after Chemotherapy.

Wang SQ, Yang X, Zhang YG, Cai EB, Zheng XM, Zhao Y, Li G, Han M, Yang LM.

Chem Pharm Bull (Tokyo). 2020 May 1;68(5):428-435. doi: 10.1248/cpb.c19-00994. Epub 2020 Mar 17.

PMID: 32188797

695. Cisplatin nephrotoxicity is induced via poly(ADP-ribose) polymerase activation in adult zebrafish and mice.

Kim MJ, Moon D, Jung S, Lee J, Kim J.

Am J Physiol Regul Integr Comp Physiol. 2020 May 1;318(5):R843-R854. doi: 10.1152/ajpregu.00130.2019. Epub 2020 Mar 18.

PMID: 32186196

696. Potential DNA **Vaccine** for Haemorrhagic Septiceamia Disease.

Chelliah S, Velappan RD, Lim KT, Swee CWK, Nor Rashid N, Rothan HA, Kabir N, Ismail S.

Mol Biotechnol. 2020 May;62(5):289-296. doi: 10.1007/s12033-020-00244-0.

PMID: 32185600

697. Characteristics and function of cathepsin L3 from Schistosoma japonicum.

Huang W, Gu M, Cheng W, Zhao QP, Ming Z, Dong H.

Parasitol Res. 2020 May;119(5):1619-1628. doi: 10.1007/s00436-020-06647-x. Epub 2020 Mar 17.

PMID: 32185481

698. The coadministration of trehalose dibehenate and monosodium urate crystals promotes an antitumor phenotype in human-derived myeloid cells.

Kodar K, McConnell MJ, Harper JL, Timmer MS, Stocker BL.

Immunol Cell Biol. 2020 May;98(5):411-422. doi: 10.1111/imcb.12329. Epub 2020 Apr 24.

PMID: 32181513

699. Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8^{+} T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.

Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, Afanasiev OK, Colunga A, Cook MM, Xie H, Greninger AL, Paulson KG, Chapuis AG, Bhatia S, Nghiem P, Koelle DM.

Cancer Immunol Res. 2020 May;8(5):648-659. doi: 10.1158/2326-6066.CIR-19-0647. Epub 2020 Mar 16.

PMID:
32179557

700. Association Between **Vaccine** Exemption Policy Change in California and Adverse Event Reporting.

Hause AM, Hesse EM, Ng C, Marquez P, McNeil MM, Omer SB.

Pediatr Infect Dis J. 2020 May;39(5):369-373. doi: 10.1097/INF.0000000000002585.

PMID: 32176185

701. Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions.

Mucker EM, Lindquist M, Hooper JW.

Virology. 2020 May;544:42-54. doi: 10.1016/j.virol.2020.02.004. Epub 2020 Feb 25.

PMID: 32174513

702. Educating first-year medical students on inactive **vaccine** components.

Chase AJ, Heck AJ.

Med Educ. 2020 May;54(5):446-447. doi: 10.1111/medu.14111. Epub 2020 Mar 16. No abstract available.

PMID: 32173893

703. Immune efficacy of carbon nanotubes recombinant subunit **vaccine** against largemouth bass ulcerative syndrome virus.

Jia YJ, Guo ZR, Ma R, Qiu DK, Zhao Z, Wang GX, Zhu B.

Fish Shellfish Immunol. 2020 May;100:317-323. doi: 10.1016/j.fsi.2020.03.025. Epub 2020 Mar 13.

PMID: 32173450

704. Development of a rapid immunochromatographic strip test for the detection of porcine epidemic diarrhea virus specific SIgA in colostrum.

Liu J, Gao R, Shi H, Cong G, Chen J, Zhang X, Shi D, Cao L, Wang X, Zhang J, Ji Z, Jing Z, Feng L.

J Virol Methods. 2020 May;279:113855. doi: 10.1016/j.jviromet.2020.113855. Epub 2020 Mar 12.

PMID: 32173373

705. A novel follicle-stimulating hormone **vaccine** for controlling fat accumulation.

Han X, Guan Z, Xu M, Zhang Y, Yao H, Meng F, Zhuo Y, Yu G, Cao X, Du X, Bu G, Kong F, Huang A, Zeng X.

Theriogenology. 2020 May;148:103-111. doi: 10.1016/j.theriogenology.2020.03.005. Epub 2020 Mar 5.

PMID: 32171969

706. **Vaccine** skepticism reflects basic cognitive differences in mortality-related event frequency estimation.

LaCour M, Davis T.

Vaccine. 2020 May 6;38(21):3790-3799. doi: 10.1016/j.**vaccine**.2020.02.052. Epub 2020 Mar 10.

PMID: 32169393

707. Burkholderia pseudomallei pathogenesis and survival in different niches.

Yip CH, Ghazali AK, Nathan S.

Biochem Soc Trans. 2020 Apr 29;48(2):569-579. doi: 10.1042/BST20190836.

PMID: 32167134

708. Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers.

Disis ML, Corulli LR, Gad EA, Koehnlein MR, Cecil DL, Senter PD, Gardai SJ, Okeley NM.

Mol Cancer Ther. 2020 May;19(5):1102-1109. doi: 10.1158/1535-7163.MCT-19-0500. Epub 2020 Mar 12.

PMID: 32165557

709. Large-scale profiling of the proteome and dual transcriptome in Nile tilapia (Oreochromis niloticus) challenged with low- and high-virulence strains of Streptococcus agalactiae.

Zhou Y, Liu Y, Luo Y, Zhong H, Huang T, Liang W, Xiao J, Wu W, Li L, Chen M.

Fish Shellfish Immunol. 2020 May;100:386-396. doi: 10.1016/j.fsi.2020.03.008. Epub 2020 Mar 9.

PMID: 32165249

710. Fluorescent microspheres as a positive indicator in an intratracheal infection model.

Leigh SA, Branton SL, Evans JD, Collier SD.

J Microbiol Methods. 2020 May;172:105886. doi: 10.1016/j.mimet.2020.105886. Epub 2020 Mar 9.

PMID: 32165162

711. In silico design of a **vaccine** candidate based on autotransporters and HSP against the causal agent of shigellosis, Shigella flexneri.

León Y, Zapata L, Salas-Burgos A, Oñate A.

Mol Immunol. 2020 May;121:47-58. doi: 10.1016/j.molimm.2020.02.008. Epub 2020 Mar 9.

PMID: 32163758

712. Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

Wettstein MS, Naimark D, Hermanns T, Herrera-Caceres JO, Ahmad A, Jewett MAS, Kulkarni GS.

Cancer Med. 2020 May;9(10):3287-3296. doi: 10.1002/cam4.2980. Epub 2020 Mar 12.

PMID: 32163677

713. Adeno-associated virus-vectored influenza **vaccine** elicits neutralizing and Fcγ receptor-activating antibodies.

Demminger DE, Walz L, Dietert K, Hoffmann H, Planz O, Gruber AD, von Messling V, Wolff T.

EMBO Mol Med. 2020 May 8;12(5):e10938. doi: 10.15252/emmm.201910938. Epub 2020 Mar 12.

PMID: 32163240

714. Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.

Zou S, Zhang S, Gaffney A, Ding H, Lu M, Grover JR, Farrell M, Nguyen HT, Zhao C, Anang S, Zhao M, Mohammadi M, Blanchard SC, Abrams C, Madani N, Mothes W, Kappes JC, Smith AB 3rd, Sodroski J.

J Virol. 2020 May 4;94(10). pii: e00148-20. doi: 10.1128/JVI.00148-20. Print 2020 May 4.

PMID: 32161177

715. Novel Insights into the Roles of Bcl-2 Homolog Nr-13 (vNr-13) Encoded by Herpesvirus of Turkeys in the Virus Replication Cycle, Mitochondrial Networks, and Apoptosis Inhibition.

Reddy VRAP, Sadigh Y, Tang N, Yao Y, Nair V.

J Virol. 2020 May 4;94(10). pii: e02049-19. doi: 10.1128/JVI.02049-19. Print 2020 May 4.

PMID: 32161176

716. Long-term effectiveness of live herpes zoster **vaccine** in patients with rheumatoid arthritis subsequently treated with tofacitinib.

Winthrop KL, Wouters A, Choy EH, Chen C, Biswas P, Wang L, Soma K, Needle E, Valdez H, Rigby WF.

Ann Rheum Dis. 2020 May;79(5):669-671. doi: 10.1136/annrheumdis-2019-216566. Epub 2020 Mar 11. No abstract available.

PMID: 32161057

717. Use of Electronic Health Records by Older Adults, 85 Years and Older, and Their Caregivers.

Ramirez-Zohfeld V, Seltzer A, Xiong L, Morse L, Lindquist LA.

J Am Geriatr Soc. 2020 May;68(5):1078-1082. doi: 10.1111/jgs.16393. Epub 2020 Mar 11.

PMID: 32159860

718. An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer.

Yu H, Ye C, Li J, Pan C, Lin W, Chen H, Zhou Z, Ye Y.

Exp Cell Res. 2020 May 1;390(1):111953. doi: 10.1016/j.yexcr.2020.111953. Epub 2020 Mar 7.

PMID: 32156601

719. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.

Lu T, Guo Q, Lin K, Chen H, Chen Y, Xu Y, Lin C, Su Y, Chen Y, Chen M, Zheng Y, Ye Y, Lin S, Zong J, Pan J.

Cancer Sci. 2020 May;111(5):1711-1723. doi: 10.1111/cas.14381. Epub 2020 Apr 9.

PMID: 32155300

720. Human papillomavirus vaccination and postural tachycardia syndrome, deconditioning and exercise-induced hyperalgesia: An alternate interpretation of the reported adverse reactions.

Ishizaki Y, Gomi H.

J Obstet Gynaecol Res. 2020 May;46(5):678-683. doi: 10.1111/jog.14227. Epub 2020 Mar 9.

PMID: 32153078

721. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.

Xiao T, Frey G, Fu Q, Lavine CL, Scott DA, Seaman MS, Chou JJ, Chen B.

Nat Chem Biol. 2020 May;16(5):529-537. doi: 10.1038/s41589-020-0496-y. Epub 2020 Mar 9.

PMID: 32152540

722. PilVax, a novel Lactococcus lactis-based mucosal **vaccine** platform, stimulates systemic and mucosal immune responses to Staphylococcus aureus.

Clow F, Peterken K, Pearson V, Proft T, Radcliff FJ.

Immunol Cell Biol. 2020 May;98(5):369-381. doi: 10.1111/imcb.12325. Epub 2020 Apr 9.

PMID: 32150301

723. Clearance of Immunodeficiency-associated **Vaccine**-derived Poliovirus Infection With Pocapavir.

Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B.

Pediatr Infect Dis J. 2020 May;39(5):435-437. doi: 10.1097/INF.0000000000002584.

PMID: 32150007

724. Presence and Concentrations of Select Bacterial Vaginosis-Associated Bacteria Are Associated With Increased Risk of Pelvic Inflammatory Disease.

Haggerty CL, Ness RB, Totten PA, Farooq F, Tang G, Ko D, Hou X, Fiedler TL, Srinivasan S, Astete SG, Fredricks DN.

Sex Transm Dis. 2020 May;47(5):344-346. doi: 10.1097/OLQ.0000000000001164.

PMID: 32149953

725. Transmission of respiratory tract infections at mass gathering events.

Petersen E, Memish ZA, Zumla A, Maani AA.

Curr Opin Pulm Med. 2020 May;26(3):197-202. doi: 10.1097/MCP.0000000000000675.

PMID: 32149751

726. Pneumococcal virulence factors in community-acquired pneumonia.

Feldman C, Anderson R.

Curr Opin Pulm Med. 2020 May;26(3):222-231. doi: 10.1097/MCP.0000000000000674.

PMID: 32149750

727. Effects of the oral adsorbent AST-120 on fecal p-cresol and indole levels and on the gut microbiota composition.

Sato E, Hosomi K, Sekimoto A, Mishima E, Oe Y, Saigusa D, Ito S, Abe T, Sato H, Kunisawa J, Niwa T, Takahashi N.

Biochem Biophys Res Commun. 2020 May 7;525(3):773-779. doi: 10.1016/j.bbrc.2020.02.141. Epub 2020 Mar 5.

PMID: 32147096

728. Wild bird-origin H5N6 avian influenza virus is transmissible in guinea pigs.

Xiang B, Chen L, Xie P, Lin Q, Liao M, Ren T.

J Infect. 2020 May;80(5):e20-e22. doi: 10.1016/j.jinf.2020.02.030. Epub 2020 Mar 5. No abstract available.

PMID: 32145213

729. Development and optimization of a DNA-based reverse genetics systems for epizootic hemorrhagic disease virus.

Guo Y, Pretorius JM, Xu Q, Wu D, Bu Z, Theron J, Sun E.

Arch Virol. 2020 May;165(5):1079-1087. doi: 10.1007/s00705-020-04583-w. Epub 2020 Mar 6.

PMID: 32144546

730. Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice.

Li H, Cao L, Zhang Y, Ren H, Zhao P, Xu W.

Arch Virol. 2020 May;165(5):1057-1067. doi: 10.1007/s00705-020-04578-7. Epub 2020 Mar 6.

PMID: 32144542

731. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.

Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J, Chang C.

J Autoimmun. 2020 May;109:102434. doi: 10.1016/j.jaut.2020.102434. Epub 2020 Mar 3. Review.

PMID: 32143990

732. Enabling sublingual peptide immunization with molecular self-assemblies.

Kelly SH, Wu Y, Varadhan AK, Curvino EJ, Chong AS, Collier JH.

Biomaterials. 2020 May;241:119903. doi: 10.1016/j.biomaterials.2020.119903. Epub 2020 Feb 24.

PMID: 32143059

733. Oral immunization with recombinant Lactobacillus casei displayed AHA1-CK6 and VP2 induces protection against infectious pancreatic necrosis in rainbow trout (Oncorhynchus mykiss).

Chen Y, Hua X, Ren X, Duan K, Gao S, Sun J, Feng Y, Zhou Y, Guan X, Li D, Wang N, Li J, Yang J, Xia D, Shi W, Liu M.

Fish Shellfish Immunol. 2020 May;100:18-26. doi: 10.1016/j.fsi.2020.03.001. Epub 2020 Mar 4.

PMID: 32142871

734. Pathogenicity and genome changes in QX-like infectious bronchitis virus during continuous passaging in embryonated chicken eggs.

Yan S, Zhao Y, Zhao J, Cheng J, Zhang G.

Virus Res. 2020 May;281:197911. doi: 10.1016/j.virusres.2020.197911. Epub 2020 Mar 3.

PMID: 32142742

735. Sentinel surveillance of selected veterinary and public health pathogens in camel population originating from Southern Punjab province, Pakistan.

Shabbir MZ, Sohail T, Ul-Rahman A, Abbas T, Ali Q, Rehman ZU, Khan I, Yaqub T, Muhammad J, Ahmad Khan S, Imran MS, Basit MA, Ullah S, Habib M, Gardezi SAM, Bashir A, Ahmad M, Abubakar M, Abbas M, Subhani A, Yasein G, Altaaf F, Aziz MH, Hussain R, Zohaib A, Chaudhry U, Wensman JJ.

Acta Trop. 2020 May;205:105435. doi: 10.1016/j.actatropica.2020.105435. Epub 2020 Mar 3.

PMID: 32142734

736. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus.

Maepa MB, Jacobs R, van den Berg F, Arbuthnot P.

Curr Opin HIV AIDS. 2020 May;15(3):200-207. doi: 10.1097/COH.0000000000000623.

PMID: 32141890

737. Distribution and persistence of residual T-2 and HT-2 toxins from moldy feed in broiler chickens.

Yang L, Tu D, Wu Y, Liu W, Hu Y, Liu T, Tan L, Li Y, Lei H, Zhan Y, Wang N, Deng Z, Guo S, Wang A.

Toxicon. 2020 Apr 30;178:82-91. doi: 10.1016/j.toxicon.2020.02.023. Epub 2020 Mar 3.

PMID: 32135197

738. Attenuated porcine-derived type 2 bovine viral diarrhea virus as vector stably expressing viral gene.

Tao J, Li B, Shi Y, Chen J, Zhu G, Shen X, Liu H.

J Virol Methods. 2020 May;279:113842. doi: 10.1016/j.jviromet.2020.113842. Epub 2020 Mar 2.

PMID: 32135175

739. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C.

Tartaglia LJ, Gupte S, Pastores KC, Trott S, Abbink P, Mercado NB, Li Z, Liu PT, Borducchi EN, Chandrashekar A, Bondzie EA, Hamza V, Kordana N, Mahrokhian S, Lavine CL, Seaman MS, Li H, Shaw GM, Barouch DH.

J Virol. 2020 May 4;94(10). pii: e01860-19. doi: 10.1128/JVI.01860-19. Print 2020 May 4.

PMID: 32132241

740. Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex.

Cotter CA, Moss B.

J Virol. 2020 May 4;94(10). pii: e00077-20. doi: 10.1128/JVI.00077-20. Print 2020 May 4.

PMID: 32132239

741. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.

Grifoni A, Voic H, Dhanda SK, Kidd CK, Brien JD, Buus S, Stryhn A, Durbin AP, Whitehead S, Diehl SA, De Silva AD, Balmaseda A, Harris E, Weiskopf D, Sette A.

J Virol. 2020 May 4;94(10). pii: e00089-20. doi: 10.1128/JVI.00089-20. Print 2020 May 4.

PMID: 32132233

742. Current status and future directions of fish **vaccines** employing virus-like particles.

Jeong KH, Kim HJ, Kim HJ.

Fish Shellfish Immunol. 2020 May;100:49-57. doi: 10.1016/j.fsi.2020.02.060. Epub 2020 Mar 1.

PMID: 32130976

743. Natural and engineered promoters for gene expression in Lactobacillus species.

Peirotén Á, Landete JM.

Appl Microbiol Biotechnol. 2020 May;104(9):3797-3805. doi: 10.1007/s00253-020-10426-0. Epub 2020 Mar 4. Review.

PMID: 32130470

744. Large-scale manufacture of VP2 VLP **vaccine** against porcine parvovirus in Escherichia coli with high-density fermentation.

Wang J, Liu Y, Chen Y, Wang A, Wei Q, Liu D, Zhang G.

Appl Microbiol Biotechnol. 2020 May;104(9):3847-3857. doi: 10.1007/s00253-020-10483-5. Epub 2020 Mar 4.

PMID: 32130468

745. Partnerships for better neglected disease drug discovery and development: how have we fared?

Sunyoto T.

Expert Opin Drug Discov. 2020 May;15(5):531-537. doi: 10.1080/17460441.2020.1736550. Epub 2020 Mar 10.

PMID: 32129688

746. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.

Lin C, Ren W, Luo Y, Li S, Chang Y, Li L, Xiong D, Huang X, Xu Z, Yu Z, Wang Y, Zhang J, Huang C, Xia N.

Cancer Immunol Res. 2020 May;8(5):632-647. doi: 10.1158/2326-6066.CIR-19-0628. Epub 2020 Mar 3.

PMID: 32127389

747. Foot-and-mouth disease virus: Prospects for using knowledge of virus biology to improve control of this continuing global threat.

Belsham GJ, Kristensen T, Jackson T.

Virus Res. 2020 May;281:197909. doi: 10.1016/j.virusres.2020.197909. Epub 2020 Feb 29. Review.

PMID: 32126297

748. The gut anti-complement activity of Aedes aegypti: Investigating new ways to control the major human arboviruses vector in the Americas.

Pereira-Filho AA, Mateus Pereira RH, da Silva NCS, Ferreira Malta LG, Serravite AM, Carvalho de Almeida CG, Fujiwara RT, Bartholomeu DC, Giunchetti RC, D'Ávila Pessoa GC, Koerich LB, Pereira MH, Araujo RN, Gontijo NF, Viana Sant'Anna MR.

Insect Biochem Mol Biol. 2020 May;120:103338. doi: 10.1016/j.ibmb.2020.103338. Epub 2020 Feb 29.

PMID: 32126277

749. Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells.

Roychoudhury P, Swan DA, Duke E, Corey L, Zhu J, Davé V, Spuhler LR, Lund JM, Prlic M, Schiffer JT.

J Clin Invest. 2020 Apr 27. pii: 132583. doi: 10.1172/JCI132583. [Epub ahead of print]

PMID: 32125285

750. Cytokine Expression in Dengue Fever and Dengue Hemorrhagic Fever Patients with Bleeding and Severe Hepatitis.

Imad HA, Phumratanaprapin W, Phonrat B, Chotivanich K, Charunwatthana P, Muangnoicharoen S, Khusmith S, Tantawichien T, Phadungsombat J, Nakayama E, Konishi E, Shioda T.

Am J Trop Med Hyg. 2020 May;102(5):943-950. doi: 10.4269/ajtmh.19-0487.

PMID: 32124729

751. Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated **Vaccine** in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study.

Diaz C, Koren M, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Febo I, Vaughn DW, Wilson TM, Paris RM, Schmidt AC, Thomas SJ.

Am J Trop Med Hyg. 2020 May;102(5):951-954. doi: 10.4269/ajtmh.19-0461.

PMID: 32124728

752. A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated **vaccine** in pigs.

Chen W, Zhao D, He X, Liu R, Wang Z, Zhang X, Li F, Shan D, Chen H, Zhang J, Wang L, Wen Z, Wang X, Guan Y, Liu J, Bu Z.

Sci China Life Sci. 2020 May;63(5):623-634. doi: 10.1007/s11427-020-1657-9. Epub 2020 Mar 1.

PMID: 32124180

753. Dual-targeting nanoparticle **vaccine** elicits a therapeutic antibody response against chronic hepatitis B.

Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, Wang Z, Zhu P, Peng H, Yan X, Li W, Fu YX, Zhu M.

Nat Nanotechnol. 2020 May;15(5):406-416. doi: 10.1038/s41565-020-0648-y. Epub 2020 Mar 2.

PMID: 32123380

754. NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.

Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, Wood O, Machado M, Lopez MA, Ganesan AP, Wang C, Chakravarthy A, Fenton TR, King EV, Vijayanand P, Ottensmeier CH, Al-Shamkhani A, Savelyeva N, Thomas GJ.

Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2.

PMID: 32122909

755. Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens.

Zhang R, Tang L, Tian Y, Ji X, Hu Q, Zhou B, Zhenyu D, Heng X, Yang L.

Biomaterials. 2020 May;241:119852. doi: 10.1016/j.biomaterials.2020.119852. Epub 2020 Feb 11.

PMID: 32120313

756. Immuno-informatics approach to design a multi-epitope **vaccine** to combat cytomegalovirus infection.

Chauhan V, Singh MP.

Eur J Pharm Sci. 2020 Apr 30;147:105279. doi: 10.1016/j.ejps.2020.105279. Epub 2020 Feb 29.

PMID: 32119992

757. Diphtheria toxoid dissolving microneedle vaccination: Adjuvant screening and effect of repeated-fractional dose administration.

Leone M, Romeijn S, Du G, Le Dévédec SE, Vrieling H, O'Mahony C, Bouwstra JA, Kersten G.

Int J Pharm. 2020 Apr 30;580:119182. doi: 10.1016/j.ijpharm.2020.119182. Epub 2020 Feb 28.

PMID: 32119899

758. Apolipoprotein M, identified as a novel hepatitis C virus (HCV) particle associated protein, contributes to HCV assembly and interacts with E2 protein.

Cai H, Yao W, Huang J, Xiao J, Chen W, Hu L, Mai R, Liang M, Chen D, Jiang N, Zhou L, Peng T.

Antiviral Res. 2020 May;177:104756. doi: 10.1016/j.antiviral.2020.104756. Epub 2020 Feb 28.

PMID: 32119870

759. Evaluation of mucoadhesive property and the effect of *Boswellia carteri* gum on intranasal vaccination against small ruminant morbillivirus infection (PPR).

Mumin FI, Emikpe BO, Odeniyi MA.

J Immunoassay Immunochem. 2020 May 3;41(3):311-321. doi: 10.1080/15321819.2020.1734935. Epub 2020 Mar 2.

PMID: 32119592

760. Science in the fight against the novel coronavirus disease 2019 (COVID-19).

Wang JW, Cao B, Wang C.

Chin Med J (Engl). 2020 May 5;133(9):1009-1011. doi: 10.1097/CM9.0000000000000777. No abstract available.

PMID: 32118642

761. Twitter as a sentinel tool to monitor public opinion on vaccination: an opinion mining analysis from September 2016 to August 2017 in Italy.

Tavoschi L, Quattrone F, D'Andrea E, Ducange P, Vabanesi M, Marcelloni F, Lopalco PL.

Hum Vaccin Immunother. 2020 May 3;16(5):1062-1069. doi: 10.1080/21645515.2020.1714311. Epub 2020 Mar 2.

PMID: 32118519

762. What risks should be permissible in controlled human infection model studies?

Binik A.

Bioethics. 2020 May;34(4):420-430. doi: 10.1111/bioe.12736. Epub 2020 Mar 1.

PMID: 32115747

763. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic **vaccines**.

Chen T, Hu R, Wan Y, Sun F, Wang Z, Yue J, Chen J, Han G, Wei G, Dong Z.

Biochem Biophys Res Commun. 2020 May 7;525(3):607-613. doi: 10.1016/j.bbrc.2020.02.132. Epub 2020 Feb 27.

PMID: 32115148

764. Effects of the sulfated polysaccharide ulvan from Ulva ohnoi on the modulation of the immune response in Senegalese sole (Solea senegalensis).

Ponce M, Zuasti E, Anguís V, Fernández-Díaz C.

Fish Shellfish Immunol. 2020 May;100:27-40. doi: 10.1016/j.fsi.2020.02.054. Epub 2020 Feb 27.

PMID: 32113938

765. Comparison of antibody repertories against Staphylococcus aureus in healthy and infected dairy cows with a distinct mastitis history and vaccinated with a polyvalent mastitis **vaccine**.

Cunha AF, Andrade HM, Souza FN, Fialho Júnior LC, Rosa DLSO, Ramos Sanchez EM, Gidlund M, Goto H, Brito MAVP, Guimarães AS, Lage AP, Reis LC, Della Libera AMMP, Heinemann MB, Cerqueira MMOP.

J Dairy Sci. 2020 May;103(5):4588-4605. doi: 10.3168/jds.2019-17084. Epub 2020 Feb 26.

PMID: 32113759

766. Assessment of a poly-epitope candidate **vaccine** against Hepatitis B, C, and poliovirus in interaction with monocyte-derived dendritic cells: An ex-vivo study.

Bahrami AA, Bandehpour M, Kazemi B, Bozorgmehr M, Mosaffa N, Chegeni R.

Hum Immunol. 2020 May;81(5):218-227. doi: 10.1016/j.humimm.2020.02.010. Epub 2020 Feb 26.

PMID: 32113655

767. Improved Mycobacterium tuberculosis clearance after the restoration of IFN-γ^+ TNF-α^+ $CD4^+$ T cells: Impact of PD-1 inhibition in active tuberculosis patients.

Kamboj D, Gupta P, Basil MV, Mohan A, Guleria R, Bhatnagar A, Mehta G, Kumar P, Saurabh A, Deepak R, Thakral D, Misra P, Tandon R, Gupta UD, Mitra DK.

Eur J Immunol. 2020 May;50(5):736-747. doi: 10.1002/eji.201948283. Epub 2020 Mar 24.

PMID: 32113187

768. Rubella seroepidemiology among Korean women: Two decades after a combined vaccination strategy.

Choe SA, Choe YJ, Paek JY.

Int J Infect Dis. 2020 May;94:25-28. doi: 10.1016/j.ijid.2020.02.045. Epub 2020 Feb 26.

PMID: 32112963

769. Multivalent DNA **vaccine** protects against genital herpes by T-cell immune induction in vaginal mucosa.

Kim HC, Oh DS, Park JH, Kim HJ, Seo YB, Yoo HJ, Jang HS, Shin J, Kim CW, Kwon MS, Jin HT, Lee SK, Oh JE, Lee HK.

Antiviral Res. 2020 May;177:104755. doi: 10.1016/j.antiviral.2020.104755. Epub 2020 Feb 26.

PMID: 32112797

770. Characterization of 100 extended major histocompatibility complex haplotypes in Indonesian cynomolgus macaques.

Shortreed CG, Wiseman RW, Karl JA, Bussan HE, Baker DA, Prall TM, Haj AK, Moreno GK, Penedo MCT, O'Connor DH.

Immunogenetics. 2020 May;72(4):225-239. doi: 10.1007/s00251-020-01159-5. Epub 2020 Feb 29.

PMID: 32112172

771. Responding to Covid-19 - A Once-in-a-Century Pandemic?

Gates B.

N Engl J Med. 2020 Apr 30;382(18):1677-1679. doi: 10.1056/NEJMp2003762. Epub 2020 Feb 28. No abstract available.

PMID: 32109012

772. Transgenic Eimeria parasite: A potential control strategy for chicken coccidiosis.

Fatoba AJ, Adeleke MA.

Acta Trop. 2020 May;205:105417. doi: 10.1016/j.actatropica.2020.105417. Epub 2020 Feb 24. Review.

PMID: 32105666

773. Glycoprotein 5 Is Cleaved by Cathepsin E during Porcine Reproductive and Respiratory Syndrome Virus Membrane Fusion.

Hou J, Li R, Qiao S, Chen XX, Xing G, Zhang G.

J Virol. 2020 May 4;94(10). pii: e00097-20. doi: 10.1128/JVI.00097-20. Print 2020 May 4.

PMID: 32102888

774. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.

Hartlage AS, Walker CM, Kapoor A.

J Virol. 2020 May 4;94(10). pii: e00035-20. doi: 10.1128/JVI.00035-20. Print 2020 May 4.

PMID: 32102885

775. Establishment of a Reverse Genetics System for Influenza D Virus.

Ishida H, Murakami S, Kamiki H, Matsugo H, Takenaka-Uema A, Horimoto T.

J Virol. 2020 May 4;94(10). pii: e01767-19. doi: 10.1128/JVI.01767-19. Print 2020 May 4.

PMID: 32102883

776. Maternal Diarrhea and Antibiotic Use are Associated with Increased Risk of Diarrhea among HIV-Exposed, Uninfected Infants in Kenya.

Deichsel EL, Pavlinac PB, Mbori-Ngacha D, Walson JL, Maleche-Obimbo E, Farquhar C, Bosire R, John-Stewart GC.

Am J Trop Med Hyg. 2020 May;102(5):1001-1008. doi: 10.4269/ajtmh.19-0705.

PMID: 32100682

777. Vaxign-ML: supervised machine learning reverse vaccinology model for improved prediction of bacterial protective antigens.

Ong E, Wang H, Wong MU, Seetharaman M, Valdez N, He Y.

Bioinformatics. 2020 May 1;36(10):3185-3191. doi: 10.1093/bioinformatics/btaa119.

PMID: 32096826

778. Main B-cell epitopes of PvAMA-1 and PvMSP-9 are targeted by naturally acquired antibodies and epitope-specific memory cells in acute and convalescent phases of vivax malaria.

Soares RR, Nakaie CR, Rodrigues-da-Silva RN, da Silva RL, Lima-Junior JDC, Scopel KKG.

Parasite Immunol. 2020 May;42(5):e12705. doi: 10.1111/pim.12705. Epub 2020 Mar 19.

PMID: 32096238

779. Epitopes for a 2019-nCoV **vaccine**.

Lucchese G.

Cell Mol Immunol. 2020 May;17(5):539-540. doi: 10.1038/s41423-020-0377-z. Epub 2020 Feb 24. No abstract available.

PMID: 32094505

780. PDL1-targeted **vaccine** exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.

Tian H, Kang Y, Song X, Xu Y, Chen H, Gong X, Zhang W, Xu Y, Xia X, Gao X, Yao W.

Cancer Lett. 2020 Apr 28;476:170-182. doi: 10.1016/j.canlet.2020.02.024. Epub 2020 Feb 21.

PMID: 32092355

781. Recombinant zoster **vaccine** administration in an allergy and immunology practice: A medical and economic case.

Russell HG, Tankersley MS.

Ann Allergy Asthma Immunol. 2020 May;124(5):517-518. doi: 10.1016/j.anai.2020.02.006. Epub 2020 Feb 21. No abstract available.

PMID: 32088321

782. Current prospects and challenges in fish **vaccine** development in India with special reference to Aeromonas hydrophila **vaccine**.

Nayak SK.

Fish Shellfish Immunol. 2020 May;100:283-299. doi: 10.1016/j.fsi.2020.01.064. Epub 2020 Feb 20.

PMID: 32088285

783. Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study.

Quee FA, de Hoog MLA, Schuurman R, Bruijning-Verhagen P.

Lancet Infect Dis. 2020 May;20(5):598-606. doi: 10.1016/S1473-3099(20)30058-X. Epub 2020 Feb 20.

PMID: 32087775

784. Human papillomavirus prevalence and distribution in self-collected samples from female university students in Maputo.

Bule YP, Silva J, Carrilho C, Campos C, Sousa H, Tavares A, Medeiros R.

Int J Gynaecol Obstet. 2020 May;149(2):237-246. doi: 10.1002/ijgo.13126. Epub 2020 Mar 25.

PMID: 32086940

785. Acute Gastroenteritis in Children of the World: What Needs to Be Done?

Guarino A, Aguilar J, Berkley J, Broekaert I, Vazquez-Frias R, Holtz L, Lo Vecchio A, Meskini T, Moore S, Rivera Medina JF, Sandhu B, Smarrazzo A, Szajewska H, Treepongkaruna S.

J Pediatr Gastroenterol Nutr. 2020 May;70(5):694-701. doi: 10.1097/MPG.0000000000002669.

PMID: 32079974

786. Prioritisation of the human papillomavirus **vaccine** in a time of constrained supply.

Kreimer AR, Cernuschi T, Rees H, Saslow D, Porras C, Schiller J.

Lancet Child Adolesc Health. 2020 May;4(5):349-351. doi: 10.1016/S2352-4642(20)30038-9. Epub 2020 Feb 17. No abstract available.

PMID: 32078808

787. Dismissal policies for **vaccine** refusal among US physicians: a literature review.

Garcia TB, O'Leary ST.

Hum Vaccin Immunother. 2020 May 3;16(5):1189-1193. doi: 10.1080/21645515.2020.1724742. Epub 2020 Feb 20.

PMID: 32078411

788. Characterizing the **vaccine** knowledge, attitudes, beliefs, and intentions of pregnant women in Georgia and Colorado.

Dudley MZ, Limaye RJ, Omer SB, O'Leary ST, Ellingson MK, Spina CI, Brewer SE, Chamberlain AT, Bednarczyk RA, Malik F, Frew PM, Salmon DA.

Hum Vaccin Immunother. 2020 May 3;16(5):1109-1117. doi: 10.1080/21645515.2020.1717130. Epub 2020 Feb 20.

PMID: 32078395

789. Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation?

Pechsrichuang P, Jacquet A.

Clin Exp Allergy. 2020 May;50(5):543-557. doi: 10.1111/cea.13588. Epub 2020 Mar 9. Review.

PMID: 32078207

790. Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital.

Smithgall M, Maykowski P, Zachariah P, Oberhardt M, Vargas CY, Reed C, LaRussa P, Saiman L, Stockwell MS.

Influenza Other Respir Viruses. 2020 May;14(3):247-256. doi: 10.1111/irv.12723. Epub 2020 Feb 20.

PMID: 32077641

791. Crystal Structure of African Swine Fever Virus pS273R Protease and Implications for Inhibitor Design.

Li G, Liu X, Yang M, Zhang G, Wang Z, Guo K, Gao Y, Jiao P, Sun J, Chen C, Wang H, Deng W, Xiao H, Li S, Wu H, Wang Y, Cao L, Jia Z, Shang L, Yang C, Guo Y, Rao Z.

J Virol. 2020 May 4;94(10). pii: e02125-19. doi: 10.1128/JVI.02125-19. Print 2020 May 4.

PMID: 32075933

792. Assessing the Validity and Accuracy of Online Videos on **Vaccine** Health Risks.

Murphy M, Nanadiego FA, McCavera L, Nichols C, Kalekas P, Wachs D.

Clin Pediatr (Phila). 2020 May;59(4-5):458-466. doi: 10.1177/0009922820905866. Epub 2020 Feb 19.

PMID: 32075426

793. Injectable dual-scale mesoporous silica cancer **vaccine** enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold.

Nguyen TL, Cha BG, Choi Y, Im J, Kim J.

Biomaterials. 2020 May;239:119859. doi: 10.1016/j.biomaterials.2020.119859. Epub 2020 Feb 10.

PMID: 32070828

794. Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania **Vaccine** Candidate.

Chen WH, Nyon MP, Poongavanam MV, Liu Z, Biter AB, Kundu RT, Strych U, Hotez PJ, Bottazzi ME.

J Pharm Sci. 2020 May;109(5):1673-1680. doi: 10.1016/j.xphs.2020.02.004. Epub 2020 Feb 15.

PMID: 32070701

795. Freeze-dried meningococcal **vaccine**: Total error assessment of a near-infrared method for water content determination.

Zubak AM, Horvat A, Čavužić D, Fabijanić I.

Talanta. 2020 May 1;211:120659. doi: 10.1016/j.talanta.2019.120659. Epub 2019 Dec 27.

PMID: 32070574

796. Influenza Classification Suite: An automated Galaxy workflow for rapid influenza sequence analysis.

Eisler D, Fornika D, Tindale LC, Chan T, Sabaiduc S, Hickman R, Chambers C, Krajden M, Skowronski DM, Jassem A, Hsiao W.

Influenza Other Respir Viruses. 2020 May;14(3):358-362. doi: 10.1111/irv.12722. Epub 2020 Feb 16.

PMID: 32064792

797. Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.

Jordaens S, Cooksey L, Bonney S, Orchard L, Coutinho M, Van Tendeloo V, Mills KI, Orchard K, Guinn BA.

Br J Haematol. 2020 May;189(3):500-512. doi: 10.1111/bjh.16407. Epub 2020 Feb 16.

PMID: 32064588

798. Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice.

Achyut BR, Zhang H, Angara K, Mivechi NF, Arbab AS, Ko L.

Cancer Lett. 2020 Apr 28;476:57-66. doi: 10.1016/j.canlet.2020.02.005. Epub 2020 Feb 12.

PMID: 32061755

799. Binge drinking, HIV/HPV co-infection risk, and HIV testing: Factors associated with HPV vaccination among young adults in the United States.

Olusanya OO, Wigfall LT, Rossheim ME, Tomar A, Barry AE.

Prev Med. 2020 May;134:106023. doi: 10.1016/j.ypmed.2020.106023. Epub 2020 Feb 28.

PMID: 32061685

800. Synthesis of Poly(acyclic orthoester)s: Acid-Sensitive Biomaterials for Enhancing Immune Responses of Protein **Vaccine**.

Xing Y, Xu Z, Liu T, Shi L, Kohane D, Guo S.

Angew Chem Int Ed Engl. 2020 Apr 27;59(18):7235-7239. doi: 10.1002/anie.202001169. Epub 2020 Mar 9.

PMID: 32061182

801. Hepatitis C **Vaccine**: 10 Good Reasons for Continuing.

Roingeard P, Beaumont E.

Hepatology. 2020 May;71(5):1845-1850. doi: 10.1002/hep.31182. Review. No abstract available.

PMID: 32060946

802. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.

Beaugerie L, Rahier JF, Kirchgesner J.

Clin Gastroenterol Hepatol. 2020 May;18(6):1324-1335.e2. doi: 10.1016/j.cgh.2020.02.009. Epub 2020 Feb 12. Review.

PMID: 32059920

803. mRNA profiling reveals response regulators of decreased fungal keratitis symptoms in a tree shrew model.

Jia J, Wang W, Kuang D, Lu C, Li N, Tong P, Han Y, Sun X, Dai J.

Gene. 2020 May 5;737:144450. doi: 10.1016/j.gene.2020.144450. Epub 2020 Feb 11.

PMID: 32057930

804. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.

Li X, Li J, Feng Y, Cai H, Li YP, Peng T.

Antiviral Res. 2020 May;177:104734. doi: 10.1016/j.antiviral.2020.104734. Epub 2020 Feb 10.

PMID: 32057770

805. Corrigendum to "Epidemiology study of pediatric primary intussusception aged ≤24 months in pre-rotavirus **vaccine** era of Jinan, China" [**Vaccine** 37(11) (2019) 1436-1442].

Yu X, Zhang T, Cui L, Geng X, Zhang J.

Vaccine. 2020 Apr 29;38(20):3697. doi: 10.1016/j.**vaccine**.2020.01.069. Epub 2020 Feb 11. No abstract available.

PMID: 32057579

806. Confidence in the National Immunization Program among parents in Sweden 2016 - A cross-sectional survey.

Byström E, Lindstrand A, Bergström J, Riesbeck K, Roth A.

Vaccine. 2020 May 8;38(22):3909-3917. doi: 10.1016/j.**vaccine**.2020.01.078. Epub 2020 Feb 11.

PMID: 32057573

807. Potential interventions for novel coronavirus in China: A systematic review.

Zhang L, Liu Y.

J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.

PMID: 32052466

808. FluPhenotype-a one-stop platform for early warnings of the influenza A virus.

Lu C, Cai Z, Zou Y, Zhang Z, Chen W, Deng L, Du X, Wu A, Yang L, Wang D, Shu Y, Jiang T, Peng Y.

Bioinformatics. 2020 May 1;36(10):3251-3253. doi: 10.1093/bioinformatics/btaa083.

PMID: 32049310

809. Long-Term Immunity to Measles after Allogeneic Hematopoietic Cell Transplantation: Factors Associated with Seroprotection before Revaccination.

Robin C, Mariaggi AA, Redjoul R, Leclerc M, Beckerich F, Cabanne L, Pautas C, Maury S, Rozenberg F, Cordonnier C.

Biol Blood Marrow Transplant. 2020 May;26(5):985-991. doi: 10.1016/j.bbmt.2020.02.001. Epub 2020 Feb 8.

PMID: 32045654

810. A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions.

Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, Elliott S, Odedra A, Khoury D, Ballard E, Shelper TB, Lucantoni L, Avery VM, Chalon S, Moehrle JJ, McCarthy JS.

J Clin Invest. 2020 Apr 27. pii: 134923. doi: 10.1172/JCI134923. [Epub ahead of print]

PMID: 32045385

811. Immunotherapy for glioma: Current management and future application.

Xu S, Tang L, Li X, Fan F, Liu Z.

Cancer Lett. 2020 Apr 28;476:1-12. doi: 10.1016/j.canlet.2020.02.002. Epub 2020 Feb 7.

PMID: 32044356

812. Recommending immunizations to adolescents in Turkey: a study of the knowledge, attitude, and practices of physicians.

Kara Elitok G, Bulbul L, Altuntas SB, Altuntas B, Günindi G, Haltaş M, Yuvarlan A, Toprak D, Bulbul A.

Hum Vaccin Immunother. 2020 May 3;16(5):1132-1138. doi: 10.1080/21645515.2020.1715146. Epub 2020 Feb 10.

PMID: 32040380

813. Insights into *irr* and *rirA* gene regulation on the virulence of *Brucella melitensis* M5-90.

Zhang H, Wang B, Wu W, Deng X, Shao Z, Yi J, Wang Z, Yang N, Wang Y, Wang Y, Chen C.

Can J Microbiol. 2020 May;66(5):351-358. doi: 10.1139/cjm-2019-0393. Epub 2020 Feb 10.

PMID: 32040345

814. Impact of influenza **vaccine**-modified infectivity on attack rate, case fatality ratio and mortality.

Nah K, Alavinejad M, Rahman A, Heffernan JM, Wu J.

J Theor Biol. 2020 May 7;492:110190. doi: 10.1016/j.jtbi.2020.110190. Epub 2020 Feb 6.

PMID: 32035827

815. Evaluation of canine leishmaniosis **vaccine** CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial.

Velez R, Domenech E, Rodríguez-Cortés A, Barrios D, Tebar S, Fernández-Arévalo A, Aguilar R, Dobaño C, Alberola J, Cairó J, Gállego M.

Acta Trop. 2020 May;205:105387. doi: 10.1016/j.actatropica.2020.105387. Epub 2020 Feb 5.

PMID: 32035053

816. Commercially approved **vaccines** for canine leishmaniosis: a review of available data on their safety and efficacy.

Velez R, Gállego M.

Trop Med Int Health. 2020 May;25(5):540-557. doi: 10.1111/tmi.13382. Epub 2020 Mar 2. Review.

PMID: 32034985

817. The fully synthetic glycopeptide MAG-Tn3 therapeutic **vaccine** induces tumor-specific cytotoxic antibodies in breast cancer patients.

Rosenbaum P, Artaud C, Bay S, Ganneau C, Campone M, Delaloge S, Gourmelon C, Loirat D, Medioni J, Pein F, Sablin MP, Tredan O, Varga A, Leclerc C.

Cancer Immunol Immunother. 2020 May;69(5):703-716. doi: 10.1007/s00262-020-02503-0. Epub 2020 Feb 7.

PMID: 32034426

818. Cancer Liquid Biopsy Using Integrated Microfluidic Exosome Analysis Platforms.

Li G, Tang W, Yang F.

Biotechnol J. 2020 May;15(5):e1900225. doi: 10.1002/biot.201900225. Epub 2020 Feb 20. Review.

PMID: 32032977

819. Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018.

Deghmane AE, Haeghebaert S, Hong E, Jousset A, Barret AS, Taha MK.

J Infect. 2020 May;80(5):519-526. doi: 10.1016/j.jinf.2020.01.020. Epub 2020 Feb 4.

PMID: 32032620

820. Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.

Freitag TL, Podojil JR, Pearson RM, Fokta FJ, Sahl C, Messing M, Andersson LC, Leskinen K, Saavalainen P, Hoover LI, Huang K, Phippard D, Maleki S, King NJC, Shea LD, Miller SD, Meri SK, Getts DR.

Gastroenterology. 2020 May;158(6):1667-1681.e12. doi: 10.1053/j.gastro.2020.01.045. Epub 2020 Feb 4.

PMID: 32032584

821. PRIMVAC **vaccine** adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.

Sirima SB, Richert L, Chêne A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouédraogo A, Nébié I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konaté E, Roussillon C, Kanté M, Belarbi L, Diarra A, Henry N, Soulama I, Ouédraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B.

Lancet Infect Dis. 2020 May;20(5):585-597. doi: 10.1016/S1473-3099(19)30739-X. Epub 2020 Feb 4.

PMID: 32032566

822. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.

Ryu S, Gao H, Wong JY, Shiu EYC, Xiao J, Fong MW, Cowling BJ.

Emerg Infect Dis. 2020 May;26(5):961-966. doi: 10.3201/eid2605.190993. Epub 2020 May 17.

PMID: 32027587

823. **Vaccine** rejection and hesitation in Turkey.

Özceylan G, Toprak D, Esen ES.

Hum Vaccin Immunother. 2020 May 3;16(5):1034-1039. doi: 10.1080/21645515.2020.1717182. Epub 2020 Feb 6.

PMID: 32027218

824. Oxidative Stress in Autism Spectrum Disorder.

Bjørklund G, Meguid NA, El-Bana MA, Tinkov AA, Saad K, Dadar M, Hemimi M, Skalny AV, Hosnedlová B, Kizek R, Osredkar J, Urbina MA, Fabjan T, El-Houfey AA, Kałużna-Czaplińska J, Gątarek P, Chirumbolo S.

Mol Neurobiol. 2020 May;57(5):2314-2332. doi: 10.1007/s12035-019-01742-2. Epub 2020 Feb 5. Review.

PMID: 32026227

825. Mixed 20-peptide cancer **vaccine** in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.

Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K, Uemura H, Nakagawa M, Nasu Y, Eto M, Suekane S, Sasada T, Shichijo S, Yamada A, Kakuma T, Itoh K.

Cancer Immunol Immunother. 2020 May;69(5):847-857. doi: 10.1007/s00262-020-02498-8. Epub 2020 Feb 5.

PMID: 32025848

826. **Vaccine** effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent **vaccine**.

Rose AMC, Kissling E, Gherasim A, Casado I, Bella A, Launay O, Lazăr M, Marbus S, Kuliese M, Syrjänen R, Machado A, Kurečić Filipović S, Larrauri A, Castilla J, Alfonsi V, Galtier F, Ivanciuc A, Meijer A, Mickiene A, Ikonen N, Gómez V, Lovrić Makarić Z, Moren A, Valenciano M; I-MOVE Hospital study team.

Influenza Other Respir Viruses. 2020 May;14(3):302-310. doi: 10.1111/irv.12714. Epub 2020 Feb 5.

PMID: 32022450

827. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV.

Baruah V, Bose S.

J Med Virol. 2020 May;92(5):495-500. doi: 10.1002/jmv.25698. Epub 2020 Mar 3.

PMID: 32022276

828. Zoonotic disease awareness survey of backyard poultry and swine owners in southcentral Pennsylvania.

Nicholson CW, Campagnolo ER, Boktor SW, Butler CL.

Zoonoses Public Health. 2020 May;67(3):280-290. doi: 10.1111/zph.12686. Epub 2020 Feb 4.

PMID: 32020787

829. Challenges to develop an equine herpesvirus **vaccine** in China.

Ji C, Cai S, Lu G, Zhang G.

J Infect. 2020 May;80(5):578-606. doi: 10.1016/j.jinf.2020.01.013. Epub 2020 Feb 1. No abstract available.

PMID: 32017972

830. Exploring the relationship between newspaper coverage of **vaccines** and childhood vaccination rates in Spain.

Catalan-Matamoros D, Peñafiel-Saiz C.

Hum Vaccin Immunother. 2020 May 3;16(5):1055-1061. doi: 10.1080/21645515.2019.1708163. Epub 2020 Feb 4.

PMID: 32017659

831. **Vaccine** hesitancy and influenza beliefs among parents of children requiring a second dose of influenza **vaccine** in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study.

Nekrasova E, Stockwell MS, Localio R, Shults J, Wynn C, Shone LP, Berrigan L, Kolff C, Griffith M, Johnson A, Torres A, Opel DJ, Fiks AG.

Hum Vaccin Immunother. 2020 May 3;16(5):1070-1077. doi: 10.1080/21645515.2019.1707006. Epub 2020 Feb 4.

PMID: 32017643

832. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.

Collignon O, Gartner C, Haidich AB, James Hemmings R, Hofner B, Pétavy F, Posch M, Rantell K, Roes K, Schiel A.

Clin Pharmacol Ther. 2020 May;107(5):1059-1067. doi: 10.1002/cpt.1804. Epub 2020 Apr 1. Review.

PMID: 32017052

833. Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell **vaccines**.

Sheng L, Chen X, Wang Q, Lyu S, Li P.

Biomed Pharmacother. 2020 May;125:109966. doi: 10.1016/j.biopha.2020.109966. Epub 2020 Jan 31.

PMID: 32014686

834. Helminth infections and immunosenescence: The friend of my enemy.

Abdoli A, Ardakani HM.

Exp Gerontol. 2020 May;133:110852. doi: 10.1016/j.exger.2020.110852. Epub 2020 Jan 30.

PMID: 32007545

835. Strain specificities in influence of ageing on germinal centre reaction to inactivated influenza virus antigens in mice: Sex-based differences.

Bufan B, Arsenović-Ranin N, Petrović R, Živković I, Stoiljković V, Leposavić G.

Exp Gerontol. 2020 May;133:110857. doi: 10.1016/j.exger.2020.110857. Epub 2020 Feb 6.

PMID: 32006634

836. Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011-2016.

Degnah AA, Al-Amri SS, Hassan AM, Almasoud AS, Mousa M, Almahboub SA, Alhabbab RY, Mirza AA, Hindawi SI, Alharbi NK, Azhar EI, Hashem AM.

J Infect Public Health. 2020 May;13(5):697-703. doi: 10.1016/j.jiph.2020.01.001. Epub 2020 Jan 28.

PMID: 32005618

837. Knockdown of Virus Antigen Expression Increases Therapeutic **Vaccine** Efficacy in High-Titer Hepatitis B Virus Carrier Mice.

Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel ML, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, Protzer U.

Gastroenterology. 2020 May;158(6):1762-1775.e9. doi: 10.1053/j.gastro.2020.01.032. Epub 2020 Jan 28.

PMID: 32001321

838. Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models.

Ohsawa H, Baba T, Enami J, Hiramatsu K.

J Infect Chemother. 2020 May;26(5):520-522. doi: 10.1016/j.jiac.2019.12.018. Epub 2020 Jan 28.

PMID: 32001173

839. Human Papillomavirus 16/18-Associated Cervical Lesions: Differences by Area-Based Measures of Race and Poverty.

Brackney MM, Gargano JW, Hannagan SE, Meek J, Querec TD, Niccolai LM.

Am J Prev Med. 2020 May;58(5):e149-e157. doi: 10.1016/j.amepre.2019.12.003. Epub 2020 Jan 28.

PMID: 32001053

840. Socioeconomic Impact of the Rotavirus **Vaccine** in Korea: Comparing the Epidemiologic and Economic Characteristics of Rotavirus Gastroenteritis Before and After the Introduction of **Vaccines**.

Cho H, Lee H, Kim DS, Kim HM, Kim JH, Kim AY, Kang HY.

Pediatr Infect Dis J. 2020 May;39(5):460-465. doi: 10.1097/INF.0000000000002582.

PMID: 31990891

841. Sustained-immunostimulatory nanocellulose scaffold to enhance **vaccine** efficacy.

Nishiguchi A, Taguchi T.

J Biomed Mater Res A. 2020 May;108(5):1159-1170. doi: 10.1002/jbm.a.36890. Epub 2020 Feb 4.

PMID: 31990447

842. Does Dysregulation of Redox State Underpin the Decline of Innate Immunity with Aging?

Griffiths HR, Rooney MCO, Perrie Y.

Antioxid Redox Signal. 2020 May 1;32(13):1014-1030. doi: 10.1089/ars.2020.8021. Epub 2020 Feb 27.

PMID: 31989832

843. Ehrlichia canis TRP36 diversity in naturally infected-dogs from an urban area of Colombia.

Arroyave E, Rodas-González JD, Zhang X, Labruna MB, González MS, Fernández-Silva JA, McBride JW.

Ticks Tick Borne Dis. 2020 May;11(3):101367. doi: 10.1016/j.ttbdis.2019.101367. Epub 2020 Jan 7.

PMID: 31987818

844. *Brucella melitensis omp*31 Mutant Is Attenuated and Confers Protection Against Virulent *Brucella melitensis* Challenge in BALB/c Mice.

Verdiguel-Fernández L, Oropeza-Navarro R, Ortiz A, Robles-Pesina MG, Ramírez-Lezama J, Castañeda-Ramírez A, Verdugo-Rodríguez A.

J Microbiol Biotechnol. 2020 Apr 28;30(4):497-504. doi: 10.4014/jmb.1908.08056.

PMID: 31986561

845. Is antibody titer useful to verify the immunization after VZV **Vaccine** in MS patients treated with Fingolimod? A case series.

Signoriello E, Bonavita S, Sinisi L, Russo CV, Maniscalco GT, Casertano S, Saccà F, Lanzillo R, Morra VB, Lus G.

Mult Scler Relat Disord. 2020 May;40:101963. doi: 10.1016/j.msard.2020.101963. Epub 2020 Jan 20.

PMID: 31986424

846. Variability of CD4+ Cell Counts in HIV-1-Uninfected Volunteers Who Are Eligible for a Phase I HIV **Vaccine** Study.

Stafford KA, Mayer BT, Fulp W, Chua J, Davis C, Gilliam B, Dong D, Gallo RC, Sajadi MM.

J Acquir Immune Defic Syndr. 2020 May 1;84(1):37-44. doi: 10.1097/QAI.0000000000002306.

PMID: 31985697

847. Use of tetanus-diphtheria (Td) **vaccine** in children 4-7 years of age: World Health Organization consultation of experts.

Desai S, Scobie HM, Cherian T, Goodman T; Expert Group on the Use of Td **vaccine** in Childhood.

Vaccine. 2020 May 6;38(21):3800-3807. doi: 10.1016/j.**vaccine**.2020.01.018. Epub 2020 Jan 23.

PMID: 31983584

848. What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature.

Pourcher V.

Rev Neurol (Paris). 2020 May;176(4):235-243. doi: 10.1016/j.neurol.2019.08.012. Epub 2020 Jan 23. Review.

PMID: 31983473

849. Administering an additional hepatitis B vaccination dose after 18 years maintains adequate long-term protection levels in healthcare workers.

Hess L, Riesenberg K, Rolston KVI, Nesher L.

Infect Dis (Lond). 2020 May;52(5):330-335. doi: 10.1080/23744235.2020.1718201. Epub 2020 Jan 25.

PMID: 31983251

850. Chitosan nanoparticles as a delivery platform for neurotoxin II from Androctonus australis hector scorpion venom: Assessment of toxicity and immunogenicity.

Rebbouh F, Martin-Eauclaire MF, Laraba-Djebari F.

Acta Trop. 2020 May;205:105353. doi: 10.1016/j.actatropica.2020.105353. Epub 2020 Jan 23.

PMID: 31982432

851. Rhipicephalus microplus cystatin as a potential cross-protective tick **vaccine** against Rhipicephalus appendiculatus.

Parizi LF, Rangel CK, Sabadin GA, Saggin BF, Kiio I, Xavier MA, da Silva Matos R, Camargo-Mathias MI, Seixas A, Konnai S, Ohashi K, Githaka NW, da Silva Vaz I Jr.

Ticks Tick Borne Dis. 2020 May;11(3):101378. doi: 10.1016/j.ttbdis.2020.101378. Epub 2020 Jan 20.

PMID: 31982372

852. Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT-MSEL) in Rural Guatemala.

Colbert AM, Lamb MM, Asturias EJ, Muñoz FM, Bauer D, Arroyave P, Hernández S, Martínez MA, Paniagua-Avila A, Olson D, Calvimontes DM, Bolaños GA, El Sahly HM, Connery AK.

Child Care Health Dev. 2020 May;46(3):327-335. doi: 10.1111/cch.12748. Epub 2020 Feb 3.

PMID: 31978249

853. Impact of school-entry vaccination requirement changes on clinical practice implementation and adolescent vaccination rates in metropolitan Philadelphia.

Srivastava T, Emmer K, Feemster KA.

Hum Vaccin Immunother. 2020 May 3;16(5):1155-1165. doi: 10.1080/21645515.2020.1712934. Epub 2020 Jan 24.

PMID: 31977274

854. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.

Jordaens S, Cooksey L, Freire Boullosa L, Van Tendeloo V, Smits E, Mills KI, Orchard KH, Guinn BA.

Cancer Immunol Immunother. 2020 May;69(5):867-877. doi: 10.1007/s00262-020-02484-0. Epub 2020 Jan 22. Review.

PMID: 31970440

855. Portrayal of Immunization in American Cinema: 1925 to 2016.

Auwen A, Emmons M, Dehority W.

Clin Pediatr (Phila). 2020 May;59(4-5):360-368. doi: 10.1177/0009922819901004. Epub 2020 Jan 22.

PMID: 31965824

856. "Flu-Floppers": Factors Influencing Families' Fickle Flu Vaccination Patterns.

Fogel BN, Hicks SD.

Clin Pediatr (Phila). 2020 May;59(4-5):352-359. doi: 10.1177/0009922819901002. Epub 2020 Jan 22.

PMID: 31965822

857. The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization.

Schussek S, Bernasconi V, Mattsson J, Wenzel UA, Strömberg A, Gribonika I, Schön K, Lycke NY.

Mucosal Immunol. 2020 May;13(3):545-557. doi: 10.1038/s41385-020-0253-2. Epub 2020 Jan 20.

PMID: 31959882

858. Advancing the understanding of treponemal disease in the past and present.

Baker BJ, Crane-Kramer G, Dee MW, Gregoricka LA, Henneberg M, Lee C, Lukehart SA, Mabey DC, Roberts CA, Stodder ALW, Stone AC, Winingear S.

Am J Phys Anthropol. 2020 May;171 Suppl 70:5-41. doi: 10.1002/ajpa.23988. Epub 2020 Jan 19.

PMID: 31956996

859. Interleukin-2 (IL-2) of flounder (Paralichthys olivaceus) as immune adjuvant enhance the immune effects of E. tarda subunit **vaccine** OmpV against Edwardsiellosis.

Tang X, Guo M, Sheng X, Xing J, Zhan W.

Dev Comp Immunol. 2020 May;106:103615. doi: 10.1016/j.dci.2020.103615. Epub 2020 Jan 11.

PMID: 31956084

860. Detection of anti-NS1 antibodies after pandemic influenza exposure: Evaluation of a serological method for distinguishing H1N1pdm09 infected from vaccinated cases.

Robertson AH, Mahic M, Savic M, Tunheim G, Hungnes O, Trogstad L, Lipkin WI, Mjaaland S.

Influenza Other Respir Viruses. 2020 May;14(3):294-301. doi: 10.1111/irv.12712. Epub 2020 Jan 19.

PMID: 31955522

861. Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons.

Kato-Miyashita S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, Kawaoka Y, Imai M.

Influenza Other Respir Viruses. 2020 May;14(3):311-319. doi: 10.1111/irv.12713. Epub 2020 Jan 19.

PMID: 31955521

862. In silico Evaluation of PLAC1-fliC As a Chimeric **Vaccine** against Breast Cancer

Taheri-Anganeh M, Amiri A, Movahedpour A, Khatami SH, Ghasemi Y, Savardashtaki A, Mostafavi-Pour Z.

Iran Biomed J. 2020 May;24(3):173-82. Epub 2019 Nov 18.

PMID: 31952435

863. Visualization of Leishmania tropica Infection in BALB/c Mice by Bioluminescence Imaging

Eskandar M, Gholami E, Seyed N, Taslimi Y, Habibzadeh, S, Rafati S, Taheri T.

Iran Biomed J. 2020 May;24(3):164-72. Epub 2019 Dec 1.

PMID: 31952434

864. Live attenuated pertussis **vaccine** BPZE1 induces a broad antibody response in humans.

Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Loré K.

J Clin Invest. 2020 May 1;130(5):2332-2346. doi: 10.1172/JCI135020.

PMID: 31945015

865. Genetic characterization of influenza A(H3N2) viruses circulating in coastal Kenya, 2009-2017.

Owuor DC, Ngoi JM, Otieno JR, Otieno GP, Nyasimi FM, Nyiro JU, Agoti CN, Chaves SS, Nokes DJ.

Influenza Other Respir Viruses. 2020 May;14(3):320-330. doi: 10.1111/irv.12717. Epub 2020 Jan 13.

PMID: 31943817

866. Knowledge of the Human Papillomavirus by Social Stratification Factors.

Fernández-Feito A, Lana A, Parás Bravo P, Pellico López A, Paz-Zulueta M.

Nurs Res. 2020 May/Jun;69(3):E18-E25. doi: 10.1097/NNR.0000000000000413.

PMID: 31934943

867. The study of seroprevalence of hepatitis E virus and an investigation into the lifestyle behaviours of the aborigines in Malaysia.

Wong LP, Alias H, Choy SH, Goh XT, Lee SC, Lim YAL, Kee BP, Chua KH, Kamaruzaman A, Zheng Z, Zhao Q, Wu T.

Zoonoses Public Health. 2020 May;67(3):263-270. doi: 10.1111/zph.12681. Epub 2020 Jan 12.

PMID: 31927794

868. Impact of thirteen-valent pneumococcal conjugate **vaccine** on nasopharyngeal carriage in healthy children under 24 months in Okinawa, Japan.

Chang B, Akeda H, Nakamura Y, Hamabata H, Ameku K, Toma T, Miyagi M, Ohnishi M.

J Infect Chemother. 2020 May;26(5):465-470. doi: 10.1016/j.jiac.2019.12.009. Epub 2020 Jan 8.

PMID: 31926843

869. Ixodes scapularis saliva components that elicit responses associated with acquired tick-resistance.

Narasimhan S, Kurokawa C, Diktas H, Strank NO, Černý J, Murfin K, Cao Y, Lynn G, Trentleman J, Wu MJ, DePonte K, Kantor F, Anguita J, Hovius J, Fikrig E.

Ticks Tick Borne Dis. 2020 May;11(3):101369. doi: 10.1016/j.ttbdis.2019.101369. Epub 2020 Jan 3.

PMID: 31924502

870. Long-term surviving cancer patients as a source of therapeutic TCR.

Inderberg EM, Wälchli S.

Cancer Immunol Immunother. 2020 May;69(5):859-865. doi: 10.1007/s00262-019-02468-9. Epub 2020 Jan 8. Review.

PMID: 31915853

871. A Summary of the Fourth Annual Virology Education HIV Microbiome Workshop.

Williams B, Ghosh M, Boucher C, Bushman F, Carrington-Lawrence S, Collman RG, Dandekar S, Dang Q, Malaspina A, Paredes R, Wilson C, Cardoso SP, Lagenaur L, Santos J, Joy C, Landay A.

AIDS Res Hum Retroviruses. 2020 May;36(5):349-356. doi: 10.1089/AID.2019.0197. Epub 2020 Mar 9.

PMID: 31914785

872. Chagas disease **vaccine** design: the search for an efficient Trypanosoma cruzi immune-mediated control.

Bivona AE, Alberti AS, Cerny N, Trinitario SN, Malchiodi EL.

Biochim Biophys Acta Mol Basis Dis. 2020 May 1;1866(5):165658. doi: 10.1016/j.bbadis.2019.165658. Epub 2020 Jan 3. Review.

PMID: 31904415

873. Antigen discovery unveils resident memory and migratory cell roles in antifungal resistance.

Dobson HE, Dias LDS, Kohn EM, Fites S, Wiesner DL, Dileepan T, Kujoth GC, Abraham A, Ostroff GR, Klein BS, Wüthrich M.

Mucosal Immunol. 2020 May;13(3):518-529. doi: 10.1038/s41385-019-0244-3. Epub 2020 Jan 3.

PMID: 31900406

874. Management and control of an outbreak of **vaccine**-preventable severe pneumococcal disease at a shipyard in Norway.

Berild JD, Steens A, Winje BA, Danielsen TE, Fjeldheim JH, Holmemo HD, Vestrheim DF.

J Infect. 2020 May;80(5):578-606. doi: 10.1016/j.jinf.2019.12.015. Epub 2019 Dec 28. No abstract available.

PMID: 31891730

875. Cardiovascular-targeted patient education and uptake of influenza vaccination in elderly patients.

Schattner A.

Patient Educ Couns. 2020 May;103(5):1052-1054. doi: 10.1016/j.pec.2019.12.008. Epub 2019 Dec 16.

PMID: 31883819

876. Effect of ventilation improvement during a tuberculosis outbreak in underventilated university buildings.

Du CR, Wang SC, Yu MC, Chiu TF, Wang JY, Chuang PC, Jou R, Chan PC, Fang CT.

Indoor Air. 2020 May;30(3):422-432. doi: 10.1111/ina.12639. Epub 2020 Jan 16.

PMID: 31883403

877. Three-percent sucrose acts as a thermostabilizer for cell-adapted foot-and-mouth disease virus without any negative effect on viral growth.

Hwang JH, Moon Y, Lee G, Kim MY, Lee KN, Park JH, Lee M, Kim B, Kim SM.

J Appl Microbiol. 2020 May;128(5):1524-1531. doi: 10.1111/jam.14565. Epub 2020 Jan 15.

PMID: 31883170

878. Heparin induces neutrophil elastase-dependent vital and lytic NET formation.

Lelliott PM, Momota M, Shibahara T, Lee MSJ, Smith NI, Ishii KJ, Coban C.

Int Immunol. 2020 May 8;32(5):359-368. doi: 10.1093/intimm/dxz084.

PMID: 31879779

879. Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016.

Dawood FS, Garg S, Fink RV, Russell ML, Regan AK, Katz MA, Booth S, Chung H, Klein NP, Kwong JC, Levy A, Naleway A, Riesel D, Thompson MG, Wyant BE, Fell DB.

J Infect Dis. 2020 Apr 27;221(10):1703-1712. doi: 10.1093/infdis/jiz670.

PMID: 31875916

880. Correlates of Nonrandom Patterns of Serotype Switching in Pneumococcus.

Joshi SS, Al-Mamun MA, Weinberger DM.

J Infect Dis. 2020 Apr 27;221(10):1669-1676. doi: 10.1093/infdis/jiz687.

PMID: 31875229

881. Masculine gender norms, male circumcision, and men's engagement with health care in the Dominican Republic.

Wiginton JM, Fleming PJ, Barrington C, Donastorg Y, Lerebours L, Brito MO.

Glob Public Health. 2020 May;15(5):654-665. doi: 10.1080/17441692.2019.1704817. Epub 2019 Dec 24.

PMID: 31874065

882. Epidemiological and molecular characterization of invasive Streptococcus pneumoniae isolated following introduction of 7-valent conjugate **vaccine** in Kinki region, Japan, 2008-2013.

Toda H, Tanaka Y, Satoh K, Komatsu M, Wada Y, Tobe T, Kamisako T.

J Infect Chemother. 2020 May;26(5):451-458. doi: 10.1016/j.jiac.2019.11.010. Epub 2019 Dec 20.

PMID: 31870586

883. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.

Kann H, Hortlund M, Eklund C, Dillner J, Faust H.

Int J Cancer. 2020 May 1;146(9):2539-2546. doi: 10.1002/ijc.32848. Epub 2020 Jan 24.

PMID: 31868230

884. A Bayesian approach to sequential analysis in post-licensure **vaccine** safety surveillance.

Li R, Stewart B, Rose C.

Pharm Stat. 2020 May;19(3):291-302. doi: 10.1002/pst.1991. Epub 2019 Dec 22.

PMID: 31867860

885. Association of cognitive biases with human papillomavirus **vaccine** hesitancy: a cross-sectional study.

Pomares TD, Buttenheim AM, Amin AB, Joyce CM, Porter RM, Bednarczyk RA, Omer SB.

Hum Vaccin Immunother. 2020 May 3;16(5):1018-1023. doi: 10.1080/21645515.2019.1698243. Epub 2019 Dec 20.

PMID: 31859593

886. First Two Cases of Infected Aortic Aneurysm Caused by Non-**Vaccine** *Streptococcus pneumoniae* Serotype 23A.

Kakuta R, Nakano R, Yano H, Ozawa D, Ohta N, Matsuoka T, Motoyoshi N, Kawamoto S, Saiki Y, Katori Y, Kaku M.

Ann Lab Med. 2020 May;40(3):270-273. doi: 10.3343/alm.2020.40.3.270. No abstract available.

PMID: 31858770

887. Radiation effects on *Toxoplasma* antigens: different immune responses of irradiated intact tachyzoites or soluble antigens in experimental mice models.

da Costa A, Nascimento ND, Galisteo AJ Jr, Dias Dos Passos AB, de Andrade HF Jr.

Int J Radiat Biol. 2020 May;96(5):697-706. doi: 10.1080/09553002.2020.1704298. Epub 2020 Feb 6.

PMID: 31855098

888. The influence of indigestible protein on broiler digestive tract morphology and caecal protein fermentation metabolites.

Bryan DDSL, Abbott DA, Van Kessel AG, Classen HL.

J Anim Physiol Anim Nutr (Berl). 2020 May;104(3):847-866. doi: 10.1111/jpn.13256. Epub 2019 Dec 18.

PMID: 31854098

889. Effectiveness of single-dose administration of inactivated hepatitis A virus vaccination in the Republic of Korea armed forces, 2013-2016.

Im JH, Woo HT, Ha B, Jung J.

J Viral Hepat. 2020 May;27(5):537-539. doi: 10.1111/jvh.13249. Epub 2020 Jan 1.

PMID: 31854016

890. Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Chin KL, Sarmiento ME, Alvarez-Cabrera N, Norazmi MN, Acosta A.

Eur J Clin Microbiol Infect Dis. 2020 May;39(5):799-826. doi: 10.1007/s10096-019-03771-0. Epub 2019 Dec 18. Review.

PMID: 31853742

891. Global immunization systems strengthening through pediatric societies: the promise of private-public partnerships in Indonesia.

Tan TQ, Gunardi H, Smith S, Goentoro PL, Foehringer Merchant H, Carter T, Patterson J, Pulungan A.

Hum Vaccin Immunother. 2020 May 3;16(5):1194-1201. doi: 10.1080/21645515.2019.1697108. Epub 2019 Dec 18.

PMID: 31851571

892. Observational study of vaccination in cancer patients: How can **vaccine** coverage be improved?

Monier A, Puyade M, Hernanz MPG, Bouchaert P, Leleu X, Tourani JM, Roblot F, Rammaert B.

Med Mal Infect. 2020 May;50(3):263-268. doi: 10.1016/j.medmal.2019.11.006. Epub 2019 Dec 14.

PMID: 31848105

893. Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection.

Schmidt ME, Meyerholz DK, Varga SM.

Mucosal Immunol. 2020 May;13(3):507-517. doi: 10.1038/s41385-019-0243-4. Epub 2019 Dec 16.

PMID: 31844172

894. Animal Models of Hepatitis C Virus Infection.

Ploss A, Kapoor A.

Cold Spring Harb Perspect Med. 2020 May 1;10(5). pii: a036970. doi: 10.1101/cshperspect.a036970. Review.

PMID: 31843875

895. Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay.

Li S, Zhao H, Yang H, Hou W, Cruz-Cosme R, Cao R, Chen C, Wang W, Xu L, Zhang J, Zhong W, Xia N, Tang Q, Cheng T.

ACS Infect Dis. 2020 May 8;6(5):811-819. doi: 10.1021/acsinfecdis.9b00333. Epub 2019 Dec 30.

PMID: 31840495

896. Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia.

Sohrab SS, Azhar EI.

J Infect Public Health. 2020 May;13(5):709-717. doi: 10.1016/j.jiph.2019.11.007. Epub 2019 Dec 9.

PMID: 31831395

897. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV **Vaccine**.

Henss L, Yue C, Von Rhein C, Tschismarov R, Lewis-Ximenez LL, Dölle A, Baylis SA, Schnierle BS.

J Infect Dis. 2020 Apr 27;221(10):1713-1723. doi: 10.1093/infdis/jiz658.

PMID: 31828322

898. Diagnostic criteria for acute FPIES: What are we missing?

Vazquez-Ortiz M, Argiz L, Machinena A, Echeverria L, Blasco C, Prieto A, Infante S, Vila L, Garcia E, Gonzalez-Delgado P, Vazquez-Cortes S, Barni S, Martinon-Torres F; BIO-FPIES study network.

J Allergy Clin Immunol Pract. 2020 May;8(5):1717-1720.e2. doi: 10.1016/j.jaip.2019.11.034. Epub 2019 Dec 9. No abstract available.

PMID: 31821916

899. Congenital infections as contributors to the onset of diabetes in children: A longitudinal study in the United States, 2001-2017.

Rogers MAM, Kim C.

Pediatr Diabetes. 2020 May;21(3):456-459. doi: 10.1111/pedi.12957. Epub 2020 Feb 19.

PMID: 31820549

900. Therapeutic efficacy of hepatitis B virus **vaccine** in treatment of chronic HBV infections: A systematic review and meta-analysis.

Ghozy S, Nam NH, Radwan I, Karimzadeh S, Tieu TM, Hashan MR, Abbas AS, Eid PS, Vuong NL, Khang NV, Elgabalawy E, Sayed AK, Hoa PTL, Huy NT.

Rev Med Virol. 2020 May;30(3):e2089. doi: 10.1002/rmv.2089. Epub 2019 Dec 6. Review.

PMID: 31811678

901. The use of immature platelet fraction to predict time to platelet recovery in patients with dengue infection.

Chuansumrit A, Apiwattanakul N, Sirachainan N, Paisooksantivatana K, Athipongarporn A, Tangbubpha N, Kadegasem P, Tangnararatchakit K, Yoksan S.

Paediatr Int Child Health. 2020 May;40(2):124-128. doi: 10.1080/20469047.2019.1697574. Epub 2019 Dec 6.

PMID: 31809660

902. An educational intervention to improve attitudes regarding HPV vaccination and comfort with counseling among US medical students.

Berenson AB, Hirth JM, Fuchs EL, Chang M, Rupp RE.

Hum Vaccin Immunother. 2020 May 3;16(5):1139-1144. doi: 10.1080/21645515.2019.1692558. Epub 2019 Dec 6.

PMID: 31809635

903. Behavior of nurses and nurse aides toward influenza **vaccine**: the impact of the perception of occupational working conditions.

Mignot A, Wilhelm MC, Valette A, Gavard-Perret ML, Abord-De-Chatillon E, Epaulard O.

Hum Vaccin Immunother. 2020 May 3;16(5):1125-1131. doi: 10.1080/21645515.2019.1694328. Epub 2019 Dec 6.

PMID: 31809633

904. Evaluating the effectiveness of two bovine mastitis **vaccines** and their influences on oxidant and antioxidant capacities of milk.

Tashakkori N, Khoramian B, Farhoodi Moghadam M, Heidarpour M, Mashayekhi K, Farzaneh N.

Trop Anim Health Prod. 2020 May;52(3):1493-1501. doi: 10.1007/s11250-019-02156-x. Epub 2019 Dec 4.

PMID: 31802364

905. Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection.

Gyurova IE, Ali A, Waggoner SN.

Viral Immunol. 2020 May;33(4):334-341. doi: 10.1089/vim.2019.0129. Epub 2019 Dec 3.

PMID: 31800366

906. Finding a way to address a wicked problem: **vaccines**, vaccination, and a shared understanding.

Shen AK.

Hum Vaccin Immunother. 2020 May 3;16(5):1030-1033. doi: 10.1080/21645515.2019.1695458. Epub 2019 Dec 18.

PMID: 31799892

907. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.

Wu JJ, Zhao L, Hu HG, Li WH, Li YM.

Med Res Rev. 2020 May;40(3):1117-1141. doi: 10.1002/med.21649. Epub 2019 Dec 2. Review.

PMID: 31793026

908. Non-structural protein 1 from Japanese encephalitis virus expressed in E. coli retains its molecular weight and immunogenicity.

Choi JW, Eom HJ, Kim HY.

Protein Expr Purif. 2020 May;169:105548. doi: 10.1016/j.pep.2019.105548. Epub 2019 Nov 29.

PMID: 31786309

909. Role of the Gonococcal Neisserial Heparin Binding Antigen in Microcolony Formation, and Serum Resistance and Adherence to Epithelial Cells.

Semchenko EA, Mubaiwa TD, Day CJ, Seib KL.

J Infect Dis. 2020 Apr 27;221(10):1612-1622. doi: 10.1093/infdis/jiz628.

PMID: 31781772

910. Transcriptomic immune profiles of human flavivirus-specific T-cell responses.

Grifoni A, Tian Y, Sette A, Weiskopf D.

Immunology. 2020 May;160(1):3-9. doi: 10.1111/imm.13161. Epub 2020 Jan 7. Review.

PMID: 31778581

911. Current challenges in biotherapeutic particles manufacturing.

Moleirinho MG, Silva RJS, Alves PM, Carrondo MJT, Peixoto C.

Expert Opin Biol Ther. 2020 May;20(5):451-465. doi: 10.1080/14712598.2020.1693541. Epub 2019 Nov 27.

PMID: 31773998

912. The ATPases of the mycobacterial type VII secretion system: Structural and mechanistic insights into secretion.

Crosskey TD, Beckham KSH, Wilmanns M.

Prog Biophys Mol Biol. 2020 May;152:25-34. doi: 10.1016/j.pbiomolbio.2019.11.008. Epub 2019 Nov 22. Review.

PMID: 31765647

913. *In Silico* Identification of Probable Drug and **Vaccine** Candidates Against Antibiotic-Resistant *Acinetobacter baumannii*.

Zadeh Hosseingholi E, Zarrini G, Pashazadeh M, Gheibi Hayat SM, Molavi G.

Microb Drug Resist. 2020 May;26(5):456-467. doi: 10.1089/mdr.2019.0236. Epub 2019 Nov 19.

PMID: 31742478

914. Unintended HIV-1 Infection During Analytical Therapy Interruption.

Ugarte A, Romero Y, Tricas A, Casado C, Lopez-Galindez C, Garcia F, Leal L.

J Infect Dis. 2020 Apr 27;221(10):1740-1742. doi: 10.1093/infdis/jiz611. No abstract available.

PMID: 31742347

915. Dog demographics and husbandry practices related with rabies in Cameroon.

Bouli FPNO, Awah-Ndukum J, Mingoas KJ, Tejiokem MC, Tchoumboue J.

Trop Anim Health Prod. 2020 May;52(3):979-987. doi: 10.1007/s11250-019-02085-9. Epub 2019 Nov 18.

PMID: 31741308

916. Psychological reactance impacts ratings of pediatrician **vaccine**-related communication quality, perceived **vaccine** safety, and vaccination priority among U.S. parents.

Finkelstein SR, Boland WA, Vallen B, Connell PM, Sherman GD, Feemster KA.

Hum Vaccin Immunother. 2020 May 3;16(5):1024-1029. doi: 10.1080/21645515.2019.1694815. Epub 2019 Dec 12.

PMID: 31738632

917. Role of neutrophils in tuberculosis: A bird's eye view.

Hilda JN, Das S, Tripathy SP, Hanna LE.

Innate Immun. 2020 May;26(4):240-247. doi: 10.1177/1753425919881176. Epub 2019 Nov 17.

PMID: 31735099

918. [1,2,4]Triazolo[1,5-a]pyrimidine derivative (Mol-5) is a new NS5-RdRp inhibitor of DENV2 proliferation and DENV2-induced inflammation.

Wan YH, Wu WY, Guo SX, He SJ, Tang XD, Wu XY, Nandakumar KS, Zou M, Li L, Chen XG, Liu SW, Yao XG.

Acta Pharmacol Sin. 2020 May;41(5):706-718. doi: 10.1038/s41401-019-0316-7. Epub 2019 Nov 15.

PMID: 31729469

919. Development and validation of nucleic acid tests to diagnose Aleutian mink disease virus.

Virtanen J, Aaltonen K, Vapalahti O, Sironen T.

J Virol Methods. 2020 May;279:113776. doi: 10.1016/j.jviromet.2019.113776. Epub 2019 Nov 11.

PMID: 31726112

920. Determinants of change in intention to receive influenza vaccination among health-care workers in Singapore.

Lim DW, Ho HJ, Lee LT, Chow A, Kyaw WM.

Hum Vaccin Immunother. 2020 May 3;16(5):1118-1124. doi: 10.1080/21645515.2019.1688037. Epub 2019 Nov 14.

PMID: 31725352

921. Seasonal influenza **vaccine** uptake and **vaccine** refusal among pregnant women in France: results from a national survey.

Descamps A, Launay O, Bonnet C, Blondel B.

Hum Vaccin Immunother. 2020 May 3;16(5):1093-1100. doi: 10.1080/21645515.2019.1688035. Epub 2019 Nov 14.

PMID: 31725346

922. Identification and genetic analysis of infectious bursal disease viruses from field outbreaks in Kerala, India.

Nandhakumar D, Rajasekhar R, Logeshwaran G, Ravishankar C, Sebastian SR, Anoopraj R, Sumod K, Mani BK, Chaithra G, Deorao CV, John K.

Trop Anim Health Prod. 2020 May;52(3):989-997. doi: 10.1007/s11250-019-02084-w. Epub 2019 Nov 8.

PMID: 31705355

923. First report of seroprevalence and genetic characterization of avian orthoreovirus in Egypt.

Al-Ebshahy E, Mohamed S, Abas O.

Trop Anim Health Prod. 2020 May;52(3):1049-1054. doi: 10.1007/s11250-019-02100-z. Epub 2019 Nov 8.

PMID: 31705354

924. Patient characteristics of Medicare beneficiaries who report not getting influenza and pneumococcal vaccinations, 2001-2013.

Shen AK, Warnock R, Selna W, Chu S, Kelman JA.

Hum Vaccin Immunother. 2020 May 3;16(5):1086-1092. doi: 10.1080/21645515.2019.1688033. Epub 2019 Dec 6.

PMID: 31692400

925. Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) **vaccine**: the HPV type may not determine the outcome.

Hayashi A, Matsumoto K, Mitsuishi T.

Br J Dermatol. 2020 May;182(5):1285-1287. doi: 10.1111/bjd.18645. Epub 2019 Nov 28. No abstract available.

PMID: 31675436

926. What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review.

Bolotin S, Hughes SL, Gul N, Khan S, Rota PA, Severini A, Hahné S, Tricco A, Moss WJ, Orenstein W, Turner N, Durrheim D, Heffernan JM, Crowcroft N.

J Infect Dis. 2020 Apr 27;221(10):1576-1583. doi: 10.1093/infdis/jiz380.

PMID: 31674648

927. Is There a Correlate of Protection for Measles **Vaccine**?

Plotkin SA.

J Infect Dis. 2020 Apr 27;221(10):1571-1572. doi: 10.1093/infdis/jiz381. No abstract available.

PMID: 31674645

928. Production analysis of broiler farming in central Punjab, Pakistan.

Rahman NU, Mehmood S, Ahmad S, Javid A, Mahmud A, Hussain J, Shaheen MS, Usman M, Mohayud Din Hashmi SG.

Trop Anim Health Prod. 2020 May;52(3):1125-1131. doi: 10.1007/s11250-019-02107-6. Epub 2019 Oct 29.

PMID: 31664648

929. **Vaccine** stockouts and vaccination rate: examination of unique administrative data from Nigeria.

Sato R.

Int Health. 2020 May 1;12(3):170-176. doi: 10.1093/inthealth/ihz091.

PMID: 31647527

930. Single peptides and combination modalities for triple negative breast cancer.

Razazan A, Behravan J.

J Cell Physiol. 2020 May;235(5):4089-4108. doi: 10.1002/jcp.29300. Epub 2019 Oct 22. Review.

PMID: 31642059

931. Association between access to a health facility and continuum of vaccination behaviors among Nigerian children.

Sato R.

Hum Vaccin Immunother. 2020 May 3;16(5):1215-1220. doi: 10.1080/21645515.2019.1678360. Epub 2019 Nov 5.

PMID: 31634047

932. Legislative and administrative actions to increase vaccination coverage in Washington schools.

Delamater PL, Omer SB.

Hum Vaccin Immunother. 2020 May 3;16(5):1171-1177. doi: 10.1080/21645515.2019.1678358. Epub 2019 Nov 26.

PMID: 31634042

933. Tuberculosis control in crisis-causes and solutions.

Kaplan G.

Prog Biophys Mol Biol. 2020 May;152:6-9. doi: 10.1016/j.pbiomolbio.2019.10.001. Epub 2019 Oct 15. Review.

PMID: 31626823

934. Glycogen as a Building Block for Advanced Biological Materials.

Besford QA, Cavalieri F, Caruso F.

Adv Mater. 2020 May;32(18):e1904625. doi: 10.1002/adma.201904625. Epub 2019 Oct 16. Review.

PMID: 31617264

935. Postnatally acquired cytomegalovirus infection in extremely premature infants: how best to manage?

Kadambari S, Whittaker E, Lyall H.

Arch Dis Child Fetal Neonatal Ed. 2020 May;105(3):334-339. doi: 10.1136/archdischild-2019-317650. Epub 2019 Oct 15. Review.

PMID: 31615830

936. Importance of **vaccine** history in suspected measles.

Ewe YH, Palasanthiran P, Rawlinson WD, McMullan B.

J Paediatr Child Health. 2020 May;56(5):804-805. doi: 10.1111/jpc.14647. Epub 2019 Oct 15. No abstract available.

PMID: 31613030

937. Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects.

Subissi L, Rodeghiero C, Martini H, Litzroth A, Huygen K, Leroux-Roels G, Piérard D, Desombere I.

Clin Microbiol Infect. 2020 May;26(5):645.e1-645.e8. doi: 10.1016/j.cmi.2019.10.001. Epub 2019 Oct 11.

PMID: 31610300

938. *It just doesn't feel right* - the relevance of emotions and intuition for parental **vaccine** conspiracy beliefs and vaccination uptake.

Tomljenovic H, Bubic A, Erceg N.

Psychol Health. 2020 May;35(5):538-554. doi: 10.1080/08870446.2019.1673894. Epub 2019 Oct 7.

PMID: 31588791

939. Validation study of the Parent Attitudes About Childhood **Vaccines** (PACV) questionnaire: the Malay version.

Abd Halim H, Abdul-Razak S, Md Yasin M, Isa MR.

Hum Vaccin Immunother. 2020 May 3;16(5):1040-1049. doi: 10.1080/21645515.2019.1674112. Epub 2019 Oct 29.

PMID: 31567057

940. 8 months to 5 days: what happened when Pennsylvania changed the vaccination regulations for provisional enrollment?

Mohanty S, Delamater P, Feemster K, Buttenheim AM.

Hum Vaccin Immunother. 2020 May 3;16(5):1166-1170. doi: 10.1080/21645515.2019.1673120. Epub 2019 Nov 5.

PMID: 31567048

941. Effect of cash incentives on tetanus toxoid vaccination among rural Nigerian women: a randomized controlled trial.

Sato R, Fintan B.

Hum Vaccin Immunother. 2020 May 3;16(5):1181-1188. doi: 10.1080/21645515.2019.1672493. Epub 2019 Oct 7.

PMID: 31567041

942. Sir Matthew Tierney and the foundation of the 1804 Sussex **Vaccine** Institution.

Cooper MJ, Morris H, Whiston B.

J Med Biogr. 2020 May;28(2):83-89. doi: 10.1177/0967772019870443. Epub 2019 Sep 29.

PMID: 31566102

943. Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study.

Nikiphorou E, de Lusignan S, Mallen C, Khavandi K, Roberts J, Buckley CD, Galloway J, Raza K.

Rheumatology (Oxford). 2020 May 1;59(5):997-1005. doi: 10.1093/rheumatology/kez344.

PMID: 31501866

944. Association of breast milk gamma-linolenic acid with infant anthropometric outcomes in urban, low-income Bangladeshi families: a prospective, birth cohort study.

Mychaleckyj JC, Zhang D, Nayak U, Ross Colgate E, Carmolli M, Dickson D, Ahmed T, Alam M, Kirkpatrick BD, Haque R, Petri WA Jr.

Eur J Clin Nutr. 2020 May;74(5):698-707. doi: 10.1038/s41430-019-0498-6. Epub 2019 Sep 9.

PMID: 31501475

945. Measles-related hospitalizations and associated complications in Jerusalem, 2018-2019.

Ben-Chetrit E, Oster Y, Jarjou'i A, Megged O, Lachish T, Cohen MJ, Stein-Zamir C, Ivgi H, Rivkin M, Milgrom Y, Averbuch D, Korem M, Wolf DG, Wiener-Well Y.

Clin Microbiol Infect. 2020 May;26(5):637-642. doi: 10.1016/j.cmi.2019.08.022. Epub 2019 Sep 6.

PMID: 31499179

946. Multifocal outbreak of equine influenza in vaccinated horses in Argentina in 2018: Epidemiological aspects and molecular characterisation of the involved virus strains.

Olguin-Perglione C, Vissani MA, Alamos F, Tordoya MS, Barrandeguy M.

Equine Vet J. 2020 May;52(3):420-427. doi: 10.1111/evj.13176. Epub 2019 Oct 4.

PMID: 31494962

947. Knowledge matters and empowers: HPV **vaccine** advocacy among HPV-related cancer survivors.

Shelal Z, Cho D, Urbauer DL, Lu Q, Ma BY, Rohrer AM, Kurian S, Sturgis EM, Ramondetta LM.

Support Care Cancer. 2020 May;28(5):2407-2413. doi: 10.1007/s00520-019-05035-1. Epub 2019 Sep 6.

PMID: 31489512

948. Containing a measles outbreak in Minnesota, 2017: methods and challenges.

Banerjee E, Griffith J, Kenyon C, Christianson B, Strain A, Martin K, McMahon M, Bagstad E, Laine E, Hardy K, Grilli G, Walters J, Dunn D, Roddy M, Ehresmann K.

Perspect Public Health. 2020 May;140(3):162-171. doi: 10.1177/1757913919871072. Epub 2019 Sep 4.

PMID: 31480896

949. Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries.

Jalloh MF, Wilhelm E, Abad N, Prybylski D.

Hum Vaccin Immunother. 2020 May 3;16(5):1208-1214. doi: 10.1080/21645515.2019.1661206. Epub 2019 Oct 29.

PMID: 31464551

950. The pharmacist and pharmacy have evolved to become more than the corner drugstore: a win for vaccinations and public health.

Shen AK, Peterson A.

Hum Vaccin Immunother. 2020 May 3;16(5):1178-1180. doi: 10.1080/21645515.2019.1660119. Epub 2019 Sep 17.

PMID: 31456479

951. Perspectives on state **vaccine** education mandate policy and implementation among public health department officials: a qualitative study.

Caplan H, Srivastava T, Feemster KA.

Hum Vaccin Immunother. 2020 May 3;16(5):1145-1154. doi: 10.1080/21645515.2019.1654352. Epub 2019 Sep 30.

PMID: 31424331

952. Complexities in Predicting the Immunogenicity of Live Attenuated Influenza **Vaccines**.

Lindsey BB, Höschler K, de Silva TI.

Clin Infect Dis. 2020 May 6;70(10):2235-2236. doi: 10.1093/cid/ciz773. No abstract available.

PMID: 31412109

953. Reply to Lindsey, Höschler, and de Silva.

Matrajt L, Halloran ME, Antia R.

Clin Infect Dis. 2020 May 6;70(10):2236-2237. doi: 10.1093/cid/ciz774. No abstract available.

PMID: 31412101

954. Measles outbreaks and public attitudes towards **vaccine** exemptions: some cautions and strategies for addressing **vaccine** hesitancy.

Quinn SC, Jamison AM, Freimuth VS.

Hum Vaccin Immunother. 2020 May 3;16(5):1050-1054. doi: 10.1080/21645515.2019.1646578. Epub 2019 Oct 22.

PMID: 31403354

955. Using Lean Six Sigma to Improve Pneumococcal Vaccination Rates in a Veterans Affairs Rheumatology Clinic.

Wilson J, Swee M, Mosher H, Scott-Cawiezell J, Levins L, Fort K, Kumar B.

J Healthc Qual. 2020 May/Jun;42(3):166-174. doi: 10.1097/JHQ.0000000000000218.

PMID: 31385855

956. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) **Vaccine** Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.

Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C, Hutchings C, Moris P, Janssens M, Fissette LA, Picciolato M, Leach A, Gonzalez-Lopez A, Dieussaert I, Snape MD.

Clin Infect Dis. 2020 May 6;70(10):2073-2081. doi: 10.1093/cid/ciz653.

PMID: 31340042

957. Sustained Cellular and Humoral Immune Responses From an Adenoviral Vector-based Respiratory Syncytial Virus **Vaccine**.

Korsten K, Bont LJ.

Clin Infect Dis. 2020 May 6;70(10):2082-2083. doi: 10.1093/cid/ciz659. No abstract available.

PMID: 31339994

958. Analysis of factors influencing parents' willingness to accept the quadrivalent influenza **vaccine** for school-aged children in the Nanhai District, China.

Li P, Qiu Z, Feng W, Zeng H, Chen W, Ke Z, Chen W, Lv H, Luo G, Huang X.

Hum Vaccin Immunother. 2020 May 3;16(5):1078-1085. doi: 10.1080/21645515.2019.1644881. Epub 2019 Aug 23.

PMID: 31339789

959. Embedding the delivery of antenatal vaccination within routine antenatal care: a key opportunity to improve uptake.

Wilcox CR, Woodward C, Rowe R, Jones CE.

Hum Vaccin Immunother. 2020 May 3;16(5):1221-1224. doi: 10.1080/21645515.2019.1640558. Epub 2019 Jul 24.

PMID: 31339429

960. Role of cell surface proteoglycans in cancer immunotherapy.

Espinoza-Sánchez NA, Götte M.

Semin Cancer Biol. 2020 May;62:48-67. doi: 10.1016/j.semcancer.2019.07.012. Epub 2019 Jul 20. Review.

PMID: 31336150

961. Autophagy induction by the pathogen receptor NECTIN4 and sustained autophagy contribute to peste des petits ruminants virus infectivity.

Yang B, Xue Q, Guo J, Wang X, Zhang Y, Guo K, Li W, Chen S, Xue T, Qi X, Wang J.

Autophagy. 2020 May;16(5):842-861. doi: 10.1080/15548627.2019.1643184. Epub 2019 Jul 18.

PMID: 31318632

962. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care.

Qendro T, de la Torre ML, Panopalis P, Hazel E, Ward BJ, Colmegna I, Hudson M.

J Rheumatol. 2020 May 1;47(5):770-778. doi: 10.3899/jrheum.181376. Epub 2019 Jul 15.

PMID: 31308211

963. Is maternal HIV infection a risk factor for delayed or missed infant measles vaccination in western Kenya?

Ochieng BO, Khagayi S, Kamire V, Kwaro D.

AIDS Care. 2020 May;32(5):577-584. doi: 10.1080/09540121.2019.1640852. Epub 2019 Jul 9.

PMID: 31288543

964. HPV prevalence around the time of sexual debut in adolescent girls in Tanzania.

Baisley KJ, Andreasen A, Irani J, Nnko S, Changalucha J, Crucitti T, Francis S, Holm Hansen C, Hayes RJ, Buvé A, Watson-Jones D.

Sex Transm Infect. 2020 May;96(3):211-219. doi: 10.1136/sextrans-2019-054012. Epub 2019 Jun 20.

PMID: 31221744

965. Dynamic and structural insights into tick serpin from *Ixodes ricinus*.

Pongprayoon P, Niramitranon J, Kaewhom P, Kaewmongkol S, Suwan E, Stich RW, Jittapalapong S.

J Biomol Struct Dyn. 2020 May;38(8):2296-2303. doi: 10.1080/07391102.2019.1630003. Epub 2019 Jun 19.

PMID: 31215334

966. A Social Networks Approach to Understanding **Vaccine** Conversations on Twitter: Network Clusters, Sentiment, and Certainty in HPV Social Networks.

Himelboim I, Xiao X, Lee DKL, Wang MY, Borah P.

Health Commun. 2020 May;35(5):607-615. doi: 10.1080/10410236.2019.1573446. Epub 2019 Jun 14.

PMID: 31199698

967. Does Rotavirus Vaccination Affect Longer-Term Intussusception Risk in US Infants?

Burke RM, Tate JE, Dahl RM, Aliabadi N, Parashar UD.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):257-260. doi: 10.1093/jpids/piz035.

PMID: 31197368

968. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease.

Marshall GS, Dempsey AF, Srivastava A, Isturiz RE.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):244-247. doi: 10.1093/jpids/piz024.

PMID: 31077326

969. Invasive Group A Streptococcus Infection in Children in Southern Israel Before and After the Introduction of Varicella **Vaccine**.

Hasin O, Hazan G, Rokney A, Dayan R, Sagi O, Ben-Shimol S, Greenberg D, Danino D.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):236-239. doi: 10.1093/jpids/piz013.

PMID: 30927745

970. Immunogenicity and Safety of a Measles-Mumps-Rubella **Vaccine** Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194-201. doi: 10.1093/jpids/piz010.

PMID: 30849175

971. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.

McLean HQ, King JP, Talley P, Flannery B, Spencer S, Levine MZ, Friedrich TC, Belongia EA.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):173-180. doi: 10.1093/jpids/piz001.

PMID: 30759228

972. Evidence for Household Transmission of Rotavirus in the United States, 2011-2016.

Wikswo ME, Parashar UD, Lopman B, Selvarangan R, Harrison CJ, Azimi PH, Boom JA, Sahni LC, Englund JA, Klein EJ, Staat MA, McNeal MM, Halasa N, Chappell J, Weinberg GA, Szilagyi PG, Esona MD, Bowen MD, Payne DC.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):181-187. doi: 10.1093/jpids/piz004.

PMID: 30753568

973. Maternal Priming: Bacillus Calmette-Guérin (BCG) **Vaccine** Scarring in Mothers Enhances the Survival of Their Child With a BCG **Vaccine** Scar.

Berendsen MLT, Øland CB, Bles P, Jensen AKG, Kofoed PE, Whittle H, de Bree LCJ, Netea MG, Martins C, Benn CS, Aaby P.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):166-172. doi: 10.1093/jpids/piy142.

PMID: 30715451

974. Dengue **Vaccine**, A Double-Edged Sword.

Plotkin SA.

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):107-109. doi: 10.1093/jpids/piy140. No abstract available.

PMID: 30657941

975. Burden of Children Hospitalized With Pertussis in Canada in the Acellular Pertussis **Vaccine** Era, 1999-2015.

Abu-Raya B, Bettinger JA, Vanderkooi OG, Vaudry W, Halperin SA, Sadarangani M; Members of the Canadian Immunization Monitoring Program, Active (IMPACT) .

J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):118-127. doi: 10.1093/jpids/piy128.

PMID: 30535079

976. A mixed methods study: Midlife African American women's knowledge, beliefs, and barriers to well-woman visit, flu **vaccine**, and mammogram use.

Henderson V, Madrigal JM, Handler A.

J Women Aging. 2020 May-Jun;32(3):292-313. doi: 10.1080/08952841.2018.1549433. Epub 2018 Nov 22.

PMID: 30466373

977. Cohort study design for estimating the effectiveness of seasonal influenza **vaccines** in real time based on register data: The Finnish example.

Baum U, Auranen K, Kulathinal S, Syrjänen R, Nohynek H, Jokinen J.

Scand J Public Health. 2020 May;48(3):316-322. doi: 10.1177/1403494818808635. Epub 2018 Nov 2.

PMID: 30387371

Patentes registradas en Spacenet (European Patent Office (EPO))

Estrategia de búqueda: *Vaccine in the title or abstract AND 20200201:20200206 as the publication date*
404 resultados

1.GUT BACTERIA DERIVED MICROVESICLES FOR VACCINE DELIVERY
WO2020084295A2 • 2020-04-30 •
QUADRAM INST BIOSCIENCE [GB]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30
...The present invention relates to a vaccine suitable for immunisation against influenza, plague or Y. pestis infection said vaccine comprising outer membrane vesicles (OMVs) and the plague vaccine including the V and/or F1 antigens of Y. pestis. ...

2.RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYANHYDRIDE NANOPARTICLE VACCINE
US2020129446A1 • 2020-04-30 •
UNIV IOWA RES FOUND [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-04-30
... vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant. ...

3.Rabies virus vaccine
AU2018360288A1 • 2020-05-07 •
INTERVET INT BV
Earliest priority: 2017-11-06 • Earliest publication: 2019-05-09
The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

4.COMPOSITIONS AND METHODS FOR PRODUCTION OF COLD-CHAIN VACCINES
US2020129610A1 • 2020-04-30 •
UNIV SOUTHERN CALIFORNIA [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30
...This disclosure provides a novel lyophilized formulation that incorporates a surfactant solution to stabilize the Sabin inactivated polio vaccine and demonstrate the vaccine efficacy in an in vivo challenge model. Furthermore, SE-HPLC analysis of D-antigen content in in inactivated polio vaccine can be used to provide a method for high throughput evaluation of inactivated poliovirus stability. ...

5.NOVEL TUMOR VACCINE AND USE THEREOF
EP3646883A1 • 2020-05-06 •
UNIV SICHUAN [CN]
Earliest priority: 2017-06-28 • Earliest publication: 2019-01-03

...The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve... responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex... tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application. ...

6.CHLAMYDIA NANOEMULSION VACCINE
US2020138935A1 • 2020-05-07 •
NANOBIO CORP [US]
Earliest priority: 2017-07-13 • Earliest publication: 2019-01-17
The present application relates to the field of human immunology, in particular, a chlamydia vaccine. The subunit vaccine composition may...

7.VACCINES AND METHODS FOR CREATING A VACCINE FOR INDUCING IMMUNITY TO ALL DENGUE VIRUS SEROTYPES
US2020129607A1 • 2020-04-30 •
ISERN SHARON [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-04-30
... protein, such as from yellow fever virus 17D vaccine strain, is modified replacing amino acids surrounding the fusion loop of... vaccine to stimulate an immune response against DENV infection, thereby producing broadly neutralizing (protective) antibodies against dengue virus and reduce ...

8.POXVIRUS VECTORS ENCODING HIV ANTIGENS, AND METHODS OF USE THEREOF
US2020138938A1 • 2020-05-07 •
BAVARIAN NORDIC AS [DK]
Earliest priority: 2017-06-15 • Earliest publication: 2018-12-20
... and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine... antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV. ...

9.GENOMIC VARIANTS IN IG GENE REGIONS AND USES OF SAME
WO2020087071A1 • 2020-04-30 •
DANA FARBER CANCER INST INC [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30
... to methods of preparing a vaccine composition. For example, the vaccine composition can be specific to a subject or a group of subjects with a genotype responsive to the vaccine composition. Aspects of the disclosure are further drawn towards methods ...

10.Attenuated African Swine Fever Virus Vaccine
US2020129609A1 • 2020-04-30 •
THE PIRBRIGHT INST [GB]
Earliest priority: 2014-06-19 • Earliest publication: 2015-12-23
.... The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the...

11.Vaccine to pathogenic immune activation cells during infections
US10632186B1 • 2020-04-28 •

21C BIO [FR]
Earliest priority: 2019-03-21 • Earliest publication: 2020-04-28
... vaccine specific for at least one infectious disease-related antigen, a second part including an agent neutralizing circulating alpha interferon...

12.Genetically Attenuated Nucleic Acid Vaccine
US2020138937A1 • 2020-05-07 •
KERNER MATTHEW [US]
Earliest priority: 2017-06-02 • Earliest publication: 2018-12-06
The disclosed compositions and methods provide an approach for the rational development of a nucleic acid vaccine. Methods are disclosed...

13.Regimens for Immunisation With Meningococcal Conjugates
US2020138932A1 • 2020-05-07 •
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Earliest priority: 2006-03-22 • Earliest publication: 2007-10-04

Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.

14.PROSTATE CANCER VACCINE
US2020138925A1 • 2020-05-07 •
WISCONSIN ALUMNI RES FOUND [US]
Earliest priority: 2006-09-01 • Earliest publication: 2008-03-13

Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.

15.HERPES SIMPLEX VIRUS VACCINE
US2020129615A1 • 2020-04-30 •
MODERNATX INC [US]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20
... and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

16.ATTENUATED FISH VACCINE FOLLOWING CULTURE IN IRON LIMITED MEDIA
US2020138930A1 • 2020-05-07 •
UNIV OF IDAHO [US]
Earliest priority: 2011-08-25 • Earliest publication: 2013-02-28

Protection of fish from bacterial disease by vaccination with a live attenuated strain of the causative bacterium is enhanced when the attenuated strain has been grown in an iron-limited medium.

17.VACCINE ADJUVANT COMPOSITION BASED ON AMPHIPHILIC POLYAMINO ACID POLYMER, CONTAINING SQUALENE
US2020138939A1 • 2020-05-07 •
HUVET BIO INC [KR]
Earliest priority: 2015-12-16 • Earliest publication: 2017-06-22
... present invention is prepared using an amphiphilic poly-amino acid polymer, it allows the provision of a vaccine immunoadjuvant composition...

18.Feline calicivirus vaccine
AU2018380582A1 • 2020-05-07 •
INTERVET INT BV
Earliest priority: 2017-12-08 • Earliest publication: 2019-06-13

The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.

19.RESPIRATORY SYNCYTIAL VIRUS VACCINE
US2020129608A1 • 2020-04-30 •
MODERNATX INC [US]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20

The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

20.CANCER SPECIFIC IMMUNOTHERAPEUTIC TARGETS GENERATED BY CHEMOTHERAPEUTIC DRUG TREATMENT
WO2020092382A1 • 2020-05-07 •
GEORGIA STATE UNIV RESEARCH FOUNDATION INC [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07
...Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods...), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine. ...

21.Vaccine for Malignant Tumor Treatment
US2020129602A1 • 2020-04-30 •
INTELLEXON GMBH [DE]
Earliest priority: 2017-06-20 • Earliest publication: 2018-12-20
..., and preparing an individual vaccine for eliciting a specific immunological response by lysing those cells on which a part of the expression pattern has been masked or removed.

22.-SPECTRUM VACCINE AGAINST INFECTIONS DUE TO ENTEROPATHOGENIC BACTERIA
US2020129606A1 • 2020-04-30 •
BIOSYNTH SRL [IT]

Earliest priority: 2014-07-25 • Earliest publication: 2016-01-28

The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.

23.INFORMATION PUSHING METHOD AND APPARATUS, SERVER AND COMPUTER-READABLE STORAGE MEDIUM
WO2020082810A1 • 2020-04-30 •
PING AN MEDICAL AND HEALTHCARE MAN CO LTD [CN]
Earliest priority: 2018-10-23 • Earliest publication: 2019-03-29

An information pushing method and apparatus, a server and a computer-readable storage medium. Said method comprises: acquiring preset inoculation information (S101); setting a vaccination prompting message set according to the preset inoculation information (S102), the vaccination prompting message set comprising prompting messages regarding vaccines to be inoculated corresponding to various age groups and prompting messages regarding suggested vaccines to be inoculated corresponding to various age groups; detecting a target age group to which a target infant belongs (S103); determining, from the vaccination prompting message set, a target vaccination prompting message corresponding to the target age group (S104); and sending the target vaccination prompting message to a terminal (S105). Said method can be used to effectively push, in time, vaccination prompting messages to infants, so as to facilitate the vaccination of the infants.

24.PERSONALIZED VACCINE
US2020138923A1 • 2020-05-07 •
TRANSGENE [FR]
Earliest priority: 2017-06-21 • Earliest publication: 2018-12-27
...The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s... personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and ...

25.ANTI-HIV ANTIBODIES
WO2020086446A1 • 2020-04-30 •
INT AIDS VACCINE INITIATIVE [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.

26.COMPOSITIONS COMPRISING BACTERIAL STRAINS
WO2020089488A1 • 2020-05-07 •
4D PHARMA RES LTD [GB]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07
...The invention provides compositions comprising bacterial strains for use as a vaccine adjuvant; for use in treating, preventing or delaying immunosenescence; or for use in enhancing a cell therapy, such as CAR-T. The invention also provides vaccine compositions comprising bacterial strains and one or more antigens. ...

27.Zika Virus Like Particle (VLP) Based Vaccine and Microneutralization Assay
US2020140891A1 • 2020-05-07 •
UNIV TEXAS TECH SYSTEM [US]
Earliest priority: 2017-06-20 • Earliest publication: 2018-12-27

The present invention includes compositions, methods, vectors, vaccines, cell lines and other constructs for making and used Zika virus Reporter Virus Particles (RVPs) and/or Virus Like Particles (VLPs) that are safe for handling and manufacturing and are able to generate an effective immune response against Zika virus and can be readily scaled up for cost-effective production.

28.THERAPEUTIC MITIGATION OF EPITHELIAL INFECTION
WO2020092015A1 • 2020-05-07 •
UNIV ROCHESTER [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

This invention relates to dermatology and to treatments of infectious skin disease.

29.Universal Non-Classical MHC I Vaccines: HLA-E-Restricted Antigenic Peptides as Universal Vaccines to Treat Allergy, Inflammation, Autoimmune and Infectious Diseases, and Cancers
US2020138928A1 • 2020-05-07 •
CHEN SWEY SHEN [US]
Earliest priority: 2018-02-26 • Earliest publication: 2020-05-07
.... Derlin-1 and UL40 pathways are utilized to enable antigen presentation and vaccine efficacies in the non-classical MHC I pathways.

30.VACCINE ADJUVANT
WO2020086625A1 • 2020-04-30 •
CARSON DENNIS A [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

Compounds useful as an adjuvant, e.g., formulas (I)-(VI) and uses thereof, for example, with immunogenic moieties or other adjuvants, are provided.

31.IMMUNOGENIC PEPTIDE COMPOSITION
US2020138929A1 • 2020-05-07 •
CANCER RES MALAYSIA [MY]

Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20
... and a peptide vaccine for inducing the anti-cancer immune response in the subject.

32.NON-CROSS-LINKED ACELLULAR PERTUSSIS ANTIGENS FOR USE IN COMBINATION VACCINES
US2020138927A1 • 2020-05-07 •
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Earliest priority: 2012-10-12 • Earliest publication: 2014-04-17

The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.

33.EHRLICHIA RUMINANTIUM IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THEREOF
US2020129604A1 • 2020-04-30 •
KANSAS STATE UNIV RESEARCH FOUNDATION [US]
Earliest priority: 2017-07-12 • Earliest publication: 2019-01-17

The present disclosure provides compositions and methods for reducing the incidence of and/or severity of diseases associated with tick-borne pathogens. In preferred forms, the compositions comprise a recombinant antigenic protein subunit that has been glycosylated. Some preferred subunits include the MAP1 protein of Ehrlichia ruminantium, the p30-1 sequence from Ehrlichia canis, the p28-Omp19 protein from Ehrlichia chaffeensis, and the MSP4 protein from Anaplasma marginale. Administration of such compositions to an animal in need thereof provides protection against clinical signs of infection in susceptible animals.

34.RSV VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF
WO2020092365A1 • 2020-05-07 •
ANDERSON LARRY J [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07
The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV...

35.GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
US2020138931A1 • 2020-05-07 •
CHILDRENS HOSPITAL & RES CENTER AT OAKLAND [US]
Earliest priority: 2005-01-27 • Earliest publication: 2006-08-03

The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.

36.SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF
WO2020082162A1 • 2020-04-30 •

ALBERTA RES CHEMICALS INC [CA]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30
... vaccine formulation comprises the adjuvant formulation and an immunogen. Methods of vaccinating an animal include delivering the vaccine formulation to the animal.

37.PEPTIDES FOR INDUCING HETEROSUBTYPIC INFLUENZA T CELL RESPONSES
WO2020086927A1 • 2020-04-30 •
EPIVAX INC [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present invention provides compositions and methods for generation of an anti- influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.

38.MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME
US2020140508A1 • 2020-05-07 •
WISTAR INST [US]
Earliest priority: 2017-06-07 • Earliest publication: 2018-12-13

Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.

39.METHODS AND COMPOSITIONS FOR PREVENTING OR AMELIORATING PSEUDOMONAS AERUGINOSA PULMONARY INFECTIONS
US2020138934A1 • 2020-05-07 •
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US]
Earliest priority: 2018-10-03 • Earliest publication: 2020-05-07

The invention provides methods and compositions for preventing or ameliorating pulmonary infections with Pseudomonas aeruginosa.

40.Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (RSV) infections
AU2018331467A1 • 2020-04-30 •
OHIO STATE INNOVATION FOUNDATION [US]
Earliest priority: 2017-09-15 • Earliest publication: 2019-03-21

Disclosed herein are vaccines, immunogenic compositions, and methods of using the same to treat and prevent respiratory syncytial virus (RSV). Specifically, disclosed are immunogenic compositions wherein a protein or immunogenic fragment of RSV is delivered to a subject in a recombinant viral vector platform, such as vesicular stomatis virus (rVSV).

41.ANTI-RABIES MONOCLONAL ANTIBODIES AND COCKTAIL THEREOF

WO2020089742A1 • 2020-05-07 •
CADILA HEALTHCARE LTD [IN]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07
... two monoclonal antibodies and anti-rabies vaccine for use in post-exposure prophylaxis (PEP) with rabies or rabies-related viruses.

42.MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAME
WO2020085457A1 • 2020-04-30 •
KM BIOLOGICS CO LTD [JP]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30
... CMV gB protein; and a CMV vaccine including the same. This modified CMV gB protein includes a modification in the...

43.Compositions of phosphorylated tau peptides and uses thereof
AU2018355325A1 • 2020-05-07 •
AC IMMUNE SA
Earliest priority: 2017-10-25 • Earliest publication: 2019-04-25

Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.

44.Phenotypically Wild-Type and Genetically Attenuated Viruses
US2020138936A1 • 2020-05-07 •
KERNER MATTHEW [US]
Earliest priority: 2017-06-02 • Earliest publication: 2018-12-06
... as a vaccine, vaccine seed strain, therapy, and/or research tool. Methods are disclosed to generate a virus that is...

45.VACCINE FORMULATIONS
PL3170508T3 • 2020-04-30 •
WYETH LLC [US]
Earliest priority: 2010-06-04 • Earliest publication: 2011-12-08
No abstract available

46.A NOVEL DNA VACCINE AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS (CCHFV)
WO2020092880A1 • 2020-05-07 •
WISTAR INST [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. Method of preventing infection by

CCHFV and methods of treating individuals infected with CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

47.COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES
US2020129640A1 • 2020-04-30 •
UNIV MICHIGAN REGENTS [US]
Earliest priority: 2017-06-05 • Earliest publication: 2018-12-13

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

48.Novel gamma delta T-cell receptor and its ligand
AU2018369698A1 • 2020-04-30 •
UNIV COLLEGE CARDIFF CONSULTANTS LTD [GB]
Earliest priority: 2017-11-20 • Earliest publication: 2019-05-23
... of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone... agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds. ...

49.Immunogenic Influenza Composition
US2020129611A1 • 2020-04-30 •
BIOLOGICAL MIMETICS INC [US]
Earliest priority: 2010-01-24 • Earliest publication: 2011-07-28

Methods for providing novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. The novel immunogens can be used as vaccines or to develop antibodies.

50.BROADLY REACTIVE IMMUNOGENS OF INFLUENZA VIRUS, COMPOSITIONS, AND METHODS OF USE THEREOF
WO2020092207A1 • 2020-05-07 •
UNIV OF GEORGIA RESEARCH FOUNDATION [US]
Earliest priority: 2018-10-28 • Earliest publication: 2020-05-07

Provided herein are non-naturally occurring, broadly reactive, pan-epitopic antigens derived from H1 influenza virus that are immunogenic and elicit a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against H1 virus following introduction into a subject. Also

provided are non-naturally, pan-epitopic occurring influenza virus immunogens, vaccines, virus-like particles (VLPs), subviral particles (SVPs), and compositions comprising the influenza virus antigens, immunogens, VLPs, SVPs, and vaccines of the disclosure. Methods of generating an immune response in a subject by administering the influenza virus antigens, immunogens, vaccines, VLPs, SLPs, or compositions thereof as disclosed here are provided. For example, the antigens and immunogens comprise the hemagglutinin (HA) protein of H1 influenza virus strains.

51.A HIGH-YIELD PERFUSION-BASED TRANSIENT GENE EXPRESSION BIOPROCESS
WO2020086408A1 • 2020-04-30 •
US HEALTH [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

High efficiency methods are disclosed for producing a heterologous protein using transient gene expression in host cells. The heterologous protein can then be isolated from the host cells.

52.PROTEINS DERIVED FROM CLPB AND USES THEREOF
US2020131495A1 • 2020-04-30 •
INST NAT SANTE RECH MED [FR]
Earliest priority: 2017-04-03 • Earliest publication: 2018-10-10

Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.

53.Human cytomegalovirus immunogenic composition
AU2018331874A1 • 2020-04-30 •
SANOFI PASTEUR [FR]
Earliest priority: 2017-09-13 • Earliest publication: 2019-03-21
... complex antigen and a Th1 -inducing adjuvant. If further relates to the immunogenic composition for use as an HCMV vaccine.

54.IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS
US2020140567A1 • 2020-05-07 •
US HEALTH [US]
Earliest priority: 2014-08-29 • Earliest publication: 2016-03-03

The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.

55.DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV
WO2020086782A1 • 2020-04-30 •

INOVIO PHARMACEUTICALS INC [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.

56.IMPROVED INTRA-ARTERIAL TUMOR TARGETING FOR DIAGNOSIS AND/OR TREATMENT
WO2020092815A1 • 2020-05-07 •
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07
.... The methods of the present technology also relate to localized intra- arterial delivery of a vaccine adjuvant into a tumor...

57.ZIKA VIRUS IMMUNOGENIC COMPOSITIONS
WO2020087038A1 • 2020-04-30 •
NEW YORK BLOOD CENTER INC [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

Provided herein are methods of use of subunit immunogenic compositions, in particular for the prevention and treatment of Zika virus infections.

58.PRIMARY CONTAINERS WITH IMPROVED PROTEIN DRUG STABILITY AND LOWER IMMUNE RESPONSE
WO2020092373A1 • 2020-05-07 •
SIO2 MEDICAL PRODUCTS INC [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

A primary drug container is described having an injection-molded thermoplastic wall having an internal surface defining a lumen, a PECVD (plasma-enhanced chemical vapor deposition) drug-contact coating, and a polypeptide composition contained in the lumen. The drug-contact coating is on or adjacent to the internal surface, positioned to contact a fluid in the lumen, and consists essentially of SiOxCyHz. The primary drug container contains between a lower limit of 1,000 and an upper limit of 100,000 particles having effective spherical diameters greater than 2 and no more than 10 micrometers (μm) per mL of solution.

59.CANINE DISTEMPER VACCINES AND METHODS OF TREATMENT USING THE SAME
WO2020086939A1 • 2020-04-30 •
WISTAR INST [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

Disclosed herein are compositions and methods for treating and/or preventing Canine Distemper Virus (CDV) in mammals susceptible to CDV. In one embodiment, the invention relates to an immunogenic composition comprising a nucleic acid molecule encoding at least one Canine Distemper Virus (CDV)

antigen. In one embodiment, the CDV antigen is a hemagglutinin glycoprotein (H) antigen, a nucleoprotein (N) antigen, a fusion glycoprotein (F) antigen, or any a combination thereof.

60.GENOME-WIDE IDENTIFICATION OF IMMUNE EVASION FUNCTIONS IN A VIRUS
US2020129612A1 • 2020-04-30 •
UNIV CALIFORNIA [US]
Earliest priority: 2017-03-14 • Earliest publication: 2018-09-20
.... The resulting attenuated pathogen causes a strong immunologic response and can be used in a live attenuated vaccine.

61.Applicator for applying a microneedle array to skin
AU2018352317A1 • 2020-04-30 •
3M INNOVATIVE PROPERTIES CO [US]
Earliest priority: 2017-10-17 • Earliest publication: 2019-04-25

An applicator and method for applying a microneedle array to skin. The applicator can include a body having a first portion and a second portion defining a cavity, the second portion having a slot presented on an outside surface for insertion of the microneedle array into the cavity. The first portion and the second portion are slidable relative to one other along an axis enabling the body to be in an unprimed configuration and a primed configuration. The applicator further includes a door operable with the second portion, the door being movable from a first door position to a second door position, wherein when the device is in the unprimed configuration, the door at least partially obstructs the slot and access into the cavity. When the device is in the primed configuration, the door does not obstruct the slots and enables access into the cavity.

62.H52 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
US2020129614A1 • 2020-04-30 •
BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

63.COMBINATION IMMUNOTHERAPY FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
WO2020086412A1 • 2020-04-30 •
SLSG LTD LLC [US]
Earliest priority: 2018-10-21 • Earliest publication: 2020-04-23

The present invention concerns a method for treating triple-negative breast cancer (TNBC) in an individual, and/or for inducing an immune response to HER2/neu in an individual with a triple-negative breast cancer expressing low levels of HER2/neu, the method comprising administering to the individual: (a) an effective amount of trastuzumab, or derivative thereof; and (b) an effective amount of nelipepimut-S, or variant thereof, optionally with an immunological adjuvant. Preferably, the method includes a preparatory or priming phase comprising a frequency and duration of trastuzumab or trastuzumab derivative administration sufficient to substantially increase the major histocompatibility complex (MHC)-mediated presentation of HER2 peptide fragments to the patient immune system. The invention also includes medicaments and kits for treating TNBC in an individual, and/or for inducing an immune response to HER2/neu in an individual with a TNBC expressing HER2/neu.

64.4/91 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
US2020129613A1 • 2020-04-30 •
BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

65.T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE
WO2020092475A1 • 2020-05-07 •
CHILDRENS HOSPITAL PHILADELPHIA [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present disclosure provides improved compositions and methods for T-cell-based immunotherapy employing a modified T cells obtained from the lymphatic system of normal and cancer patient donors. These cells can then be used to treat patients for a variety of different blood and solid tumor cancers.

66.STABILIZED PRE-FUSION RSV F PROTEINS
US2020138940A1 • 2020-05-07 •
JANSSEN VACCINES & PREVENTION BV [NL]
Earliest priority: 2016-05-30 • Earliest publication: 2017-12-07

Stable pre-fusion respiratory syncitial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.

67.HYALURONIC ACID AS A NATURAL ADJUVANT FOR PROTEIN AND PEPTIDE-BASED VACCINES
WO2020084558A1 • 2020-04-30 •

ST ONCOLOGICO VENETO IOV IRCCS [IT]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present invention finds application in the field of medicine and, in particular, it relates to the preparation of hyaluronic acid based vaccines.

68.Pegylated Liposomes and Methods of Use
US2020138715A1 • 2020-05-07 •
INFECTIOUS DISEASE RES INST [US]
Earliest priority: 2016-05-16 • Earliest publication: 2017-11-23
... for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods...

69.PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY
US2020140477A1 • 2020-05-07 •
UNIV TEXAS [US]
Earliest priority: 2012-12-19 • Earliest publication: 2014-06-26
... and 3′3′-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.

70.DRUG CONJUGATE PREPARED USING ALDEHYDE GROUP AT END OF HYALURONIC ACID
WO2020085734A1 • 2020-04-30 •
PHI BIOMED INC [KR]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The present invention relates to a hyaluronic acid-drug conjugate synthesized by introducing a drug to an aldehyde group at the end of hyaluronic acid. A hyaluronic acid-drug conjugate according to the present invention allows a drug to be conjugated without modifying the repeating structure of hyaluronic acid, thereby simplifying degradation products.

71.HERPES SIMPLEX VIRUS VACCINE
EP3641810A1 • 2020-04-29 •
MODERNATX INC [US]
Earliest priority: 2017-04-26 • Earliest publication: 2018-11-01
No abstract available

72.Articles and methods directed to personalized therapy of cancer
AU2018344859A1 • 2020-04-30 •
GABIBOV ALEXANDER GABIBOVICH [RU]
Earliest priority: 2017-10-04 • Earliest publication: 2019-04-11

Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

73.FERRITIN NANOPARTICLES COMPRISING A CHEMOTHERAPEUTIC AGENT
WO2020089394A1 • 2020-05-07 •
INTHENA S R L [IT]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07
... of T cells. In particular, the present invention relates to the use of nanoparticles for the treatment of recurrent cancer and for use as a cancer vaccine.

74.Adenovirus Polynucleotides and Polypeptides
US2020140886A1 • 2020-05-07 •
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Earliest priority: 2015-06-12 • Earliest publication: 2016-12-15

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:

(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1,(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

75.RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION
WO2020086483A1 • 2020-04-30 •
BECERRA FLORES MANUEL [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

76.METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER USING ANTISENSE
WO2020092684A1 • 2020-05-07 •
UNIV JEFFERSON [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07
... to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising...

77.NOVEL POLYSACCHARIDE AND USES THEREOF
US2020129605A1 • 2020-04-30 •
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Earliest priority: 2014-02-24 • Earliest publication: 2015-08-27

Provided herein is an E. Coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

78.PHARMACEUTICAL COMPOSITIONS, VACCINES AND THEIR USES IN THE PREVENTION OR TREATMENT OF A PERSISTENT INFECTION OR OF CANCER
EP3646882A1 • 2020-05-06 •
UNIV DER JOHANNES GUTENBERG UNIV MAINZ [DE]
Earliest priority: 2018-11-05 • Earliest publication: 2020-05-06

The present invention relates to pharmaceutical compositions, comprising at least one oxidative stress substance selected from the group consisting of dithranol (anthralin, cignolin), or other anthrones or hydroxyanthracenes, at least one Toll-like receptor 7 (TLR7) ligand, and at least one peptide antigen. The invention further relates pharmaceutical combination preparations comprising these components and the use of such pharmaceutical compositions or combination preparations for use in the prevention or treatment of a persistent viral, bacterial or fungal infection or of cancer. The pharmaceutical compositions or combination preparations of the invention are in particular useful for topical application on the skin of a human or animal body.

79.IMMUNE CHECKPOINT THERAPEUTIC METHODS
WO2020092589A1 • 2020-05-07 •
NANTOMICS LLC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Contemplated systems and methods are directed to omics analysis of various tumors, especially as it relates to prediction of treatment outcomes using immune checkpoint therapy of colorectal cancer. More particularly, patients with tumors having high TMB and CMS2 and that exhibit Wnt pathway activation can be excluded from immune therapy due to an immunosuppressive TME.

80.Combination Drug Therapy
US2020138845A1 • 2020-05-07 •
VIIV HEALTHCARE CO [US]
Earliest priority: 2017-07-18 • Earliest publication: 2019-01-24

A novel combination comprising the integrase strand transfer inhibitor, cabotegravir or a pharmaceutically acceptable salt or solvate thereof, with the nucleoside reverse transcriptase translocation inhibitor EFdA (MK-8591), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of the HIV integrase or reverse transcriptase is beneficial, e.g., HIV.

81.A TELOMERASE ENCODING DNA VACCINE
SI3062824T1 • 2020-04-30 •

INVECTYS [FR]
Earliest priority: 2013-10-28 • Earliest publication: 2015-05-07
No abstract available

82.NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS
US2020138924A1 • 2020-05-07 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2016-04-06 • Earliest publication: 2017-10-12
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

83.METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE
WO2020092682A1 • 2020-05-07 •
UNIV JEFFERSON [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07
... may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated...

84.VACCINATION AND ANTIBODY GENERATION PLATFORM
WO2020084072A1 • 2020-04-30 •
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS [DE]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30
... effective immune response when used as a vaccine or in immunization for antibody production. The herein disclosed antigenic particles are...

85.Compositions and Methods Related to Protein A (SpA) Variants
US2020140494A1 • 2020-05-07 •
UNIV CHICAGO [US]
Earliest priority: 2010-07-02 • Earliest publication: 2012-01-05

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

86.Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
AU2018357989A1 • 2020-05-07 •
ROUSSY INST GUSTAVE
Earliest priority: 2017-10-31 • Earliest publication: 2019-05-01

The invention relates to the prognosis and treatment of colon cancer. In particular, the present invention concerns the role of intestinal microbiota in the anticancer immune response elicited by ileal enterocytes

succumbing to apoptosis, and provides immunogenic compositions for treating colorectal cancer (CRC), as well as signatures for prognosing CRC evolution.

87.ALZHEIMER'S DISEASE TREATMENT METHOD
US2020140488A1 • 2020-05-07 •
ARACLON BIOTECH SL [ES]
Earliest priority: 2003-05-08 • Earliest publication: 2004-11-18

The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Aβ40 and Aβ42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

88.VACCINES TARGETING M. CATHARRHALIS
WO2020083904A1 • 2020-04-30 •
EVAXION BIOTECH APS [DK]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

Disclosed are immunogenic proteins from Moraxella catharrhalis as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Moraxella catharrhalis using the proteins, nucleic acids, vectors or transformed cells.

89.USE OF HYDROGEN PEROXIDE IN PREPARATION OF DRUGS FOR ERADICATION OF HELICOBACTER PYLORI INFECTION AND PREPARED DRUGS
WO2020082840A1 • 2020-04-30 •
UNIV XI AN JIAOTONG [CN]
Earliest priority: 2018-10-22 • Earliest publication: 2019-01-18

Disclosed are the use of hydrogen peroxide in preparation of drugs for eradication of Helicobacter pylori infection and the prepared drugs. The appropriate concentration of hydrogen peroxide quickly decomposes in the stomach and releases a large amount of oxygen, which significantly increases the oxygen concentration in the stomach, and enables effective eradication of Helicobacter pylori infection. The experiments show that the appropriate concentration of hydrogen peroxide has better killing effects on both Helicobacter pylori international standard strain and Helicobacter pylori wild type strain. The Helicobacter pylori infection model in mice shows no recurrence after treatment with hydrogen peroxide.

90.IMMUNOGENIC COMPOSITIONS
EP3641828A1 • 2020-04-29 •
NOSOCOMIAL VACCINE CORP [US]
Earliest priority: 2017-06-23 • Earliest publication: 2018-12-27
No abstract available

91.LIQUID FEEDING DEVICE FOR THE GENERATION OF DROPLETS
US2020141647A1 • 2020-05-07 •
SANOFI PASTEUR SA [FR]

Earliest priority: 2014-07-21 • Earliest publication: 2016-01-28

The present invention provides, inter alia, for a liquid feeding device for the generation of droplets, in particular for the use in a process line for the production of freeze-dried particles, with a droplet ejection section for ejecting liquid droplets in an ejection direction, the droplet ejection section comprising at least one inlet port for receiving a liquid to be ejected, a liquid chamber for retaining the liquid, and a nozzle for ejecting the liquid from the liquid chamber to form droplets, wherein the liquid chamber is restricted by a membrane on one side thereof, the membrane being vibratable by an excitation unit, wherein the longitudinal axis of the liquid chamber is tilted relative to the longitudinal axis of the nozzle, and/or the liquid feeding device further comprises a deflection section for separating the droplets from each other by means of at least one gas jet, wherein the deflection section gas jet intersects perpendicular with an ejection path of the liquid ejected from the liquid chamber.

92.PYRALID MOTH EGG, PRODUCING METHOD THEREOF, AND METHOD FOR PRODUCING RECOMBINANT PROTEIN BY USING PYRALID MOTH EGG
US2020140890A1 • 2020-05-07 •
ENBLOC CELL LLC [KR]
Earliest priority: 2017-06-08 • Earliest publication: 2017-09-01

The present invention relates to means and methods for increasing the efficiency of recombinant protein expression and, more particularly, to means and methods for optimizing the industrial production of recombinant proteins in pyralid moths eggs (which are insect pests of stored foods), especially Mediterranean flour moth eggs (Ephestia kuehniella). Furthermore, the present invention relates to the pyralid moths eggs itself which contains a recombinant baculovirus and, infection of recombinant baculovirus into pyralid moths eggs and, transformation or transduction or transfection by recombinant baculoviruses or bacmids. In addition, it relates to an appropriate device for carrying out the method of the present invention.

93.KOC1-Derived peptide and vaccine including same
AU2020202435A1 • 2020-05-07 •
ONCOTHERAPY SCIENCE INC
Earliest priority: 2014-08-04 • Earliest publication: 2016-02-11

The present invention provides an epitope peptide that is derived from KOC 1 and that has cytotoxic T cell induction potency. The present invention also provides a 5 polynucleotide that codes for the peptide, antigen-presenting cells that present the peptide and cytotoxic T cells that target the peptide, and a method for inducing the antigen presenting cells or the cytotoxic T cells. The present invention also provides a composition and a pharmaceutical composition that include the peptide, etc. as active components. The present invention also 10 provides a method for the treatment and/or prevention of cancer and/or the prevention of the post 0 operative recurrence of cancer, the method using the peptide, the polynucleotide, the antigen-presenting cells, and the cytotoxic T cells of the present invention or using the pharmaceutical composition of the present invention. The present invention also provides f a method for inducing an immune response to cancer.

94.GUANABENZ AS AN ADJUVANT FOR IMMUNOTHERAPY
WO2020083982A1 • 2020-04-30 •
UNIV LOUVAIN [BE]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-30
... vaccination. The present invention relates more specifically to guanabenz for use with an adoptive cell therapy, with a therapeutic vaccine...

95.ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS
WO2020092887A2 • 2020-05-07 •
UNIV NORTH CAROLINA STATE [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

Disclosed are compositions and methods related to the use of adipocytes for sustained release of anti-cancer therapeutics and treatment of cancer.

96.BIOCOMPATIBLE AND BIODEGRADABLE EMULSIONS AND COMPOSITIONS, AND METHODS OF USE THEREOF
US2020129429A1 • 2020-04-30 •
VIVAVAX INC [CA]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20

Emulsions and layered compositions for improving thermal resistance of a substrate, such as a therapeutic or prophylactic medicinal substrate, are provided. Also provided are methods and kits for making the emulsions and layered compositions of the invention. The layered compositions and emulsions can be used to extend the shelf life of a product.

97.METHODS OF TREATING CANCER
WO2020086943A1 • 2020-04-30 •
JOUNCE THERAPEUTICS INC [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present disclosure provides methods of treating cancer and methods for selecting treatment approaches for cancer.

98.HUMAN ANTIBODIES TARGETING ZIKA VIRUS NS1, NS1 POLYPEPTIDES AND USES THEREOF
WO2020092564A1 • 2020-05-07 •
ICAHN SCHOOL MED MOUNT SINAI [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

In one aspect, provided herein are antibodies that bind to Zika virus non- structural protein 1 (NS1) and compositions comprising the same. In a specific embodiment, such antibodies or compositions thereof may be used to passively immunize a subject against Zika virus. In another embodiment, such antibodies or compositions thereof may be used to diagnose a Zika virus infection. In another aspect, provided herein are

recombinant NS 1 polypeptides and compositions comprising the same that may be used to immunize a subject against Zika virus disease.

99.BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
SI3335728T1 • 2020-04-30 •
BETH ISRAEL DEACONESS MEDICAL CT INC [US]
Earliest priority: 2008-10-10 • Earliest publication: 2010-04-15
No abstract available

100.MUTANT CAS9 PROTEINS
EP3647418A1 • 2020-05-06 •
HARVARD COLLEGE [US]
Earliest priority: 2013-11-19 • Earliest publication: 2015-05-28
The present invention relates to the fields of genetically modified Agrobacterium strains, vaccine adjuvants, and generally molecular biology and immunology...

101.Anti-IL-23 Antibodies, Compositions, Methods and Uses
US2020138943A1 • 2020-05-07 •
JANSSEN BIOTECH INC [US]
Earliest priority: 2005-06-30 • Earliest publication: 2007-01-11

An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

102.CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
US2020140888A1 • 2020-05-07 •
UNIV OREGON HEALTH & SCIENCE [US]
Earliest priority: 2013-03-05 • Earliest publication: 2014-09-12

Disclosed herein are CMV vectors that include a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL128 protein (or ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an ortholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II.

103.METHOD FOR CONVECTIVE DRYING OF FINELY DISPERSED BIOMATERIALS
RU2720175C1 • 2020-04-27 •
FEDERALNOE BYUDZHETNOE UCHREZHDENIE NAUKI MOSKOVSKIJ NAUCHNO ISSLEDOVATELSKIJ INST EPIDEMIOLOGII I M [RU]
Earliest priority: 2018-12-28 • Earliest publication: 2020-04-27

FIELD: medicine; pharmaceuticals. SUBSTANCE: invention refers to medicine and pharmaceutical industry and concerns a method for producing dry biomaterials by convective drying. Substance of the invention consists in the fact that the high-disperse biomaterials containing the active substances of the biological nature in the liquid phase are dried out of a microdroplet state stabilized with a dry highly dispersed hydrophobic aerosil at temperature of 25–45 °C and relative humidity of 20–80 %.EFFECT: technical result of invention is reduced inactivation of active substances of biological nature during drying of finely dispersed biomaterials, high concentration of active substances, as well as reduced inactivation of active substances during storage of dry materials.1 cl, 1 tbl, 5 ex

104.Conjoint therapies for immunomodulation
AU2018360389A1 • 2020-05-07 •
AURIGENE DISCOVERY TECH LIMITED
Earliest priority: 2017-11-06 • Earliest publication: 2019-05-09

The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1 or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1 or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.

105.Target peptides for immunotherapy and diagnostics
AU2020202434A1 • 2020-04-30 •
THE UNIV OF BIRMINGHAM [GB]
Earliest priority: 2012-08-31 • Earliest publication: 2014-03-06
... or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for...

106.A natural product comprising fermented fig to combat viral diseases, bacterial diseases, fungus diseases and cancer diseases
AU2017323652A1 • 2020-04-30 •
AL SOUD MALEK
Earliest priority: 2016-09-09 • Earliest publication: 2018-03-15

The present invention relates to composition of natural product which is fermented fig treated with Acetobacter pasteurianus for improving health. The composition is prepared to fight cancers, viruses, and bacteria. Thus people will improve their health and reduce the risk of death due to dangerous diseases. Experiments proved that this drug is completely safe, its taste is acceptable, and it does not have any side effects. I have a great hope to meet the market's need to this drug especially after producing it chemically in drugs companies.

107.MEDICAL TREATMENT METHOD WITH ADMINISTRATION OF DENDRITIC CELLS
US2020129603A1 • 2020-04-30 •
MEDIZINISCHE HOCHSCHULE HANNOVER [DE]
Earliest priority: 2014-04-29 • Earliest publication: 2015-11-04

A medical treatment method includes administering to a recipient a first composition comprising dendritic cells (DC) which are immunologically compatible with the recipient and which are associated with a target antigen. The method also includes administering to the recipient a second composition comprising at least a portion of the target antigen in soluble form and a co-stimulatory antibody effective for activating T-cells and/or the dendritic cells (DC), wherein the second composition is administered at least 1 day subsequent to administration of the first composition. The dendritic cells are preferably autologous dendritic cells.

108.TREATMENTS FOR ZIKA VIRUS INFECTION
WO2020092193A1 • 2020-05-07 •
SAINT LOUIS UNIV [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present disclosure is directed to methods of treating Zika virus infections using selective estrogen receptor modulators (SERMs), such as Tamoxifen, or a compound selected from CALP-l, A7, PMA, Chelerythrine, PHTPP, Tariquidar or S-Equol.

109.METHODS AND COMPOSITIONS TO INDUCE OR SUPPRESS IMMUNE RESPONSES THROUGH THE USE OF MEMBRANE BOUND COMPLEMENT SPLIT PRODUCTS
WO2020092140A2 • 2020-05-07 •
INSIDEOUTBIO INC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Methods and compositions for stimulating or inhibiting antigen-specific immune responses using surface-anchored complement split products are described herein.

110.METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
WO2020086802A1 • 2020-04-30 •
JOUNCE THERAPEUTICS INC [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The invention provides compositions and methods for the treatment of cancer and infectious diseases.

111.Dual inhibitors of TIM-3 and PD-1 pathways
AU2018360386A1 • 2020-05-07 •
AURIGENE DISCOVERY TECH LIMITED
Earliest priority: 2017-11-03 • Earliest publication: 2019-05-09

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-Ll, and/or PD- L2.

112.System and method for the production of biomolecules such as viral vaccines
AU2018348962A1 • 2020-04-30 •

UNIVERCELLS S A [BE]
Earliest priority: 2017-09-27 • Earliest publication: 2019-04-18

The current disclosure concerns a system for producing biomolecules comprising a bioreactor including a chamber (1) suitable for receiving a liquid comprising cells and viral particles; and a concentrator (2), wherein said concentrator is equipped with a retentate conduit (300, 303) suitable for collecting said retentate and facilitating recirculating of the retentate to an input of said bioreactor or to an input of an intermediate vessel (4) positioned between said concentrator and said bioreactor. In a second and third aspect the disclosure concerns a method for producing biomolecules and the use of the disclosed system for the production of biomolecules.

113.Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
AU2018373508A1 • 2020-04-30 •
OTTAWA HOSPITAL RES INSTITUTE [CA]
Earliest priority: 2017-11-24 • Earliest publication: 2019-05-31

Provided herein are fumaric and maleic acid-containing compounds, compositions comprising the same and methods for using such compounds to enhance production, growth, spread or titer of interferon-sensitive viruses in cells, particularly cancer and tumor cells. Also provided are methods of treating tumors or cancers in a subject by administering the compounds and compositions.

114.FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
US2020131265A1 • 2020-04-30 •
MACROGENICS INC [US]
Earliest priority: 2002-08-14 • Earliest publication: 2009-01-15
... also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

115.SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY
WO2020092528A1 • 2020-05-07 •
GILEAD SCIENCES INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

116.ANTI-GLUCOSAMINIDASE PASSIVE IMMUNIZATION FOR STAPHYLOCOCCUS AUREUS INFECTIONS
EP3643323A1 • 2020-04-29 •
UNIV ROCHESTER [US]

Earliest priority: 2011-11-02 • Earliest publication: 2013-05-10

The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

117.METHODS FOR CHARACTERIZING LOSS OF ANTIGEN PRESENTATION
US2020140945A1 • 2020-05-07 •
BIONTECH RNA PHARMACEUTICALS GMBH [DE]
Earliest priority: 2017-06-09 • Earliest publication: 2018-12-13

This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

118.SYSTEMS AND METHODS FOR IDENTIFYING CANCER TREATMENTS FROM NORMALIZED BIOMARKER SCORES
US2020135302A1 • 2020-04-30 •
BOSTONGENE CORP [US]
Earliest priority: 2017-06-13 • Earliest publication: 2018-12-13
...-2 therapy, an IFN alpha therapy, an anti-cancer vaccine therapy, an anti-angiogenic therapy, and an anti-CD20 therapy...

119.Viral Vector Stabilization
US2020129436A1 • 2020-04-30 •
TRIZELL LTD
Earliest priority: 2016-04-14 • Earliest publication: 2017-10-19

Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.

120.IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE
US2020138933A1 • 2020-05-07 •
WYETH HOLDINGS LLC [US]
Earliest priority: 2001-10-11 • Earliest publication: 2003-08-07

The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

121.PD-1/PD-L1 INHIBITORS
WO2020086556A1 • 2020-04-30 •
GILEAD SCIENCES INC [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed. (I)

122.MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO TARGET PROTEINS
US2020140853A1 • 2020-05-07 •
UNIV BRANDEIS [US]
Earliest priority: 2013-12-02 • Earliest publication: 2015-06-11

The invention relates to a glycopolypeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopolypeptide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopolypeptide, and pharmaceutical compositions that include the glycopolypeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopolypeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody.

123.Broadly Neutralizing Anti-Influenza Human Monoclonal Antibody and Uses Thereof
US2020140526A1 • 2020-05-07 •
UNIV ROCHESTER [US]
Earliest priority: 2017-05-15 • Earliest publication: 2018-11-22

The present invention relates to broadly neutralizing anti-influenza monoclonal antibodies or antigen-binding fragments thereof. The present invention further relates to therapeutic uses of the isolated antibody or the antigen-binding fragment thereof.

124.CAR T CELL TRANSCRIPTIONAL ATLAS
WO2020092455A2 • 2020-05-07 •
BOROUGHS ANGELA [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

The invention relates to gene expression profiles and signatures of CAR T cells. The invention provides methods and compositions of CAR T cells and populations. The invention provides assays and methods of screening subjects to assess efficacy and safety of CAR T cell treatments and therapies. The invention provides assays and methods of engineering and/or administering CAR T cells to promote efficacy and safety.

125.IMMUNITY-INDUCING AGENT
US2020138926A1 • 2020-05-07 •
TORAY INDUSTRIES [JP]

Earliest priority: 2015-04-30 • Earliest publication: 2016-11-03

This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

126.Vaccine composition comprising conjugated native N. Meningitidis capsular polysaccharides
HUE047211T2 • 2020-04-28 •
GLAXOSMITHKLINE BIOLOGICALS SA [BE]
Earliest priority: 2005-06-27 • Earliest publication: 2007-01-04
No abstract available

127.RECOMBINANT MUMPS VIRUS JERYL LYNN 2 BASED VACCINE
HUE047571T2 • 2020-04-28 •
CADILA HEALTHCARE LTD [IN]
Earliest priority: 2015-03-27 • Earliest publication: 2016-10-06
No abstract available

128.ENHANCED MONITORING METHOD IN A DRUG CONTAINERS HANDLING LINE AND DRUG CONTAINERS HANDLING LINE THEREOF
US2020130948A1 • 2020-04-30 •
NUOVA OMPI S R L [IT]
Earliest priority: 2017-06-20 • Earliest publication: 2018-12-20

A method for reconciliation in a drug filling line includes providing a batch number relating to a predetermined batch of containers to be filled with a drug. Each one of the containers is marked with a unique identifier differentiating and/or identifying each container among others. Each unique identifier is stored and associated with the batch number by a processing and control unit, before starting the filling step of each container. Filled containers are flashed by at least one identifier reader to check correspondence between the batch number being processed and each filled container, in order to validate or reject in real time each container with respect to a predetermined batch being processed by the filling line.

129.NOVEL MULTIVALENT POLYSACCHARIDE PROTEIN CONJUGATE VACCINE COMPOSITION AND FORMULATION THEREOF
EP3645045A1 • 2020-05-06 •
MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT LTD [IN]
Earliest priority: 2017-06-27 • Earliest publication: 2019-01-03
No abstract available

130.METHODS OF TREATING DISEASES USING KINASE MODULATORS

WO2020092743A2 • 2020-05-07 •
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy.

131.RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAME
WO2020091529A1 • 2020-05-07 •
SK BIOSCIENCE CO LTD [KR]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07
... protein of the present invention, and vaccine composition containing same.

132.APPARATUS AND METHOD FOR NON-INVASIVELY MEASURING PHYSIOLOGICAL PARAMETERS OF MAMMAL SUBJECT AND APPLICATIONS THEREOF
WO2020092786A1 • 2020-05-07 •
UNIV NORTHWESTERN [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Provided are apparatuses and methods for non-invasively and continuously measuring physiological parameters of a mammal subject. The apparatus includes multiple sensor systems attached to the mammal subject, and a microcontroller unit (MCU). The sensor systems are time-synchronized and communicate with each other wirelessly and bidirectionally. Each of the sensor systems includes at least one sensor configured to detect a vital sign of the mammal subject and generate a corresponding one of the physiological parameters. The MCU is in wireless communication with the plurality of sensor systems. In operation, the MCU receives, from the sensor systems, and displays the physiological parameters of the mammal subject. The apparatus and method can be used in applications such as developing therapeutics or vaccines for a disease, or diagnosing a disease.

133.Anti-LAG3 antibody and uses thereof
AU2018396877A1 • 2020-05-07 •
INNOVENT BIOLOGICS SUZHOU CO LTD
Earliest priority: 2017-12-27 • Earliest publication: 2019-07-05

(12) J fd* -9JW1NFFIL IN -E P il$ (1019)l (43) d VTWO 2019/129137 A1 2019 4 7 P 4 (04.07.2019) WIPO I PCT (51) M p']-414 : [CN/CN]; +P 3 [N T f I L N E C07K 16/28 (2006.01) C12P 21/02 (2006.01) TW168, Jiangsu 215123 (CN)o A61K39/395 (2006.01) A 61P 3100 (2006.01) A61P35/00 (2006.01) GOiN 33/68 (2006.01) (72)&flRX:t 'i-MIAO,Xiaoniu); + 41 C12N 15/13 (2006.01) IT)i H I 1 I i EX 3T 168 , Jiangsu 215123 (CN)0 1tH (HU, Huajing); + [4I (21p PCT/CN2018/124315 I)+ [[I +1 H R X 3T 168 (22) MI8i H: 2018 4 12 n 27 H (27.12.2018) Jiangsu215123 (CN)o It- $(TSUN, Andy); li T I W IT) r IT & A T R ¶ X 3T, 168 (25) $ Jiangsu215123 (CN) o 'J2lW (LIU,Junjian); (26): +l I & 3 A if IT 1 I N X 3T, H S 168

(30) vItyf Z, Jiangsu 215123 (CN)o Al0'J%**(LIU,Xiaolin); 201711449486.7 2017*12f]27H (27.12.2017) CN + 4 I)H&i)H1 kH2 X3'F 201811561512.X 2018*12A 19 H (19.12.2018) CN 168t, Jiangsu 215123 (CN)o (71) $LA : : " f $I] jR (-3, 1,1f) ;h PR 15 (INNOVENT BIOLOGICS (SUZHOU) CO., LTD.) (54) Title: ANTI-LAG-3 ANTIBODY AND USES THEREOF (54)&fl $: ri LAG-3IMt74 f)j HEK293-LAG-3 AA 15000- -4- ADI-26789 AA HEK293-LAG-3 Cell Bonding Experiment -+- ADI-26869 BB Mean Fluorescence Intensity [MFI] 1000 -- 25F7 CC Antibody Concentration (nM) 4 5000 ADI-26789 12.137 AD-26869 2.909 0.01 01 1 10 1(0 1000 CC AINVf)! ("M) (57) Abstract: The present invention relates to new-type antibodies and antibody fragments that specifically bind to LAG-3 and com positions containing the antibodies or antibody fragments. Furthermore, the present invention relates to nucleic acids encoding the antibodies or antibody fragments thereof, and host cells comprising the antibodies or antibody fragments thereof, and related uses. enlFurthermore, the present invention relates to the therapeutic and diagnostic uses of these antibodies and antibody fragments. In partic ular, the present invention relates to therapy combining these antibodies and antibody fragments with other therapeutic agents, such e as anti-PD-i or anti-PD-L I antibodies.

134.LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF
WO2020084162A1 • 2020-04-30 •
UNIV BRUSSEL VRIJE [BE]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly liver- directed gene therapy, and for vaccination purposes.

135.METHODS FOR TREATING ALZHEIMER'S DISEASE
WO2020092107A1 • 2020-05-07 •
CYCLO THERAPEUTICS INC [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

Methods for the prevention or treatment of Alzheimer's disease in a human patient are disclosed comprising administering a hydroxypropyl-beta-cyclodextrin.

136.METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY
US2020131534A1 • 2020-04-30 •
UNIV PENNSYLVANIA [US]
Earliest priority: 2001-11-13 • Earliest publication: 2003-05-13

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

137.ANTI-TREM2 ANTIBODIES AND RELATED METHODS
US2020140546A1 • 2020-05-07 •

PIONYR IMMUNOTHERAPEUTICS INC [US]
Earliest priority: 2017-12-12 • Earliest publication: 2019-06-20

Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.

138.ORALLY ADMINISTRABLE CANNABINOIDS-CONTAINING COMPOSITIONS AND METHODS
WO2020089905A1 • 2020-05-07 •
YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD [IL]
Earliest priority: 2018-11-04 • Earliest publication: 2020-05-07

Essentially water-free liquid composition for oral administration, comprising: from 25% to 75% by weight of one or more cannabinoid (s); and from 25% to 59% by weight one or more phospholipid (s); and optionally one or more antioxidants (s).

139.MICRONEEDLE, APPARATUS FOR MANUFACTURING MICRONEEDLE, AND METHOD OF MANUFACTURING MICRONEEDLE USING APPARATUS
US2020129745A1 • 2020-04-30 •
UNIV GACHON IND ACAD COOP FOUND [KR]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

Disclosed are a microneedle, an apparatus for manufacturing a microneedle including a support part containing a medicinal solution for coating a microneedle, a controller for controlling the temperature of the medicinal solution contained in the support part, and a dryer for drying the medicinal solution coated on the microneedle, and a method of manufacturing the microneedle using the apparatus. According to the configuration, the temperature of the medicinal solution can be adjusted such that a viscosity suitable for coating with the medicinal solution is maintained, whereby the quality of a microneedle coated with the medicinal solution can be improved, and denaturation of active ingredients in the medicinal solution can be prevented, which causes stability increase.

140.NOVEL PEPTIDE BINDING SPECIFICALLY TO HUMAN SERUM ALBUMIN, AND USES THEREOF
WO2020085766A1 • 2020-04-30 •
KOREA ADVANCED INST SCI & TECH [KR]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The present invention relates to a novel peptide binding specifically to human serum albumin, more specifically to a peptide binding specifically to human serum albumin, polynucleotides coding for the polypeptide, an expression vector comprising the polynucleotides, a transgenic organism into which the expression vector has been introduced, and a method for producing the polypeptide by means of the transgenic organism. The novel peptide according to the present invention binds specifically to human serum albumin and increases the in-blood circulation time and half-life of low molecular weight protein or

peptide to increase the bioavailability thereof, and thus can be broadly applied as a new system that increases the effectiveness of drug treatment.

141.METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION
US2020140529A1 • 2020-05-07 •
REEF PHARMACEUTICALS PTY LTD [AU]
Earliest priority: 2010-04-09 • Earliest publication: 2018-05-17

The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.

142.Human Monoclonal Antibodies to Human Endogenous Retrovirus K Envelope (HERV-K) and Use Thereof
US2020140527A1 • 2020-05-07 •
UNIV ROCHESTER [US]
Earliest priority: 2016-08-31 • Earliest publication: 2018-03-08

The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

143.COMPOSITIONS FOR TRANSFECTING mRNA INTO A CELL AND THEIR APPLICATIONS
WO2020089342A1 • 2020-05-07 •
POLYPLUS TRANSFECTION [FR]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-06

The present invention relates to compositions for transfecting a messenger RNA (m RNA) into a cell and their applications. The present invention is directed to a composition for transfecting a mRNA into a cell comprising a mRNA, at least one neutral lipid and a cationic lipid of formula (I), wherein R1 R2, R3, R4 and R5, (CH2)n and A- are as defined in the description. The present invention also relates to uses of said composition and to a method for in vitro transfection of live cells.

144.HETERODIMERIC FC-FUSED PROTEINS
WO2020086758A1 • 2020-04-30 •
DRAGONFLY THERAPEUTICS INC [US]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-30

The present invention provides Fc-fused protein constructs, which as monovalent dimers have a higher serum half-life compared to a native/natural molecule, and are, therefore, advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are Fc-fused protein constructs having mutations in the Fc region that reduce effector functions, which have increased activity to inhibit tumor growth and are, therefore, advantageous when used as a cancer therapy.

145.Periodic Countercurrent Chromatography Separation of Plasmids
US2020141912A1 • 2020-05-07 •
GE HEALTHCARE BIOPROCESS R&D AB [SE]
Earliest priority: 2017-06-26 • Earliest publication: 2019-01-03

A method of continuous separation of a plasmid from a process feed in an apparatus with at least three chromatography columns packed with separation matrix particles, wherein while one chromatography column is loaded with the process feed, another chromatography column is eluted with an eluent to recover the separated plasmid, and yet another chromatography column is eluted with a further eluent to remove contaminants.

146.ANTI-HUMAN INTERLEUKIN-2 ANTIBODIES AND USES THEREOF
US2020140538A1 • 2020-05-07 •
INST BASIC SCIENCE [KR]
Earliest priority: 2017-05-25 • Earliest publication: 2018-11-29

Provided is an antibody that binds to human interleukin-2 (hIL-2), and more particularly to an anti-hIL-2 antibody that binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25.

The anti-hIL-2 antibody of the subject matter binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25, thereby minimizing expansion of Treg cells. In addition, it stimulates the CD8+ T cells and NK cells that exhibit anti-tumor activity. Thus, the anti-hIL-2 antibody of the present invention is useful as a new anticancer therapeutic agent.

147.PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS
US2020137992A1 • 2020-05-07 •
UNIV MISSOURI [US]
Earliest priority: 2011-05-16 • Earliest publication: 2012-11-22

The present invention generally relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.

148.SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS
WO2020092621A1 • 2020-05-07 •
GILEAD SCIENCES INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the

treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

149.ENGINEERED FC
WO2020084104A1 • 2020-04-30 •
CLEGG RICHARD IAN [GB]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

Antigen-binding molecules comprising an Fc region comprising a polypeptide having: (i) C at the position corresponding to position 242, and C at the position corresponding to position 334, and (ii) one or more of: A at the position corresponding to position 236, D at the position corresponding to position 239, E at the position corresponding to position 332, L at the position corresponding to position 330, K at the position corresponding to position 345, and G at the position corresponding to position 430 are disclosed. Also discloses are constituent polypeptides of such Fc regions, nucleic acids encoding such antigen- binding molecules and polypeptides, compositions comprising such antigen-binding molecules, polypeptides and nucleic acids, and methods using the same.

150.DIFFERENTIATION OF LYME DISEASE AND SOUTHERN TICK-ASSOCIATED RASH ILLNESS
US2020140915A1 • 2020-05-07 •
THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC [US]
Earliest priority: 2017-06-08 • Earliest publication: 2018-12-13

The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.

151.An attenuated infectious bronchitis virus and a vaccine composition for infectious bronchitis including the same
KR20200043742A • 2020-04-28 •
No applicant available
Earliest priority: 2018-10-18 • Earliest publication: 2020-04-28

152.SYK 억제제의 다형체
KR20200044068A • 2020-04-28 •
No applicant available
Earliest priority: 2017-08-25 • Earliest publication: 2019-02-28

153.RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
HUE047102T2 • 2020-04-28 •
BAVARIAN NORDIC AS [DK]
Earliest priority: 2012-08-01 • Earliest publication: 2019-05-09
No abstract available

154.PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION
US2020129426A1 • 2020-04-30 •
MEDILABO RFP INC [JP]
Earliest priority: 2017-07-06 • Earliest publication: 2019-01-10

The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect.

155.DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
US2020129519A1 • 2020-04-30 •
GENENTECH INC [US]
Earliest priority: 2016-06-08 • Earliest publication: 2017-12-14

The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SIV1ARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).

156.COMPOSITIONS AND METHODS RELATED TO ENGINEERED ERYTHROID CELLS COMPRISING IL-15
US2020129556A1 • 2020-04-30 •
RUBIUS THERAPEUTICS INC [US]
Earliest priority: 2016-01-11 • Earliest publication: 2017-07-20

The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.

157.ALUMINIUM PHOSPHATE NANO ADJUVANT WITH CONTROLLABLE ISOELECTRIC POINT AND PREPARATION METHOD THEREFOR
WO2020088494A1 • 2020-05-07 •
UNIV DALIAN TECH [CN]
Earliest priority: 2018-11-01 • Earliest publication: 2019-03-08
Disclosed are an aluminium phosphate nano adjuvant for a vaccine based on a chemical precipitation principle, a preparation method therefor...

Select result

158.GITRL FUSION PROTEINS AND USES THEREOF
US2020140510A1 • 2020-05-07 •
MEDIMMUNE LTD [GB]
Earliest priority: 2015-08-12 • Earliest publication: 2017-02-16

The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

159.STRAIN OF SINDBIS FEVER VIRUS 1383 CLONE 3
RU2720518C1 • 2020-04-30 •
FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ ISSLEDOVATELSKIJ TSENTR EPIDEMIOLOG [RU]
Earliest priority: 2018-12-18 • Earliest publication: 2020-04-30
... Sindbis fever virus 1383 clone 3 is a convenient biotechnological model for obtaining diagnostic and vaccine preparations, as well as...

160.STRENGTHENED GLASS ARTICLES WITH REDUCED DELAYED BREAKAGE AND METHODS OF MAKING THE SAME
WO2020092036A1 • 2020-05-07 •
CORNING INC [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

A method of strengthening glass articles includes introducing potassium ions to a surface region of the glass by an initial ion-exchange process, thermally treating the glass at a thermal treatment temperature and time sufficient to diffuse the potassium ions further into the glass to a depth of layer, and introducing a compressive stress of greater than 400 MPa at the surface through a final ion-exchange process. The final ion-exchange process may be conducted at a final ion-exchange temperature of no more than 450 °C. The method of strengthening produces a glass article having a compressive stress of at least 400 MPa at the surface, a depth of compression of at least 30 μm, and a central tension less than a threshold central tension above which flaws penetrating into the central region of the glass exhibit spontaneous self-propagation of the flaw front through and across the glass.

161.UNMANNED AERIAL VEHICLE MANAGEMENT SYSTEM
US2020143693A1 • 2020-05-07 •
ZIPLINE INT INC [US]
Earliest priority: 2015-01-22 • Earliest publication: 2016-09-01

An Unmanned Aerial System configured to receive a request from a user and fulfill that request using an Unmanned Aerial Vehicle. The Unmanned Aerial System selects a distribution center that is within range of the user, and deploys a suitable Unmanned Aerial Vehicle to fulfill the request from that distribution center. The Unmanned Aerial System is configured to provide real-time information about the flight route to the Unmanned Aerial Vehicle during its flight, and the Unmanned Aerial Vehicle is configured to dynamically update its mission based on information received from the Unmanned Aerial System.

162.ALOOH NANO-ADJUVANT HAVING REGULATED LENGTH-TO-DIAMETER RATIO AND PREPARATION METHOD THEREFOR
WO2020088495A1 • 2020-05-07 •
UNIV DALIAN TECH [CN]
Earliest priority: 2018-11-01 • Earliest publication: 2019-03-08
... uniformity of the particle size, good stability, and good application prospects in the field of biological medicines such as a vaccine adjuvant.

163.SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PREGNANCY
US2020141935A1 • 2020-05-07 •
BARCELONA INST FOR GLOBAL HEALTH [ES]
Earliest priority: 2017-06-23 • Earliest publication: 2018-12-27

The present invention, in at least some embodiments, is of a system, method, apparatus and diagnostic test for monitoring infections by Plasmodium falciparum that is specific for pregnant women. The monitoring is performed by examining samples from the pregnant women, typically blood samples, for the presence of antibodies to a known P. falciparum protein, VAR2CSA. Preferably, the antibodies bind specifically to p5 and/or p8.

164.VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS
US2020140964A1 • 2020-05-07 •
UNIV ERASMUS MED CT ROTTERDAM [NL]
Earliest priority: 2001-01-19 • Earliest publication: 2002-07-25

The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.

165.METHOD OF MANUFACTURING RECOMBINANT LECTIN PROTEIN AND RECOMBINANT LECTIN PROTEIN MANUFACTURED BY USING THE SAME
US2020140499A1 • 2020-05-07 •
NAT MARINE BIODIVERSITY INSTITUTE OF KOREA [KR]
Earliest priority: 2017-12-28 • Earliest publication: 2019-07-04

Provided is a recombinant BPL3 protein having β-GlcNAc-Sp and a glycan binding specificity, the recombinant BPL3 protein produced by synthesizing a recombinant BPL3 (rBPL3) gene encoding a Bryopsis plumosa lectin (BPL3) protein; preparing a tandem repeat rBPL3 gene including a repeating structure of the rBPL3 gene by tandemly binding the rBPL3 genes through spacers; preparing a recombinant plasmid by inserting the tandem repeat rBPL3 gene into an expression vector; and transforming an expression host by the recombinant plasmid. According to the method, the expression efficiency of the recombinant lectin is maximized and the activity of the manufactured recombinant lectin is enhanced.

166.BIO-ROBOTIC DEVICE FOR LURING AND KILLING HEMATOPHAGOUS ARTHROPODS
WO2020084590A1 • 2020-04-30 •

HUMAN CENTERED AND BIO INSPIRED IDEAS FOR DAILY LIFE S R L IN SIGLA HUBILIFE S R L [IT]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present invention concerns a device for luring and killing hematophagous arthropods in its inside, in an effective and selective way, without emitting to the outside harmful substances to human health and the environment, comprising multi-sensory lures for the aforesaid arthropods that guide them inside the device where 5 there is an eradication means for the target arthropod.

167.Novel fusion molecules and uses thereof
AU2020202555A1 • 2020-05-07 •
FOUNDATION MEDICINE INC [US]
Earliest priority: 2012-11-05 • Earliest publication: 2014-05-08

Novel fusion molecules and uses are disclosed.

168.HIGH-COVERAGE AND ULTRA-ACCURATE IMMUNE REPERTOIRE SEQUENCING USING MOLECULAR IDENTIFIERS
US2020131564A1 • 2020-04-30 •
UNIV TEXAS [US]
Earliest priority: 2017-07-07 • Earliest publication: 2019-01-10

The present disclosure provides methods for the amplification and sequencing of the immune repertoire using barcoded oligonucleotides with molecular identifiers (MIDs). Further provided are methods for clustering-based data analysis of the sequencing reads to determine the immune repertoire.

169.IRON GLYCINE SULFATE COMPOSITIONS AND USES THEREOF
US2020129544A1 • 2020-04-30 •
ROZEGEN LLC [US]
Earliest priority: 2017-06-30 • Earliest publication: 2019-01-03

Compositions containing iron, glycine, and sulfate are provided.

170.ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
US2020140824A1 • 2020-05-07 •
CALIDI BIOTHERAPEUTICS INC [US]
Earliest priority: 2018-11-06 • Earliest publication: 2020-05-07

Provided herein are enhanced systems for potentiating cell-mediated oncolytic viral therapy. Also provided are modified viruses for such systems, and methods of treatment of cancers by administering such systems.

171.SYSTEM AND METHOD FOR HUMAN OPERATOR INTERVENTION IN AUTONOMOUS VEHICLE OPERATIONS
US2020133260A1 • 2020-04-30 •
ZIPLINE INT INC [US]

Earliest priority: 2015-04-14 • Earliest publication: 2016-11-08

An autonomous vehicle system is configured to receive vehicle commands from one or more parties and to execute those vehicle commands in a way that prevents the execution of stale commands. The autonomous vehicle system includes a finite state machine and a command counter or stored vehicle timestamp, which are used to help reject invalid or stale vehicle commands.

172.PHARMACEUTICALLY ACCEPTABLE SALTS OF BETA-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US2020138759A1 • 2020-05-07 •
RGENIX INC [US]
Earliest priority: 2015-08-25 • Earliest publication: 2017-03-02

The present invention relates to new pharmaceutical salts of β-GPA which exhibit improved physical properties. In particular, the invention relates to salts of β-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of β-GPA, as well as methods of treating cancer including administration of a formulation including a β-GPA salt of the invention to a subject in need thereof.

173.METHOD OF GENERATING NATURAL KILLER CELLS AND DENDRITIC CELLS FROM HUMAN EMBRYONIC STEM CELL-DERIVED HEMANGIOBLASTS
US2020131475A1 • 2020-04-30 •
ASTELLAS INST FOR REGENERATIVE MEDICINE [US]
Earliest priority: 2009-12-04 • Earliest publication: 2011-06-09

This invention provides methods of generating natural killer (NK) cells and dendritic cells (DCs). The methods utilize human hemangioblasts as intermediate cells to generate the NK cells and DCs. In various embodiments, the methods do not require the use of stromal feeder layers.

174.HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US2020140864A1 • 2020-05-07 •
ALNYLAM PHARMACEUTICALS INC [US]
Earliest priority: 2014-11-10 • Earliest publication: 2016-05-19

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.

175.SELF REPLICATING RNA SYSTEM
WO2020092387A1 • 2020-05-07 •
NANTBIO INC [US]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-07

Compositions, methods and uses of self-replicating RNA molecules that include a recombinant nucleic acid encoding a protein of interest such as a chimeric antigenic receptor or an antibody are presented. The self-replicating RNA molecule are introduced into an immune competent cell such that the chimeric antigenic receptor or the antibody are efficiently expressed in the immune competent cell while increasing the stability of the recombinant nucleic acid in the cell and reducing the potential integration of the recombinant nucleic acid into the genome of the immune competent cell.

176.CELL TRANSFER AGENT
US2020140892A1 • 2020-05-07 •
AKAIKE TOSHIHIRO [JP]
Earliest priority: 2017-05-29 • Earliest publication: 2018-12-06

The present invention is a cell transfer agent comprising a composite particle coated by a sugar chain polymer wherein the composite particle consisting of an apatite comprising phosphate, carbonic acid, and calcium.

177.DOSAGE FORM FOR TREATING INFLUENZA AND ACUTE VIRAL RESPIRATORY TRACT INFECTIONS
WO2020085952A1 • 2020-04-30 •
LTD “VALENTA INTELLEKT” [RU]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-23

The invention relates to the chemical and pharmaceutical industry and to medicine, and concerns a novel liquid dosage form for oral administration for the treatment and prophylaxis of influenza and acute viral respiratory tract infections, said dosage form comprising 2-(imidazol-4-yl)-ethanamide pentanedioic-1,5 acid in an effective amount, and excipients.

178.NON-FACTOID QUESTION-ANSWERING DEVICE
US2020134263A1 • 2020-04-30 •
NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECH [JP]
Earliest priority: 2017-07-13 • Earliest publication: 2019-01-17

A question answering device includes: a general word vector converter converting a question and an answer to semantic vectors in accordance with general context; a general sentence level CNN 214, in response to similarities of semantic vectors between words in question and answer and to strength of causality between the words, for weighting each semantic vector to calculate sentence level representations of the question and the answer; a general passage level CNN 218, in response to similarity between sentence level representations of question and answer, and to strength of relation of vectors in the sentence level representations viewed from causality, for weighting the sentence level representation to calculate a passage level representation for the question and answer passage; and a classifier determining whether or not an answer is a correct answer, based on the similarities between outputs from CNNs 214 and 218.

179.PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
WO2020086327A1 • 2020-04-30 •

LILLY CO ELI [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.

180.VIRUS DE LA VACCINE MUTANTS ET LEUR UTILISATION
WO2020086423A1 • 2020-04-30 •
ICELL KEALEX THERAPEUTICS [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30
...La présente invention concerne des virions de virus de la vaccine (VV) recombinants qui sont résistants aux défenses antivirales et...'un polypeptide bloquant la voie PD-1. Les virions de virus de la vaccine recombinants peuvent être utilisés pour traiter le cancer chez un sujet. ...

181.COMPOSITIONS COMPRISING BACTERIAL STRAINS
US2020129567A1 • 2020-04-30 •
4D PHARMA PLC [GB]
Earliest priority: 2016-12-12 • Earliest publication: 2018-06-21

Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.

182.Endosialin (CD248) as epigenetic marker for the identification of immune cells, in particular naïve CD8+ T-cells
AU2018356473A1 • 2020-05-07 •
EPIONTIS GMBH
Earliest priority: 2017-10-26 • Earliest publication: 2019-05-02

The present invention relates to a method, in particular an

183.METHODS FOR EFFECTIVELY AND RAPIDLY DESENSITIZING ALLERGIC PATIENTS
US2020129616A1 • 2020-04-30 •
PEROSPHERE TECH INC [US]
Earliest priority: 2011-08-31 • Earliest publication: 2013-03-07

Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or microparticles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.

184.DRUG DELIVERY DEVICE WITH AN IMPROVED PISTON ROD
EP3643347A1 • 2020-04-29 •
SANOFI AVENTIS DEUTSCHLAND [DE]
Earliest priority: 2009-03-30 • Earliest publication: 2010-10-07

An improved drug delivery device is provided having a piston rod that incorporates on its proximal end at least one guidepost that is configured for transmitting axial and rotational forces from a drive mechanism. The device comprises a drug delivery device housing and a medicament contained in the drug delivery device housing.

185.USE OF ERIBULIN AND CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
US2020129473A1 • 2020-04-30 •
EISAI R&D MAN CO LTD [JP]
Earliest priority: 2017-07-21 • Earliest publication: 2019-01-24

The invention features methods for treating and preventing cancer (e.g., an estrogen receptor-positive (ER+) breast cancer) in a patient in need thereof by administering eribulin (e.g., eribulin mesylate) in combination with a cyclin dependent kinase (CDK) inhibitor.

186.METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
US2020131276A1 • 2020-04-30 •
GENENTECH INC [US]
Earliest priority: 2013-12-17 • Earliest publication: 2015-06-25

The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

187.METHOD
WO2020089621A1 • 2020-05-07 •
UNIV OXFORD INNOVATION LTD [GB]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Provided herein is a method of functionalizing a particle, as well as methods of optically tracking a particle, isolating enveloped viral particles from a sample, quantifying enveloped virus particles in a sample and assessing enveloped viral aggregation in a sample. Kits are also provided. The particle is typically a viral particle.

188.NEW TOOLS FOR IMPROVING GENE THERAPY AND USE THEREOF
WO2020084161A1 • 2020-04-30 •
UNIV BRUSSEL VRIJE [BE]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present invention relates to a nucleic acid molecule encoding human albumin for increasing the levels and/or activity of a protein or polypeptide encoded by a transgene, comprising a sequence defined by SEQ ID NO: 14 or a sequence having at least 80% sequence identity to said sequence, its use in nucleic acid expression cassettes and vectors containing liver-specific regulatory elements and codon- optimized factor IX, factor VIII, factor VII or factor VIIa transgenes, methods employing these expression cassettes and vectors and uses thereof. The present invention is particularly useful for applications using liver-directed gene therapy, in particular for the treatment of hemophilia A, hemophilia B or factor VII deficiency.

189.INHIBITORS OF CXCR2
US2020140418A1 • 2020-05-07 •
CHEMOCENTRYX INC [US]
Earliest priority: 2015-11-19 • Earliest publication: 2017-05-25

Compounds are provided as inhibitors of CXCR2, having the structure:

190.CO-ADMINISTRATION OF A HYALURONIDASE AND ANTI-C5 ANTIBODY FOR TREATMENT OF COMPLEMENT-ASSOCIATED CONDITIONS
WO2020092546A1 • 2020-05-07 •
ALEXION PHARMA INC [US]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-07

Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).

191.TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
WO2020093051A1 • 2020-05-07 •
FIGENE LLC [US]
Earliest priority: 2018-11-04 • Earliest publication: 2020-05-07

Disclosed are methods, compositions of matter, and means of treatment or prophylaxis using fibroblasts possessing regenerative properties for the treatment of brain injuries including stroke, transient ischemic injuries, chronic traumatic encephalopathy, traumatic brain injury, and tauopathies. Embodiments of the disclosure administer fibroblasts with regenerative properties either systemically, locally, or a combination of the two prior to, concurrent with, or subsequent to a brain injury. In some embodiments of the disclosure fibroblasts or products thereof, are administered intranasally, intrathecally, and/or intravenously.

192.Macromolecular platform for targeting scavenger receptor A1
AU2018350825A1 • 2020-05-07 •
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
Earliest priority: 2017-10-16 • Earliest publication: 2019-04-25

The present invention is directed to a polymer platform comprising poly(L-lysine succinylated) which specifically targets scavenger receptor A1. This platform may be used to conjugate different types of drugs

to the polymer for treatment of specific diseases or conditions in a patient. The resulting conjugates display moderate stability or controlled drug release of about 3-80 hours in plasma, and allow delivery and release of drugs and other therapeutic moieties to tissues/cells that express scavenger receptor A1 in a controlled manner.

193.IGG4 FC Fragment Comprising Modified Hinge Region
AU2020202581A1 • 2020-05-07 •
HANMI PHARM CO LTD
Earliest priority: 2013-05-31 • Earliest publication: 2014-12-04

The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

194.Stx2eA-C- -Stx2eB- Vaccine composition for preventing or treating porcine edema disease comprising Stx2eA-C-terminal fragment-Stx2eB5 recombinant protein as an antigen
KR102105021B1 • 2020-04-27 •
No applicant available
Earliest priority: 2018-11-30 • Earliest publication: 2020-04-27

195.Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2018357917A1 • 2020-05-07 •
BAXALTA GMBH
Earliest priority: 2017-10-30 • Earliest publication: 2019-05-09

The present invention relates to methods for inactivating a lipid-enveloped virus using environmentally compatible detergents, and to methods for preparing a biopharmaceutical drug using environmentally compatible detergents. The invention also provides environmentally compatible detergents.

196.Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
AU2018345751A1 • 2020-05-07 •
HUMANIGEN INC
Earliest priority: 2017-10-02 • Earliest publication: 2019-04-11

Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.

197.METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
US2020138756A1 • 2020-05-07 •
UNIV BATH [GB]
Earliest priority: 2017-07-14 • Earliest publication: 2019-01-17

Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.

198.MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO CARBOHYDRATE-BINDING MONOCLONAL ANTIBODY FAMILY PGT128
WO2020086885A2 • 2020-04-30 •
UNIV BRANDEIS [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The invention relates to a glycopeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopeptide binds specifically to a carbohydrate-binding monoclonal antibody from PGT128 family, preferably with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopeptide, and pharmaceutical compositions that include the glycopeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral infection, treating a cancerous condition, and detecting a neutralizing antibody.

199.ANTI-OX40 ANTIBODY AND USE THEREOF
US2020140562A1 • 2020-05-07 •
INNOVENT BIOLOGICS SUZHOU CO LTD [CN]
Earliest priority: 2017-03-25 • Earliest publication: 2018-10-04

The present invention relates to a novel antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.

200.CONTAINER PRECURSOR HAVING A WALL OF GLASS WHICH IS SUPERIMPOSED BY A PLURALITY OF PARTICLES
EP3647287A1 • 2020-05-06 •
SCHOTT AG [DE]
Earliest priority: 2018-10-30 • Earliest publication: 2020-04-30

The invention refers to a container precursor (100), comprising a wall of glass (101) which at least partially encloses an interior volume (102) of the container precursor (100); wherein, on a side of the wall of glass (101) which faces away from the interior volume (102), the wall of glass (101) is at least partially

superimposed by a plurality of particles (1201). Further, the invention refers to an arrangement (200), comprising a packaging and a multitude of the container precursors (100); to a process (400) for preparing a functionalised container precursor; to a functionalised container precursor, obtainable by that process (400); to a container (500); to a process (600) for preparing a functionalised container; to a functionalised container, obtainable by that process (600); to a closed container (700); to a process (800) for packaging a pharmaceutical composition (701); to a closed container obtainable by this process (800); and to uses of a container precursor (100) for making a packaging container, of a container (500) for packaging a pharmaceutical composition (701), and of a plurality of particles (1201).

201.Novel Combinations for Antigen Based Therapy
US2020138920A1 • 2020-05-07 •
DIAMYD MEDICAL AB [SE]
Earliest priority: 2014-06-04 • Earliest publication: 2020-05-07

Provided herein, among other things, is a method for prevention and/or treatment of an autoimmune disease. In some embodiments, the method may comprise administering to a subject a composition, said composition comprising at least one β cell autoantigen, by intralymphatic injection or injection directly into a lymph node.

202.METHODS FOR GENERATING THERAPEUTIC DELIVERY PLATFORMS
WO2020086471A1 • 2020-04-30 •
KANSAS STATE UNIV RESEARCH FOUNDATION [US]
Earliest priority: 2018-10-21 • Earliest publication: 2020-04-30

Methods for producing engineered exosomes and other vesicle-like biological targets in a microfluidic device, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

203.COMBINATION THERAPY USING ANTI-SSEA-4 ANTIBODY IN COMBINATION WITH THERAPEUTIC ONCOLOGY AGENTS
US2020138967A1 • 2020-05-07 •
OBI PHARMA INC [TW]
Earliest priority: 2018-10-02 • Earliest publication: 2020-04-09

The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.

204.COMPOSITIONS COMPRISING BACTERIAL STRAINS

US2020138874A1 • 2020-05-07 •
4D PHARMA RES LTD [GB]
Earliest priority: 2015-06-15 • Earliest publication: 2016-12-22

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

NY-ESO-1 T CELL RECEPTORS AND METHODS OF USE THEREOF
WO2020086647A1 • 2020-04-30 •
REGENERON PHARMA [US]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-30

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an H LA-displayed New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) peptides, as well as therapeutic and diagnostic methods of using those isolated TCRs.

206.NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE
WO2020083855A1 • 2020-04-30 •
HOFFMANN LA ROCHE [CH]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The present application provides compounds having the general formula: formula (I), wherein R1, R 2, A, X and m are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of cccDNA for treating Hepatitis B Virus (HBV) infections.

207.RECOMBINATION ACTIVATING GENE (RAG) INDUCED V(D)J GENE TARGETING
US2020131540A1 • 2020-04-30 •
RAMOF AT TEL AVIV UNIV LTD [IL]
Earliest priority: 2017-04-20 • Earliest publication: 2018-10-25

The present invention relates to methods for targeted insertion of at least one nucleic acid sequence/s of interest into a target genomic locus of a mammalian cell. More specifically, the methods of the invention are based on using nucleic acid cassettes comprising the nucleic acid sequence/s of interest and at least one recognition signal sequence (RSS), for insertion of the nucleic acid sequence of interest into the target genomic locus that is mediated by RAG-catalyzed recombination. The invention further provides cassettes, vectors and vehicles and cells comprising said cassettes, compositions and uses thereof in immunotherapy.

208.DASATINIB AND ANOTHER 5-THIAZOLECARBOXAMIDE KINASE INHIBITOR, AND USES THEREOF
WO2020083909A1 • 2020-04-30 •
IOMX THERAPEUTICS AG [DE]
Earliest priority: 2018-04-20 • Earliest publication: 2019-10-24

The invention relates to a kinase inhibitor, in particular an inhibitor of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitor of the invention displays, eg functional and ADMET properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise the kinase inhibitor, including those formulated for oral administration, such as in unit dose form that comprise particular ranges or amounts of the kinase inhibitor. The kinase inhibitor or pharmaceutical composition may be used in the treatment of a proliferative disorder, such as a leukaemia or solid tumour. The kinase inhibitor or pharmaceutical composition may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

209.ILDR2 antagonists and combinations thereof
AU2018376231A1 • 2020-05-07 •
BAYER AG
Earliest priority: 2017-11-30 • Earliest publication: 2019-06-06

The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

210.POLYPEPTIDE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, KIT FOR IMMUNOLOGICAL SCREENING FOR HCV AND/OR FOR DIAGNOSING HEPATITIS C, COMPOSITION, USE OF AT LEAST ONE POLYPEPTIDE AND METHODS FOR PRODUCING A POLYPEPTIDE, FOR IMMUNOLOGICAL SCREENING FOR HCV AND FOR DIAGNOSING HEPATITIS C
WO2020082145A1 • 2020-04-30 •
FUND OSWALDO CRUZ [BR]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present invention relates to polypeptides that have immunogenic activity, which can be used alone or together, having high discriminatory capacity for screening the hepatitis C virus (HCV). The polypeptides according to the invention comprise at least two antigenic HCV regions selected from the nucleocapsid region and nonstructural regions NS3, NS4 and NS5. The invention also relates to the nucleic acid, expression cassette, expression vector, host cell, method for producing the polypeptides, composition, use of the polypeptides, kit for immunological screening for HCV and/or for diagnosing hepatitis C, and also to the methods for immunological screening for HCV and for diagnosing hepatitis C.

211.GRAFT COPOLYMERS, METHODS OF FORMING GRAFT COPOLYMERS, AND METHODS OF USE THEREOF
WO2020092633A1 • 2020-05-07 •
UNIV VANDERBILT [US]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-07

A graft copolymer and a method of delivering an active agent to a subject are provided. The graft copolymer includes a polymer backbone, a hydrophilic segment grafted to the polymer backbone, a pH-responsive segment grafted to the polymer backbone, and an endosomal disruption segment grafted to the polymer backbone. The method of delivering an active agent to a subject includes encapsulating the active agent with the graft copolymer and administering the encapsulated active agent to the subject.

212.RECOMBINANT MODIFIED MICROORGANISMS DISPLAYING MEMBRANE FUNCTIONALIZATION FOR VARIOUS BIOTECHNOLOGICAL APPLICATIONS
EP3647425A1 • 2020-05-06 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-06

The invention relates to a recombinant modified Gammaproteobacteriaceae that displays, on its cell surface, a modified Curli system comprising i) a CsgA protein or a CsgA homologous protein associated to the surface of said Gammaproteobacteriaceae, and ii) a scaffoldin comprising at least one cellulosomal component, said scaffolding being fused to the C-terminus of the CsgA protein. The invention also concerns uses of the recombinant modified Gammaproteobacteriaceae in biotechnological applications.

213.MEDICAMENT DELIVERY DEVICE HAVING AN ACTIVATING MECHANISM
US2020129697A1 • 2020-04-30 •
SANOFI SA [FR]
Earliest priority: 2014-05-12 • Earliest publication: 2015-11-18

The disclosure relates to medicament delivery device including an activating mechanism, wherein the activating mechanism includes a hollow injection needle, a cartridge containing a dosage of a medicament, a cartridge carrier including at least one resilient arm for holding the cartridge, a removable needle cap for covering the injection needle, and a drive element adapted to couple with the cartridge, wherein the cartridge is retained in a position spaced apart from the injection needle in a proximal direction (P) by the at least one resilient arm when the medicament delivery device is in an initial position (P1), and wherein by removing the needle cap, the cartridge is releasable to be pushed into a distal direction (D) by the drive element with respect to the cartridge carrier.

214.METHOD OF TREATING LUNG CANCER USING PARABACTEROIDES GOLDSTEINII
US2020129568A1 • 2020-04-30 •
MULTISTARS BIOTECHNOLOGY COMPANY LTD [TW]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

The present disclosure provides a use of Parabacteroides goldsteinii for treating lung cancer.

215.ACTIVATING MECHANISM FOR A MEDICAMENT DELIVERY DEVICE AND MEDICAMENT DELIVERY DEVICE
US2020129699A1 • 2020-04-30 •
SANOFI SA [FR]
Earliest priority: 2014-06-05 • Earliest publication: 2015-12-10

The disclosure relates to an activating mechanism for a medicament delivery device, comprising an outer body, a cartridge containing a dosage of a medicament and sealed with a sealing element that is arranged across an open distal end of the cartridge, a cartridge carrier adapted to hold the cartridge, a needle safety mechanism adapted to hold a double-ended hollow needle and to relatively move along a longitudinal axis with respect to the cartridge and to the outer body to cover or to expose the needle, wherein in an initial position of the medicament delivery device, the double-ended hollow needle is spaced from the cartridge in a distal direction, and wherein when the needle safety mechanism is pressed into the outer body, a proximal end of the needle pierces the sealing element. The disclosure further relates to a medicament delivery device comprising such an activating mechanism.

216.ANTI-CD27 ANTIBODIES
US2020131272A1 • 2020-04-30 •
MERCK SHARP & DOHME [US]
Earliest priority: 2016-09-26 • Earliest publication: 2018-03-29

The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

217.Cell compositions comprising antigen-specific T cells for adoptive therapy
AU2018337960A1 • 2020-04-30 •
NEXIMMUNE INC [US]
Earliest priority: 2017-09-20 • Earliest publication: 2019-03-28

The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.

218.NEEDLELESS SYRINGE, METHOD FOR ADJUSTING FINALLY REACHED DEPTH OF NEEDLELESS SYRINGE, AND EJECTION PARAMETER CALCULATION PROGRAM FOR NEEDLELESS SYRINGE
EP3646908A1 • 2020-05-06 •
DAICEL CORP [JP]
Earliest priority: 2017-06-27 • Earliest publication: 2019-01-03

A needleless injector pressurizes a substance to be injected having an ejection pressure defined as a pressure of the substance to be injected ejected through an ejection port. The ejection pressure is raised to a first peak pressure after pressurizing is started, is lowered to a pressure lower than the first peak pressure afterward, and then is raised to a second peak pressure again. An on-completion reached depth that is an on-completion reached depth of the substance to be injected in a target region when the pressurizing portion completes pressurizing is adjustable, the on-completion reached depth being increased along with increase of the first peak pressure and being increased along with reduction of a length between peaks from a first timing at

which the ejection pressure reaches the first peak pressure to a second timing at which the ejection pressure reaches the second peak pressure. With the configuration described above, the reached depth of the ejected substance to be injected in the target region can be adjusted accurately.

219.Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation
AU2018363682A1 • 2020-05-07 •
INTERVET INT BV
Earliest priority: 2017-11-07 • Earliest publication: 2019-05-16

An injectable pharmaceutical composition comprising an isoxazoline compound of Formula (I) or a salt or N-oxide thereof wherein the isoxazoline compound has a particle size of from about 25 microns to about 250 microns and a method of preventing or treating a parasite infestation using the same.

220.IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF
US2020131251A1 • 2020-04-30 •
SERUM INSTITUTE OF INDIA PRIVATE LTD [IN]
Earliest priority: 2016-12-23 • Earliest publication: 2018-06-28

The invention describes an efficient platform for antibody manufacturing and formulation that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include IgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and IgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.

221.Novel NTRK1 fusion molecules and uses thereof
AU2020202544A1 • 2020-05-07 •
FOUNDATION MEDICINE INC [US]
Earliest priority: 2012-11-05 • Earliest publication: 2014-05-08

Novel NTRKI fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

222.POLYMER-LIPIDS AND COMPOSITIONS
WO2020086965A1 • 2020-04-30 •
MASSACHUSETTS INST TECHNOLOGY [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.

223.IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis
US2020131576A1 • 2020-04-30 •
BRIGHAM & WOMENS HOSPITAL INC [US]
Earliest priority: 2017-04-25 • Earliest publication: 2018-11-01

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

224.MATERIALS AND METHODS FOR TREATING CANCER
WO2020092850A1 • 2020-05-07 •
HUMANIGEN INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF

225.COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES
WO2020086158A2 • 2020-04-30 •
CALIFORNIA INST OF TECHN [US]
Earliest priority: 2018-09-05 • Earliest publication: 2020-04-30

Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

226.COMBINATION OF A KINASE INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT, COMPOSITIONS AND METHODS COMPRISING THE SAME
WO2020084347A2 • 2020-04-30 •
AUCKLAND UNISERVICES [NZ]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

Disclosed herein are combinations comprising a tyrosine kinase inhibitor (TKI) and an immunotherapeutic agent, formulations, and methods of treating cancer comprising the same.

227.ANTI-IL1RAP ANTIBODIES AND ANTIBODY DRUG CONJUGATES
US2020140561A1 • 2020-05-07 •
BLUEFIN BIOMEDICINE INC [US]
Earliest priority: 2017-06-12 • Earliest publication: 2018-12-20

Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

228.Vista antigen-binding molecules
US10633456B1 • 2020-04-28 •
HUMMINGBIRD BIOSCIENCE HOLDINGS PTE LTD [SG]
Earliest priority: 2018-09-07 • Earliest publication: 2020-04-28

VISTA antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the VISTA antigen-binding molecules.

229.RNA POLYMERASE VARIANTS
US2020131550A1 • 2020-04-30 •
MODERNATX INC [US]
Earliest priority: 2017-08-18 • Earliest publication: 2019-02-21

The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.

230.SELF-RIGHTING SYSTEMS AND RELATED COMPONENTS AND METHODS
US2020129441A1 • 2020-04-30 •
BRIGHAM & WOMENS HOSPITAL INC [US]
Earliest priority: 2017-05-17 • Earliest publication: 2018-11-22

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage with a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components.

231.SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2020092549A1 • 2020-05-07 •
ALEXION PHARMA INC [US]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-07

Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).

232.SYSTEM AND METHODS FOR MASSIVELY PARALLEL ANALYSIS OF NUCLEIC ACIDS IN SINGLE CELLS
US2020140947A1 • 2020-05-07 •
GIGAGEN INC [US]
Earliest priority: 2010-12-16 • Earliest publication: 2012-06-21

Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences.

233.Combination therapies for treating cancer
AU2018338901A1 • 2020-05-07 •
TESARO INC
Earliest priority: 2017-09-30 • Earliest publication: 2019-04-04

The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death- 1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.

234.MARKER FOR DETECTING HIGHLY PATHOGENIC INFLUENZA VIRUS AND USE THEREOF
US2020132688A1 • 2020-04-30 •
DANDI BIOSCIENCE INC [KR]
Earliest priority: 2016-11-29 • Earliest publication: 2018-06-01

Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

235.DRUG DELIVERY DEVICE FOR DELIVERY OF A MEDICAMENT
US2020129704A1 • 2020-04-30 •
SANOFI AVENTIS DEUTSCHLAND [DE]

Earliest priority: 2009-04-30 • Earliest publication: 2010-11-04

Various embodiments of drug delivery devices and methods of assembling such devices are provided. In one embodiment, a drug delivery device for dispensing medicament comprises a medicament cartridge, wherein the cartridge comprises (i) a distal end, (ii) a proximal end that is opposite the distal end along a body axis of the cartridge, and (iii) a movable piston arranged substantially at the proximate end of the cartridge. The drug delivery device further comprises a piston rod having a distal end for axially moving the piston in the distal direction during dispensing of a set dose of medicament, wherein a relative axial distance between the distal end of the piston rod and a proximal face of the piston is set during assembly of the drug delivery system. The relative axial position between may be set such that the piston rod and the proximal face of the piston abut each other.

236.COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS
WO2020087170A1 • 2020-05-07 •
REPARE THERAPEUTICS INC [CA]
Earliest priority: 2018-10-30 • Earliest publication: 2020-05-07

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

237.CONTINUOUS LIQUID INTERPHASE PRINTING
US2020139617A1 • 2020-05-07 •
CARBON INC [US]
Earliest priority: 2013-02-12 • Earliest publication: 2014-08-21

A method of forming a three-dimensional object, comprises providing a carrier and an optically transparent member having a build surface, the carrier and the build surface defining a build region therebetween; filling the build region with a polymerizable liquid; irradiating the build region through the optically transparent member to form a solid polymer from the polymerizable liquid while concurrently advancing the carrier away from the build surface to form the three-dimensional object from the solid polymer, while also concurrently: (i) continuously maintaining a dead zone of polymerizable liquid in contact with the build surface, and (ii) continuously maintaining a gradient of polymerization zone between the dead zone and the solid polymer and in contact with each thereof, the gradient of polymerization zone comprising the polymerizable liquid in partially cured form. Apparatus for carrying out the method is also described.

238.Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
US2020140555A1 • 2020-05-07 •
YEDA RES & DEV [IL]
Earliest priority: 2014-03-12 • Earliest publication: 2018-01-11

The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

239.Animal feed composition
AU2018344097B1 • 2020-04-30 •
PROAGNI PTY LTD [AU]
Earliest priority: 2018-12-14 • Earliest publication: 2020-04-30

The present disclosure relates to compositions, concentrates, supplements and animal feeds for feeding to ruminant animals. The present disclosure further relates to methods of improving feed conversion, resource utilisation, water utilisation in livestock, as well as methods of reducing livestock emissions and reducing antibiotic use in livestock feed, methods of inducing satiety in livestock and methods of preventing lactic acidosis in ruminant animals.

240.PHARMACEUTICAL COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF PANCREATIC CANCER
WO2020089850A1 • 2020-05-07 •
CENTRO DE INVESTIGACION Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITECNICO NAC [MX]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

The present invention describes pharmaceutical compositions comprising compounds that have the formula and formula (compounds D14 and C22 respectively) that specifically inhibit the KRas4B- PDE6δ interaction, making them useful for the effective treatment of pancreatic cancer. The compounds of the invention stabilized the protein-protein interaction in the KRas4B-PDE6δ complex showing antineoplastic activity against pancreatic cancer cells, reduced the viability in the human pancreatic cancer cells but not in the normal pancreatic cells and induced cellular death via apoptosis.

241.PROCEDURE FOR THE GLOBAL UNIFIED REGISTRATION AND UNIVERSAL IDENTIFICATION OF PRODUCTS OF BIOLOGICAL ORIGIN FOR MEDICINAL PURPOSES
WO2020084173A1 • 2020-04-30 •
CONECTATE SOLUCIONES Y APLICACIONES SL [ES]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

A procedure for the global unified registration and universal identification of products of biological origin for medicinal purposes, comprising: - Generation of a global and unique data container in the system for each product and related parts, one or more containers for local data associated with the global container, one or more data profiles associated with the containers, a unique and non-transferable public and private identifier associated with the global container, one or more alphanumeric/hexadecimal translation maps associated with the public identifier and the private identifier, and a public unique and non-transferable identification code, and the storage of said data in a database than can be accessed by different parties depending on the access permissions for said data. - Identification of the data container and type of data

stored by way of a unique and non-transferable identification code and automatic updating of the information in the containers and profiles stored in the database that can be accessed by different parties.

242.LIPONUCLEOTIDE-BASED THERAPY FOR ASTHMA
US2020129624A1 • 2020-04-30 •
OHIO STATE INNOVATION FOUNDATION [US]
Earliest priority: 2017-06-27 • Earliest publication: 2019-01-03

Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating asthma.

243.INTRATUMORAL ALPHA-EMITTER RADIATION AND ACTIVATION OF CYTOPLASMATIC SENSORS FOR INTRACELLULAR PATHOGEN
WO2020089819A1 • 2020-05-07 •
ALPHA TAU MEDICAL LTD [IL]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

A method of treating a patient with a tumor, and kits (200) for such treatment. The method includes administering, to the patient, a substance (204) which activates cytoplasmatic sensors for intracellular pathogen in the tumor and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor.

244.Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
US2020138942A1 • 2020-05-07 •
PROVECTUS PHARMATECH INC [US]
Earliest priority: 2011-03-10 • Earliest publication: 2012-09-13

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

245.METHOD FOR PREDICTING EFFECT OF TUMOR IMMUNOTHERAPY USING TUMOR CYTOTOXIC ACTIVITY OF PERIPHERAL BLOOD T CELLS AS INDEX
EP3647433A1 • 2020-05-06 •
UNIV OSAKA [JP]
Earliest priority: 2017-06-30 • Earliest publication: 2019-01-03

An object of the present invention is to provide a companion diagnostic for predicting the effect of a tumor immunotherapy. The effect of a tumor immunotherapy is predicted by a method including step 1: contacting directly or indirectly peripheral blood mononuclear cells collected from a patient who is a target for treatment of a malignant tumor with tumor cells in vitro; step 2: determining whether the tumor cells that contacted with the peripheral blood mononuclear cells in step 1 are damaged; and step 3: determining that the tumor immunotherapy is effective against the malignant tumor in the patient when the tumor cells are determined to have been damaged in step 2.

246.CELL MEDIATED IMMUNE RESPONSE ASSAY
US2020141927A1 • 2020-05-07 •
CELLESTIS LTD [AU]
Earliest priority: 2012-12-28 • Earliest publication: 2014-07-03

This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.

247.A PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR TYPE 1 DIABETES DIAGNOSIS
US2020132698A1 • 2020-04-30 •
UNIV JOHNS HOPKINS [US]
Earliest priority: 2017-07-12 • Earliest publication: 2019-01-17

Methods of detecting ZNT8 antibodies in serum are described. The methods include proteoliposomes comprising a transmembrane domain (TMD) and a cytosolic domain (CTD) of ZnT8 proteins exposed on the exterior of the proteoliposome; serum comprising antibodies targeting the ZnT8 proteins; and labelled captured autoantibodies that bind to ZnT8 antibodies.

248.CHIMERIC ANTIGEN RECEPTOR (CAR) COMPRISING A CD19-BINDING DOMAIN
US2020140544A1 • 2020-05-07 •
UCL BUSINESS PLC [GB]
Earliest priority: 2015-03-05 • Earliest publication: 2016-09-09

There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

249.COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY
US2020138864A1 • 2020-05-07 •
CARSGEN THERAPEUTICS CO LTD [CN]
Earliest priority: 2017-05-31 • Earliest publication: 2018-12-06

Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

250.LIPONUCLEOTIDE-BASED THERAPY FOR COPD
US2020129623A1 • 2020-04-30 •
OHIO STATE INNOVATION FOUNDATION [US]
Earliest priority: 2017-06-27 • Earliest publication: 2019-01-03

Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.

251.Controlling Access To A Medical Monitoring System
US2020138289A1 • 2020-05-07 •
BRAEMAR MFG LLC [US]
Earliest priority: 2001-04-23 • Earliest publication: 2005-06-02

Systems and techniques for remote medical monitoring. In one implementation, a method includes monitoring a first medical condition of an individual, the monitoring being initiated remotely by a monitoring service, receiving a query relating to a second medical condition of the individual, transmitting a response to the query to the monitoring service, receiving a prompt from the monitoring service, and transmitting a response to the prompt to the monitoring service. The query is received from the monitoring service. The prompt is designed to provoke a particular action.

252.PHARMACEUTICAL COMPOSITION FOR VIRAL INFECTIONS
US2020138749A1 • 2020-05-07 •
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US]
Earliest priority: 2018-02-23 • Earliest publication: 2019-08-29

Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.

253.PREPARING GENETICALLY MODIFIED CELLS USING A DEVICE THAT IS CONFIGURED FOR STERILE PROCESSING OF CELLS AT THE BEDSIDE OR IN A SURGICAL ROOM
US2020141942A1 • 2020-05-07 •
MILTENYI BIOTEC GMBH 022370 [DE]
Earliest priority: 2007-12-07 • Earliest publication: 2009-06-11

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

254.TREATMENT METHODS
WO2020092379A1 • 2020-05-07 •
GENOCEA BIOSCIENCES INC [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

Methods and compositions for identifying tumor antigens of human lymphocytes, and for identifying subjects for cancer therapy, are provided herein.

255.HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF
WO2020083926A1 • 2020-04-30 •
IOMX THERAPEUTICS AG [DE]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-29

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

256.LIPID NANOPARTICLE FORMULATION
US2020129445A1 • 2020-04-30 •
MODERNATX INC [US]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

257.Monoclonal Antibodies to Programmed Death 1 (PD-1)
US2020138945A1 • 2020-05-07 •
ONO PHARMACEUTICAL CO [JP]
Earliest priority: 2005-05-09 • Earliest publication: 2006-11-16

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

258.ANTI-CTLA4 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF
WO2020092155A1 • 2020-05-07 •
BIOATLA LLC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.

259.COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER
US2020140859A1 • 2020-05-07 •
BETH ISRAEL DEACONESS MEDICAL CT INC [US]
Earliest priority: 2016-12-22 • Earliest publication: 2018-07-12

Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.

260.PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF
US2020131233A1 • 2020-04-30 •
UNIV OXFORD INNOVATION LTD [GB]
Earliest priority: 2017-04-24 • Earliest publication: 2018-11-01

The present invention relates to a two-part linker comprising a peptide tag (peptide) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly wherein: a) said peptide

comprises an amino acid sequence as set forth in SEQ ID NO: 1, wherein: (i) X at position 1 is arginine or no amino acid; (ii) X at position 2 is glycine or no amino acid; (iii) X at position 5 is histidine or threonine; (iv) X at position 11 is alanine, glycine or valine; and (v) X at position 14 is arginine or lysine, wherein when X at position 1 is no amino acid, X at position 2 is no amino acid; and b) said polypeptide comprises: i) an amino acid sequence as set forth in SEQ ID NO: 2; ii) a portion of (i) comprising an amino acid sequence as set forth in SEQ ID NO: 101; iii) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 2, wherein said amino acid sequence comprises a lysine at position 34, a glutamic acid at position 80 and one or more of the following: 1) threonine at position 5; 2) proline at position 16; 3) arginine at position 40; 4) histidine at position 65; 5) proline at position 92; 6) aspartic acid at position 100: 7) glutamic acid at position 108; and 8) threonine at position 116, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 2; or iv) a portion of (iii) comprising an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 101, wherein the amino acid sequence comprises a lysine at position 10, a glutamic acid at position 56 and one or more of the following: 1) arginine at position 16; 2) histidine at position 41; 3) proline at position 68; and 4) aspartic acid at position 76, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 101, and wherein said peptide and polypeptide are capable of spontaneously forming an isopeptide bond between the aspartic acid residue at position 10 of SEQ ID NO: 1 and the lysine residue at position 34 of SEQ ID NO: 2 or position 10 of SEQ ID NO: 101.

261.스피로티에탄 뉴클레오시드

KR20200044084A • 2020-04-28 •
No applicant available
Earliest priority: 2017-09-01 • Earliest publication: 2019-03-07

262.METHODS TO DIAGNOSE AND TREAT CANCER USING NON-HUMAN NUCLEIC ACIDS
WO2020093040A1 • 2020-05-07 •
UNIV CALIFORNIA [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Methods for diagnosing cancer, its subtypes, molecular features, and likelihood of response to therapy, as well as other diseases, based on microbial presence or abundance in tissues, including blood-derived tissues, of the host subject. Methods of treatment of the identified cancer in subjects are also provided.

263.TARGETING CLPTM1L FOR TREATMENT AND PREVENTION OF CANCER
WO2020086328A1 • 2020-04-30 •
THE MEDICAL COLLEGE OF WISCONSIN INC [US]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

Provided herein are therapeutic agents having specificity for human CLPTM1L/CRR9 polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function). In particular, provided herein are fully human monoclonal antibodies against human CLPTM1L/CRR9 protein and methods of using such antibodies for

treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function).

264.Peptide vaccines and pembrolizumab for treating breast cancer
AU2018353984A1 • 2020-05-07 •
ONCOPEP INC
Earliest priority: 2017-10-24 • Earliest publication: 2019-05-02

The disclosure features,

265.ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
WO2020086555A1 • 2020-04-30 •
UNIV NEBRASKA [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present invention provides prodrugs and methods of use thereof.

266.Zinc ionophores and uses thereof
AU2018348796A1 • 2020-05-07 •
THE UNIV OF ADELAIDE
Earliest priority: 2017-10-13 • Earliest publication: 2019-04-18

This invention relates to the use of zinc(II) salts in combination with a zinc ionophore to resensitize a previously resistant pathogenic bacteria to an antibiotic. Methods of restoring the sensitivity of a resistant pathogenic bacterium to an antibiotic comprising administering a zinc ionophore in combination with a zinc(II) salt and methods of treating a bacterial infection comprising administering a zinc ionophore in combination with a zinc (II) salt concurrently and/or sequentially with administration of a therapeutically effective amount of an antibiotic is also described.

267.NUCLEIC ACID COMPOSITIONS, METHODS AND KITS FOR RAPID PAIRING OF AFFINITY AGENTS
US2020140573A1 • 2020-05-07 •
TEXAS BIOMEDICAL RES INSTITUTE [US]
Earliest priority: 2011-08-03 • Earliest publication: 2013-02-07

Methods for identifying a polypeptide of interest with desired properties, like specific binding affinity to a molecule of interest or greater stability or improved solubility, from vast numbers of variants. The polypeptides of interest can be antibodies that are selected from an antibody library.

268.Anti-TREM1 Antibodies and Methods of Use Thereof
US2020131264A1 • 2020-04-30 •
ALECTOR LLC [US]
Earliest priority: 2016-03-04 • Earliest publication: 2017-09-08

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

269.Methods and compositions for topical delivery
AU2018347514A1 • 2020-05-07 •
ILLUSTRIS PHARMACEUTICALS INC
Earliest priority: 2017-10-11 • Earliest publication: 2019-04-11

Compositions for topical delivery of an active agent and methods for using such compositions are described herein. Compositions include one or more active agents and about 0.001 wt. % to about 10 wt. % of a extracellular matrix component having average molecular weight of about 2,000 daltons to about 20,000 daltons. The extracellular components include hyaluronic acid, collagen, fibronectin, elastin, lectin, and fragments thereof and combinations thereof.

270.PURIFIED POLLEN PARTICLES AND USE THEREOF FOR ADMINISTERING NANOSYSTEMS
US2020129575A1 • 2020-04-30 •
UNIV SANTIAGO COMPOSTELA [ES]
Earliest priority: 2017-02-09 • Earliest publication: 2018-08-16

The present invention relates to a purified pollen particle that retains its intine and of exine layer and comprises nanosystems, to compositions including same, and to uses thereof.

271.GLYCOTARGETING THERAPEUTICS
US2020129625A1 • 2020-04-30 •
ECOLE POLYTECHNIQUE FED LAUSANNE EPFL [CH]
Earliest priority: 2014-02-21 • Earliest publication: 2018-09-27

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

272.MIT BIOMARKERS AND METHODS USING THE SAME
US2020138944A1 • 2020-05-07 •
GENENTECH INC [US]
Earliest priority: 2014-05-23 • Earliest publication: 2015-11-26

Provided are therapies related to the treatment of pathological conditions, such as cancer.

273.APPARATUS FOR GUM INJECTION DURING MEDICAL PROCEDURE INJECTIONS
WO2020093027A1 • 2020-05-07 •
GULESSERIAN ARA [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

A gum numbing system includes a wristband configured to be attached to a user' wrist; an electronics housing; two or more finger coverings; two or more gum stimulation assemblies, the two or more gum stimulation assemblies detachably connected to the two or more finger coverings and the two or more gum stimulation assemblies to stimulate a patient's gum before a needle is inserted into the patient's gum; and two or more cables or wires, the two or more cables or wires connecting the electronics housing to the two or more gum stimulation assemblies. The electronics housing is integrated into the wristband or the top surface of the wristband.

274.METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
US2020138908A1 • 2020-05-07 •
UNIV CENTRAL FLORIDA RES FOUND INC [US]
Earliest priority: 2012-06-28 • Earliest publication: 2014-01-03

The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.

275.ICOS BINDING PROTEINS
US2020140551A1 • 2020-05-07 •
GLAXOSMITHKLINE IP DEV LTD [GB]
Earliest priority: 2015-01-28 • Earliest publication: 2016-07-28

The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

276.Cloud-Controlled Manufacturing Execution System (CLO-cMES) for use in pharmaceutical manufacturing process control, methods, and systems thereof
US2020133224A1 • 2020-04-30 •
SMP LOGIC SYSTEMS LLC [US]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

“Cloud” based manufacturing execution systems (“MES”) and methods thereof used to control, execute, and monitor pharmaceutical or biopharmaceutical production processes and systems are disclosed herein. Consequently, the methods and systems provide a means to quality manufacturing on an integrated level whereby drug or biologic manufacturers can achieve data and product integrity and ultimately minimize cost.

277.METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE
WO2020089273A1 • 2020-05-07 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present invention relates to the treatment of T- helper type 2 (Th2)-mediated disease. Here, the inventors set out to investigate at the genome level the effects of SETDB1-dependent H3K9me3 deposition on CD4 T cell activation, differentiation and commitment. By using conditional Setdb1-/- mice, they show that SETDB1 restricts Th1 cell priming and ensures Th2 cell integrity. Unlike their wild-type counterparts, SETDB1-deficient Th2 cells readily express the entire Th1 gene network when exposed to the Th1-instructing cytokine IL-12. More, SETDB1 methylates H3K9 at a subset of ERVs that flank and repress Th1 enhancers or behave themselves as cis-regulatory elements of a large network of Th1 genes, including Ifng, Stat4, Runx3 and Tbx21. Therefore, H3K9me3 deposition by SETDB1 locks the Th1 gene expression program and thus ensures T cell lineage integrity by repressing a repertoire of ERVs that have been co-opted to behave as Th1 lineage-specific cis-regulatory modules. Thus, the invention relates to a SETDB1 inhibitor for use in a method for increasing the Th1/Th2 ratio of an immune response in a subject in need thereof.

278.Methods For Predicting Risk Of Metastasis In Cutaneous Melanoma
AU2020202536A1 • 2020-05-07 •
CASTLE BIOSCIENCES INC
Earliest priority: 2013-03-14 • Earliest publication: 2014-09-18

The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.

279.SEX-LINKED RNAI INSECTICIDE MATERIALS AND METHODS
WO2020087053A1 • 2020-04-30 •
UNIV INDIANA RES & TECH CORP [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The present disclosure provides insecticides that can specifically target mosquitoes based on their sex. These sex-specific insecticides prevent maturation or development of larvae into adult insects using

interfering RNA (iRNA). The present disclosure further provides compositions comprising sex-linked iRNA and methods of controlling, reducing, or treating an insect infestation with the iRNA or compositions described herein. The compositions and methods described herein can be used to sort mosquitoes based on sex.

280.Drug delivery devices and methods for use with a urinary catheter
AU2018364626A1 • 2020-05-07 •
TARIS BIOMEDICAL LLC
Earliest priority: 2017-11-09 • Earliest publication: 2019-05-16

Drug delivery devices (200) and methods of their use are provided. In one embodiment, a drug delivery device (200) for use with a urinary catheter (100) includes a drug reservoir configured to be disposed outside of a patient's body, and a flexible elongate body (220) attached to the drug reservoir (230) and configured to traverse the patient's urethra to reach the bladder. The drug reservoir (230) includes a drug chamber (234) containing a drug therein, a fluid chamber (236) containing a fluid therein, and an osmotic barrier (238) separating the drug chamber (234) and the fluid chamber (236). The body includes a drug delivery lumen (222) extending therethrough and in fluid communication with the drug chamber (234).

281.SYSTEMS METHODS AND COMPUTATIONAL DEVICES FOR AUTOMATED CONTROL OF INDUSTRIAL PRODUCTION PROCESSES
WO2020089922A1 • 2020-05-07 •
AZMON ERAN [IL]
Earliest priority: 2018-11-04 • Earliest publication: 2020-05-07

A method of automated control of an industrial reactor-based production process comprises the steps of: a) collecting data associated with performance of a production process of a reactor; b) defining a set of monitored parameters and a set of controlled parameters in the production process; c) defining a model comprising a set of equations mimicking a dynamic behavior of the process of a reactor, wherein in the model, changes in the monitored parameters are linked to changes in the controlled parameters; and d) creating a trained agent obtained by iterative machine learning training code and using the model, wherein the trained agent capable of making decisions regarding controlled parameters to be applied to the reactor based on monitored parameters of the production process.

282.Engineering Virus-like Nanocarriers for Biomolecule Delivery
US2020140493A1 • 2020-05-07 •
UNIV UTAH RES FOUND [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-05-07

Disclosed herein are modified capsid proteins comprising a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the capsid forming protein. Disclosed are capsids comprising a plurality of modified capsid proteins. Disclosed are multimeric assemblies comprising a plurality of capsids within a membrane. Also disclosed are modified non-enveloped viruses comprising a capsid wherein the capsid comprises a plurality of modified capsid proteins, wherein the plurality of modified capsid proteins comprise a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein

at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the modified capsid protein, wherein the capsid forming protein is a capsid forming protein of a non-enveloped virus.

283.COMBINATION THERAPY METHOD OF TREATING MYELOPROLIFERATIVE NEOPLASMS WITH A DIPHTHERIA TOXIN-HUMAN INTERLEUKIN-3 CONJUGATE IN COMBINATION WITH OTHER AGENTS
WO2020092505A1 • 2020-05-07 •
STEMLINE THERAPEUTICS INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present invention provides methods for treating or inhibiting a myeloproliferative neoplasm (MPN) in a subject in need thereof, comprising administering to the subject a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) and one or more Jak inhibitors and/or one or more hypomethylating agents.

284.NON-NATURAL NKG2D RECEPTORS THAT DO NOT DIRECTLY SIGNAL THE CELLS TO WHICH THEY ARE ATTACHED
US2020138866A1 • 2020-05-07 •
XYPHOS BIOSCIENCES INC [US]
Earliest priority: 2018-11-05 • Earliest publication: 2020-05-07

The present disclosure relates to non-natural NKG2D receptors attached to mammalian cell surfaces wherein the non-natural receptors do not directly signal or directly activate the cell when the receptor is bound by cognate non-natural α1-α2 domains of NKG2D ligands modified to specifically bind the non-natural NKG2D receptors. The non-natural α1-α2 domains of NKG2D ligands may be attached to heterologous atoms or molecules including polypeptides, in some embodiments cytokines or modified cytokines, antibodies or fragments of antibodies.

285.ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS
US2020129552A1 • 2020-04-30 •
NANTKWEST INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

286.NOVEL RATIONALLY DESIGNED PROTEIN COMPOSITIONS
WO2020088459A1 • 2020-05-07 •
1GLOBE BIOMEDICAL CO LTD [CN]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-

tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating T reg are provided. The fusion protein can be used to prevent or therapeutically treat cancer.

287.METHODS FOR SEPARATING LARGE NUCLEIC ACIDS UNDER DENATURED CONDITIONS
WO2020086366A1 • 2020-04-30 •
KLEIN LEE [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present disclosure provides methods for separating nucleic acids in a sample based on the length of the nucleic acids using a capillary electrophoresis device with formamide as a denaturing agent and a non-aqueous separation matrix comprising a formamide-soluble polymer. Such methods can also be used to determine the length and/or purity of the nucleic acid in the sample using the methods described herein. Also provided is a non-aqueous separation matrix for capillary electrophoresis of denatured nucleic acids. In one aspect, the separation matrix comprises a formamide-soluble polymer dissolved in a non-aqueous buffer.

288.CUP FOR IMMUNOASSAY, METHOD FOR PRODUCING SAME, AND IMMUNOASSAY METHOD
WO2020085104A1 • 2020-04-30 •
TOPPAN PRINTING CO LTD [JP]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

This cup for a fluorescence immunoassay is for using beads serving as fluorescent labels to analyze an immune system that uses an antigen-antibody reaction. The cup for a fluorescence immunoassay comprises a bottom surface part and a side surface part connected to the bottom surface part. The bottom surface part has a plurality of hole-shaped parts that are each for accommodating a single bead. The upper surface of the area between the hole-shaped parts is a flat surface.

289.COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES
US2020138796A1 • 2020-05-07 •
TEXAS A & M UNIV SYS [US]
Earliest priority: 2015-08-26 • Earliest publication: 2017-03-02

Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.

290.MULTI-COMPONENT VECTOR SYSTEMS, METHODS OF MAKING, AND USES THEREOF
WO2020091958A1 • 2020-05-07 •
ONCONETICS PHARMACEUTICALS INC [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

Provided herein are vectors, vector systems, compositions and methods for treating cancer. In an exemplary embodiment, the present disclosure provides a vector system comprising a transgene, the expression of which is regulated by an inducible promoter and a microRNA binding domain (MBD). In some embodiments, the inducible promoter is activated using a tetracycline-on/tetracycline-off expression system. The presence of the MBD in the vector system facilitates the expression in a specific cell type. Also provided is a vector for the expression of an antigen or an immunogenic epitope of an antigen, wherein the vector comprises a MBD that facilitates the expression of the antigen or the immunogenic epitope specifically in cancer cells. The present disclosure also provides compositions comprising the vector system, compositions comprising the vector, and methods of using the vector systems and the vectors for treating cancer.

291.SUBSTITUTED INDOLE MCL-1 INHIBITORS
US2020140447A1 • 2020-05-07 •
UNIV VANDERBILT [US]
Earliest priority: 2014-03-27 • Earliest publication: 2015-10-01

The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

292.ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY
US2020140465A1 • 2020-05-07 •
US HEALTH [US]
Earliest priority: 2014-04-01 • Earliest publication: 2015-10-08

The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.

293.GLYCOTARGETING THERAPEUTICS
US2020129629A1 • 2020-04-30 •
ECOLE POLYTECHNIQUE FED LAUSANNE EPFL [CH]
Earliest priority: 2014-02-21 • Earliest publication: 2017-01-12

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

294.AUTOMATED BIOLOGICAL SAMPLE COLLECTION SYSTEM AND METHODS
US2020140804A1 • 2020-05-07 •
INNOVO MIMETICS LTD [IL]
Earliest priority: 2010-02-01 • Earliest publication: 2016-09-08

An egg sealing unit for an automated biological sample collection system and method of use. The egg sealing unit seals the section of egg from which the shell has been removed. The egg sealing unit includes a sampler, an applicator and an imaging adaptor providing an optical conduit between the surface of an egg and the CAM. The applicator is configured to deliver exogenous material to the CAM, the sampler is configured to collect samples from the CAM and the imaging adaptor allows the CAM to be monitored.

295.TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS
WO2020092523A1 • 2020-05-07 •
ACCELERON PHARMA INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Provided herein are methods for treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts by subcutaneous administration of an ActRIIA or ActRIIB ligand trap.

296.INJECTOR
EP3646909A1 • 2020-05-06 •
DAICEL CORP [JP]
Earliest priority: 2017-06-27 • Earliest publication: 2019-01-03

An injector according to the present invention includes an encapsulating portion configured to encapsulate a substance intended for injection, a first application portion configured to combust ignition charge and discharge a combustion product thereby applying a primary ejection energy to the substance intended for injection that is encapsulated in the encapsulating portion, an energy accumulation portion configured to accumulate an energy to be further applied to the substance intended for injection, the energy being different from the primary ejection energy applied by the first application portion, and a second application portion configured to release the energy accumulated in the energy accumulation portion by using the discharged combustion product thereby applying, as a secondary ejection energy, the released energy to the substance intended for injection. With this configuration, the substance intended for injection can be caused to suitably reach the target region without affecting the substance intended for injection to be ejected.

297.DETECTION METHOD FOR NATURAL AND MODIFIED SMALL NUCLEIC ACIDS
WO2020086970A1 • 2020-04-30 •
ZATA PHARMACEUTICALS INC [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

The invention relates to a method for the detection of natural or modified nucleic acids by their sequence specific hybridization with charge-modified oligonucleotide probes having charge-modifying groups attached to their backbones. The charge-modifying groups partially or fully neutralize the net negative charge of the backbone of the oligonucleotide probes or render them with a net positive charge. The charge-modified oligonucleotide probes may or may not be labeled, for example, with fluorescent, visible or near-infrared dye, with radioactive or stable isotopes, or with high specific affinity binding groups. The charge-modified oligonucleotide probes facilitate the separation of their hybrids with the targeted nucleic acids

from the unhybridized probes or from any other components of the analyzed sample. They also allow for the modification and optimization of the properties of the hybrids with the targeted nucleic acids, such as melting temperature, chromatographic properties and off-target specificity.

298.TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS
US2020138722A1 • 2020-05-07 •
THERABIOME LLC [US]
Earliest priority: 2013-03-14 • Earliest publication: 2014-09-25

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.

299.MODIFIED CTLA4 AND METHODS OF USE THEREOF
WO2020088645A1 • 2020-05-07 •
BEIJING VDJBIO CO LTD [CN]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

In some aspects, provided are polypeptides with high binding affinities for ligands, as well as compositions comprising the same, and methods of using the same. In some embodiments, provided are polypeptides having high binding affinity for CD80, CD86, or both.

300.SYSTEMS AND METHODS FOR PARTICLE FOCUSING IN MICROCHANNELS
US2020139372A1 • 2020-05-07 •
MASSACHUSETTS GEN HOSPITAL [US]
Earliest priority: 2007-04-16 • Earliest publication: 2008-10-30

Various systems, methods, and devices are provided for focusing particles suspended within a moving fluid into one or more localized stream lines. The system can include a substrate and at least one channel provided on the substrate having an inlet and an outlet. The system can further include a fluid moving along the channel in a laminar flow having suspended particles and a pumping element driving the laminar flow of the fluid. The fluid, the channel, and the pumping element can be configured to cause inertial forces to act on the particles and to focus the particles into one or more stream lines.

301.MULTIPLEXED DETERMINISTIC ASSEMBLY OF DNA LIBRARIES
US2020131508A1 • 2020-04-30 •
ZYMERGEN INC [US]

Earliest priority: 2018-10-31 • Earliest publication: 2020-04-30

The present disclosure relates to methods of joining three or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro or in vivo. The method allows the joining of a large number of DNA fragments, in a deterministic fashion. It can be used to rapidly generate nucleic acid libraries that can be subsequently used in a variety of applications that include, for example, genome editing and pathway assembly. Kits for performing the method are also disclosed.

302.Methods of administering chimeric antigen receptor immunotherapy
AU2018351046A1 • 2020-04-30 •
KITE PHARMA INC [US]
Earliest priority: 2017-10-18 • Earliest publication: 2019-04-25

The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

303.DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION
EP3643355A1 • 2020-04-29 •
POP TEST ABUSE DETERRENT TECH LLC [US]
Earliest priority: 2014-06-03 • Earliest publication: 2015-12-03

This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

304.Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
AU2018357221A1 • 2020-04-30 •
PFIZER [US]
Earliest priority: 2017-10-27 • Earliest publication: 2019-05-02

The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).

305.BICYCLIC PEPTIDE LIGANDS AND USES THEREOF
WO2020084305A1 • 2020-04-30 •
BICYCLETX LTD [GB]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-30

The present invention provides cyclic and bicyclic peptide ligands compositions thereof, and methods of using the same.

306.SMALL MOLECULE MODULATORS OF HUMAN STING
US2020138827A1 • 2020-05-07 •
CURADEV PHARMA LTD [GB]
Earliest priority: 2017-06-22 • Earliest publication: 2018-12-27

The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.

307.COMPOSITIONS AND METHODS COMPRISING LYSOCINS AS BIOENGINEERED ANTIMICROBIALS FOR USE IN TARGETING GRAM-NEGATIVE BACTERIA
WO2020093057A1 • 2020-05-07 •
CONTRAFECT CORP [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Provided are polypeptides and compositions comprising the polypeptides for use in killing and/or inhibiting growth of Gram-negative bacteria, particularly P. aeruginosa. The polypeptides are contiguous polypeptides (lysocins) that contain an engineered bacteriocin segment that can be translocated through an outer membrane channel of the Gram-negative bacteria, such as Domain I of the S-type poycin from P. aeruginosa bacterocin pyocin S2 (PyS2) linked to a lysin catalytic segment that has peptidoglycan (PG) hydrolase activity. The lysin catalytic segment can be a catalytic segment of GN4 lysin or any other lysin catalytic segment or a hydrolytic enzyme thereof that has PG hydrolase activity.

308.COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS
US2020138777A1 • 2020-05-07 •
ULTUPHARMA AB [SE]
Earliest priority: 2015-12-02 • Earliest publication: 2017-06-03

wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula I in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.

309.ST-246 LIQUID FORMULATIONS AND METHODS
US2020138974A1 • 2020-05-07 •
SIGA TECH INC [US]
Earliest priority: 2010-08-05 • Earliest publication: 2012-02-09

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

310.USE OF LONG NON-CODING RNA FOR THE DIAGNOSIS OF PROSTATE CANCER

WO2020084035A1 • 2020-04-30 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

The present invention provides long noncoding RNAs (lncRNAs) that allow to diagnose prostate cancer much more accurately than the existent non-invasive diagnostic tools. So, this invention relates to the use of at least one of these lncRNA or a combination thereof as a diagnosis marker for prostate cancer. It also relates to an in vitro method for prostate cancer diagnosis of a subject as well as to a kit for performing this method.

311.SHIP INHIBITION TO INDUCE EXPRESSION OF GRANULOCYTE COLONY STIMULATING FACTOR IN A SUBJECT
US2020129523A1 • 2020-04-30 •
UNIV NEW YORK STATE RES FOUND [US]
Earliest priority: 2014-06-17 • Earliest publication: 2015-12-23

The present invention relates to the use SHIP inhibitors to induce expression of granulocyte colony stimulating factor (G-CSF) in a subject, thereby promoting expansion of hematopoietic and mesenchymal stem cells. The present invention generally relates to new uses of SHIP inhibitors for therapeutic purposes. More particularly, the present invention relates to the use of SHIP inhibitors, including, without limitation, SHIP and/or pan-SHIP1/2 inhibitors, for the inhibition of SHIP to induce expression of granulocyte colony stimulating factor (G-CSF) to treat various-diseases or conditions.

312.LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS
AU2020202407A1 • 2020-05-07 •
EAGLE BIOLOGICS INC
Earliest priority: 2013-09-11 • Earliest publication: 2015-03-12

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics. WO 2015/038818 PCT/US2014/055254 Viscositiesof biosimilar Erbitux with and without 0.25 NICSAL -- VIAL Jbklosmflar rbituNj., mghL Viscosities of biosimilar Avastin with and without 0.25NI CSAL 50(40 to 05 .200 200 300 IhisjninrvninmignxLstn

313.MICROBEADS FOR TAGLESS ENCODED CHEMICAL LIBRARY SCREENING
WO2020084084A1 • 2020-04-30 •
NANNA THERAPEUTICS LTD [GB]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

Disclosed is an encoded chemical library microbead, which microbead has immobilized thereon and/or therein: (i) an encoding tag; and (ii) a target assay system reporter moiety, wherein the reporter moiety

exists in a first state in the absence of activity against the target and in a second state in the presence of said activity, and wherein said microbead further comprises a clonal population of one or more chemical structure(s) releasably linked thereto and encoded by said tag.

314.PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES
US2020131106A1 • 2020-04-30 •
NEONC TECH INC [US]
Earliest priority: 2010-03-03 • Earliest publication: 2011-09-09

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

315.NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089452A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

316.RECOMBINANT PARVOVIRAL VECTORS AND METHOD OF MAKING AND USE THEREOF
WO2020092904A1 • 2020-05-07 •
NIKEGEN LLC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

A parvovirus vectors with a viral genome having a covalently closed end (ccePV vectors), methods for producing such vectors and DNA constructs used for producing such vectors.

317.BORNA VIRAL VECTOR AND USE THEREOF
US2020131531A1 • 2020-04-30 •
UNIV KYOTO [JP]
Earliest priority: 2017-03-14 • Earliest publication: 2018-09-20

Disclosed is a viral vector comprising (a) a cDNA of a recombinant viral RNA having a sequence of a Borna disease viral genome comprising a disrupted G gene of the Borna disease viral genome and an inserted G gene of an avian bornaviral genome, wherein the cDNA of the recombinant viral RNA has at least an N gene, an X gene, a P gene and an L gene of the Borna disease viral genome in the same order as in the Borna disease viral genome and has an inserted foreign gene; (b) DNAs encoding ribozymes; and (c) a promoter sequence, wherein (b) the DNAs encoding ribozymes are located upstream and downstream of (a) the cDNA of the recombinant viral RNA, and (a) the cDNA of the recombinant viral RNA and (b) the DNAs encoding ribozymes are located downstream of (c) the promoter sequence. The present invention can be used as a gene introduction technique that does not affect a host chromosome and can be suitable for the application in various fields, such as the treatment and prevention of brain and neurological diseases, visualization techniques of nerve cells in the field of neuroscience, etc.

318.Substituted nucleosides, nucleotides and analogs thereof
AU2018332540A1 • 2020-04-30 •
JANSSEN BIOPHARMA INC [US]
Earliest priority: 2017-09-18 • Earliest publication: 2019-03-21

Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a

319.METHODS AND IMMUNOGENIC COMPOSITIONS RELATING TO HER2 WITH SELECTIVE SEQUENCE MODIFICATIONS
US2020129628A1 • 2020-04-30 •
UNIV WAYNE STATE [US]
Earliest priority: 2018-06-06 • Earliest publication: 2020-04-30

Zwitterionic monomers, carnitine-derived zwitterionic polymers, carnitine ester cationic monomers, carnitine ester cationic polymers, conjugate compositions including a carnitine-derived zwitterionic polymer, and related compositions' and methods are provided which have various uses including as coatings, pharmaceuticals, diagnostics, encapsulation materials, and antifouling materials, among other utilities.

320.NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089459A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

321.NOVEL UREA 6,7-DIHYDRO-4H-THIAZOLO[5,4-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089460A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

322.COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY
US2020138710A1 • 2020-05-07 •
CHILDRENS MEDICAL CENTER [US]
Earliest priority: 2016-09-14 • Earliest publication: 2018-03-22

The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and has rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of infectious disease (e.g., otitis media). Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

323.MANAGEMENT OF RISK OF CATION OVERLOAD AND ELECTROLYTE IMBALANCE WITH TOPICALLY APPLIED BUFFERS
WO2020093069A1 • 2020-05-07 •
AMPERSAND BIOPHARMACEUTICALS INC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Provided herein are formulations for the safe and effective topical delivery of buffering agents. The invention includes formulations and methods to balance electrolytes, overcome cation overload, and/or deliver buffers with and without counterions that can be combined in a single use formulation or alternatively in separately applied formulations. Also provided are methods of using the formulations for the treatment of a wide variety of disorders relating to electrolyte imbalance, cation overload, or related conditions.

324.IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF
US2020131192A1 • 2020-04-30 •
IMPACT THERAPEUTICS INC [CN]
Earliest priority: 2017-07-10 • Earliest publication: 2019-01-17

or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

325.5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
WO2020083856A1 • 2020-04-30 •
MERCK PATENT GMBH [DE]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

326.IMMUNOMODULATORY COMPOUNDS
WO2020086440A1 • 2020-04-30 •
BETH ISRAEL DEACONESS MEDICAL CT INC [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present disclosure provides compounds and methods for modulating immune response, such as compounds that modulate 6-phosphogluconate dehydrogenase (6PGD).

327.MODULATION OF MITOCHONDRIAL BIOGENESIS BY INCREASE IN IRON SULFUR CLUSTER ACTIVITY
WO2020092877A1 • 2020-05-07 •
CHILDRENS HOSPITAL PHILADELPHIA [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present disclosure relates to compositions and methods using the same to modulate mitochondrial biogenesis. The subject may suffer from a disease or disorder stemming from mitochondrial dysfunction, such as sideroblastic anemia. The agonist may be an AMPK protein or expression construct coding therefore, PCG- 1a protein or expression construct coding therefore, metformin, resveratrol or AICAR.

328.Novel bispecific CD3/CD19 polypeptide complexes
AU2018337142A1 • 2020-05-07 •
WUXI BIOLOGICS SHANGHAI CO LTD
Earliest priority: 2017-09-22 • Earliest publication: 2019-03-28

A bispecific anti-CD3 x CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3 x CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3 x CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3 x CD19 polypeptide complex,

vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3 x CD19 polypeptide complex are provided.

329.Rapamycin Analog
US2020131196A1 • 2020-04-30 •
MOUNT TAM THERAPEUTICS INC [US]
Earliest priority: 2017-02-10 • Earliest publication: 2018-08-16

The present invention relates to a novel rapamycin analogue (e.g., of Formula I or Formula II), mixtures, methods for its production, and its use in cancer therapy (e.g., prevention and/or treatment).

330.Method
AU2018350372A1 • 2020-04-30 •
CANADIAN BLOOD SERVICES [CA]
Earliest priority: 2017-10-20 • Earliest publication: 2019-04-25

The invention relates to an antibody to a red blood cell for use in treating or preventing an inflammatory disorder, and to methods of treating or preventing an inflammatory disorder comprising administering to a subject in need thereof a therapeutically effective amount of an antibody to a red blood cell.

331.ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF
WO2020092907A1 • 2020-05-07 •
DANA FARBER CANCER INST INC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Disclosed are bifunctional compounds (degraders) that target HAT EP300 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

332.METHODS OF ADMINISTERING ANTI-TIM-3 ANTIBODIES
WO2020093024A2 • 2020-05-07 •
MERCK PATENT GMBH [DE]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). More specifically, this invention relates to a method of treating cancer by administering an anti-TIM-3 antibody in combination with an anti-PD-Ll/ TOPβ Trap fusion protein. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model.

333.3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
WO2020087202A1 • 2020-05-07 •
ACTON JOHN J III [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-05-07

Provided are cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor, compositions comprising said compounds, and uses of said compounds in the treatment or prevention of diseases in which M4 muscarinic acetylcholine receptors are involved, especially neurological and psychiatric disorders and diseases.

334.Methods and systems for processing a cell culture
AU2020202568A1 • 2020-05-07 •
GENZYME CORP
Earliest priority: 2013-09-16 • Earliest publication: 2015-03-19

Abstract Provided herein are methods of processing a cell culture and open circuit filtration systems. The filtration systems comprise a tangential flow filtration (TFF) unit having independent inlet and outlet ports connected to the cell culture bioreactor and a pump adapted to reverse the flow of fluid through the filtration unit.

335.INJECTABLE HYDROGELS AND USES THEREOF
US2020138711A1 • 2020-05-07 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2017-01-17 • Earliest publication: 2020-05-07

The invention relates to a hydrogel, in particular degradable or non degradable, comprising monomers of formula (I) and organosilica particles or porous silicon particles covalently bound thereto, optionally with non covalently bound organosilica and/or silicon particles mixed therewith, in particular degradable organosilica nanoparticles or core-shell nanocapsules; pharmaceutical, veterinary or cosmetic compositions thereof; and uses thereof as a medicament. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.

336.USE OF A SMALL NATIVE PEPTIDE ACTIVATOR OF SERCA PUMP FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS CHARACTERIZED BY CYTOSOLIC CALCIUM OVERLOAD
US2020140502A1 • 2020-05-07 •
UNIV TEXAS [US]
Earliest priority: 2016-04-19 • Earliest publication: 2017-10-19

The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

337.FUSION MOLECULES AND IL-15 VARIANTS
US2020140513A1 • 2020-05-07 •
ALTOR BIOSCIENCE CORP [US]
Earliest priority: 2007-05-11 • Earliest publication: 2008-11-27

The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

338.NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089456A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for mating the compounds.

339.GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS
US2020129536A1 • 2020-04-30 •
GLYCOMIMETICS INC [US]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20

Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

340.Oral rifamycin SV compositions
AU2018364617A1 • 2020-05-07 •
COSMO TECHNOLOGIES LTD
Earliest priority: 2017-11-10 • Earliest publication: 2019-05-16

Oral pharmaceutical compositions containing rifamycin SV, or a pharmaceutically salt thereof, characterized in that they are formulated in a higher strength (about 600 mg/tablet) and in such a manner to obtain a modified profile of the rifamycin SV, or a pharmaceutically acceptable salt thereof, in the proximal portion of the intestine, i.e. in the small intestine (duodenum, jejunum and ileum). In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of small intestine bacterial overgrowth (SIBO) and/or irritable bowel syndrome (IBS) and/or in the treatment of cholera. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of hepatic encephalopathy, hepatic cirrhosis, pouchitis and/or spontaneous bacterial perotinitis. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of non- alcoholic fatty liver disease, non-alcoholic fatty liver or non-alcoholic steatohepatitis.

341.Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
AU2018361975A1 • 2020-05-07 •

NOVARTIS AG
Earliest priority: 2017-11-02 • Earliest publication: 2019-05-09

The present disclosure relates to methods for treating tendinopathy, e.g., rotator cuff tendinopathy, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating tendinopathy patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

342.NOVEL ANTI-PD-L1 ANTIBODIES
US2020140554A1 • 2020-05-07 •
WUXI BIOLOGICS IRELAND LTD [IE]
Earliest priority: 2015-08-06 • Earliest publication: 2017-02-09

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

343.COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
WO2020087107A1 • 2020-05-07 •
THE WESTMEAD INSTITUTE FOR MEDICAL RES [AU]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

The present disclosure relates to compositions and methods for treating viral infections and in particular for treating hepatitis B and hepatitis D viral infections. A method of treating a hepatitis B virus infection in a subject the method comprising administering to the subject an inhibitor wherein the inhibitor inhibits or suppresses a regulator of liver lipid metabolism in the subject.

344.CROSSLINKED MATERIALS
WO2020093022A1 • 2020-05-07 •
FOUNT BIO INC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present application describes to the synthesis, formulation and uses of crosslinkable entities and crosslinked materials.

345.CARRIER-LINKED PRODRUGS HAVING REVERSIBLE CARBOXYLIC ESTER LINKAGES
EP3643306A2 • 2020-04-29 •
ASCENDIS PHARMA AS [DK]
Earliest priority: 2011-08-12 • Earliest publication: 2013-02-21

The invention provides a carrier-linked prodrugs, wherein the biologically active moieties comprise at least one carboxylic acid and wherein the linkage between the drug moiety and linker is in the form of an ester wherein the hydroxyl group required for ester formation is provided by the linker moiety and the carboxyl group required for ester formation is provided by the drug moiety. The hydroxyl group of the linker is

sterically hindered by the presence of an alkyl or aryl group on the carbon directly bound to or adjacent to the carbon carrying the hydroxyl group (a-carbon). The steric effect of the alkyl or aryl group enables greater control of the rate of hydrolytic degradation of such carrier-linked prodrugs.

346.POTENCY ASSAY
US2020140822A1 • 2020-05-07 •
MESOBLAST INT SARL [CH]
Earliest priority: 2015-05-05 • Earliest publication: 2016-11-10

The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

347.Polypeptide compositions comprising spacers
AU2018352984A1 • 2020-05-07 •
INTREXON CORP
Earliest priority: 2017-10-18 • Earliest publication: 2019-04-18

Disclosed herein are methods and compositions including antigen-binding polypeptides comprising a stalk region and a stalk extension region. In some cases, the antigen-binding compositions comprising the stalk extension region has increased expression on a cell surface and, in some cases, has increased antigen-binding efficiency. A subject antigen binding polypeptide can be a chimeric antigen receptor (CAR).

348.ER TUNABLE PROTEIN REGULATION
WO2020086742A1 • 2020-04-30 •
OBSIDIAN THERAPEUTICS INC [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins.

349.METHODS FOR TREATING CANCER
US2020138804A1 • 2020-05-07 •
X4 PHARMACEUTICALS INC [US]
Earliest priority: 2017-06-21 • Earliest publication: 2018-12-27

The present invention relates to methods of treating cancer, in which a CXCR4 inhibitor such as X4P-001 or a pharmaceutically acceptable salt thereof or pharmaceutical composition thereof is administered in combination with an additional therapeutic agent, such as an immune checkpoint inhibitor. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.

350.Pyrrolotriazine compounds and methods of inhibiting TAM kinases

AU2018347296A1 • 2020-05-07 •
SYROS PHARMACEUTICALS INC
Earliest priority: 2017-10-10 • Earliest publication: 2019-04-18

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer. (II), or a pharmaceutically acceptable salt thereof, wherein: R

351.MODIFIED PDC LINE FOR SECRETING A CYTOKINE
WO2020083974A1 • 2020-04-30 •
ETABLISSEMENT FRANCAIS DU SANG [FR]
Earliest priority: 2018-10-23 • Earliest publication: 2020-04-24

The present invention relates to a genetically modified PDC (plasmacytoid dendritic cell) line for secreting a cytokine and to its use for increasing the expansion of antigen-specific cells in immunotherapies.

352.5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
WO2020083878A1 • 2020-04-30 •
MERCK PATENT GMBH [DE]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

353.Methods for Diagnosis of Sepsis
US2020131577A1 • 2020-04-30 •
UNIV LELAND STANFORD JUNIOR [US]
Earliest priority: 2015-03-12 • Earliest publication: 2016-09-15

Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

354.ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY
WO2020084102A2 • 2020-04-30 •
BAYLOR COLLEGE MEDICINE [US]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

Methods of treating a cancer, comprising administering to a subject: (i) a virus comprising nucleic acid encoding an antigen-binding molecule comprising:(a) an antigen-binding moiety specific for an immune cell

surface molecule, and (b) an antigen-binding moiety specific for a cancer cell antigen; and (ii) an oncolytic virus, and/or (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen are disclosed. Also disclosed are articles and compositions for use in such methods.

355.MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
US2020140547A1 • 2020-05-07 •
UNIV JOHNS HOPKINS [US]
Earliest priority: 2017-05-26 • Earliest publication: 2018-11-29

The invention provides multifunctional antibody-ligand traps and methods of using them to counteract immune tolerance and/or immune dysfunction. The multifunctional antibody-ligand traps and fusion proteins of the invention can counteract immune dysfunction in order to restore and unleash antitumor or pathogen-directed immune responses. Provided here are promising immunotherapeutic agents for treatment and prevention of cancers, infectious diseases, and immuno-inflammatory disorders.

356.METHOD FOR SECRETORY PRODUCTION OF PROTEIN
WO2020085511A1 • 2020-04-30 •
AJINOMOTO KK [JP]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

A method for the efficient secretory production of a heterologous protein by a coryneform bacterium utilizing the TorA signal peptide is provided through the development of a novel technique for reducing missed cleavages of the TorA signal peptide. The secretory production of a heterologous protein is carried out by culturing a coryneform bacterium that has been modified to exhibit the ability to produce and secrete the heterologous protein utilizing the TorA signal peptide and to exhibit an increased LepB protein activity.

357.LIPID COMPOSITIONS
US2020138955A1 • 2020-05-07 •
ARBUTUS BIOPHARMA CORP [CA]
Earliest priority: 2009-05-05 • Earliest publication: 2010-11-11

Also disclosed are methods of producing the cationic lipid of formula (I).

358.BIOREMEDIATION OF XENOBIOTICS IN THE HONEY BEE HIVE
WO2020087005A1 • 2020-04-30 •
UNIV OF FLORIDA RESEARCH FOUNDATION [US]
Earliest priority: 2018-10-25 • Earliest publication: 2020-04-30

Described herein are engineered cells, enzymes, methods of use, and bee bread incorporating engineered cells and enzymes as described herein. In certain aspects, described herein are a bacterium containing therein one or more stably-expressing expression vectors for exogenous expression of one or more recombinant carboxylesterase enzymes or oxalate decarboxylase enzymes, thereby providing the engineered cell an exogenous pathway for hydrolyzing ester bonds or removing a carboxyl group. Engineered cells and recombinant enzymes as described herein can be incorporated into bee bread to be fed to a member of the Apidae family of bees or of the Apis or Bombus genus. In additional aspects, such bacteria can also be

selected and amplified from the milieu of the hive microorganisms and in some cases they can be molecularly bred to enhance their metabolic capabilities without genetic engineering.

359.CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE
WO2020086858A1 • 2020-04-30 •
GENENTECH INC [US]
Earliest priority: 2018-10-24 • Earliest publication: 2020-04-30

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

360.Multiplex production and barcoding of genetically engineered cells
AU2018334273A1 • 2020-04-30 •
UNIV BRANDEIS [US]
Earliest priority: 2017-09-15 • Earliest publication: 2019-03-21

The present disclosure relates to multiplex production and phenotyping of genetically engineered cells using RNA-guided nucleases and genomic barcoding. In particular, high-throughput multiplex genome editing is achieved utilizing a system that facilitates precise genome editing at desired target chromosomal loci by homology directed repair. Integration of guide RNA and donor DNA sequences as a genomic barcode at a separate chromosomal locus allows identification, isolation, and massively-parallel validation of individual variants from a pool of transformants. Strains can be arrayed according to their precise genetic modifications, as specified by donor DNA incorporation in heterologous or native genes. The present disclosure further relates to a method of editing codons outside of canonical guide RNA recognition regions, which enables complete saturation mutagenesis of protein-coding genes, a marker-based internal cloning method, which removes background due to oligonucleotide synthesis errors and incomplete vector backbone cleavage, and a method of enhancing homology directed repair by active donor recruitment.

361.COMPOSITIONS FOR DRUG ADMINISTRATION
US2020138956A1 • 2020-05-07 •
AEGIS THERAPEUTICS LLC [US]
Earliest priority: 2004-08-25 • Earliest publication: 2014-04-17

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

362.METHOD OF MODULATING THE ALKALOID CONTENT OF A PLANT
WO2020089645A1 • 2020-05-07 •
BRITISH AMERICAN TOBACCO INVESTMENTS LTD [GB]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention provides a method for modulating the alkaloid content of a plant (e.g. a tobacco plant), the method comprising modifying said plant by modulating the activity or expression of at least one protein kinase. The present invention also provides for the use of at least protein kinase gene for modulating the alkaloid content of a plant, as well as tobacco cells, plants, plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention.

363.SYSTEMS AND METHODS FOR IDENTIFICATION OF NUCLEIC ACIDS IN A SAMPLE
US2020131506A1 • 2020-04-30 •
BLUEDOT LLC [US]
Earliest priority: 2017-06-21 • Earliest publication: 2018-12-27

Provided herein are compositions and methods for analyzing nucleic acids in a sample. Compositions include simple barcode sets having reduced DNA sequencing instrument-specific error rates. Methods include methods to deconvolute sequence reads from different samples.

364.GLYCOTARGETING THERAPEUTICS
US2020129601A1 • 2020-04-30 •
ECOLE POLYTECHNIQUE FED LAUSANNE EPFL [CH]
Earliest priority: 2014-02-21 • Earliest publication: 2016-08-25

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

365.Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
AU2020202457A1 • 2020-05-07 •
DANA FARBER CANCER INSTITUTE INC [US]
Earliest priority: 2013-07-24 • Earliest publication: 2015-01-29

Abstract The present invention is based, in part, on the discovery of galectin 1 (Gall) 5 epitopes against which anti-Gall agents can neutralize Gall function, as well as anti-Gall agents and methods useful for neutralizing Gall function.

366.Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of a Retinal Degeneration Disorder
US2020140553A1 • 2020-05-07 •
YEDA RES & DEV [IL]
Earliest priority: 2014-03-12 • Earliest publication: 2017-02-02

The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

367.Method for expansion of lymphocytes

AU2018361561A1 • 2020-05-07 •
LUDWIG INST FOR CANCER RES LTD
Earliest priority: 2017-11-06 • Earliest publication: 2019-05-09

The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).

368.ANTI-TIM-3 ANTIBODIES
WO2020093023A1 • 2020-05-07 •
MERCK PATENT GMBH [DE]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). The antibodies contain TIM-3 binding sites based on the CDRs of the antibodies. The antibodies can be used as therapeutic agents as a monotherapy or in combination with another therapeutic agent. When used as therapeutic agents, the antibodies can be optimized, e.g., affinity-matured, to improve biochemical and/or biophysical properties and/or to reduce or eliminate immunogenicity, when administered to a human patient. The antibodies inhibit TIM-3 from binding to TIM-3 ligands, e.g., galectin-9, phosphatidylserine (PtdSer) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). The disclosed antibodies can be used to inhibit the proliferation of tumor cells in vitro or in vivo. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model.

369.DETECTING COLORECTAL NEOPLASM
US2020131588A1 • 2020-04-30 •
EXACT SCIENCES DEV CO LLC [US]
Earliest priority: 2014-03-31 • Earliest publication: 2015-10-01

Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.

370.ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF
US2020140530A1 • 2020-05-07 •
MERCK SHARP & DOHME [US]
Earliest priority: 2018-10-10 • Earliest publication: 2020-04-16

Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

371.6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089455A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to antiviral agents. Specifically, the present invention relates to compounds of formula I which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

372.ANTIBODIES
US2020131267A1 • 2020-04-30 •
KYMAB LTD [GB]
Earliest priority: 2017-06-20 • Earliest publication: 2018-12-27

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

373.NOVEL STING AGONISTS
WO2020092127A1 • 2020-05-07 •
VENENUM BIODESIGN LLC [US]
Earliest priority: 2018-10-29 • Earliest publication: 2020-04-30

The present invention provides compounds of Formula (I'): wherein Ⓐ, W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.

374.Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
AU2018338647A1 • 2020-05-07 •
UNIV SOUTHERN CALIFORNIA
Earliest priority: 2017-09-27 • Earliest publication: 2019-04-04

The disclosure provides compositions and method that promote adoptive cellular therapy. The disclosure provides polynucleotides, vectors, systems and cells comprising chimeric antigen receptors (CARs), synthetic immune receptors (SIRs), and the like in combination the specific activators of NFkB activity, thus improving cellular proliferation, expression and reduced apoptosis, which improves cell persistence in adoptive cell therapy.

375.NLRP3 MODULATORS
US2020129500A1 • 2020-04-30 •
INNATE TUMOR IMMUNITY INC [US]
Earliest priority: 2017-07-14 • Earliest publication: 2019-01-17

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

376.Methods and Compositions for Promoting Immune Cell Function
US2020131239A1 • 2020-04-30 •
TORQUE THERAPEUTICS INC [US]
Earliest priority: 2016-06-13 • Earliest publication: 2017-12-21

The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.

377.Method for detecting inflammasome proteins as biomarkers of neurological disorders
AU2018336897A1 • 2020-04-30 •
UNIV MIAMI [US]
Earliest priority: 2017-09-20 • Earliest publication: 2019-03-28

The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.

378.ANTIBODY CONJUGATES COMPRISING STING AGONIST
WO2020089815A1 • 2020-05-07 •
ADURO BIOTECH INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Provided herein are STING agonists and immunoconjugates comprising STING agonists. Also disclosed are methods of making the STING agonists and immunoconjugates and methods of treating cancer using them.

379.NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089453A1 • 2020-05-07 •
AICURIS GMBH & CO KG [DE]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the

function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for mating the compounds.

380.Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy
US2020140556A1 • 2020-05-07 •
UNIV LELAND STANFORD JUNIOR [US]
Earliest priority: 2017-06-28 • Earliest publication: 2019-01-03

Provided are methods and compositions for treating an individual with cancer or infectious disease. Multivalent Dectin-2 stimulating agents are provided that include: (a) an agent that binds to Dectin-2 and stimulates Dectin-2 signaling; and (b) an antibody and/or an immunomodulatory agent, wherein (a) and (b) are conjugated to one another. In some cases, (a) is a mannobiose glycopolypeptide that binds to Dectin-2. In some cases (b) is a stimulatory ligand for a TLR (e.g., TLR7, TLR8, TLR7/8, TLR2, and the like). Methods of treating an individual with cancer and/or an infectious disease can include administering to the individual an effective amount of a Dectin-2 stimulating composition. In some cases, the Dectin-2 stimulating composition comprises a Dectin-2 stimulating glycopolymer. In some cases the Dectin-2 stimulating composition comprises a multivalent Dectin-2 stimulating agent.

381.DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
US2020141937A1 • 2020-05-07 •
ABBOTT LAB [US]
Earliest priority: 2013-03-14 • Earliest publication: 2014-09-18

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

382.5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV
WO2020086533A1 • 2020-04-30 •
ASSEMBLY BIOSCIENCES INC [US]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-30

The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

383.CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS
US2020140378A1 • 2020-05-07 •
UNIV TEXAS [US]
Earliest priority: 2016-05-16 • Earliest publication: 2017-11-23

wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

384.ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
WO2020092881A1 • 2020-05-07 •
CYTOMX THERAPEUTICS INC [US]
Earliest priority: 2018-11-02 • Earliest publication: 2020-05-07

Provided herein are activatable antibodies that when activated specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

385.COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA
WO2020087031A1 • 2020-04-30 •
ROSALIND FRANKLIN UNIV OF MEDICINE AND SCIENCE [US]
Earliest priority: 2018-10-26 • Earliest publication: 2020-04-30

A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.

386.COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS
US2020129458A1 • 2020-04-30 •
AJINOMOTO KK [JP]
Earliest priority: 2016-03-30 • Earliest publication: 2017-10-05

wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.

387.Targeted gene integration of CRS inhibitor genes for improved immune cells therapy
AU2018351689A1 • 2020-04-30 •
CELLECTIS [FR]
Earliest priority: 2017-10-19 • Earliest publication: 2019-04-25

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) into genetically engineered immune cells to prevent cytokine release syndrome to arise during the course of cell therapy. These exogenous coding sequences are more particularly soluble human polypeptides placed under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

388.SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS
US2020140461A1 • 2020-05-07 •
BAYER AG [DE]
Earliest priority: 2017-06-14 • Earliest publication: 2018-12-20

The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle

389.Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
AU2018351000A1 • 2020-04-30 •
ALPINE IMMUNE SCIENCES INC [US]
Earliest priority: 2017-10-18 • Earliest publication: 2019-04-25

Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

390.POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE
US2020131498A1 • 2020-04-30 •
MODERNATX INC [US]
Earliest priority: 2017-06-14 • Earliest publication: 2018-12-20

The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering a polynucleotide sequence encoding an MCM polypeptide.

391.Condensed imidazole derivatives substituted by tertiary hydroxy groups as PI3K-gamma inhibitors
AU2018350980A1 • 2020-04-30 •
INCYTE CORP [US]
Earliest priority: 2017-10-18 • Earliest publication: 2019-04-25

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

392.Genetic regulation of immunoresponse by chromosome interactions
AU2018361833A1 • 2020-04-30 •
OXFORD BIODYNAMICS LTD [GB]

Earliest priority: 2017-11-03 • Earliest publication: 2019-05-09

A process for analysing chromosome regions and interactions relating to immunoresponsiveness.

393.N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
US2020140456A1 • 2020-05-07 •
C4 THERAPEUTICS INC [US]
Earliest priority: 2017-06-20 • Earliest publication: 2018-12-27

This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

394.SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
US2020131176A1 • 2020-04-30 •
CS PHARMATECH LTD [KR]
Earliest priority: 2017-07-05 • Earliest publication: 2019-01-10

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

395.DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS
WO2020092617A1 • 2020-05-07 •
ADURO BIOTECH INC [US]
Earliest priority: 2018-10-31 • Earliest publication: 2020-05-07

Provided herein are immunoconjugates comprising an anti-DC-SiGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

396.INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES
US2020140571A1 • 2020-05-07 •
ATYR PHARMA INC [US]
Earliest priority: 2010-05-03 • Earliest publication: 2011-11-10

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

397.ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
US2020128832A1 • 2020-04-30 •
SNIPR TECH LIMITED [GB]
Earliest priority: 2015-05-06 • Earliest publication: 2016-11-10

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

398.Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
AU2018358067A1 • 2020-05-07 •
JUNO THERAPEUTICS INC
Earliest priority: 2017-11-01 • Earliest publication: 2019-05-09

Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.

399.Combination pharmaceutical agents as RSV inhibitors
AU2018339068A1 • 2020-05-07 •
ENANTA PHARM INC
Earliest priority: 2017-09-29 • Earliest publication: 2019-04-04

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

400.DIAGNOSIS OF BLISTERING AUTOIMMUNE DISEASES
EP3644060A1 • 2020-04-29 •
EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]
Earliest priority: 2018-10-22 • Earliest publication: 2020-04-23

Die vorliegende Erfindung betrifft ein Polypeptid umfassend Laminin beta-4, ein Träger umfassend das Polypeptid, einen Antikörper, bevorzugt Autoantikörper gegen Laminin beta-4, eine Verwendung des Polypeptides, Trägers oder Autoantikörpers zur Diagnose einer Krankheit sowie ein Verfahren umfassend den Schritt Nachweisen eines Autoantikörpers gegen Laminin beta-4 in einer Probe.

401.METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN
WO2020092848A2 • 2020-05-07 •
JUNO THERAPEUTICS INC [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.

402.HEPATITIS B CORE PROTEIN MODULATORS
US2020131168A1 • 2020-04-30 •
ASSEMBLY BIOSCIENCES INC [US]
Earliest priority: 2015-09-15 • Earliest publication: 2017-03-23

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

403.CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)
WO2020092854A2 • 2020-05-07 •
JUNO THERAPEUTICS INC [US]
Earliest priority: 2018-11-01 • Earliest publication: 2020-05-07

Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy.

404.COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
US2020129627A1 • 2020-04-30 •
ARVINAS OPERATIONS INC [US]
Earliest priority: 2016-12-23 • Earliest publication: 2020-04-30

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein).

Patentes registradas en la United States Patent and Trademark Office (USPTO)

Results of Search in US Patent Collection db for: (ABST/vaccine AND ISD/20200427->20200508),
14 resultados.

	PAT. NO.	Title
1	10,640,752	Salmon gill poxvirus
2	10,639,364	PRRS virus variant, european PRRS virus cDNA clone, and uses thereof
3	10,639,332	Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
4	10,639,331	Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
5	10,639,280	Surface display of antigens on gram-negative outer membrane vesicles
6	10,636,514	Using subject sequencing data and a database of therapy biomarker distributions to determine normalized biomarker scores and therapy scores
7	10,633,667	Recombinant NDV antigen and uses thereof
8	10,633,639	Chimeras of Brucella lumazine synthase and beta subunit of AB.sub.5 toxins
9	10,633,637	Pestivirus vaccines for congenital tremors
10	10,633,411	Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
11	10,632,192	Pyrimidine compounds and their use as vaccine adjuvants
12	10,632,191	Synthetic glucopyranosyl lipid adjuvants
13	10,632,186	Vaccine to pathogenic immune activation cells during infections
14	10,632,182	Methods for freeze-drying and rehydrating biologics

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY
EDICIONES